

Friday, August 31, 2018

Volume 49 No. 8



NOTICE – Items in this issue will be listed online weekly and printed monthly.

NAME CHANGES

(For details on individual listings, see the News Section of this issue)

Depomed Inc (to Asserlio Therapeutics Inc)
Strayer Education Inc (to Strategic Education Inc)
TCP Capital Corp (to BlackRock TCP Capital Corp)

1347 PROPERTY INSURANCE HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		2018	2017
Total Revenues		27,823	17,640
Cost & expenses		18,250	10,587
Operating income		2,661	1,941
Net before taxes		2,661	1,941
Income taxes		575	774
Net income		2,086	1,167
Balance for common		1,678	1,167
Earnings common share			
Primary		\$0.28	\$0.20
Fully Diluted		\$0.27	\$0.20
Common Shares:			
Full Diluted		6,104	5,957
Year-end		5,985	5,957

2U INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		2018	2017
Total Revenues		189,711	129,824
Cost & expenses		227,702	144,234
Operating income		(37,991)	(14,410)
Interest income		1,254	249
Interest expense		54	1
Foreign currency		(1,220)	(1,031)
Net before taxes		(38,011)	
Income taxes		(4,793)	
Net income		(33,218)	(15,193)
Earnings common share			
Primary		\$(0.62)	\$(0.32)
Fully Diluted		\$(0.62)	\$(0.32)
Common Shares:			
Full Diluted		53,841	47,454
Year-end		57,316	47,858

3D SYSTEMS CORP. (DE)

Earnings, 6 mos. to Jun 30(Consol. – \$):		2017	2016
Total Revenues		315,898,000	310,666,000
Cost & expenses		331,833,000	331,142,000
Operating income		(15,935,000)	(20,476,000)
Net before taxes		(14,801,000)	(20,142,000)
Income taxes		3,108,000	2,879,000
Net income		(17,909,000)	(23,021,000)
Earnings common share			
Primary		\$(0.17)	\$(0.20)
Fully Diluted		\$(0.17)	\$(0.20)
Common Shares:			
Full Diluted		111,350,000	111,288,000
Year-end		113,881,000	112,175,000

AAON, INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):		2018	2017
Net Sales		208,670	187,404
Cost & expenses		188,555	152,976
Operating income		19,681	34,116
Other income (expense), net		6	45
Net before taxes		19,822	34,292
Income taxes		3,871	10,281
Net income		15,951	24,011

Earnings common share

Primary	\$0.30	\$0.46
Fully Diluted	\$0.30	\$0.45
Common Shares:		
Full Diluted	52,754	53,176
Year-end	52,290	52,616

ABAXIS, INC.

Merger Completed On July 31, 2018, Zoetis Inc. ("Zoetis") indirect wholly-owned subsidiary, Zeus Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Zoetis (the "Merger"). As the result of the merger, each outstanding share of common stock, no par value, of Co. ("Co. Common Stock") (other than shares, if any, held by Co., Zoetis, Merger Sub or any of their subsidiaries and shares with respect to which dissenters rights were properly demanded in accordance with the Corporations Code of the State of California) was converted into the right to receive \$83.00 in cash, without interest, per share (the "Merger Consideration"). Additionally, subject to the terms and conditions of the Merger Agreement, certain Co. time- and performance-based restricted stock unit awards vested automatically upon the occurrence of the Effective Time in accordance with their existing terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Co. Common Stock underlying such awards. All other Co. time- and performance-based restricted stock unit awards were cancelled and automatically converted at the Effective Time into time-vesting restricted stock unit awards with respect to shares of common stock, par value \$0.01 per share, of Zoetis (the "Zoetis Common Stock"), with the number of underlying shares adjusted to reflect an exchange ratio based on the closing prices of shares of Zoetis Common Stock and Co. Common Stock for the ten full trading days before the closing of the Merger, and on substantially the same terms and conditions (including the time-based vesting schedule) as were applicable to such Co. restricted stock unit awards immediately prior to the Effective Time, except that any performance goals underlying such Co. performance-based restricted stock unit awards were deemed satisfied as of the Effective Time. The aggregate consideration was approximately \$2,000,000,000.

ABIOMED, INC.

Earnings, 3 mos. to Jun 30(Consol. – \$):		2018	2017
Total Revenues		180,010,000	132,468,000
Cost & expenses		133,262,000	99,390,000
Operating income		46,748,000	33,078,000
Other income (expense), net		188,000	79,000
Invest. income		1,551,000	635,000
Net before taxes		48,487,000	33,792,000
Income taxes		(41,579,000)	(3,582,000)
Net income		90,066,000	37,374,000
Earnings common share			
Primary		\$2.02	\$0.85
Fully Diluted		\$1.95	\$0.82
Common Shares:			
Full Diluted		46,169,000	45,608,000
Year-end		44,876,271	44,080,941

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		61,288,000
Inventories		55,781,000
Current assets		497,297,000
Net property & equip.		127,324,000
Total assets		812,039,000
Liabilities:		
Current liabilities		76,678,000
Stockholders' equity		723,359,000
Net current assets		420,619,000

ACACIA COMMUNICATIONS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		2018	2017
Total Revenues		137,944	193,565
Cost & expenses		164,725	170,357
Operating income		(26,781)	23,208
Other income (expense), net		(262)	(39)
Net before taxes		(24,198)	24,441
Income taxes		(11,875)	(15,932)
Net income		(12,323)	40,373
Earnings common share			
Primary		\$(0.31)	\$1.05
Fully Diluted		\$(0.31)	\$0.97
Common Shares:			
Full Diluted		40,074	41,639
Year-end		40,493	

ACACIA RESEARCH CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):		2018	2017
Total Revenues		68,578,000	25,311,000
Cost & expenses		99,444,000	44,811,000
Operating income		(30,866,000)	(19,500,000)
Other income (expense), net		(29,750,000)	(12,712,000)
Gains or losses			7,287,000
Net before taxes		(60,141,000)	(23,666,000)
Income taxes		476,000	2,719,000
Net income		(60,617,000)	(26,385,000)
Earnings common share			
Primary		\$(1.20)	\$(0.52)
Fully Diluted		\$(1.20)	\$(0.52)
Common Shares:			
Full Diluted		50,345,808	50,416,611
Year-end		49,495,064	

ACADIA HEALTHCARE COMPANY INC.

Earnings, 6 mos. to Jun 30(Consol. – \$):		2018	2017
Total Revenues		1,507,979,000	1,395,090,000
Cost & expenses		1,310,932,000	1,211,576,000
Operating income		117,346,000	114,700,000
Net before taxes		117,346,000	114,700,000
Income taxes		7,582,000	30,289,000
Net income		109,764,000	84,411,000
Earnings common share			
Primary		\$1.26	\$0.97
Fully Diluted		\$1.26	\$0.97
Common Shares:			
Full Diluted		87,351,000	86,997,000
Year-end		87,330,276	86,991,051

ACADIA PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):		2018	2017
Total Revenues		105,931,000	45,761,000
Net Sales		105,931,000	45,761,000
Cost & expenses		224,829,000	202,518,000
Operating income		(118,898,000)	(156,757,000)
Other income (expense), net		(247,000)	
Net before taxes		(116,696,000)	(154,801,000)
Income taxes		866,000	483,000
Net income		(117,562,000)	(155,284,000)
Earnings common share			
Primary		\$(0.94)	\$(1.27)
Fully Diluted		\$(0.94)	\$(1.27)
Common Shares:			
Full Diluted		124,819,000	121,888,000
Year-end		124,999,365	122,336,580

ACCELERON PHARMA, INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	6,917	6,762
Cost & expenses	64,462	62,530
Operating income	(57,545)	(55,768)
Interest income	2,660	977
Other income (expense), net	(250)	(272)
Net before taxes	(55,135)	(55,063)
Income taxes	21	12
Net income	(55,156)	(55,075)
Earnings common share		
Primary	\$(1.21)	\$(1.43)
Fully Diluted	\$(1.21)	\$(1.43)
Common Shares:		
Full Diluted	45,654	38,631
Year-end	45,845	38,637

ACELRX PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	1,161	5,768
Cost & expenses	16,583	27,782
Operating income	(15,422)	(22,014)
Net before taxes	(22,131)	(28,608)
Income taxes	2	2
Net income	(22,133)	(28,610)
Earnings common share		
Primary	\$(0.43)	\$(0.63)
Fully Diluted	\$(0.43)	\$(0.63)
Common Shares:		
Full Diluted	51,389	45,364
Year-end	53,327	

ACHAOGEN, INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	103,387	56,406
Operating income	(98,682)	(47,677)
Interest expense	900	1,430
Other income (expense), net	2,384	(10,221)
Net income	(97,198)	(59,328)
Earnings common share		
Primary	\$(2.18)	\$(1.61)
Fully Diluted	\$(2.19)	\$(1.61)
Common Shares:		
Full Diluted	45,426	36,906
Year-end	45,012	42,232

ACHILLION PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	40,375	44,758
Operating income	(40,375)	(44,758)
Interest income	2,609	2,092
Interest expense	21	29
Net income	(37,787)	(42,695)
Earnings common share		
Primary	\$(0.27)	\$(0.31)
Fully Diluted	\$(0.27)	\$(0.31)
Common Shares:		
Full Diluted	138,221	136,729
Year-end	138,586	136,762

ACI WORLDWIDE INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	444,305	472,061
Cost & expenses	420,789	462,138
Operating income	(18,862)	(34,820)
Interest income	5,486	256
Interest expense	19,082	20,824
Other income (expense), net	(1,732)	(1,117)
Net before taxes	(34,190)	(56,505)
Income taxes	(188)	(25,088)
Net income	(34,002)	(31,417)
Earnings common share		
Primary	\$(0.29)	\$(0.27)
Fully Diluted	\$(0.29)	\$(0.27)
Common Shares:		
Full Diluted	115,595	116,881
Year-end	115,765	118,166

ACLARIS THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	4,794	28,225
Cost & expenses	67,720	(28,225)
Operating income	(62,926)	(28,225)
Other income (expense), net	1,479	828
Net income	(61,447)	(27,397)
Earnings common share		
Primary	\$(1.99)	\$(1.04)
Fully Diluted	\$(1.99)	\$(1.04)
Common Shares:		
Full Diluted	30,916	26,339
Year-end	30,965	26,737

ACM RESEARCH INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	30,616	14,423
Cost & expenses	30,189	16,178
Operating income	427	(1,755)
Interest income	17	5
Interest expense	252	164
Other income (expense), net	429	(292)
Net before taxes	621	(2,206)
Income taxes	186	749
Net income	435	(2,955)
Earnings common share		
Primary	\$0.03	\$(0.56)
Fully Diluted	\$0.02	\$(0.56)
Common Shares:		
Full Diluted	17,670	4,928
Year-end	15,878	5,037

ACORDA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	259,467,000	258,824,000
Net Sales	253,415,000	245,349,000
Cost & expenses	199,978,000	271,401,000
Operating income	59,489,000	(12,577,000)
Interest income	1,236,000	73,000
Other income (expense), net	24,000	
Net before taxes	49,831,000	(22,547,000)
Income taxes	11,833,000	4,552,000
Net income	37,998,000	(27,099,000)
Earnings common share		
Primary	\$0.82	\$(0.59)
Fully Diluted	\$0.81	\$(0.59)
Common Shares:		
Full Diluted	46,974,000	45,876,000
Year-end	47,143,752	46,640,807

ACTIVISION BLIZZARD, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	3,607,000	3,356,000
Cost & expenses	2,578,000	2,525,000
Operating income	1,029,000	831,000
Net before taxes	975,000	746,000
Income taxes	73,000	77,000
Net income	902,000	669,000
Earnings common share		
Primary	\$1.19	\$0.89
Fully Diluted	\$1.17	\$0.88
Common Shares:		
Full Diluted	770,000	763,000
Year-end	762,166	

ACXIOM CORP.

Earnings, 3 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	226,960	212,514
Cost & expenses	232,661	218,221
Operating income	(5,701)	(5,707)
Other income (expense), net	524	(672)
Net before taxes	(8,015)	(8,721)
Income taxes	(5,000)	(7,421)
Net income	(3,015)	(1,300)
Earnings common share		
Primary	\$(0.04)	\$(0.02)
Fully Diluted	\$(0.04)	\$(0.02)
Common Shares:		
Full Diluted	76,935	78,672
Year-end	77,354	79,204

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	95,099
Current assets	310,794
Net property & equip.	151,407
Total assets	1,166,968
Liabilities:	
Current liabilities	161,493
Long-term debt	227,435
Stockholders' equity	722,056
Net current assets	149,301

ADAMAS PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	10,118	2
Cost & expenses	71,154	36,523
Operating income	(61,036)	(36,521)
Interest expense	9,938	729
Net before taxes		(36,824)
Income taxes		(51)
Net income	(68,964)	(36,773)
Earnings common share		
Primary	\$(2.61)	\$(1.65)
Fully Diluted	\$(2.61)	\$(1.65)
Common Shares:		
Full Diluted	26,454	22,300
Year-end	27,184	22,463

ADDUS HOMECARE CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	225,090	189,253
Deprec., depl. & amort.	4,141	3,030
Operating income	11,453	12,882
Interest income	2,355	20
Interest expense	2,293	2,759
Other income (expense), net		101
Net before taxes	11,515	10,244
Income taxes	2,360	3,285
Net income	9,155	6,959
Earnings common share		
Primary	\$0.79	\$0.61
Fully Diluted	\$0.78	\$0.60
Common Shares:		
Full Diluted	11,767	11,604
Year-end	11,697	11,625

ADDUS HOMECARE CORP

Offering On Aug. 15, 2018, Co. announced the pricing of an underwritten public offering of 2,100,000 shares of common stock ("Common Stock") at the public offering price of \$59.00 per share. In the offering, Co. has agreed to sell 1,075,267 shares of Common Stock and Eos Capital Partners III, L.P. (the "Selling Stockholder") has agreed to sell 1,024,733 shares of Common Stock. Co. has granted the underwriters a 30-day option to purchase up to 315,000 additional shares of Common Stock at the public offering price. The gross proceeds to Co. from the offering, before deducting underwriting discounts and estimated offering expenses, are expected to be \$63,440,753.00, excluding any proceeds from the exercise of the underwriters' option to purchase additional shares. Co. intends to use the net proceeds from this offering for general corporate purposes, including to potentially fund a portion of any future acquisitions that it may complete. Co. will not receive any proceeds from the sale of the shares of Common Stock by the Selling Stockholder. The offering is expected to close on or about Aug. 20, 2018, subject to customary closing conditions.

ADVANTAGE TECHNOLOGIES GROUP, INC.

Earnings, 9 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	36,508,192	36,380,572
Cost & expenses	38,566,637	35,867,839
Operating income	(2,058,445)	512,733
Other income (expense), net	(258,558)	
Net before taxes	(2,504,158)	232,969
Income taxes	(31,000)	72,000
Net income	(2,473,158)	160,969
Earnings common share		
Primary	\$(0.24)	\$0.02
Fully Diluted	\$(0.24)	\$0.02
Common Shares:		
Full Diluted	10,261,617	10,160,582
Year-end	10,306,145	10,192,244

ADTRAN, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

Fully Diluted	\$1.75	\$0.25	Other income (expense), net	(2,748)	(121)		2018	2017
Common Shares:			Net before taxes	119,246	190,468	Cost & expenses	7,722,255	7,326,127
Full Diluted	398,400	338,900	Income taxes	22,471	59,133	Net income	7,259,748	9,435,991
Year-end	434,100	355,600	Net income	96,775	131,335	Earnings common share		
AGROFRESH SOLUTIONS INC			Earnings common share			Primary	\$0.52	\$0.68
Earnings, 6 mos. to Jun 30 (Consol. – \$):			Primary	\$0.57	\$0.76	Fully Diluted	\$0.52	\$0.68
	2018	2017	Common Shares:	\$0.56	\$0.75	Common Shares:		
Net Sales	56,771,000	49,119,000	Full Diluted	172,156	174,305	Full Diluted	13,960,729	13,783,414
Cost & expenses	55,206,000	45,647,000	Year-end	169,311		Year-end	13,582,751	14,245,220
Operating income	(20,776,000)	(17,418,000)	AKCEA THERAPEUTICS INC			ALDER BIOPHARMACEUTICALS INC		
Interest expense	17,118,000	18,857,000	Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
Other income (expense), net	608,000	255,000		2018	2017		2018	2017
Foreign currency	5,203,000	11,071,000	Total Revenues	35,429	11,807	Cost & expenses	150,682	176,177
Net before taxes	(32,083,000)	(24,949,000)	Cost & expenses	129,179	94,872	Operating income	(150,682)	(175,494)
Income taxes	(805,000)	(15,527,000)	Operating income	(93,750)	(83,065)	Interest income	4,176	923
Net income	(31,278,000)	(9,422,000)	Interest expense		1,507	Interest expense	7,539	
Balance for common	(31,351,000)	(9,422,000)	Other income (expense), net	(123)	50	Other income (expense), net	(1,505)	
Earnings common share			Gains or losses	2,414	308	Equity earnings	222	279
Primary	\$(0.63)	\$(0.19)	Net before taxes	(91,459)		Foreign currency	352	(107)
Fully Diluted	\$(0.63)	\$(0.19)	Income taxes	214		Net income	(155,420)	(174,957)
Common Shares:			Net income	(91,673)	(84,214)	Balance for common	(188,265)	(174,957)
Full Diluted	49,814,744	49,941,993	Earnings common share			Earnings common share		
Year-end	50,486,962	50,337,705	Primary	\$(2.52)	\$(2.92)	Primary	\$(2.77)	\$(3.47)
AILERON THERAPEUTICS INC			Fully Diluted	\$(2.52)	\$(2.92)	Fully Diluted	\$(2.77)	\$(3.47)
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Common Shares:			Common Shares:		
	2018	2017	Full Diluted	74,515	28,885	Full Diluted	67,906	50,412
Cost & expenses	17,422	9,541	Year-end	85,681		Year-end	68,153	50,462
Operating income	(17,422)	(9,541)	AKEBIA THERAPEUTICS INC			ALEXION PHARMACEUTICALS INC.		
Interest income	343	61	Earnings, 6 mos. to Jun 30 (Consol. – \$):			Earnings, 6 mos. to Jun 30 (Consol. – \$):		
Net income	(17,079)	(9,480)		2018	2017		2018	2017
Balance for common	(17,079)	(9,521)	Cost & expenses	154,883,000	116,493,000	Total Revenues	1,975,900,000	782,300,000
Earnings common share			Operating income	(60,160,000)	(67,108,000)	Cost & expenses	1,948,500,000	183,500,000
Primary	\$(1.16)	\$(21.56)	Other income (expense), net	36,000	4,000	Operating income	(132,700,000)	438,700,000
Fully Diluted	\$(1.16)	\$(21.56)	Net income	(57,487,000)	(66,060,000)	Interest expense	49,100,000	48,300,000
Common Shares:			Earnings common share			Other income (expense), net	1,300,000	1,500,000
Full Diluted	14,735	442	Primary	\$(1.09)	\$(1.66)	Gains or losses	113,500,000	8,400,000
Year-end	14,737	451	Fully Diluted	\$(1.09)	\$(1.66)	Net before taxes	(67,000,000)	400,300,000
AIMMUNE THERAPEUTICS INC			Common Shares:			Income taxes	141,300,000	65,000,000
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Full Diluted	52,774,794	39,795,282	Net income	(208,300,000)	335,300,000
	2018	2017	Year-end	56,913,886		Earnings common share		
Cost & expenses	103,932	59,345	AKORN INC			Primary	\$(0.94)	\$1.49
Operating income	(103,932)	(59,345)	Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Fully Diluted	\$(0.94)	\$1.49
Net before taxes	(102,002)			2018	2017	Common Shares:		
Income taxes	50		Total Revenues	375,007	452,560	Full Diluted	222,300,000	225,700,000
Net income	(102,052)	(58,367)	Cost & expenses	465,616	332,898	Year-end	222,800,000	224,000,000
Earnings common share			Operating income	(116,981)	88,687	ALICO, INC.		
Primary	\$(1.83)	\$(1.16)	Other income (expense), net	(2,662)	2,335	Earnings, 9 mos. to Jun 30 (Consol. – \$):		
Fully Diluted	\$(1.83)	\$(1.16)	Net before taxes	(140,283)	72,076		2018	2017
Common Shares:			Income taxes	(23,552)	28,512	Total Revenues	79,650,000	125,163,000
Full Diluted	55,752	50,150	Net income	(116,731)	43,564	Cost & expenses	69,235,000	103,782,000
Year-end	58,461	50,396	Earnings common share			Operating income	10,415,000	21,381,000
AIR TRANSPORT SERVICES GROUP, INC.			Primary	\$(0.93)	\$0.35	Other income (expense), net	158,000	(120,000)
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Fully Diluted	\$(0.93)	\$0.35	Gains or losses	9,083,000	1,989,000
	2018	2017	Common Shares:			Net before taxes	12,974,000	16,326,000
Total Revenues	406,647	491,128	Full Diluted	125,286	124,855	Income taxes	674,000	6,713,000
Cost & expenses	273,482	375,850	Year-end	125,404		Net income	12,300,000	9,613,000
Deprec., depl. & amort.	81,624	74,223	ALARM.COM HOLDINGS INC			Balance for common	12,332,000	9,577,000
Operating income	51,541	41,055	Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Earnings common share		
Interest income	77	48		2018	2017	Primary	\$1.50	\$1.15
Interest expense	10,728	7,307	Total Revenues	197,244	160,182	Fully Diluted	\$1.48	\$1.15
Other income (expense), net	9,949	(66,134)	Cost & expenses	166,478	142,091	Common Shares:		
Net before taxes	50,839	(32,338)	Operating income	20,503	10,381	Full Diluted	8,314,000	8,340,000
Income taxes	10,693	11,784	Interest expense	1,423	890	Year-end	8,192,398	8,261,308
Income contin. oper.	40,146	(44,122)	Other income (expense), net	816	374	ALIGN TECHNOLOGY INC		
Net income	40,512	(43,738)	Net before taxes	19,896	9,865	Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
Earnings common share			Income taxes	(1,352)	(3,963)		2018	2017
Primary	\$0.69	\$(0.74)	Net income	21,248	13,828	Total Revenues	927,183	666,823
Fully Diluted	\$0.48	\$(0.74)	Balance for common	21,244	13,820	Cost & expenses	706,300	521,581
Common Shares:			Earnings common share			Operating income	220,883	145,242
Full Diluted	68,784	59,084	Primary	\$0.45	\$0.30	Interest income	4,093	2,636
Year-end	59,080	59,123	Fully Diluted	\$0.43	\$0.28	Other income (expense), net	(6,922)	2,221
AKAMAI TECHNOLOGIES INC			Common Shares:			Equity earnings	5,478	3,336
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Full Diluted	49,406	48,907	Net before taxes	218,054	150,099
	2018	2017	Year-end	47,692	46,685	Income taxes	10,605	8,164
Total Revenues	1,331,483	1,206,125	ALCENTRA CAPITAL CORP			Net income	201,971	138,599
Cost & expenses	1,189,084	999,876	Earnings, 6 mos. to Jun 30 (Consol. – \$):			Earnings common share		
Operating income	125,674	190,927		2018	2017	Primary	\$2.52	\$1.73
Interest income	10,374	8,905	Total Revenues	197,244	160,182	Fully Diluted	\$2.48	\$1.70
Interest expense	14,054	9,243	Cost & expenses	166,478	142,091	Common Shares:		

Common Shares:		
Full Diluted	182,303,128	142,886,614
Year-end	189,053,214	

AMKOR TECHNOLOGY INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Net Sales	2,091,003	1,907,669
Cost & expenses	2,000,943	1,716,626
Operating income	90,060	191,043
Other income (expense), net	3,229	(227)
Net before taxes	56,491	138,203
Income taxes	13,112	32,141
Net income	43,379	106,062
Earnings common share		
Primary	\$0.18	\$0.44
Fully Diluted	\$0.18	\$0.44
Common Shares:		
Full Diluted	239,805	239,601
Year-end	239,366	

AMPHASTAR PHARMACEUTICALS INC (DE)**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	129,433	121,857
Cost & expenses	142,208	118,268
Operating income	(12,775)	3,589
Interest income	230	178
Interest expense	118	428
Other income (expense), net	(483)	1,338
Net before taxes	(13,146)	4,677
Income taxes	(3,110)	1,812
Net income	(10,036)	2,865
Earnings common share		
Primary	\$(0.22)	\$0.06
Fully Diluted	\$(0.22)	\$0.06
Common Shares:		
Full Diluted	46,535	47,962
Year-end	46,417	

AMTECH SYSTEMS, INC.**Earnings, 9 mos. to Jun 30**(Consol. – \$):

	2018	2017
Total Revenues	147,594,000	109,839,000
Cost & expenses	136,827,000	107,451,000
Operating income	10,767,000	2,388,000
Other income (expense), net	234,000	(200,000)
Gains or losses	2,883,000	
Net before taxes	14,108,000	2,037,000
Income taxes	(150,000)	1,270,000
Net income	14,258,000	767,000
Earnings common share		
Primary	\$0.96	\$0.14
Fully Diluted	\$0.94	\$0.14
Common Shares:		
Full Diluted	15,181,000	13,288,000
Year-end	14,986,620	13,328,656

AMYRIS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	46,192	38,660
Cost & expenses	84,345	87,802
Operating income	(38,153)	(49,142)
Interest expense	17,029	21,486
Other income (expense), net	(34,781)	34,146
Net before taxes	(36,482)	
Income taxes		269
Net income	(89,963)	(36,751)
Balance for common	(90,757)	(47,636)
Earnings common share		
Primary	\$(1.71)	\$(2.24)
Fully Diluted	\$(1.71)	\$(2.24)
Common Shares:		
Full Diluted	53,077	21,226
Year-end	50,341	25,272

ANALOG DEVICES INC**Earnings, 9 mos. to** (Consol. – \$000):

	08/04/18	07/29/17
Total Revenues	4,604,356	3,566,333
Cost & expenses	2,914,436	2,760,406
Operating income	1,368,363	606,924
Interest income	6,592	27,945

Interest expense	194,487	187,323
Other income (expense), net	527	(725)
Net before taxes	1,180,995	446,821
Income taxes	118,528	67,212
Net income	1,062,467	379,609
Earnings common share		
Primary	\$2.86	\$1.12
Fully Diluted	\$2.82	\$1.10
Common Shares:		
Full Diluted	374,880	343,286
Year-end	371,670	367,668

ANAPTYSBIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Cost & expenses	30,172	19,543
Operating income	(30,172)	(12,543)
Interest income	2,482	404
Interest expense	887	867
Other income (expense), net	(127)	(1,113)
Net income	(28,704)	(14,119)
Earnings common share		
Primary	\$(1.20)	\$(0.79)
Fully Diluted	\$(1.20)	\$(0.79)
Common Shares:		
Full Diluted	23,867	17,797
Year-end	24,029	20,290

ANDERSONS INC

Dividend Announcement On Aug. 24, 2018, Co. announced a fourth quarter 2018 cash dividend of \$0.165 per share payable Oct. 22, 2018, to shareholders of record on Oct. 1, 2018.

ANDERSONS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Cost & expenses	1,520,278	1,870,313
Operating income	26,863	(24,635)
Net before taxes	26,863	(24,635)
Income taxes	7,432	5,117
Net income	19,431	(29,752)
Balance for common	19,829	(29,742)
Earnings common share		
Primary	\$0.70	\$(1.05)
Fully Diluted	\$0.70	\$(1.05)
Common Shares:		
Full Diluted	28,436	28,316
Year-end	28,487	28,350

ANGIODYNAMICS INC**Annual Report****Consolidated Income Statement, Years Ended May 31** (\$000):

	2018	2017	2016
		(revised)	(revised)
Net sales	344,285	349,643	353,890
Cost of sales	167,410	173,474	179,574
Gross profit	176,875	176,169	174,316
Research & development expenses	25,459	25,269	25,053
Sales & marketing expenses	77,276	78,819	83,743
General & administrative expenses	31,265	31,406	30,583
Amortization of intangibles	16,635	17,296	17,964
Change in fair value of contingent consideration	250	(15,261)	948
Acquisition, restructuring & other items, net	15,432	27,510	12,591
Medical device excise tax		(1,837)	2,416
Total operating expenses	166,317	163,202	173,298
Operating income (loss)	10,558	12,967	1,018
Interest expense	3,062	2,839	3,385
Other expenses	31	281	886
Total other income (expenses), net	(3,093)	(3,120)	(4,271)
Income (loss)			

before income tax provision (benefit)			
- U.S.	6,274	8,825	(4,444)
Income (loss) before income tax provision (benefit)			
- non U.S.	1,191	1,022	1,191
Income (loss) before income tax expense (benefit)	7,465	9,847	(3,253)
Current federal income tax provision (benefit)	(148)		34
Current state & local income tax provision (benefit)	152	141	103
Current non U.S. income tax provision	73	270	217
Total current income tax provision (benefit)	77	411	354
Deferred income tax provision (benefit)	(8,947)	4,428	39,983
Income tax expense (benefit)	(8,870)	4,839	40,337
Net income (loss)	16,335	5,008	(43,590)
Weighted average shares outstanding			
- basic	37,075	36,617	36,161
Weighted average shares outstanding			
- diluted	37,539	36,959	36,161
Year end shares outstanding	37,224	36,840	36,278
Net earnings (loss) per share - basic	\$0.44	\$0.14	\$(1.21)
Net earnings (loss) per share - diluted	\$0.44	\$0.14	\$(1.21)
Number of full time employees	1,145	1,250	1,300
Number of common stockholders	184	197	202
Foreign currency translation adjustments	270	(545)	(112)

□ Reclassified to conform with 2017 presentation; □ Approximately; □ As is; □ As of July 20, 2018; □ As of August 2, 2017; □ As of July 22, 2016

Consolidated Balance Sheet, Years Ended May 31 (\$000):

	2018	2017
		(revised)
Cash & cash equivalents	74,096	47,544
Marketable securities, at fair value	1,317	1,215
Accounts receivable, gross	41,867	47,468
Less: allowance for doubtful accounts	2,466	2,945
Accounts receivable, net	39,401	44,523
Raw materials	18,678	17,563
Work in process	10,808	12,602
Finished goods	19,430	24,341
Inventories, net	48,916	54,506
Software licenses	1,043	582
Licensee fees	143	118
Trade shows	223	162
Prepaid rent	134	121
Other prepaid taxes	254	544
Medical device excise tax receivable		1,837
Other current assets	2,505	2,762
Total current assets	168,032	153,914
Building & building improvements	39,887	40,597
Machinery & equipment	22,668	25,434
Computer software & equipment	24,899	25,668
Construction in progress	2,153	1,464
Less accumulated depreciation & amortization	48,794	49,652

Land & land improvements	1,648	1,723
Property, plant & equipment, net	42,461	45,234
Other assets	3,417	1,886
Intangible assets, net	130,310	145,675
Goodwill	361,252	361,252
Total assets	705,472	707,961
Accounts payable	15,775	18,087
Accrued payroll & related expenses	10,235	11,383
Accrued royalties	1,537	2,885
Accrued severance	1,940	2,075
Accrued sales & franchise taxes	683	856
Accrued outside services	2,396	1,622
Accrued litigation matters	12,500	12,500
Accrued acculis recall liability	...	2,563
Other accrued liabilities	5,135	4,920
Current portion of long-term debt	5,000	5,000
Current portion of contingent consideration	2,100	9,625
Total current liabilities	57,301	71,516
Long-term debt, net of current portion	86,621	91,320
Deferred income taxes, long-term	17,173	26,112
Contingent consideration, net of current portion	1,161	3,136
Other long term liabilities	621	850
Total liabilities	162,877	192,934
Common stock	370	367
Additional paid-in capital	543,762	532,705
Retained earnings (accumulated deficit)	5,129	(11,007)
Treasury stock, at cost	5,714	5,714
Foreign currency translation	(1,035)	(1,305)
Unrealized holding gain (loss) on marketable securities	83	(19)
Accumulated other comprehensive income (loss)	(952)	(1,324)
Total stockholders' equity (deficit)	542,595	515,027

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. AngioDynamics Inc common.
No dividends paid.

Annual Dividends:

1. AngioDynamics Inc common.
No dividends paid.

ANI PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	93,751,000	81,392,000
Cost & expenses	63,443,000	55,966,000
Deprec., depl. & amort.	16,508,000	13,807,000
Operating income	13,800,000	11,619,000
Interest expense	7,364,000	5,957,000
Other income (expense), net	(91,000)	(37,000)
Net before taxes	6,345,000	5,625,000
Income taxes	1,318,000	1,792,000
Net income	5,027,000	3,833,000
Earnings common share		
Primary	\$0.43	\$0.33
Fully Diluted	\$0.42	\$0.33
Common Shares:		
Full Diluted	11,748,000	11,659,000
Year-end	11,817,376	11,648,736

ANIKA THERAPEUTICS INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	51,812,000	56,848,000
Cost & expenses	48,398,000	31,116,000
Operating income	3,414,000	25,732,000

Net before taxes	3,799,000	25,806,000
Net income	3,405,000	16,862,000
Earnings common share		
Primary	\$0.23	\$1.16
Fully Diluted	\$0.23	\$1.12
Common Shares:		
Full Diluted	15,045,000	15,046,000
Year-end	14,584,000	14,658,000

ANSYS INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	588,786	517,329
Cost & expenses	378,242	327,217
Operating income	203,614	183,866
Interest income	4,461	2,917
Other income (expense), net	8	(54)
Foreign currency	(1,323)	(1,290)
Net before taxes	206,760	185,439
Income taxes	29,884	52,403
Net income	176,876	133,036
Earnings common share		
Primary	\$2.11	\$1.56
Fully Diluted	\$2.06	\$1.53
Common Shares:		
Full Diluted	86,069	87,060
Year-end	84,247	84,713

APELLIS PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	54,923,588	21,184,896
Operating income	(54,923,588)	(21,184,896)
Other income (expense), net	(64,341)	(7,995)
Net income	(55,070,606)	(21,176,925)
Earnings common share		
Primary	\$(1.05)	\$(2.51)
Fully Diluted	\$(1.05)	\$(2.51)
Common Shares:		
Full Diluted	52,534,806	8,428,366
Year-end	56,154,438	...

APOLLO ENDOSURGERY INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	31,531,000	31,626,000
Cost & expenses	43,072,000	40,263,000
Operating income	(15,145,000)	(12,278,000)
Interest expense	1,979,000	2,516,000
Other income (expense), net	(465,000)	(168,000)
Net before taxes	(17,589,000)	(14,962,000)
Income taxes	86,000	113,000
Net income	(17,675,000)	(15,075,000)
Earnings common share		
Primary	\$(1.00)	\$(1.41)
Fully Diluted	\$(1.00)	\$(1.41)
Common Shares:		
Full Diluted	17,654,777	10,700,431
Year-end	21,877,332	10,709,846

APPFOLIO INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	89,580	68,003
Cost & expenses	71,019	58,529
Operating income	11,482	3,364
Other income (expense), net	(21)	(88)
Net before taxes	11,863	3,498
Income taxes	69	41
Net income	11,794	3,457
Earnings common share		
Primary	\$0.35	\$0.10
Fully Diluted	\$0.33	\$0.10
Common Shares:		
Full Diluted	35,361	34,879
Year-end	33,981	33,909

APPIAN CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	111,579	81,527
Cost & expenses	130,111	99,860
Operating income	(18,532)	(18,333)
Interest expense	67	453

Other income (expense), net	(1,675)	1,233
Net before taxes	(20,274)	(17,553)
Income taxes	246	301
Net income	(20,520)	(17,854)
Balance for common	(20,520)	(18,211)
Earnings common share		
Primary	\$(0.34)	\$(0.47)
Fully Diluted	\$(0.34)	\$(0.47)
Common Shares:		
Full Diluted	61,128	38,561
Year-end	61,613	60,103

APPLE INC

Earnings, 9 mos. to (Consol. - \$000):

	06/30/18	07/01/17
Net Sales	202,695,000	176,655,000
Cost & expenses	147,915,000	128,431,000
Operating income	54,780,000	48,224,000
Interest expense	2,372,000	1,657,000
Other income (expense), net	(301,000)	(228,000)
Net before taxes	56,482,000	50,172,000
Income taxes	11,076,000	12,535,000
Net income	45,406,000	37,637,000
Earnings common share		
Primary	\$9.07	\$7.18
Fully Diluted	\$8.99	\$7.14
Common Shares:		
Full Diluted	5,050,963	5,274,394
Year-end	4,842,917	5,169,782

APPLIED OPTOELECTRONICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	153,061	213,595
Cost & expenses	141,948	155,015
Operating income	11,113	58,580
Interest expense	350	544
Other income (expense), net	300	196
Gains or losses	5	(40)
Net before taxes	11,454	57,597
Income taxes	1,300	8,737
Net income	10,154	48,860
Earnings common share		
Primary	\$0.52	\$2.59
Fully Diluted	\$0.51	\$2.45
Common Shares:		
Full Diluted	20,012	19,956
Year-end	19,634	...

APPROACH RESOURCES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	28,025	28,644
Deprec., depl. & amort.	32,529	37,505
Operating income	(1,456)	(14,825)
Interest expense	12,070	10,379
Other income (expense), net	(6,824)	9,731
Net before taxes	(20,350)	(15,473)
Income taxes	(3,832)	134,191
Net income	(16,518)	(149,664)
Earnings common share		
Primary	\$(0.17)	\$(1.91)
Fully Diluted	\$(0.17)	\$(1.91)
Common Shares:		
Full Diluted	94,549	78,419
Year-end	94,471	86,481

APTIO INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	113,115	89,156
Cost & expenses	125,058	103,622
Operating income	(11,943)	(14,466)
Interest income	1,249	533
Interest expense	2,124	20
Other income (expense), net	(28)	(13)
Foreign currency	(462)	66
Net before taxes	(13,308)	(13,900)
Income taxes	88	151
Net income	(13,396)	(14,051)
Balance for common	(13,396)	(14,051)
Earnings common share		
Primary	\$(0.31)	\$(0.35)
Fully Diluted	\$(0.31)	\$(0.35)

Common Shares:			Full Diluted	26,653	26,378	Common Shares:				
Full Diluted	43,345	38,793	Year-end	25,684	25,690	Full Diluted	3,554	3,532		
Year-end	44,568					Year-end	3,470	3,426		
APTEVO THERAPEUTICS INC		ARCH THERAPEUTICS INC		AROTECH CORP						
Earnings, 6 mos. to Jun 30(Consol. – \$000):		Earnings, 9 mos. to Jun 30(Consol. – \$):		Earnings, 6 mos. to Jun 30(Consol. – \$):						
	2018	2017		2018	2017		2018	2017		
Total Revenues	10,897	5,668	Cost & expenses	5,216,352	5,421,121	Total Revenues	49,123,118	43,796,138		
Cost & expenses	36,843	32,448	Operating income	(5,216,352)	(5,421,121)	Cost & expenses	46,598,432	42,917,876		
Operating income	(25,946)	(26,780)	Interest expense		52,385	Operating income	1,617,944	(341,391)		
Other income (expense), net	(1,118)	(920)	Other income (expense), net	1,837,527	426,832	Other income (expense), net	(515,488)	(538,784)		
Net before taxes		(27,700)	Net income	(3,378,825)	(5,046,674)	Net before taxes	1,102,456	(880,175)		
Income taxes		(1,819)	Earnings common share			Income taxes	423,385	482,760		
Net income	(26,999)	(21,134)	Primary	\$(0.02)	\$(0.04)	Net income	679,071	(1,362,935)		
Earnings common share			Fully Diluted	\$(0.02)	\$(0.04)	Earnings common share				
Primary	\$(1.21)	\$(1.01)	Common Shares:			Primary	\$0.03	\$(0.05)		
Fully Diluted	\$(1.21)	\$(1.01)	Full Diluted	150,331,682	140,924,128	Fully Diluted	\$0.03	\$(0.05)		
Common Shares:			Year-end	154,052,013	150,769,042	Common Shares:				
Full Diluted	22,308	21,013	ARCHROCK PARTNERS LP		ARQUE INC.		Earnings, 6 mos. to Jun 30(Consol. – \$000):			
Year-end	22,668		Earnings, 6 mos. to Jun 30(Consol. – \$000):		Earnings, 6 mos. to Jun 30(Consol. – \$000):					
				2018	2017		2018	2017		
			Total Revenues	297,868	275,550	Cost & expenses	17,184	14,117		
			Cost & expenses	208,771	199,169	Deprec., depl. & amort.	660	(14,117)		
			Deprec., depl. & amort.	68,224	73,160	Operating income	329	59		
			Operating income	20,873	3,221	Interest expense	813	719		
			Net before taxes	20,873	3,221	Other income (expense), net	(1,552)			
			Income taxes	102	2,262	Net income	(1,376)	(14,777)		
			Net income	20,771	959	Earnings common share				
			Earnings common share			Primary	\$(0.02)	\$(0.21)		
			Primary	\$	\$0.01	Fully Diluted	\$(0.02)	\$(0.21)		
			Fully Diluted		\$0.01	Common Shares:				
			Common Shares:			Full Diluted	89,691	71,143		
			Full Diluted		65,382	Year-end	96,103	71,172		
			Year-end	71,540	66,909	ARRAY BIOPHARMA INC.				
			ARDELIX INC		Annual Report					
			Earnings, 6 mos. to Jun 30(Consol. – \$000):		Consolidated Income Statement, Years Ended Jun. 30 (\$):					
				2018	2017		2018	2017	2016	2015
			Total Revenues	2,350		Reimbursement	80,958,000	107,197,000	107,330,000	
			Cost & expenses	42,189	54,852	revenue				
			Operating income	(39,839)	(54,852)	License & milestone revenue	56,537,000	19,844,000	3,876,000	
			Other income (expense), net	535	1,123	Collaboration & other revenue	36,273,000	23,811,000	26,673,000	
			Net before taxes	(39,304)		Total revenue	173,768,000	150,852,000	137,879,000	
			Income taxes	6		Cost of partnered programs	59,374,000	35,395,000	23,166,000	
			Net income	(39,310)	(53,729)	Research & development for proprietary programs	185,821,000	178,199,000	160,655,000	
			Earnings common share			General & administrative expenses	58,500,000	39,336,000	36,267,000	
			Primary	\$(0.78)	\$(1.13)	Income (loss) from operations	(129,927,000)	(102,078,000)	(82,209,000)	
			Fully Diluted	\$(0.78)	\$(1.13)	Loss on extinguishment of notes	(6,457,000)			
			Common Shares:			Impairment (loss) related to cost method investment		1,500,000		
			Full Diluted	50,206	47,373	Realized gain (losses) on investments & other	69,000	897,000		
			Year-end	62,054	47,443	Change in fair value of notes payable	(2,387,000)	(2,600,000)		
			ARENA PHARMACEUTICS INC		ARK RESTAURANTS CORP		Interest income			
			Earnings, 6 mos. to Jun 30(Consol. – \$):		Earnings, 9 mos. to Jun 30(Consol. – \$000):		Interest expense			
				2018	2017		06/30/18	07/01/17		
			Total Revenues	5,749,000	3,558,000	Total Revenues	119,428	114,410	Total other income (expense), net	
			Cost & expenses	69,884,000	47,714,000	Cost & expenses	111,484	105,705	Income (loss) before income taxes	
			Operating income	(64,135,000)	(44,156,000)	Operating income	4,107	5,164	Income tax provision (benefit)	
			Interest income	3,276,000	50,000	Interest income	43	126	Net income (loss)	
			Interest expense	2,920,000	3,108,000	Interest expense	834	470		
			Other income (expense), net	813,000	900,000	Net before taxes	3,316	4,820		
			Income contin. oper.	(62,966,000)	(46,314,000)	Income taxes	(661)	1,338		
			Net income	(63,796,000)	(46,113,000)	Net income	3,977	3,482		
			Earnings common share			Earnings common share				
			Primary	\$(1.43)	\$(1.66)	Primary	\$1.06	\$0.80		
			Fully Diluted	\$(1.43)	\$(1.66)	Fully Diluted	\$1.03	\$0.77		
			Common Shares:			Common Shares:				
			Full Diluted	44,655,000	27,371,000	Full Diluted				
			Year-end	49,348,189		Year-end				
			ARCBEST CORP		ARCTIC THERAPEUTICS INC					
			Earnings, 6 mos. to Jun 30(Consol. – \$000):		Earnings, 9 mos. to Jun 30(Consol. – \$000):					
				2018	2017		06/30/18	07/01/17		
			Total Revenues	1,493,351	1,371,456	Total Revenues	119,428	114,410		
			Cost & expenses	1,423,797	1,304,986	Cost & expenses	111,484	105,705		
			Deprec., depl. & amort.	53,673	50,603	Operating income	4,107	5,164		
			Operating income	15,881	15,867	Interest income	43	126		
			Other income (expense), net	(3,324)	(2,234)	Interest expense	834	470		
			Net before taxes	9,725	11,488	Net before taxes	3,316	4,820		
			Income taxes	(1,462)	3,118	Income taxes	(661)	1,338		
			Net income	11,187	8,370	Net income	3,977	3,482		
			Earnings common share			Earnings common share				
			Primary	\$0.43	\$0.32	Primary	\$1.06	\$0.80		
			Fully Diluted	\$0.42	\$0.32	Fully Diluted	\$1.03	\$0.77		
			Common Shares:			Common Shares:				
			Full Diluted	22,308	21,013	Full Diluted				
			Year-end	22,668		Year-end				

- basic	198,490,000	163,207,000	142,964,000
Weighted average shares outstanding			
- diluted	198,490,000	163,207,000	142,964,000
Year end shares outstanding	211,289,922	171,307,715	143,690,104
Net income (loss) per share - basic	\$(0.74)	\$(0.72)	\$(0.65)
Net income (loss) per share - diluted	\$(0.74)	\$(0.72)	\$(0.65)
Number of full time employees	298	209	177
Number of common stockholders	355	353	354

Reclassified to conform with 2018 presentation; Approximate; As of August 9, 2018; As of August 4, 2017; As of August 12, 2016

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):		
	2018	2017
		(revised)
Cash & cash equivalents	114,748,000	125,933,000
Marketable securities	297,739,000	108,390,000
Accounts receivables, net	32,084,000	31,279,000
Prepaid expenses & other current assets	6,972,000	4,575,000
Total current assets	451,543,000	270,177,000
Marketable securities	919,000	732,000
Furniture & fixtures	2,791,000	2,701,000
Equipment	26,814,000	26,493,000
Computer hardware & software	17,009,000	16,994,000
Leasehold improvements	18,105,000	17,434,000
Property & equipment, gross	64,719,000	63,622,000
Less: accumulated depreciation & amortization	57,591,000	55,490,000
Property & equipment, net	7,128,000	8,132,000
Other long-term assets	774,000	104,000
Total long-term assets	8,821,000	8,968,000
Total assets	460,364,000	279,145,000
Accounts payable	14,059,000	8,636,000
Accrued outsourcing costs	31,853,000	31,388,000
Accrued compensation & benefits	16,695,000	10,172,000
Other accrued expenses	1,868,000	1,575,000
Notes payable at fair value	15,899,000	...
Deferred rent	707,000	624,000
Deferred revenue	12,350,000	17,156,000
Current portion of long-term debt	2,500,000	...
Total current liabilities	95,931,000	69,551,000
Deferred rent	5,598,000	5,714,000
Deferred revenue	44,470,000	57,325,000
Term loan	16,200,000	16,200,000
Convertible senior notes	126,060,000	132,250,000
Less: unamortized debt discount & fees	(46,384,000)	(27,145,000)
Less: current portion	2,500,000	...
Long-term debt, net	93,376,000	121,305,000
Notes payable at fair value	...	12,600,000
Other long-term liabilities	1,246,000	923,000
Total long-term liabilities	144,690,000	197,867,000
Total liabilities	240,621,000	267,418,000
Common stock	211,000	171,000
Additional paid-in capital	1,286,000,000	930,293,000
Accumulated other comprehensive gain (loss)	(461,000)	(76,000)
Retained earnings (accumulated deficit)	(1,066,007,000)	(918,661,000)
Total stockholders' equity (deficit)	219,743,000	11,727,000

Recent Dividends:

1. Array BioPharma Inc. series B convertible preferred.
No dividends paid.

2. Array BioPharma Inc. common.

No dividends paid.

Annual Dividends:

1. Array BioPharma Inc. series B convertible preferred.

No dividends paid.

2. Array BioPharma Inc. common.

No dividends paid.

ARROWHEAD PHARMACEUTICALS INC

Earnings, 9 mos. to Jun 30 (Consol. - \$):

	2018	2017
Total Revenues	4,887,321	22,693,923
Cost & expenses	49,654,447	49,439,619
Operating income	(44,767,126)	(26,745,696)
Other income (expense), net	432,141	2,832,037
Net income	(43,689,207)	(23,648,409)
Earnings common share		
Primary	\$(0.53)	\$(0.32)
Fully Diluted	\$(0.53)	\$(0.32)
Common Shares:		
Full Diluted	82,149,381	73,603,852
Year-end	87,854,651	74,772,103

ARSANIS INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Cost & expenses	23,566	11,471
Operating income	(23,566)	(11,471)
Interest income	441	...
Interest expense	526	1,463
Other income (expense), net	888	1,844
Net income	(22,763)	(11,090)
Balance for common	(22,763)	(11,110)
Earnings common share		
Primary	\$(1.59)	\$(21.62)
Fully Diluted	\$(1.59)	\$(21.62)
Common Shares:		
Full Diluted	14,299	514
Year-end	14,315	...

ASCENT CAPITAL GROUP, INC.

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Total Revenues	268,766	281,698
Cost & expenses	351,941	139,694
Operating income	(196,969)	18,233
Interest income	1,255	958
Interest expense	79,074	75,651
Other income (expense), net	2,276	464
Net before taxes	(272,512)	(55,996)
Income taxes	2,693	6,475
Income contin. oper.	...	(62,471)
Net income	(275,205)	(62,379)
Earnings common share		
Primary	\$(22.35)	\$(5.13)
Fully Diluted	\$(22.35)	\$(5.13)
Common Shares:		
Full Diluted	12,313	12,151
Year-end	12,414	12,355

ASPEN TECHNOLOGY INC

Annual Report

Consolidated Income Statement, Years Ended Jun. 30 (\$):

	2018	2017	2016
			(revised)
Subscription & software revenue	471,041,000	453,512,000	440,408,000
Services & other revenue	28,473,000	29,430,000	31,936,000
Total revenue	499,514,000	482,942,000	472,344,000
Cost of subscription & software revenue	23,228,000	21,051,000	20,376,000
Cost of services & other revenue	27,416,000	26,415,000	28,235,000
Total cost of revenue	50,644,000	47,466,000	48,611,000
Gross profit (loss)	448,870,000	435,476,000	423,733,000
Selling & marketing expenses	101,077,000	92,633,000	91,536,000
Research & development expenses	82,076,000	79,530,000	67,152,000
General & administrative			

expenses	56,076,000	51,297,000	53,664,000
Total operating expenses	239,229,000	223,460,000	212,352,000
Income (loss) from operations	209,641,000	212,016,000	211,381,000
Interest income	231,000	808,000	441,000
Interest expense	5,691,000	3,787,000	1,212,000
Other income (expense), net	(838,000)	1,309,000	29,000
Income (loss) before provision for (benefit from) income taxes - domestic	195,442,000	202,053,000	201,885,000
Income (loss) before provision for (benefit from) income taxes - foreign	7,901,000	8,293,000	8,754,000
Income (loss) before provision for (benefit from) income taxes	203,343,000	210,346,000	210,639,000
Federal income taxes provision (benefit) - current	47,734,000	69,385,000	56,535,000
Federal income taxes provision (benefit) - deferred	2,468,000	(22,449,000)	7,496,000
State income taxes provision (benefit) - current	1,471,000	1,737,000	1,866,000
State income taxes provision (benefit) - deferred	419,000	(1,079,000)	204,000
Foreign income taxes provision (benefit) - current	2,296,000	2,067,000	4,554,000
Foreign income taxes provision (benefit) - deferred	267,000	(1,511,000)	33,000
Provision for (benefit from) income taxes	54,655,000	48,150,000	70,688,000
Net income (loss)	148,688,000	162,196,000	139,951,000
Weighted average shares outstanding - basic	72,140,000	76,491,000	82,892,000
Weighted average shares outstanding - diluted	72,956,000	76,978,000	83,309,000
Year end shares outstanding	71,186,701	73,421,153	80,177,950
Net income (loss) per share - basic	\$2.06	\$2.12	\$1.69
Net income (loss) per share - diluted	\$2.04	\$2.11	\$1.68
Number of full time employees	1,466	1,419	1,396
Number of common stockholders	358	385	430
Foreign currency translation adjustments	...	(1,192,000)	(3,841,000)

As of August 1, 2018; As of August 3, 2017; As of August 4, 2016

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2018	2017
Cash & cash equivalents	96,165,000	101,954,000
Accounts receivable, gross	24,613,000	28,955,000
Less: allowance for doubtful accounts	2,703,000	1,285,000
Accounts receivable, net	21,910,000	27,670,000
Prepaid expenses & other current assets	10,509,000	12,061,000
Prepaid income taxes	2,601,000	4,501,000
Total current assets	131,185,000	146,186,000
Computer equipment	8,344,000	8,262,000
Purchased software	24,225,000	24,091,000

Primary	\$(1.59)	\$(1.70)	Net earnings from continuing operations	1,620,800	1,733,400	1,493,400	Intangible assets, net	886,400	620,200
Fully Diluted	\$(1.59)	\$(1.70)	Earnings (losses) from discontinued operations before income taxes	(1,400)	Total assets	37,088,700	37,180,000
Common Shares:			Provision (benefit) for income taxes - discontinued operations	500	Accounts payable	135,400	149,700
Full Diluted	35,766	23,996	Net earnings (loss) from discontinued operations	(900)	Accrued expenses & other current liabilities	1,547,700	1,381,900
Year-end	37,245	...	Weighted average shares outstanding - basic	440,600	447,800	457,000	Accrued payroll & payroll-related expenses	667,700	562,500

AUTOMATIC DATA PROCESSING INC.**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$000):**

	2018	2017 (revised)	2016 (revised)
Revenues, other than interest on funds held for clients & professional employer organization ("PEO") revenues	8,985,200	8,518,100	8,234,000
Interest on funds held for clients	466,500	397,400	377,300
PEO revenues	3,874,100	3,464,300	3,056,500
Total revenues	13,325,800	12,379,800	11,667,800
Operating expenses	6,937,900	6,416,100	6,025,000
Systems development & programming costs	630,200	627,500	603,700
Depreciation & amortization	274,500	226,200	211,600
Total costs of revenues	7,842,600	7,269,800	6,840,300
Selling, general & administrative expenses	2,971,500	2,783,200	2,637,000
Interest expense	102,700	80,000	56,200
Total expenses	10,916,800	10,133,000	9,533,500
Interest income on corporate funds	83,500	76,700	62,400
Realized gains on available-for-sale securities	2,000	5,300	5,100
Realized losses on available-for-sale securities	(4,500)	(3,100)	(10,100)
Gain on sale of businesses	205,400	29,100
Gain on sale of assets	700	...	13,900
Voluntary Early Retirement Program	(319,600)
Other income, net	(237,900)	284,300	100,400
Earnings (loss) from continuing operations before income taxes - United States	1,849,800	2,232,800	2,028,500
Earnings (loss) from continuing operations before income taxes - foreign	321,300	298,300	206,200
Earnings (loss) from continuing operations before income taxes	2,171,100	2,531,100	2,234,700
Current federal income taxes	366,700	615,300	579,000
Current foreign income taxes	105,500	91,600	85,000
Current state income taxes	77,600	82,700	76,600
Total current income taxes	549,800	789,600	740,600
Deferred federal income taxes	(24,800)	6,200	17,700
Deferred foreign income taxes	19,700	7,200	(15,700)
Deferred state income taxes	5,600	(5,300)	(1,300)
Total deferred income taxes	500	8,100	700
Provision (benefit) for income taxes	550,300	797,700	741,300

Net earnings (loss) from discontinued operations	(900)
Net earnings (loss)	1,620,800	1,733,400	1,492,500
Weighted average shares outstanding - basic	440,600	447,800	457,000
Weighted average shares outstanding - diluted	443,300	450,300	459,100
Year end shares outstanding	438,800	445,000	...
Earnings (loss) per share from continuing operations - basic	\$3.68	\$3.87	\$3.27
Net earnings (loss) per share - basic	\$3.68	\$3.87	\$3.27
Earnings (loss) per share from continuing operations - diluted	\$3.66	\$3.85	\$3.25
Net earnings (loss) per share - diluted	\$3.66	\$3.85	\$3.25
Dividends per share	\$2.52	\$2.24	\$2.08
Total number of employees	57,000
Number of common stockholders	39,613
Number of beneficiary stockholders	562,262

Restated to reflect the adoption of FASB ASU No 2016-18, (Topic 230); Net of direct pass-through costs, primarily consisting of payroll wages and payroll taxes - PEO revenues: \$39,140,900,000; Net of direct pass-through costs, primarily consisting of payroll wages and payroll taxes - PEO revenues: \$34,567,400,000; Net of direct pass-through costs, primarily consisting of payroll wages and payroll taxes - PEO revenues: \$30,928,600,000; As is; Approximately

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	2,170,000	2,780,400
Accounts receivable, gross	2,035,500	1,753,200
Allowance for doubtful accounts	51,300	49,600
Accounts receivable, net	1,984,200	1,703,600
Other current assets	758,000	883,200
Total current assets before funds held for clients	4,912,200	5,367,200
Funds held for clients	27,137,800	27,291,500
Total current assets	32,050,000	32,658,700
Long-term receivables, net	25,500	28,000
Land & buildings	791,800	778,100
Data processing equipment	707,400	653,700
Furniture, leaseholds & other equipment	637,100	599,600
Property, plant & equipment, at cost	2,136,300	2,031,400
Less: accumulated depreciation	1,342,600	1,251,500
Property, plant & equipment, net	793,700	779,900
Other assets	1,089,600	1,352,200
Goodwill	2,243,500	1,741,000

Accounts payable	135,400	149,700
Accrued expenses & other current liabilities	1,547,700	1,381,900
Accrued payroll & payroll-related expenses	667,700	562,500
Dividends payable	298,900	250,500
Short-term deferred revenues	226,500	232,900
Income taxes payable	43,900	49,000
Total current liabilities before client funds obligations	2,920,100	2,626,500
Client funds obligations	27,493,500	27,189,400
Total current liabilities	30,413,600	29,815,900
Fixed-rate notes	2,000,000	2,000,000
Other long-term debt	13,000	20,300
Less current portion	2,500	7,800
Less: unamortized discount & debt issuance costs	(8,100)	(10,100)
Long-term debt	2,002,400	2,002,400
Other liabilities	728,000	830,200
Deferred income taxes	107,300	163,100
Long-term deferred revenues	377,800	391,400
Total liabilities	33,629,100	33,203,000
Common stock	63,900	63,900
Capital in excess of par value	1,014,800	867,800
Retained earnings	15,271,300	14,728,200
Treasury stock-at cost	12,209,600	11,303,700
Currency translation adjustment	(228,000)	(230,800)
Net gains (losses) on available-for-sale securities	(274,000)	68,300
Pension liability	(178,800)	(216,700)
Accumulated other comprehensive income (loss)	(680,800)	(379,200)
Total stockholders' equity	3,459,600	3,977,000

Net of allowance for doubtful accounts - Long-term receivables: \$500,000; Net of allowance for doubtful accounts - Long-term receivables: \$800,000

Recent Dividends:**1. Automatic Data Processing Inc. common.**

ExDate	Amt	Declared	Record	Payable
12/10/2014	0.49	11/11/2014	12/12/2014	01/01/2015
03/11/2015	0.49	01/21/2015	03/13/2015	04/01/2015
06/10/2015	0.49	04/08/2015	06/12/2015	07/01/2015
09/09/2015	0.49	08/04/2015	09/11/2015	10/01/2015
12/09/2015	0.53	11/10/2015	12/11/2015	01/01/2016
03/09/2016	0.53	01/19/2016	03/11/2016	04/01/2016
06/08/2016	0.53	04/06/2016	06/10/2016	07/01/2016
09/07/2016	0.53	08/02/2016	09/09/2016	10/01/2016
12/07/2016	0.57	11/08/2016	12/09/2016	01/01/2017
03/08/2017	0.57	01/17/2017	03/10/2017	04/01/2017
06/07/2017	0.57	04/05/2017	06/09/2017	07/01/2017
09/07/2017	0.57	08/01/2017	09/08/2017	10/01/2017
12/07/2017	0.63	11/07/2017	12/08/2017	01/01/2018
03/08/2018	0.63	01/16/2018	03/09/2018	04/01/2018
06/07/2018	0.69	04/11/2018	06/08/2018	07/01/2018

Annual Dividends:**1. Automatic Data Processing Inc. common.**

2015	1.96	2016	2.12	2017	2.28
2018	1.95				

AV HOMES INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	355,568	356,742
Cost & expenses	354,606	348,172
Operating income	962	5,637
Other income (expense), net	(2,933)
Net before taxes	962	5,637
Income taxes	306	2,551
Net income	656	3,086

Earnings common share			provision (benefit)				Goodwill	980,872	1,148,347		
Primary	\$0.03	\$0.14	- state & local	(10,551)	(3,934)	1,351	Intangible assets, net	219,913	277,291		
Fully Diluted	\$0.03	\$0.14	Deferred income tax				Other assets	262,552	220,568		
Common Shares:			provision (benefit)				Total assets	9,596,845	9,699,589		
Full Diluted	22,908	22,785	- foreign	11,897	15,713	5,114	Bank credit facilities & other	60,380	50,113		
Year-end	22,362	22,456	Total deferred income tax				Accounts receivable securitization program	105,000	...		
AVID TECHNOLOGY, INC.			provision (benefit)	(68,826)	(18,246)	12,038	Accounts payable	2,269,478	1,861,635		
Earnings, 6 mos. to Jun 30(Consol. - \$000):			Income tax expense (benefit)	287,966	47,053	87,104	Accrued salaries & benefits	220,245	205,979		
	2018	2017	Income (loss) from continuing operations	(142,889)	263,351	390,909	Accrued interest & banking costs	16,505	47,481		
Total Revenues	196,552	206,480	Income (loss) from discontinued operations	(13,535)	261,927	115,622	Accrued restructuring costs	29,225	16,996		
Cost & expenses	201,245	208,997	Net income (loss)	(156,424)	525,278	506,531	Accrued income taxes	108,386	61,552		
Operating income	(5,419)	(3,243)	Weighted average shares outstanding - basic	119,909	127,032	130,858	Accrued property, plant & equipment	23,400	6,491		
Net before taxes	(17,056)	(12,007)	Weighted average shares outstanding - diluted	119,909	128,651	133,173	Other accrued expenses & other current liabilities	38,041	98,777		
Income taxes	399	739	Year end shares outstanding	115,825	123,081	127,377	Total current liabilities	2,969,461	2,453,771		
Net income	(17,455)	(12,746)	Earnings (loss) per share - continuing operations - basic	\$(1.19)	\$2.07	\$2.99	Accounts receivable securitization program	...	142,000		
Earnings common share			Earnings (loss) per share - discontinued operations - basic	\$(0.11)	\$2.06	\$0.88	Credit facility	...	99,970		
Primary	\$(0.42)	\$(0.31)	Net earnings (loss) per share - basic	\$(1.30)	\$4.13	\$3.87	Notes	1,500,000	1,500,000		
Fully Diluted	\$(0.42)	\$(0.31)	Earnings (loss) per share - continuing operations - diluted	\$(1.19)	\$2.05	\$2.93	Other long-term debt	383	642		
Common Shares:			Earnings (loss) per share - discontinued operations - diluted	\$(0.11)	\$2.03	\$0.87	Less: discount & debt issuance costs	(11,164)	(13,400)		
Full Diluted	41,496	40,863	Net earnings (loss) per share - diluted	\$(1.30)	\$4.08	\$3.80	Long-term debt	1,489,219	1,729,212		
Year-end	41,790	41,130	Dividends per common share	\$0.74	\$0.70	\$0.68	Other liabilities	453,084	334,538		
AVIS BUDGET GROUP INC			Total number of employees	15,400	15,700	17,700	Total liabilities	4,911,764	4,517,521		
Earnings, 6 mos. to Jun 30(Consol. - \$000):			Number of common stockholders	1,837	2,112	...	Common stock	115,825	123,081		
	2018	2017	Foreign currency translation adjustments	...	94,116	(45,355)	Additional paid-in capital	1,528,713	1,503,490		
Total Revenues	4,296,000	4,077,000	Consolidated Balance Sheet, Years Ended (\$000):				Retained earnings (accumulated deficit)	3,235,894	3,799,363		
Cost & expenses	3,153,000	3,002,000		06/30/18	07/01/17	Accumulated translation adjustments, net	(78,848)	(86,647)			
Operating income	(91,000)	(154,000)	Cash & cash equivalents	621,125	836,384	Accumulated pension liability adjustments, net of income taxes	(116,503)	(157,219)			
Net before taxes	(91,000)	(154,000)	Marketable securities	...	281,326	Accumulated other comprehensive income (loss)	(195,351)	(243,866)			
Income taxes	(30,000)	(50,000)	Receivables, gross	3,690,098	3,384,896	Total shareholders' equity (deficit)	4,685,081	5,182,068			
Net income	(61,000)	(104,000)	Less: allowances	48,959	47,272	Recent Dividends:					
Earnings common share			Receivables, net	3,641,139	3,337,624	1. Avnet Inc common.					
Primary	\$(0.75)	\$(1.22)	Inventories	3,141,822	2,824,709	ExDate	Amt	Declared	Record	Payable	
Fully Diluted	\$(0.75)	\$(1.22)	Prepaid & other current assets	206,513	253,765	02/27/2015	0.16	02/13/2015	03/03/2015	03/16/2015	
Common Shares:			Total current assets	7,610,599	7,533,808	05/29/2015	0.16	05/15/2015	06/02/2015	06/15/2015	
Full Diluted	80,800	84,900	Buildings	132,511	136,846	09/04/2015	0.17	08/14/2015	09/09/2015	09/18/2015	
Year-end	80,000	83,000	Machinery, fixtures & equipment	200,231	215,155	11/27/2015	0.17	11/13/2015	12/01/2015	12/14/2015	
AVNET INC			Information technology hardware & software	677,179	630,352	02/26/2016	0.17	02/12/2016	03/01/2016	03/14/2016	
Annual Report			Leasehold improvements	106,242	99,208	06/03/2016	0.17	05/13/2016	06/07/2016	06/20/2016	
Consolidated Income Statement, Years Ended (\$000):			Less: accumulated depreciation	758,041	667,700	09/02/2016	0.17	08/12/2016	09/07/2016	09/16/2016	
	06/30/18	07/01/17	Land	41,984	41,627	12/02/2016	0.17	11/11/2016	12/06/2016	12/19/2016	
Sales	19,036,892	17,439,963	Construction in progress	122,803	64,087	03/10/2017	0.18	02/28/2017	03/14/2017	03/28/2017	
Cost of sales	16,509,708	15,070,521	Property, plant & equipment, net	522,909	519,575	06/02/2017	0.18	05/11/2017	06/06/2017	06/19/2017	
Gross profit (loss)	2,527,184	2,369,442				09/01/2017	0.18	08/11/2017	09/06/2017	09/15/2017	
Selling, general & administrative expenses	1,970,103	1,770,627				12/05/2017	0.18	11/10/2017	12/06/2017	12/19/2017	
Goodwill impairment expense	181,440	...				03/12/2018	0.19	02/06/2018	03/13/2018	03/27/2018	
Restructuring, integration & other expenses	145,125	137,415				06/05/2018	0.19	05/22/2018	06/06/2018	06/19/2018	
Operating income (loss)	230,516	461,400				Annual Dividends:					
Other income (expense), net	17,086	(44,305)				1. Avnet Inc common.					
Interest expense	102,525	106,691				2015	0.66	2016	0.68	2017	0.72
Income (loss) before income taxes	(385,100)	(174,300)				2018	0.38				
- U.S.						AVROBIO INC					
Income (loss) before income taxes - foreign	530,200	484,700				Earnings, 6 mos. to Jun 30(Consol. - \$000):					
Income (loss) before income taxes	145,077	310,404					2018	2017			
Current income tax provision (benefit) - federal	255,810	(45,351)				Cost & expenses	17,335	4,586			
Current income tax provision (benefit) - state & local	(3,174)	4,209				Operating income	(17,335)	(4,586)			
Current income tax provision (benefit) - foreign	104,156	106,441				Interest income	392	15			
Total current income tax provision (benefit)	356,792	65,299				Other income (expense), net	(1,806)	(40)			
Deferred income tax provision (benefit) - federal	(70,172)	(30,025)				Net income	(18,749)	(4,611)			
Deferred income tax						Balance for common	(20,992)	(4,658)			
						Earnings common share					
						Primary	\$(7.16)	\$(2.12)			

Fully Diluted	\$(7.16)	\$(2.12)	Primary	\$0.17	\$0.07	Other income (expense), net	(860)	(2,495)
Common Shares:			Fully Diluted	\$0.17	\$0.07	Invest. income		3,267
Full Diluted	2,930	2,192	Common Shares:			Net before taxes	6,853	13,036
Year-end	23,722		Full Diluted	40,289	37,645	Income taxes	3,477	4,333
			Year-end	39,511	38,655	Net income	3,376	8,703

AWARE INC. (MA)

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	6,671,000	6,698,000
Cost & expenses	7,775,000	6,412,000
Operating income	(1,104,000)	286,000
Interest income	363,000	172,000
Other income (expense), net		36,000
Net before taxes	(741,000)	494,000
Income taxes	(58,000)	79,000
Net income	(683,000)	415,000
Earnings common share		
Primary	\$(0.03)	\$0.02
Fully Diluted	\$(0.03)	\$0.02
Common Shares:		
Full Diluted	21,540,000	22,119,000
Year-end	21,520,117	21,675,149

AXCELIS TECHNOLOGIES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	241,518	189,683
Cost & expenses	203,749	166,440
Operating income	37,769	23,243
Interest income	925	180
Interest expense	2,464	2,447
Other income (expense), net	(1,118)	(138)
Net before taxes	35,112	20,838
Income taxes	6,528	(2,600)
Net income	28,584	23,438
Earnings common share		
Primary	\$0.89	\$0.78
Fully Diluted	\$0.84	\$0.72
Common Shares:		
Full Diluted	34,048	32,779
Year-end	32,331	31,180

AXON ENTERPRISE INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	200,441,000	158,885,000
Cost & expenses	181,559,000	152,711,000
Operating income	18,882,000	6,174,000
Net before taxes	19,850,000	8,064,000
Income taxes	(1,561,000)	1,208,000
Net income	21,411,000	6,856,000
Earnings common share		
Primary	\$0.39	\$0.13
Fully Diluted	\$0.38	\$0.13
Common Shares:		
Full Diluted	55,892,000	53,723,000
Year-end	58,289,613	52,808,919

AXSOME THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	15,152,803	14,422,771
Operating income	(15,152,803)	(14,422,771)
Other income (expense), net	2,674,000	
Net income	(13,086,475)	(15,079,355)
Earnings common share		
Primary	\$(0.51)	\$(0.70)
Fully Diluted	\$(0.51)	\$(0.70)
Common Shares:		
Full Diluted	25,646,985	21,578,011
Year-end	26,252,562	23,608,084

AXT INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	51,539	44,173
Cost & expenses	43,085	40,507
Operating income	8,454	3,666
Other income (expense), net	(293)	(1,175)
Net before taxes	8,442	2,703
Income taxes	701	480
Net income	7,741	2,223
Balance for common	6,688	2,507
Earnings common share		

B RILEY FINANCIAL INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	221,279	119,573
Cost & expenses	182,199	106,302
Operating income	39,080	13,271
Interest income	294	282
Interest expense	14,586	2,685
Other income (expense), net	4,221	
Net before taxes	29,009	10,868
Income taxes	6,366	(6,396)
Net income	22,643	17,264
Earnings common share		
Primary	\$0.83	\$0.85
Fully Diluted	\$0.80	\$0.82
Common Shares:		
Full Diluted	26,785	20,985
Year-end	26,070	24,378

BALCHEM CORP.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	325,097	284,810
Cost & expenses	270,066	237,276
Operating income	55,031	47,534
Other income (expense), net	(654)	(578)
Net before taxes	50,238	43,269
Income taxes	11,213	11,216
Net income	39,025	32,053
Earnings common share		
Primary	\$1.22	\$1.01
Fully Diluted	\$1.21	\$1.00
Common Shares:		
Full Diluted	32,378	32,195
Year-end	32,209	31,889

BANDWIDTH INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	101,316	79,151
Cost & expenses	91,381	69,816
Operating income	9,935	9,335
Other income (expense), net	139	(1,412)
Net before taxes	10,074	7,923
Income taxes	(6,629)	2,987
Net income	16,703	4,936
Earnings common share		
Primary	\$0.93	\$0.36
Fully Diluted	\$0.80	\$0.33
Common Shares:		
Full Diluted	20,867	12,978
Year-end	18,812	

BARRETT BUSINESS SERVICES, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	455,579	435,571
Cost & expenses	455,879	435,577
Operating income	(2,578)	(1,933)
Interest expense	110	145
Other income (expense), net	4	(4)
Gains or losses	4,220	1,550
Net before taxes	1,536	(532)
Income taxes	(581)	(431)
Net income	2,117	(101)
Earnings common share		
Primary	\$0.29	\$(0.01)
Fully Diluted	\$0.28	\$(0.01)
Common Shares:		
Full Diluted	7,658	7,252
Year-end	7,311	7,256

BASSETT FURNITURE INDUSTRIES, INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	05/26/18	05/27/17
Net Sales	227,252	220,017
Cost & expenses	219,539	207,753
Operating income	7,713	12,264

BEACON ROOFING SUPPLY INC

Earnings, 9 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	4,482,555	3,086,802
Cost & expenses	4,239,065	2,871,792
Operating income	96,511	128,772
Net before taxes	(2,975)	89,533
Income taxes	(53,291)	33,800
Net income	50,316	55,733
Balance for common	38,316	55,733
Earnings common share		
Primary	\$0.52	\$0.93
Fully Diluted	\$0.51	\$0.91
Common Shares:		
Full Diluted	69,240	61,164
Year-end	68,105	60,361

BEASLEY BROADCAST GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	116,778,923	114,753,965
Cost & expenses	102,618,837	87,246,012
Deprec., depl. & amort.	3,108,786	3,122,479
Operating income	11,051,300	24,385,474
Other income (expense), net	476,212	395,717
Net before taxes	4,096,697	15,201,808
Income taxes	2,339,277	3,809,791
Net income	1,757,420	11,392,017
Earnings common share		
Primary	\$0.06	\$0.41
Fully Diluted	\$0.06	\$0.41
Common Shares:		
Full Diluted	27,710,563	27,846,182
Year-end	27,507,231	28,788,882

BEL FUSE INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	258,961,000	245,285,000
Cost & expenses	247,857,000	235,664,000
Operating income	11,104,000	9,621,000
Interest expense	2,527,000	3,010,000
Net before taxes	8,056,000	6,135,000
Income taxes	2,724,000	2,269,000
Net income	5,332,000	3,866,000
Earnings common share		
Primary	\$0.41	\$0.30
Fully Diluted	\$0.41	\$0.30
Common Shares:		
Full Diluted	2,175,000	2,175,000
Year-end	12,013,764	12,044,014

BELLEROPHON THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	16,365	11,106
Operating income	(16,365)	(11,106)
Other income (expense), net	3,361	(12,020)
Net before taxes	(12,814)	
Income taxes	(5,439)	
Net income	(7,375)	(23,073)
Earnings common share		
Primary	\$(0.13)	\$(0.70)
Fully Diluted	\$(0.16)	\$(0.70)
Common Shares:		
Full Diluted	66,289	32,751
Year-end	57,765	

BELLICUM PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

--	--	--

Cost & expenses	2018 4,828	2017 6,291	(benefit) federal income taxes	18,560	(48,030)	132,250	Gross property, plant & equipment	939,091	927,179
Operating income	(4,741)	(6,218)	Current provision (benefit) state income taxes	6,390	(6,670)	17,560	Less: accumulated depreciation	513,707	468,995
Other income (expense), net	(11,999)	(3,501)	Total provision (benefit) current income taxes	24,950	(54,700)	149,810	Property, plant & equipment, net	425,384	458,184
Net before taxes	(11,999)	(20,795)	Deferred provision (benefit) federal income taxes	11,038	13,076	17,096	Total assets	1,150,447	1,033,094
Income taxes	4	2	Enacted rate change	(42,973)	Trade accounts payable	37,840	30,629
Net income	(12,003)	(20,797)	Deferred provision (benefit) state income taxes	(1,874)	1,757	2,296	Accrued dividends payable	17,093	...
Balance for common	(12,003)	(20,797)	Total provision (benefit) deferred income taxes	(33,809)	14,833	19,392	Accrued wages & benefits	18,967	15,809
Earnings common share			Income tax expense (benefit)	(8,859)	(39,867)	169,202	Accrued income taxes payable	17,446	...
Primary	\$(0.51)	\$(0.93)	Net income (loss) including noncontrolling interest	126,196	(74,427)	318,047	Retained earnings (accumulated deficit)	924,918	816,046
Fully Diluted	\$(0.51)	\$(0.93)	Less: Net income (loss) attributable to noncontrolling interest	(264)	149	(2,006)	Accumulated other comprehensive income (loss), net of tax	(693)	(128)
Common Shares:			Net income attributable to Cal-Maine Foods, Inc.	125,932	(74,278)	316,041	Common stock in treasury	24,966	23,914
Full Diluted	23,482	22,275	Weighted average shares outstanding - basic	48,353	48,362	48,195	Total Cal-Maine Foods, Inc. stockholders' equity	953,333	842,687
Year-end	24,425	...	Weighted average shares outstanding - diluted	48,468	48,362	48,365	Noncontrolling interest in consolidated entities	2,349	1,806

CAESARS ENTERTAINMENT CORP**Earnings, 6 mos. to Jun 30 (Consol. - \$000):**

Total Revenues	2018 4,091,000	2017 1,974,000
Cost & expenses	3,136,000	1,477,000
Operating income	407,000	299,000
Interest expense	664,000	289,000
Other income (expense), net	229,000	(1,871,000)
Net before taxes	(28,000)	(1,861,000)
Income taxes	(23,000)	79,000
Net income	(5,000)	(1,940,000)
Earnings common share		
Primary	\$(0.01)	\$(13.09)
Fully Diluted	\$(0.01)	\$(13.09)
Common Shares:		
Full Diluted	697,000	148,000
Year-end	693,509	...

CAFEPRESS INC**Earnings, 6 mos. to Jun 30 (Consol. - \$000):**

Total Revenues	2018 28,939	2017 36,142
Cost & expenses	34,118	42,740
Operating income	(5,179)	(6,598)
Interest income	132	79
Interest expense	10	3
Other income (expense), net	9	3
Net before taxes	(6,526)	(6,527)
Income taxes	1	...
Net income	(5,038)	(6,527)
Earnings common share		
Primary	\$(0.30)	\$(0.39)
Fully Diluted	\$(0.30)	\$(0.39)
Common Shares:		
Full Diluted	16,994	16,689
Year-end	17,104	...

CAL-MAINE FOODS INC**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

Net sales	06/02/18 1,502,932	06/03/17 1,074,513	05/28/16 1,908,650
Cost of sales	1,141,886	1,028,963	1,260,576
Gross profit	361,046	45,550	648,074
Selling, general & administrative	177,148	173,980	177,760
Legal settlement expense	80,750
(Gain) loss on disposal of fixed assets	(473)	(3,664)	1,563
Operating income (loss)	102,675	(132,094)	471,877
Interest expense	265	318	1,156
Interest income	3,697	3,103	4,314
Patronage dividends	8,286	7,665	6,930
Equity in income (loss) of affiliates	3,517	1,390	5,016
Other income (expenses), net	(573)	5,960	268
Total other income (expenses)	14,662	17,800	15,372
Income (loss) before income taxes & noncontrolling interest	117,337	(114,294)	487,249
Current provision

Reclassified to conform with 2017 presentation; As is; As of July 14, 2016

Consolidated Balance Sheet, Years Ended (\$000):

Cash & cash equivalents	06/02/18 48,431	06/03/17 17,564
Investments securities available-for-sale	282,586	138,462
Trade receivables, gross	80,999	61,647
Less: allowance for doubtful accounts	268	386
Trade receivables, net	80,731	61,261
Income tax receivable	...	52,691
Other receivables	5,108	3,248
Total receivables	85,839	117,200
Flocks, net of accumulated amortization	96,594	98,059
Eggs	17,313	14,911
Feed & supplies	54,737	47,722
Inventories	168,644	160,692
Total current assets	587,520	436,206
Investments in affiliates	66,806	65,731
Goodwill	35,525	35,525
Other intangibles assets	26,307	29,149
Other long-lived assets	8,905	8,299
Land & improvements	90,757	87,276
Buildings & improvements	360,030	342,933
Machinery & equipment	478,997	460,218
Construction-in-progress	9,307	36,752

Trade accounts payable	37,840	30,629
Accrued dividends payable	17,093	...
Accrued wages & benefits	18,967	15,809
Accrued income taxes payable	17,446	...
Accrued expenses & other liabilities	12,956	13,415
Current maturities of long-term debt	3,536	4,826
Total current liabilities	107,838	64,679
Notes payable	4,750	9,250
Capital lease obligations	1,340	1,689
Less: current maturities	3,536	4,826
Other noncurrent liabilities	8,318	7,527
Deferred income taxes	76,055	110,282
Total liabilities	194,765	188,601
Common stock	703	703
Class A common	48	48
Paid-in capital	53,323	49,932
Retained earnings (accumulated deficit)	924,918	816,046
Accumulated other comprehensive income (loss), net of tax	(693)	(128)
Common stock in treasury	24,966	23,914
Total Cal-Maine Foods, Inc. stockholders' equity	953,333	842,687
Noncontrolling interest in consolidated entities	2,349	1,806
Total stockholders' equity	955,682	844,493

Reclassified to conform with 2018 presentation

Recent Dividends:**1. Cal-Maine Foods Inc common.**

ExDate	Amt	Declared	Record	Payable
01/26/2015	0.25		01/28/2015	02/12/2015
04/27/2015	0.35	03/30/2015	04/29/2015	05/14/2015
07/30/2015	0.32		08/03/2015	08/18/2015
10/26/2015	0.98	09/28/2015	10/28/2015	11/12/2015
01/25/2016	0.75	12/23/2015	01/27/2016	02/11/2016
04/25/2016	0.44	03/28/2016	04/27/2016	05/12/2016
	0.00			08/15/2016
08/03/2018	0.35	07/23/2018	08/06/2018	08/21/2018

2. Cal-Maine Foods Inc class A common convertible.

No dividends paid.

Annual Dividends:**1. Cal-Maine Foods Inc common.**

2015	1.90	2016	1.19	2018	0.35
------	------	------	------	------	------

2. Cal-Maine Foods Inc class A common convertible.

No dividends paid.

CALAMP CORP**Earnings, 3 mos. to May 31 (Consol. - \$000):**

Total Revenues	2018 94,888	2017 88,081
Cost & expenses	92,714	85,551
Operating income	(784)	(1,328)
Interest expense	2,665	2,518
Other income (expense), net	13,107	116
Gains or losses	853	333
Net before taxes	10,721	(3,397)
Income taxes	1,771	(1,080)
Net income	8,511	(2,654)
Earnings common share		
Primary	\$0.24	\$(0.08)
Fully Diluted	\$0.23	\$(0.08)
Common Shares:		
Full Diluted	36,453	35,068
Year-end	35,507	35,379

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	169,509	169,509
Inventories	32,557	32,557
Current assets	294,217	294,217
Net property & equip.	21,087	21,087
Total assets	493,422	493,422
Liabilities:		
Current liabilities	101,183	101,183
Long-term debt	156,230	156,230
Stockholders' equity	202,441	202,441
Net current assets	193,034	193,034

CALITHERA BIOSCIENCES, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	22,254	11,447
Cost & expenses	39,804	22,938
Operating income	(17,550)	(11,491)
Interest income	1,269	710
Net income	(16,281)	(10,781)
Earnings common share		
Primary	\$(0.45)	\$(0.36)
Fully Diluted	\$(0.45)	\$(0.36)
Common Shares:		
Full Diluted	35,827	30,342
Year-end	35,963	35,963

CALUMET SPECIALTY PRODUCT PARTNERS LP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	1,696,000	1,853,500
Cost & expenses	1,611,100	1,759,400
Operating income	84,900	94,100
Interest expense	82,700	88,400
Other income (expense), net	(56,400)	700
Gains or losses	700	7,000
Net before taxes	(53,500)	13,400
Income taxes	600	(100)
Income contin. oper.	(54,100)	13,500
Net income	(56,700)	3,400
Earnings common share		
Primary	\$(0.71)	\$0.04
Fully Diluted	\$(0.71)	\$0.04
Common Shares:		
Full Diluted	77,644	77,726
Year-end	77,081	77,081

CALYXT INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	207	278
Cost & expenses	11,995	6,307
Operating income	(11,788)	(6,029)
Interest expense	140	44
Foreign currency	(18)	(154)
Net income	(11,946)	(6,227)
Earnings common share		
Primary	\$(0.41)	\$(0.32)
Fully Diluted	\$(0.41)	\$(0.32)
Common Shares:		
Full Diluted	28,851	19,600
Year-end	32,336	19,600

CANCER GENETICS, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	14,703,000	13,570,000
Cost & expenses	24,900,000	19,484,000
Operating income	(10,197,000)	(5,914,000)
Interest income	21,000	27,000
Interest expense	817,000	447,000
Other income (expense), net	2,904,000	(6,982,000)
Net before taxes	(13,316,000)	(13,316,000)
Income taxes	(970,000)	(970,000)
Net income	(8,089,000)	(12,346,000)
Earnings common share		
Primary	\$(0.30)	\$(0.64)
Fully Diluted	\$(0.30)	\$(0.64)
Common Shares:		
Full Diluted	27,049,000	19,301,000
Year-end	27,726,000	19,785,000

CANTERBURY PARK HOLDING CORP (NEW)

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	28,732,672	27,289,546
Cost & expenses	25,140,226	24,013,581
Operating income	2,356,221	2,052,967
Net before taxes	2,373,676	2,076,570
Income taxes	658,633	847,000
Net income	1,715,043	1,229,570
Earnings common share		
Primary	\$0.39	\$0.28
Fully Diluted	\$0.38	\$0.28
Common Shares:		
Full Diluted	4,502,397	4,378,481
Year-end	4,482,567	4,482,567

CAPELLA EDUCATION COMPANY

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	223,530	221,372
Cost & expenses	190,525	188,400
Operating income	33,005	32,972
Other income (expense), net	1,191	163
Net before taxes	34,196	33,135
Income taxes	8,559	11,209
Income contin. oper.	25,637	22,021
Net income	25,637	22,021
Earnings common share		
Primary	\$2.20	\$1.90
Fully Diluted	\$2.14	\$1.84
Common Shares:		
Full Diluted	11,957	11,965
Year-end	11,730	11,672

CAPELLA EDUCATION COMPANY

Merger Completed On Aug. 1, 2018, Strategic Education, Inc. ("SEI") wholly-owned subsidiary, Sarg Sub Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of SEI. As the result of the merger, each share of common stock, par value \$0.01 per share, of Co. ("Co. Common Stock") issued and outstanding immediately prior to the Effective Time (other than the shares that were owned by Co., SEI, Merger Sub or any of their wholly-owned subsidiaries) were automatically converted into the right to receive 0.875 (the "Exchange Ratio") newly issued shares of common stock, par value \$0.01 per share, of SEI (the "SEI Common Stock"), plus cash in lieu of fractional shares (such consideration, the "Merger Consideration"). An aggregate of 10,263,775 shares of SEI Common Stock were issued pursuant to the Merger. In addition, (i) outstanding options to purchase shares of Co. Common Stock and restricted stock units (including "performance stock units") covering shares of Co. Common Stock held by continuing Co. employees, directors or consultants were assumed by SEI and converted into a comparable SEI incentive award based on the Exchange Ratio but otherwise on the same terms and conditions, (ii) outstanding options to purchase shares of Co. Common Stock held by a Co. non-employee director who is not a member of the board of directors of SEI ("Board of Directors") immediately following the Effective Time, were cancelled in exchange for the amount of Merger Consideration the grantee would have been entitled to receive if the option had been exercised for shares of Co. Common Stock immediately prior to the Effective Time (net of the applicable exercise price) and (iii) outstanding options to purchase shares of Co. Common Stock held by a former Co. employee, director or consultant were cancelled in exchange for an amount in cash equal to the Merger Consideration such individual would have been entitled to receive if the option had been exercised immediately prior to the Effective Time (determined by multiplying such Merger Consideration by the volume weighted average price of a share of SEI Common Stock over a 10 day trading period ending on the second to last trading day prior to the Effective Time), in each case as specified in the Merger Agreement. Unvested Co. restricted stock units held by Co. non-employee directors vested in full immediately prior to the Effective Time.

CAPITAL PROPERTIES, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	2,692,000	2,630,000
Cost & expenses	1,358,000	1,775,000
Operating income	1,334,000	855,000
Net before taxes	1,334,000	855,000
Income taxes	337,000	286,000
Income contin. oper.	997,000	569,000
Net income	1,610,000	5,486,000
Earnings common share		

Primary	\$0.24	\$0.83
Common Shares:		
Year-end	6,599,912	6,599,912

CAPSTAR FINANCIAL HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	27,097,000	34,053,000
Operating income	7,855,000	(4,385,000)
Net before taxes	7,855,000	(4,385,000)
Income taxes	1,148,000	(1,375,000)
Net income	6,707,000	(3,010,000)
Earnings common share		
Primary	\$0.57	\$(0.27)
Fully Diluted	\$0.52	\$(0.24)
Common Shares:		
Full Diluted	13,021,744	12,761,989
Year-end	11,931,131	11,204,515

CARA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	2,874	911
Cost & expenses	37,811	32,869
Operating income	(34,937)	(31,958)
Other income (expense), net	778	421
Net before taxes	(34,159)	(31,537)
Income taxes	(198)	(33)
Net income	(33,961)	(31,504)
Earnings common share		
Primary	\$(1.03)	\$(1.06)
Fully Diluted	\$(1.03)	\$(1.06)
Common Shares:		
Full Diluted	33,000	29,783
Year-end	34,059	32,567

CARBON BLACK INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	99,426	74,636
Cost & expenses	136,440	99,544
Operating income	(37,014)	(24,908)
Other income (expense), net	(9,212)	237
Net before taxes	(45,770)	(24,688)
Income taxes	105	86
Net income	(45,875)	(24,774)
Balance for common	(245,367)	(33,098)
Earnings common share		
Primary	\$(8.73)	\$(3.27)
Fully Diluted	\$(8.73)	\$(3.27)
Common Shares:		
Full Diluted	28,104	10,116
Year-end	67,754	67,754

CARBONITE INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	141,760	116,133
Cost & expenses	140,376	126,677
Operating income	(3,207)	(11,526)
Interest income	413	154
Other income (expense), net	195	1,195
Net before taxes	(8,620)	(12,772)
Income taxes	(14,877)	(13,987)
Net income	6,257	1,215
Earnings common share		
Primary	\$0.22	\$0.04
Fully Diluted	\$0.20	\$0.04
Common Shares:		
Full Diluted	30,886	28,355
Year-end	28,839	28,839

CARDAX INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	585,359	174,227
Cost & expenses	2,716,607	1,005,354
Deprec., depl. & amort.	17,135	14,801
Operating income	(2,148,383)	(845,928)
Other income (expense), net	556	12,598
Net income	(2,147,985)	(833,879)
Earnings common share		
Primary	\$(0.02)	\$(0.01)
Fully Diluted	\$(0.02)	\$(0.01)

Common Shares:			Balance for common	97,300	140,600	Full Diluted	93,733	33,635
Full Diluted	122,825,595	88,409,138	Earnings common share			Year-end	86,223	
Year-end	123,300,787	91,713,848	Primary	\$0.96	\$1.61			
			Fully Diluted	\$0.87	\$1.49			
CARDLYTICS INC			Common Shares:			CASELLA WASTE SYSTEMS, INC.		
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Full Diluted	111,948	94,486	Earnings, 6 mos. to Jun 30 (Consol. – \$):		
	2018	2017	Year-end	102,120			2018	2017
Total Revenues	68,283	59,693				Total Revenues	313,104,000	287,818,000
Cost & expenses	88,040	70,526	CARRIZO OIL & GAS, INC.			Cost & expenses	263,748,000	298,815,000
Operating income	(21,451)	(12,365)	Earnings, 6 mos. to Jun 30 (Consol. – \$):			Deprec., depl. & amort.	33,370,000	29,717,000
Interest expense	2,741	4,664		2018	2017	Operating income	15,986,000	(40,714,000)
Other income (expense), net	(8,916)	3,918	Total Revenues	489,253,000	317,838,000	Interest income	108,000	121,000
Net income	(33,108)	(13,111)	Cost & expenses	288,753,000	108,057,000	Other income (expense), net	(6,921,000)	(112,000)
Balance for common	(33,265)	(18,144)	Deprec., depl. & amort.	136,897,000	113,454,000	Net before taxes	(3,749,000)	(53,489,000)
Earnings common share			Operating income	63,603,000	96,327,000	Income taxes	(1,543,000)	411,000
Primary	\$(1.99)	\$(6.18)	Net before taxes	63,603,000		Net income	(2,206,000)	(53,900,000)
Fully Diluted	\$(1.99)	\$(6.18)	Income taxes	802,000		Balance for common		(53,900,000)
Common Shares:			Net income	62,801,000	96,327,000	Earnings common share		
Full Diluted	16,716	2,935	Balance for common	44,838,000	96,327,000	Primary	\$(0.05)	\$(1.29)
Year-end	20,316		Earnings common share			Fully Diluted	\$(0.05)	\$(1.29)
			Primary	\$0.55	\$1.47	Common Shares:		
CAREDX INC			Fully Diluted	\$0.54	\$1.46	Full Diluted	42,516,000	41,698,000
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Common Shares:			Year-end	42,753,000	42,030,000
	2018	2017	Full Diluted	83,240,000	65,866,000			
Total Revenues	31,876	23,630	Year-end	82,107,544	65,835,820	CASS INFORMATION SYSTEMS INC.		
Cost & expenses	42,320	35,773				Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
Operating income	(10,444)	(12,143)	CARROLS RESTAURANT GROUP INC				2018	2017
Other income (expense), net	(10,298)	4,321	Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Cost & expenses	54,897	49,962
Net before taxes	(23,861)	(10,303)		07/01/18	07/02/17	Operating income	18,697	16,733
Income taxes	(805)	(659)	Net Sales	574,636	519,330	Net before taxes	18,697	16,733
Net income	(23,056)	(9,644)	Cost & expenses	529,268	481,884	Income taxes	3,096	3,913
Earnings common share			Deprec., depl. & amort.	28,871	26,517	Net income	15,601	12,820
Primary	\$(0.71)	\$(0.45)	Operating income	16,497	10,929	Earnings common share		
Fully Diluted	\$(0.71)	\$(0.45)	Interest expense	11,843	9,830	Primary	\$1.27	\$1.05
Common Shares:			Other income (expense), net	230		Fully Diluted	\$1.25	\$1.03
Full Diluted	32,599	21,378	Net before taxes	4,884	1,099	Common Shares:		
Year-end	35,975		Income taxes	198	656	Full Diluted	12,434	12,441
			Net income	4,686	443	Year-end	12,294	12,324
CAREER EDUCATION CORP			Balance for common	3,642	344			
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Earnings common share			CATABASIS PHARMACEUTICALS INC		
	2018	2017	Primary	\$0.10	\$0.01	Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
Total Revenues	290,101	308,331	Fully Diluted	\$0.10	\$0.01		2018	2017
Cost & expenses	253,584	281,660	Common Shares:			Cost & expenses	14,275	14,680
Operating income	31,832	18,885	Full Diluted	45,235	44,981	Operating income	(14,275)	(14,680)
Other income (expense), net	193	293	Year-end	35,723	35,427	Interest income	75	83
Net before taxes	33,186	19,806	CAS MEDICAL SYSTEMS INC			Interest expense	90	276
Income taxes	6,438	9,546	Earnings, 6 mos. to Jun 30 (Consol. – \$):			Other income (expense), net	159	23
Income contin. oper.	26,748	10,260		2018	2017	Net income	(14,131)	(14,850)
Net income	26,253	9,463	Net Sales	10,735,632	9,115,410	Earnings common share		
Earnings common share			Cost & expenses	13,008,059	12,977,443	Primary	\$(0.48)	\$(0.73)
Primary	\$0.38	\$0.14	Operating income	(2,272,427)	(3,862,033)	Fully Diluted	\$(0.48)	\$(0.73)
Fully Diluted	\$0.37	\$0.13	Interest expense	860,635	524,381	Common Shares:		
Common Shares:			Net before taxes		(4,386,414)	Full Diluted	29,659	20,452
Full Diluted	71,239	70,590	Income taxes		(153,033)	Year-end	71,038	22,482
Year-end	69,723	69,077	Income contin. oper.		(4,233,381)			
			Income discount. oper.		284,205	CAVCO INDUSTRIES INC (DE)		
CARGURUS INC			Net income	(3,133,062)	(3,949,176)	Earnings, 3 mos. to Jun 30 (Consol. – \$000):		
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Balance for common	(3,969,952)	(4,729,960)		06/30/18	07/01/17
	2018	2017	Earnings common share			Total Revenues	246,403	206,816
Total Revenues	209,026	143,275	Primary	\$(0.14)	\$(0.17)	Cost & expenses	224,140	191,155
Cost & expenses	202,323	129,700	Fully Diluted	\$(0.14)	\$(0.17)	Operating income	22,263	15,661
Operating income	5,366	12,379	Common Shares:			Interest expense	972	1,048
Other income (expense), net	985	217	Full Diluted	27,680,980	27,177,915	Other income (expense), net	2,845	1,038
Net before taxes	6,351	12,596	Year-end	28,749,621	28,229,081	Net before taxes	24,136	15,651
Income taxes	(28,565)	4,043	CASA SYSTEMS INC			Income taxes	4,445	3,898
Net income	34,916	8,553	Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Net income	19,691	11,753
Balance for common	34,916	3,508		2018	2017	Earnings common share		
Earnings common share			Total Revenues	157,796	139,354	Primary	\$2.18	\$1.30
Primary	\$0.32	\$0.08	Cost & expenses	118,285	97,688	Fully Diluted	\$2.12	\$1.28
Fully Diluted	\$0.31	\$0.08	Operating income	39,511	41,666	Common Shares:		
Common Shares:			Interest income	2,775	1,074	Full Diluted	9,267	9,162
Full Diluted	113,216	46,182	Interest expense	9,547	8,454	Year-end	9,061	
Year-end	109,385	42,242	Other income (expense), net	567	439			
			Foreign currency	(514)	635	Consolidated Balance Sheet Items, as of (\$000):		
CARLYLE GROUP LP (THE)			Net before taxes	32,792	35,360	Assets:		2018
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Income taxes	(6,401)	46	Cash & equivalents		177,487
	2018	2017	Net income	39,193	35,314	Inventories		110,437
Total Revenues	1,596,400	2,028,500	Balance for common	39,193	(15,151)	Current assets		429,237
Cost & expenses	1,233,000	1,514,900	Earnings common share			Net property & equip.		64,005
Operating income	378,300	571,400	Primary	\$0.48	\$(0.45)	Total assets		693,561
Gains or losses	14,900	57,800	Fully Diluted	\$0.42	\$(0.45)	Liabilities:		
Net before taxes	378,300	571,400	Common Shares:			Current liabilities		175,626
Income taxes	19,400	19,000	Full Diluted			Long-term debt		33,884
Net income	358,900	552,400	Year-end			Stockholders' equity		475,687
						Net current assets		253,611

CBA FLORIDA INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	1,191,615	788,093
Operating income	(1,191,615)	(788,093)
Other income (expense), net	13,230	13,896
Net before taxes	(1,178,385)	
Income taxes	(260,000)	
Income discount oper.	14,743,188	990,354
Net income	13,824,803	271,675
Earnings common share		
Primary	\$0.01	\$
Fully Diluted	\$0.01	\$
Common Shares:		
Full Diluted	1,272,066	146,272,066,146
Year-end	1,272,066,146	

CBKA ENERGY TECHNOLOGY INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	9,363,099	10,055,403
Cost & expenses	15,066,339	15,754,600
Operating income	(5,703,240)	(5,699,197)
Other income (expense), net	(310,281)	(122,399)
Net income	(6,013,521)	(5,821,596)
Earnings common share		
Primary	\$(0.23)	\$(0.29)
Fully Diluted	\$(0.23)	\$(0.29)
Common Shares:		
Full Diluted	26,530,419	20,059,236
Year-end	26,256,816	26,115,486

CBOE GLOBAL MARKETS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	1,445,200	997,000
Cost & expenses	1,043,800	772,200
Operating income	296,800	143,900
Interest income	1,300	600
Interest expense	20,200	21,000
Other income (expense), net	1,300	900
Net before taxes	279,200	124,400
Income taxes	78,100	41,200
Net income	201,100	83,200
Balance for common	199,700	82,400
Earnings common share		
Primary	\$1.78	\$0.81
Fully Diluted	\$1.77	\$0.81
Common Shares:		
Full Diluted	112,600	102,300
Year-end	112,107	124,633

CBTX INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	45,645	41,369
Operating income	24,931	21,780
Net before taxes	24,931	21,780
Income taxes	4,777	6,213
Net income	20,154	15,567
Earnings common share		
Primary	\$0.81	\$0.71
Fully Diluted	\$0.81	\$0.70
Common Shares:		
Full Diluted	24,977	22,148
Year-end	24,859	

CCOM GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	48,820,916	44,296,353
Cost & expenses	47,829,502	43,584,601
Operating income	991,414	711,752
Interest expense	360,121	316,145
Other income (expense), net	157,813	108,657
Net before taxes	789,106	504,264
Income taxes	160,628	87,923
Net income	628,478	416,341
Earnings common share		
Primary	\$0.07	\$0.04
Fully Diluted	\$0.06	\$0.04
Common Shares:		
Full Diluted	9,439,540	9,439,540
Year-end	9,154,928	9,154,928

CDK GLOBAL INC

Annual Report

Consolidated Income Statement, Years Ended Jun. 30

(\$000):

	2018	2017	2016
Revenues	2,273,200	2,220,200	2,114,600
Cost of revenues	1,182,000	1,234,900	1,243,400
Selling, general & administrative expense	475,800	477,700	448,500
Restructuring expenses	20,900	18,400	20,200
Total expense	1,678,700	1,731,000	1,712,100
Operating earnings	594,500	489,200	402,500
Interest expense	95,900	57,200	40,200
Other income, net	13,400	3,300	6,800
Income before income taxes - United States	367,300	324,900	293,100
Income before income taxes - Foreign	144,700	110,400	76,000
Earnings (loss) before income taxes	512,000	435,300	369,100
Current federal income taxes	76,600	69,600	84,900
Current foreign income taxes	35,800	27,500	24,500
Current state income taxes	21,000	14,800	16,500
Total current income taxes	133,400	111,900	125,900
Deferred federal income taxes	(14,700)	17,000	(3,300)
Deferred foreign income taxes	2,900	2,000	1,300
Deferred state income taxes	1,700	1,900	(1,600)
Total deferred income taxes	(10,100)	20,900	(3,600)
Provision for income taxes	123,300	132,800	122,300
Net earnings (loss)	388,700	302,500	246,800
Less: net earnings attributable to noncontrolling interest	(7,900)	(6,900)	(7,500)
Net earnings attributable to CDK Global, Inc.	380,800	295,600	239,300
Weighted average shares outstanding - basic	135,800	146,700	157,000
Weighted average shares outstanding - diluted	136,800	148,200	158,000
Year end shares outstanding	130,100	140,000	150,100
Net earnings per share - basic	\$2.80	\$2.01	\$1.52
Net earnings per share - diluted	\$2.78	\$1.99	\$1.51
Cash dividends declared per share	\$0.59	\$0.56	\$0.53
Number of full time employees	8,500	8,900	8,700
Number of common stockholders	15,430	16,278	17,002
Number of beneficiary stockholders	159,645	140,900	152,897
Foreign currency translation adjustments	...	2,200	(45,800)

□ As is; □ Approximately

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2018	2017
Cash & cash equivalents	804,400	726,100
Accounts receivable, gross	382,000	378,400

Less: allowance for doubtful accounts	7,400	6,300
Accounts receivable, net	374,600	372,100
Other current assets	188,300	180,600
Total current assets	1,367,300	1,278,800
Land & buildings	38,700	39,400
Data processing equipment	241,800	215,500
Furniture & fixtures, leasehold improvements, & other property, plant & equipment	79,100	80,400
Property, plant & equipment, gross	359,600	335,300
Less: accumulated depreciation	227,700	200,300
Property, plant & equipment, net	131,900	135,000
Other assets	165,500	184,100
Goodwill	1,217,200	1,181,200
Intangible assets, net	126,500	104,000
Total assets	3,008,400	2,883,100
Current maturities of long-term debt & capital lease obligations	45,200	46,500
Accounts payable	50,500	38,900
Accrued expenses & other current liabilities	198,000	188,700
Accrued payroll & payroll-related expenses	85,700	106,200
Short-term deferred revenues	169,000	172,300
Total current liabilities	548,400	552,600
Term loan facility	791,900	836,900
Senior notes	1,850,000	1,350,000
Capital lease obligations	200	1,500
Unamortized debt financing costs	(21,400)	(16,700)
Less: current maturities of long-term debt & capital lease obligations	45,200	46,500
Long-term debt & capital lease obligations	2,575,500	2,125,200
Long-term deferred revenues	110,400	136,100
Deferred income taxes	56,700	65,900
Other liabilities	64,700	60,100
Total liabilities	3,355,700	2,939,900
Common stock	1,600	1,600
Additional paid-in-capital	679,800	608,600
Retained earnings	753,000	452,700
Treasury stock, at cost	1,810,700	1,144,700
Accumulated other comprehensive income (loss)	11,500	8,000
Total CDK Global, Inc. stockholders' equity	(364,800)	(73,800)
Noncontrolling interest	17,500	17,000
Total equity	(347,300)	(56,800)

Recent Dividends:**1. CDK Global Inc common.**

No dividends paid.

Annual Dividends:**1. CDK Global Inc common.**

No dividends paid.

CDW CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	7,792,500	7,147,600
Cost & expenses	7,322,900	6,746,100
Operating income	469,600	401,500
Interest expense	74,900	75,600
Other income (expense), net	800	(56,100)
Net before taxes	395,500	269,800
Income taxes	95,500	70,800
Net income	300,000	199,000
Earnings common share		
Primary	\$1.98	\$1.26
Fully Diluted	\$1.94	\$1.24
Common Shares:		
Full Diluted	154,400	160,900
Year-end	151,500	155,600

Primary	\$(0.33)	\$(0.32)
Fully Diluted	\$(0.33)	\$(0.32)
Common Shares:		
Full Diluted	49,198	48,169
Year-end	50,310	48,575

CHIASMA INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	16,229,000	14,035,000
Operating income	(16,229,000)	(14,035,000)
Other income (expense), net	510,000	364,000
Net before taxes	(15,719,000)	(13,671,000)
Income taxes	(3,000)	203,000
Net income	(15,716,000)	(13,874,000)
Earnings common share		
Primary	\$(0.64)	\$(0.57)
Fully Diluted	\$(0.64)	\$(0.57)
Common Shares:		
Full Diluted	24,383,123	24,359,584
Year-end	24,386,383	24,359,584

CHINA XD PLASTICS CO., LTD

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	627,782,553	551,395,860
Cost & expenses	552,937,261	486,034,913
Operating income	74,845,292	65,360,947
Interest income	3,342,298	2,133,552
Interest expense	24,168,780	21,973,827
Other income (expense), net	2,856,043	2,463,453
Gains or losses	(520,981)
Net before taxes	58,031,034	45,637,063
Income taxes	11,707,055	7,672,082
Net income	46,323,979	37,964,981
Balance for common	35,033,807	28,528,370
Earnings common share		
Primary	\$0.70	\$0.58
Fully Diluted	\$0.70	\$0.58
Common Shares:		
Full Diluted	50,148,504	49,511,541
Year-end	50,287,731

CHINA YCT INTERNATIONAL GROUP INC

Annual Report
Consolidated Income Statement, Years Ended Mar. 31 (\$):

	2018	2017	2016
Sales	64,942,737	56,463,164	47,827,108
Cost of goods sold	39,603,995	33,284,237	26,554,022
Gross profit	25,338,742	23,178,927	21,273,086
Selling expenses	4,984,794	3,934,334	3,759,920
General & administrative expenses	4,719,402	4,248,095	4,446,983
Research & development expenses	492,078	809,485	724,287
Impairment of assets	332,090	986,406	1,114,942
Total operating expenses	10,528,364	9,978,320	10,046,132
Income (loss) from operations	14,810,378	13,200,607	11,226,954
Gain on disposal of acer truncatum bunge plants	642,532
Interest income (expense)	124,410	54,672	30,850
Income (loss) before tax provision	15,577,320	13,255,279	11,257,804
Current income taxes	3,499,474	3,520,126	3,055,958
Deferred income taxes	339,358	(319,501)	(214,923)
Income tax provision	3,838,832	3,200,625	2,841,035
Net income (loss)	11,738,488	10,054,654	8,416,769
Less: Net loss attributable to non-controlling interest	(352,155)	23,649
Net income			

attributable to company	11,386,333	10,078,303	8,416,769
Weighted average outstanding shares - basic	29,789,168	29,763,531	29,709,706
Weighted average outstanding shares - diluted	29,789,168	29,763,531	29,709,706
Year end shares outstanding	29,789,168	29,789,168	29,720,690
Net income (loss) per share - basic	\$0.38	\$0.34	\$0.28
Net income (loss) per share - diluted	\$0.38	\$0.34	\$0.28
Number of full time employees	313	312	313
Number of common stockholders	769	770	768

⊠ Reclassified to conform with 2017 presentation; ⊡ Including amount from a related party - cost of good sold: \$14,404,967; ⊢ Including amount from a related party - cost of good sold: \$11,015,268; ⊣ Including amount from a related party - cost of good sold: \$8,623,417; ⊤ As of June 15, 2018; ⊥ As of June 26, 2018

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2018	2017
Cash & cash equivalents	25,353,360	10,308,622
Accounts receivable	174,558	1,134,967
Raw materials	233,138	1,276,254
Packaging materials	652,179	476,803
Work-in-process	686,234	1,373,919
Finished goods	811,831	2,356,064
Inventories	2,383,382	5,483,040
Purchase deposit to related party	1,412,864	650,790
Prepaid leases - current portion	741,583	900,547
Total current assets	30,065,747	18,477,966
Prepaid leases	641,349	1,265,252
Development cost of acer truncatum bunge planting	48,984,881	42,055,972
Machinery & equipment	3,594,861	2,254,813
Office equipment & automobiles	769,589	717,259
Building	13,606,722	12,401,320
Leasehold improvements	4,240,568	2,803,052
Property, plant & equipment, gross	22,211,740	18,176,444
Less: accumulated depreciation & amortization	5,418,327	3,689,309
Plant, property & equipment, net	16,793,413	14,487,135
Intangible assets, net	11,862,017	12,042,758
Deferred tax assets	200,387	508,521
Security deposit to related party	1,590,305	1,449,422
Total assets	110,138,099	90,287,026
Accounts payable to related party	706,048
Accounts payable & other accrued expense	372,782	251,307
Advance from customer	445,829
Corporate income tax	519,875	1,382,382
Value-added tax	580,429	576,086
Other tax & fees	63,894	69,722
Taxes payable	1,164,198	2,028,190
Total current liabilities	1,982,809	2,985,545
Preferred stock	22,500	22,500
Common stock	29,789	29,789
Additional paid-in capital	4,322,838	4,322,838
Statutory reserve	1,828,504	1,828,504
Retained earnings (accumulated deficit)	94,447,937	83,061,604
Accumulated other comprehensive income	4,455,017	(4,386,845)
Total stockholders' equity attributable to the Company	105,106,585	84,878,390
Non-controlling interests	3,048,705	2,423,091

Total stockholders' equity	108,155,290	87,301,481
----------------------------------	-------------	------------

⊠ Reclassified to conform with 2018 presentation

Recent Dividends:

- China YCT International Group Inc common. No dividends paid.
 - China YCT International Group Inc 12% series A non-cumulative preferred. No dividends paid.
- Annual Dividends:**
- China YCT International Group Inc common. No dividends paid.
 - China YCT International Group Inc 12% series A non-cumulative preferred. No dividends paid.

CHINA YCT INTERNATIONAL GROUP INC

Earnings, 3 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	14,760,085	12,496,223
Operating income	6,128,762	4,638,642
Gains or losses	573,092
Net before taxes	6,168,835	5,236,837
Income taxes	1,542,209	1,309,209
Net income	4,626,626	3,927,628
Earnings common share		
Primary	\$0.15	\$0.13
Fully Diluted	\$0.15	\$0.13
Common Shares:		
Full Diluted	29,804,003	29,789,168
Year-end	29,839,168	29,789,168

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	27,863,079
Inventories	3,164,358
Current assets	33,233,983
Net property & equip.	15,687,813
Total assets	108,743,000
Liabilities:	
Current liabilities	1,457,446
Stockholders' equity	104,264,171
Net current assets	31,776,537

CHS INC

Earnings, 9 mos. to May 31(Consol. - \$000):

	2018	2017
Total Revenues	23,927,508	23,982,746
Cost & expenses	23,642,666	24,016,045
Operating income	284,842	(33,299)
Other income (expense), net	188,111	190,704
Gains or losses	131,755
Net before taxes	474,990	39,994
Income taxes	(100,901)	(137,781)
Net income	575,391	177,775
Earnings common share		
Common Shares:		

CHURCHILL DOWNS, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	568,700,000	506,800,000
Cost & expenses	412,400,000	375,400,000
Operating income	156,300,000	131,400,000
Interest expense	19,300,000	23,400,000
Other income (expense), net	15,700,000	14,500,000
Net before taxes	152,700,000	122,500,000
Income taxes	35,400,000	47,600,000
Income contin. oper.	117,300,000	74,900,000
Net income	285,100,000	85,600,000
Balance for common	285,100,000	85,500,000
Earnings common share		
Primary	\$20.36	\$5.27
Fully Diluted	\$20.26	\$5.18
Common Shares:		
Full Diluted	14,100,000	16,500,000
Year-end	13,600,000

CHUY'S HOLDINGS INC

Earnings, 6 mos. to (Consol. - \$000):

	07/01/18	06/25/17
Total Revenues	200,190	181,376
Cost & expenses	179,710	159,089
Deprec., depl. & amort.	9,615	8,468

	2018	2017
Total Revenues	64,892	64,665
Cost & expenses	51,893	48,465
Operating income	12,999	16,200
Net before taxes	13,097	16,231
Income taxes	3,001	6,294
Net income	10,096	9,937
Earnings common share		
Primary	\$0.72	\$0.71
Fully Diluted	\$0.72	\$0.71
Common Shares:		
Full Diluted	13,934	13,965
Year-end	13,941	13,988

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	45,268	
Current assets	91,777	
Net property & equip.	36,303	
Total assets	258,349	
Liabilities:		
Current liabilities	42,454	
Stockholders' equity	196,808	
Net current assets	49,323	

COMPUTER TASK GROUP, INC.**Earnings, 6 mos. to (Consol. – \$000):**

	06/29/18	06/30/17
Total Revenues	175,380	152,527
Cost & expenses	173,152	150,315
Operating income	2,228	2,212
Net before taxes	1,832	1,927
Income taxes	478	742
Net income	1,354	1,185
Earnings common share		
Primary	\$0.10	\$0.08
Fully Diluted	\$0.09	\$0.08
Common Shares:		
Full Diluted	14,871	15,454
Year-end	14,472	15,742

COMSCORE INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Total Revenues	207,308	200,300
Cost & expenses	288,387	264,849
Operating income	(97,889)	(81,727)
Interest expense	7,029	406
Other income (expense), net	884	5,867
Foreign currency	123	(1,225)
Net before taxes	(103,911)	(77,491)
Income taxes	3,516	1,927
Net income	(107,427)	(79,418)
Earnings common share		
Primary	\$(1.90)	\$(1.38)
Fully Diluted	\$(1.90)	\$(1.38)
Common Shares:		
Full Diluted	56,704	57,387
Year-end	57,887	57,277

CONATUS PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2018	2017
Total Revenues	18,511,000	17,006,507
Cost & expenses	28,125,000	26,100,845
Operating income	(9,614,000)	(9,095,000)
Interest expense	372,000	284,313
Other income (expense), net	(6,000)	(50,461)
Net income	(9,515,000)	(9,039,632)
Earnings common share		
Primary	\$(0.32)	\$(0.33)
Fully Diluted	\$(0.32)	\$(0.33)
Common Shares:		
Full Diluted	30,081,000	27,138,536
Year-end	30,145,000	29,994,275

CONCERT PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Cost & expenses	28,662	26,482
Operating income	(18,181)	(26,447)
Other income (expense), net	(627)	
Gains or losses	1,300	292
Net before taxes	(17,508)	
Income taxes	280	

Net income	(17,788)	(26,360)
Balance for common	(17,788)	(26,360)
Earnings common share		
Primary	\$(0.76)	\$(1.17)
Fully Diluted	\$(0.76)	\$(1.17)
Common Shares:		
Full Diluted	23,313	22,479
Year-end	23,415	22,616

CONFORMIS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Total Revenues	38,756	38,939
Cost & expenses	62,564	70,184
Operating income	(23,808)	(31,245)
Interest income	311	230
Interest expense	1,501	679
Foreign currency	(1,013)	2,507
Net before taxes	(26,011)	(29,187)
Income taxes	47	63
Net income	(26,058)	(29,250)
Earnings common share		
Primary	\$(0.46)	\$(0.68)
Fully Diluted	\$(0.46)	\$(0.68)
Common Shares:		
Full Diluted	57,208	43,036
Year-end	63,114	44,866

CONIFER HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Total Revenues	50,090	51,345
Cost & expenses	51,106	54,650
Operating income	(1,016)	(3,305)
Net before taxes	(1,016)	(3,305)
Income taxes	28	(275)
Net income	(900)	(2,866)
Earnings common share		
Primary	\$(0.11)	\$(0.38)
Fully Diluted	\$(0.11)	\$(0.38)
Common Shares:		
Full Diluted	8,520	7,633
Year-end	8,520	7,633

CONMED CORP.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Net Sales	414,884	383,720
Cost & expenses	380,924	373,431
Operating income	33,960	10,289
Net before taxes	24,051	1,771
Income taxes	4,675	177
Net income	19,376	1,594
Earnings common share		
Primary	\$0.69	\$0.06
Fully Diluted	\$0.67	\$0.06
Common Shares:		
Full Diluted	28,739	28,086
Year-end	28,106	27,919

CONNECTONE BANCORP INC (NEW)**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Cost & expenses	79,196	62,249
Operating income	26,820	26,564
Net before taxes	26,820	26,564
Income taxes	5,042	7,001
Net income	21,778	19,563
Balance for common	21,778	19,563
Earnings common share		
Primary	\$0.68	\$0.61
Fully Diluted	\$0.67	\$0.60
Common Shares:		
Full Diluted	32,276	32,233
Year-end	32,184	32,015

CONRAD INDUSTRIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Total Revenues	94,581	93,056
Cost & expenses	94,470	90,975
Operating income	111	2,081
Interest expense	231	258
Other income (expense), net	7,520	313

Net before taxes	7,400	2,136
Income taxes	2,094	658
Net income	5,306	1,478
Earnings common share		
Primary	\$1.06	\$0.29
Fully Diluted	\$1.06	\$0.29
Common Shares:		
Full Diluted	5,018	5,093
Year-end	5,018	5,094

CONSOLIDATED COMMUNICATIONS HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Total Revenues	706,260	339,885
Cost & expenses	472,650	217,576
Deprec., depl. & amort.	219,640	82,678
Operating income	13,970	39,631
Other income (expense), net	1,246	580
Gains or losses	20,324	13,474
Net before taxes	(30,015)	(9,904)
Income taxes	(8,257)	(3,573)
Net income	(21,758)	(6,331)
Balance for common	(22,383)	(6,577)
Earnings common share		
Primary	\$(0.32)	\$(0.13)
Fully Diluted	\$(0.32)	\$(0.13)
Common Shares:		
Full Diluted	70,598	50,411
Year-end	71,253	50,733

CONSTELLATION PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016
Research & development	32,617	27,881
General & administrative expenses	6,471	5,777
Total operating expenses	39,088	33,658
Income (loss) from operations	(39,088)	(33,658)
Interest income	169	53
Interest expense	901	1,345
Change in fair value of preferred stock tranche liability	4,443	417
Total other income (expense), net	3,711	(875)
Net income (loss)	(35,377)	(34,533)
Cumulative dividends on convertible preferred stock	18,390	14,932
Net income (loss) attributable to common stockholders	(53,767)	(49,465)
Weighted average shares outstanding - basic	958	930
Weighted average shares outstanding - diluted	958	930
Year end shares outstanding	945	963
Net earnings (loss) per share - basic	\$(56.10)	\$(53.19)
Net earnings (loss) per share - diluted	\$(56.10)	\$(53.19)
Number of full time employees	126	
Number of common stockholders	126	

□ As is; □ As of June 30, 2018; □ As of May 31, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	16,404	36,920
Prepaid expenses & other current assets	1,318	515
Total current assets	17,722	37,435
Laboratory equipment	5,468	5,140
Computer equipment & internal-use software	1,874	1,735
Furniture & fixtures	289	289

Leasehold improvements	217	217	Current liabilities	10,049	Earnings common share				
Total property & equipment, gross	7,848	7,381	Stockholders' equity	(177,057)	Primary	\$0.21	\$0.20		
Less accumulated depreciation & amortization	6,727	6,354	Net current assets	63,342	Fully Diluted	\$0.21	\$0.20		
Property & equipment, net	1,121	1,027	CONSTELLATION PHARMACEUTICALS INC						
Restricted cash	242	242	Earnings, 6 mos. to Jun 30(Consol. - \$000):						
Other assets	18	...	2018	2017					
Total assets	19,103	38,704	Cost & expenses	24,199	17,529				
Accounts payable	2,799	2,746	Operating income	(24,199)	(17,529)				
Accrued employee compensation & benefits	1,867	979	Interest income	377	66				
Accrued professional fees	233	...	Interest expense	221	553				
Accrued external research & development expense	1,347	1,570	Other income (expense), net	4,353					
Accrued final debt payment	557	...	Net income	(24,043)	(13,663)				
Other accrued expenses & other current liabilities	225	209	Balance for common	(24,043)	(22,187)				
Accrued expenses & other current liabilities	4,229	2,758	Earnings common share						
Current portion of long-term debt, net	4,103	6,546	Primary	\$(22.12)	\$(23.24)				
Total current liabilities	11,131	12,050	Fully Diluted	\$(22.12)	\$(23.24)				
Principal amount of term loans	4,116	10,742	Common Shares:						
Debt discount current portion	(13)	(88)	Full Diluted	1,087	954,750				
Less: Current portion Long-term debt, net of current portion	4,103	6,546	Year-end	1,215	...				
Debt discount net of current portion	...	(12)	CONTROL4 CORP						
Long-term debt, net of current portion	...	4,096	Earnings, 6 mos. to Jun 30(Consol. - \$000):						
Preferred stock tranche liability	...	4,443	2018	2017					
Preferred stock warrant liability	254	226	Total Revenues	128,377	111,460				
Deferred rent	317	223	Cost & expenses	120,436	109,645				
Other long-term liabilities	6	340	Operating income	7,941	1,815				
Total liabilities	11,708	21,378	Interest income	492	99				
Convertible preferred stock	173,228	148,997	Other income (expense), net	(782)	104				
Additional paid-in capital	8,079	6,864	Net before taxes	7,651	2,018				
Retained earnings (accumulated deficit)	(173,912)	(138,535)	Income taxes	45	(2,544)				
Total stockholders' equity (deficit)	(165,833)	(131,671)	Net income	7,606	4,562				
			Earnings common share						
			Primary	\$0.29	\$0.19				
			Fully Diluted	\$0.28	\$0.18				
			Common Shares:						
			Full Diluted	27,396	26,024				
			Year-end	26,087	...				
			CONVERGEONE HOLDINGS INC						
			Earnings, 6 mos. to Jun 30(Consol. - \$):						
			2018	2017					
			Total Revenues	697,352,000	...				
			Cost & expenses	660,699,000	130,865				
			Operating income	13,296,000	(130,865)				
			Interest income	65,000	326,446				
			Interest expense	37,735,000	...				
			Other income (expense), net	10,947,000	(48,739)				
			Net before taxes	(13,427,000)	146,842				
			Income taxes	(14,772,000)	49,926				
			Net income	1,345,000	96,916				
			Balance for common	(122,660,000)	...				
			Earnings common share						
			Primary	\$(1.93)	\$0.02				
			Fully Diluted	\$(1.93)	\$0.02				
			Common Shares:						
			Full Diluted	63,487,614	4,511,237				
			Year-end	76,341,016	5,560,769				
			CORBUS PHARMACEUTICALS HOLDINGS INC						
			Earnings, 6 mos. to Jun 30(Consol. - \$):						
			2018	2017					
			Cost & expenses	26,062,810	16,387,987				
			Operating income	(24,258,722)	(14,744,104)				
			Foreign currency	24,269	(24,859)				
			Net income	(23,764,736)	(14,762,326)				
			Balance for common	(23,764,736)	(14,762,326)				
			Earnings common share						
			Primary	\$(0.42)	\$(0.31)				
			Fully Diluted	\$(0.42)	\$(0.31)				
			Common Shares:						
			Full Diluted	56,764,935	48,298,135				
			Year-end	57,192,496	50,220,510				
			CORE MARK HOLDING CO INC						
			Earnings, 6 mos. to Jun 30(Consol. - \$000):						
			2018	2017					
			Net Sales	8,032,400	7,304,900				
			Cost & expenses	8,007,400	7,287,000				
			Operating income	19,900	14,300				
			Foreign currency	900	1,700				
			Net before taxes	13,600	12,100				
			Income taxes	3,900	3,100				
			Net income	9,700	9,000				
			CORNIUM INTERNATIONAL INC						
			Earnings, 9 mos. to Jun 30(Consol. - \$000):						
			2018	2017					
			Total Revenues	27,045	22,422				
			Cost & expenses	61,287	50,727				
			Operating income	(34,783)	(28,819)				
			Interest income	617	149				
			Interest expense	7,903	6,178				
			Other income (expense), net	(1,618)	...				
			Net before taxes	(43,687)	(34,848)				
			Income taxes	2	2				
			Net income	(43,689)	(34,850)				
			Earnings common share						
			Primary	\$(1.21)	\$(1.30)				
			Fully Diluted	\$(1.21)	\$(1.30)				
			Common Shares:						
			Full Diluted	36,145	26,785				
			Year-end	36,244	35,739				
			CORNERSTONE ONDEMAND, INC.						
			Earnings, 6 mos. to Jun 30(Consol. - \$000):						
			2018	2017					
			Total Revenues	265,630	228,233				
			Cost & expenses	277,571	259,949				
			Operating income	(11,941)	(31,716)				
			Interest income	4,484	1,272				
			Interest expense	17,491	6,642				
			Other income (expense), net	(2,206)	545				
			Net before taxes	(27,154)	(36,541)				
			Income taxes	1,069	935				
			Net income	(28,223)	(37,476)				
			Earnings common share						
			Primary	\$(0.49)	\$(0.66)				
			Fully Diluted	\$(0.49)	\$(0.66)				
			Common Shares:						
			Full Diluted	57,635	56,789				
			Year-end	58,244	57,177				
			CORVEL CORP						
			Earnings, 3 mos. to Jun 30(Consol. - \$):						
			2018	2017					
			Total Revenues	150,398,000	137,612,000				
			Cost & expenses	134,982,000	123,458,000				
			Operating income	15,416,000	14,154,000				
			Net before taxes	15,416,000	14,154,000				
			Income taxes	3,638,000	5,379,000				
			Net income	11,778,000	8,775,000				
			Earnings common share						
			Primary	\$0.62	\$0.47				
			Fully Diluted	\$0.62	\$0.46				
			Common Shares:						
			Full Diluted	19,102,000	19,000,000				
			Year-end	18,891,907	18,937,233				
			Consolidated Balance Sheet Items, as of (\$):						
			Assets:		2018				
			Cash & equivalents	...	73,340,000				
			Current assets	...	183,156,000				
			Net property & equip.	...	66,849,000				
			Total assets	...	291,210,000				
			Liabilities:						
			Current liabilities	...	104,801,000				
			Stockholders' equity	...	181,865,000				
			Net current assets	...	78,355,000				
			CORVUS PHARMACEUTICALS INC						
			Earnings, 6 mos. to Jun 30(Consol. - \$000):						
			2018	2017					
			Cost & expenses	26,902	31,391				
			Operating income	(26,902)	(31,391)				
			Net income	(25,932)	(31,017)				
			Earnings common share						
			Primary	\$(1.01)	\$(1.52)				
			Fully Diluted	\$(1.01)	\$(1.52)				
			Common Shares:						
			Full Diluted	25,786	20,389				
			Year-end	29,198	20,935				

COSTAR GROUP, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	570,736	463,706
Cost & expenses	458,898	388,817
Operating income	97,219	65,545
Net before taxes	101,440	61,200
Income taxes	5,374	16,886
Net income	96,066	44,314
Earnings common share		
Primary	\$2.67	\$1.37
Fully Diluted	\$2.64	\$1.36
Common Shares:		
Full Diluted	36,400	32,651
Year-end	36,391	32,821

COWEN INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	485,957	275,501
Cost & expenses	472,934	310,768
Operating income	68,931	33,854
Other income (expense), net	4,038	13,131
Gains or losses	76,692	83,856
Foreign currency	252	(307)
Net before taxes	68,931	41,800
Income taxes	10,916	1,126
Net income	58,015	40,674
Balance for common	18,856	7,028
Earnings common share		
Primary	\$0.64	\$0.25
Fully Diluted	\$0.62	\$0.24
Common Shares:		
Full Diluted	30,460	28,860
Year-end	29,609	31,074

CRA INTERNATIONAL INC**Earnings, 6 mos. to** (Consol. – \$000):

	06/30/18	07/01/17
Total Revenues	205,014	181,734
Cost & expenses	184,485	166,776
Deprec., depl. & amort.	4,664	4,199
Operating income	15,865	10,759
Interest expense	338	245
Other income (expense), net	136	(237)
Gains or losses		250
Net before taxes	15,663	10,527
Net income	11,725	6,737
Balance for common	11,656	6,622
Earnings common share		
Primary	\$1.43	\$0.79
Fully Diluted	\$1.35	\$0.77
Common Shares:		
Full Diluted	8,649	8,619
Year-end	8,026	8,198

CRAFT BREW ALLIANCE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2018	2017
Net Sales	109,310,000	104,852,000
Cost & expenses	102,717,000	104,883,000
Operating income	6,593,000	(31,000)
Interest expense	241,000	354,000
Other income (expense), net	55,000	13,000
Net before taxes	6,407,000	(372,000)
Income taxes	1,794,000	(309,000)
Net income	4,613,000	(63,000)
Earnings common share		
Primary	\$0.24	\$.....
Fully Diluted	\$0.24	\$.....
Common Shares:		
Full Diluted	19,502,000	19,270,000
Year-end	19,362,386	19,293,775

CRAY INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2018	2017
Total Revenues	199,797,000	146,166,000
Cost & expenses	237,074,000	189,881,000
Operating income	(37,277,000)	(43,715,000)
Interest income	1,369,000	1,792,000
Interest expense	(11,000)	17,000
Other income (expense), net	48,000	1,197,000
Net before taxes	(35,849,000)	(40,743,000)

Income taxes	109,000	(14,688,000)
Net income	(35,958,000)	(26,055,000)
Earnings common share		
Primary	\$(0.89)	\$(0.65)
Fully Diluted	\$(0.89)	\$(0.65)
Common Shares:		
Full Diluted	40,527,000	40,022,000
Year-end	40,815,172	40,347,022

CREDITRISKMONITOR.COM, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2018	2017
Total Revenues	6,849,747	6,577,726
Cost & expenses	7,236,299	6,912,737
Deprec., depl. & amort.	89,087	99,722
Operating income	(475,639)	(434,733)
Other income (expense), net	51,644	14,570
Net before taxes	(423,995)	(420,163)
Income taxes	(81,722)	(92,183)
Net income	(342,273)	(327,980)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	10,722,401	10,722,401
Year-end	10,722,401	10,722,401

CRINETICS PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31** (\$000):

	2017	2016
Grant revenues	2,045	589
Research & development	9,233	5,100
General & administrative expenses	1,939	1,533
Total operating expenses	11,172	6,633
Income (loss) from operations	(9,127)	(6,044)
Interest income	26	37
Interest expense	8	11
Other expenses	48	1
Total other income (expense), net	(30)	25
Income before income taxes - Domestic	(8,141)	(6,019)
Income before income taxes - Foreign	(1,016)	...
Income (loss) before income taxes	(9,157)	(6,019)
Net income (loss)	(9,157)	(6,019)
Weighted average shares outstanding - basic	1,371	1,011
Weighted average shares outstanding - diluted	1,371	1,011
Year end shares outstanding	1,550	1,165
Net earnings (loss) per share - basic	\$(6.68)	\$(5.96)
Net earnings (loss) per share - diluted	\$(6.68)	\$(5.96)
Number of full time employees	□□34	...
Number of part time employees	□□2	...
Total number of employees	□□36	...
Number of common stockholders	□□27	...

□ As of June 30, 2018; □ As is; □ As of March 31, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	14,192	12,152
Grant receivable	231	72
Prepaid research & development	141	98
Australian tax incentive receivable	503	...
Other prepaid expenses & other current assets	98	43
Prepaid expenses & other		

current assets	973	213
Total current assets	15,165	12,365
Laboratory equipment	640	360
Computers & software	27	27
Office equipment	19	19
Leasehold improvements	18	...
Total property & equipment, gross	704	406
Less accumulated depreciation & amortization	304	182
Property & equipment, net	400	224
Other assets	33	10
Total assets	15,598	12,599
Accounts payable	403	340
Accrued compensation	315	272
Accrued research & development	126	180
Other accrued expenses	53	49
Accrued expenses	494	501
Current portion of long-term debt	...	49
Total current liabilities	897	890
Long-term debt, net of current portion	...	163
Deferred rent	20	5
Unvested stock liability	3	5
Convertible preferred shares	29,700	17,740
Common stock	1	1
Additional paid-in capital	1,242	903
Retained earnings (accumulated deficit)	(16,265)	(7,108)
Total stockholders' equity (deficit)	(15,022)	(6,204)

Recent Dividends:**1. Crinetics Pharmaceuticals Inc common.**

No dividends paid.

Annual Dividends:**1. Crinetics Pharmaceuticals Inc common.**

No dividends paid.

CRINETICS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	442	45
Cost & expenses	5,968	2,654
Operating income	(5,526)	(2,609)
Interest income	64	7
Interest expense	...	2
Other income (expense), net	(2)	(2)
Net income	(5,464)	(2,606)
Earnings common share		
Primary	\$(2.92)	\$(2.18)
Fully Diluted	\$(2.92)	\$(2.18)
Common Shares:		
Full Diluted	1,870	1,198
Year-end	2,191	...

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	73,740
Current assets	74,731
Net property & equip.	476
Total assets	76,329
Liabilities:	
Current liabilities	3,136
Stockholders' equity	(19,976)
Net current assets	71,595

CROCS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	611,152	581,128
Cost & expenses	548,166	536,100
Operating income	62,986	45,028
Interest income	425	307
Interest expense	245	372
Other income (expense), net	69	133
Foreign currency	1,354	438
Net before taxes	64,589	45,534
Income taxes	13,758	12,564

Net income	50,831	32,970
Balance for common	35,744	21,270
Earnings common share		
Primary	\$0.52	\$0.29
Fully Diluted	\$0.51	\$0.29
Common Shares:		
Full Diluted	70,462	74,625
Year-end	68,100	

CROSS COUNTRY HEALTHCARE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	400,398	402,706
Operating income	8,590	9,704
Interest expense	2,713	1,754
Other income (expense), net	199	(4,910)
Gains or losses		1,581
Net before taxes	6,076	4,621
Income taxes	2,332	1,119
Net income	3,744	3,502
Balance for common	3,181	2,840
Earnings common share		
Primary	\$0.09	\$0.08
Fully Diluted	\$0.09	\$0.05
Common Shares:		
Full Diluted	35,959	36,250
Year-end	36,295	36,494

CSG SYSTEMS INTERNATIONAL INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	414,737	385,183
Cost & expenses	356,421	327,291
Operating income	49,854	51,261
Interest expense	8,746	8,452
Other income (expense), net	(1,761)	(1,666)
Net before taxes	40,928	42,653
Income taxes	11,797	10,835
Net income	29,131	31,818
Earnings common share		
Primary	\$0.89	\$0.99
Fully Diluted	\$0.88	\$0.97
Common Shares:		
Full Diluted	33,005	32,795
Year-end	33,561	33,700

CSI COMPRESSCO LP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	185,339	140,867
Cost & expenses	144,640	109,642
Deprec., depl. & amort.	34,815	34,499
Operating income	(23,165)	(20,546)
Other income (expense), net	(3,793)	3,560
Net before taxes	(23,165)	(20,546)
Income taxes	2,164	1,419
Net income	(25,329)	(21,965)
Earnings common share		
Primary	\$(0.63)	\$(0.63)
Fully Diluted	\$(0.63)	\$(0.63)
Common Shares:		
Full Diluted	39,564	33,979
Year-end	41,187	35,375

CSP INC**Earnings, 9 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	53,278	60,134
Cost & expenses	53,754	58,430
Operating income	(476)	1,704
Other income (expense), net	153	77
Foreign currency	308	27
Net before taxes	(63)	1,761
Income taxes	1,225	539
Income contin. oper.	(1,288)	1,222
Income discount. oper.	(503)	(141)
Net income	(1,791)	1,081
Balance for common	(1,791)	1,035
Earnings common share		
Primary	\$(0.47)	\$0.28
Fully Diluted	\$(0.47)	\$0.27
Common Shares:		
Full Diluted	3,811	3,811
Year-end	4,006	

CSP INC

Interest Sale Completed On July 31, 2018, Co.'s indirect wholly-owned subsidiary, CSPI Ltd. ("CSPI"), sold all the stock of Modcomp GmbH, a limited liability company incorporated under the laws of Germany ("Modcomp Germany"), a company that through itself and its wholly-owned subsidiaries provided managed security services to customers primarily in Germany, to Reply AG, a German stock corporation ("Reply AG"), an affiliate of Reply SpA, for approximately Euro12,343,000, which consisted of the original purchase price of Euro10,000,000 plus an adjustment at closing for Net Cash (as defined in the Share Purchase Agreement) of approximately Euro2,343,000. The Net Cash number was subject to certain post-closing adjustments as set forth in the Share Purchase Agreement. CSPI and Reply AG have entered into a customary escrow agreement for a three (3) year period with an aggregate holdback from the total cash consideration of Euro400,000, covering indemnity claims for certain employee matters.

CSW INDUSTRIALS INC**Earnings, 3 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	89,578	89,299
Cost & expenses	71,834	72,628
Operating income	17,744	16,671
Interest expense	384	631
Other income (expense), net	738	18
Net before taxes	18,098	16,058
Income taxes	4,091	5,771
Income contin. oper.	14,007	10,287
Net income	11,676	8,514
Earnings common share		
Primary	\$0.74	\$0.53
Fully Diluted	\$0.73	\$0.53
Common Shares:		
Full Diluted	15,932	15,923
Year-end	15,719	15,846

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	10,983	10,983
Inventories	46,335	46,335
Current assets	130,110	130,110
Net property & equip.	53,437	53,437
Total assets	338,879	338,879
Liabilities:		
Current liabilities	45,339	45,339
Long-term debt	19,319	19,319
Stockholders' equity	267,609	267,609
Net current assets	84,771	84,771

CUMBERLAND PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	18,751,329	18,303,882
Cost & expenses	20,787,874	19,440,538
Operating income	(3,321,200)	(2,338,673)
Interest income	232,200	122,016
Interest expense	40,321	61,744
Net before taxes	(3,129,321)	(2,278,401)
Income taxes	8,318	4,192,370
Net income	(3,137,639)	(6,470,771)
Earnings common share		
Primary	\$(0.20)	\$(0.40)
Fully Diluted	\$(0.20)	\$(0.40)
Common Shares:		
Full Diluted	15,682,348	16,026,935
Year-end	15,604,709	15,937,595

CUMULUS MEDIA INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	95,004	554,561
Cost & expenses	76,887	454,311
Operating income	13,738	67,848
Interest income	4	72
Interest expense	6,176	68,407
Other income (expense), net	20	(28)
Net before taxes	7,586	(515)
Income taxes	2,606	1,208
Net income	4,980	(1,723)
Balance for common	4,980	(1,723)
Earnings common share		
Primary	\$0.25	\$(0.06)
Fully Diluted	\$0.25	\$(0.06)
Common Shares:		

Full Diluted	20,300	29,306
Year-end	16,305	29,306

CURAEGIS TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	16,000	17,000
Cost & expenses	1,958,000	2,589,000
Operating income	(1,942,000)	(2,572,000)
Other income (expense), net	1,000	2,000
Net income	(2,437,000)	(2,891,000)
Balance for common	(2,545,000)	(3,015,000)
Earnings common share		
Primary	\$(0.05)	\$(0.06)
Fully Diluted	\$(0.05)	\$(0.06)
Common Shares:		
Full Diluted	49,302,000	47,591,000
Year-end	49,849,546	48,219,265

CURIS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	4,826	4,192
Cost & expenses	22,301	32,139
Operating income	(17,768)	(28,161)
Other income (expense), net		(104)
Net income	(19,411)	(29,832)
Earnings common share		
Primary	\$(0.59)	\$(1.04)
Fully Diluted	\$(0.59)	\$(1.04)
Common Shares:		
Full Diluted	33,095	28,581
Year-end	33,181	28,776

CUTERA INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	76,678	65,688
Cost & expenses	83,582	65,371
Operating income	(6,904)	317
Other income (expense), net		306
Net before taxes	(6,935)	866
Income taxes	(3,331)	(59)
Net income	(3,604)	925
Earnings common share		
Primary	\$(0.26)	\$0.07
Fully Diluted	\$(0.26)	\$0.06
Common Shares:		
Full Diluted	13,649	14,633
Year-end	13,824	14,004

CYBEROPTICS CORP.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	29,974	28,329
Cost & expenses	29,392	27,171
Operating income	557	1,123
Net before taxes	714	1,007
Income taxes	147	126
Net income	567	881
Earnings common share		
Primary	\$0.08	\$0.13
Fully Diluted	\$0.08	\$0.12
Common Shares:		
Full Diluted	7,114	7,083
Year-end	7,024	6,953

CYMABAY THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues		4,793
Cost & expenses	30,821	15,368
Operating income	(30,821)	(10,575)
Interest income	1,769	81
Interest expense	336	588
Other income (expense), net	(5,148)	(3,198)
Net income	(34,536)	(14,280)
Balance for common	(34,536)	(14,280)
Earnings common share		
Primary	\$(0.61)	\$(0.52)
Fully Diluted	\$(0.61)	\$(0.52)
Common Shares:		
Full Diluted	56,307	27,687
Year-end	58,960	28,752

DIAMONDBACK ENERGY, INC.

Merger Development On Aug. 14, 2018, Energen Corp. ("Energen") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Co. and Sidewinder Merger Sub Inc., a wholly-owned subsidiary of Co. ("Merger Sub"). The Merger Agreement provides that, among other things and subject to the terms and conditions of the Merger Agreement, (1) Merger Sub will be merged with and into Energen (the "Merger"), with Energen surviving and continuing as the surviving corporation in the Merger, and, (2) at the effective time of the Merger (the "Effective Time"), each outstanding share of common stock of Energen (other than shares held in treasury by Energen, shares owned by Co. or Merger Sub or shares with respect to which dissenters' rights have been validly exercised in accordance with Alabama law) will be converted into the right to receive 0.6442 of a share of common stock of Co., plus cash in lieu of any fractional shares that otherwise would have been issued (the "Merger Consideration"). Pursuant to the Merger Agreement, at the Effective Time, (1) each outstanding Energen stock option and stock appreciation right in respect of Energen common stock will convert into a stock option and stock appreciation right of equivalent value relating to shares of Co. common stock on the terms set forth in the Merger Agreement, (2) each outstanding Energen performance share award with a performance period that is scheduled to terminate on Dec. 31, 2018 will vest immediately prior to the Effective Time and convert into the Merger Consideration with respect to each share subject to such award and (3) each outstanding Energen time-vesting restricted stock unit award and (other than as provided in clause (2)) performance share award will convert into a time-vesting Co. restricted stock unit award of equivalent value on the terms set forth in the Merger Agreement. Performance goals applicable to Energen performance share awards will be deemed satisfied at the greater of target and actual performance as of the Effective Time. The transaction is valued at approximately \$9,200,000,000, including Energen's net debt of \$830,000,000 as of June 30, 2018.

DICERNA PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):		
	2018	2017
Cost & expenses	54,755	29,607
Operating income	(51,665)	(29,607)
Interest income	619	181
Interest expense	176	
Net income	(51,222)	(29,426)
Balance for common	(51,222)	(38,192)
Earnings common share		
Primary	\$(0.98)	\$(1.84)
Fully Diluted	\$(0.98)	\$(1.84)
Common Shares:		
Full Diluted	52,142	20,793
Year-end	52,868	20,794

DIGI INTERNATIONAL INC

Earnings, 9 mos. to Jun 30(Consol. - \$):		
	2018	2017
Total Revenues	162,704,000	136,529,000
Cost & expenses	162,287,000	131,886,000
Operating income	417,000	4,643,000
Interest income	343,000	434,000
Interest expense	12,000	45,000
Other income (expense), net	(37,000)	210,000
Net before taxes	711,000	5,242,000
Income taxes	3,016,000	219,000
Net income	(2,305,000)	5,023,000
Earnings common share		
Primary	\$(0.09)	\$0.19
Fully Diluted	\$(0.09)	\$0.19
Common Shares:		
Full Diluted	27,002,000	27,110,000
Year-end	27,242,693	26,535,816

DIGIMARC CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):		
	2018	2017
Total Revenues	11,051	11,678
Cost & expenses	27,707	25,174
Operating income	(16,656)	(13,496)
Other income (expense), net	526	234
Net before taxes	(16,130)	(13,262)
Income taxes	20	(101)
Net income	(16,150)	(13,161)
Earnings common share		
Primary	\$(1.43)	\$(1.29)
Fully Diluted	\$(1.43)	\$(1.29)

Common Shares:		
Full Diluted	11,302	10,214
Year-end	11,876	11,263

DIGIRAD CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):		
	2018	2017
Total Revenues	52,545,000	52,525,000
Cost & expenses	53,689,000	55,227,000
Operating income	(1,857,000)	(3,449,000)
Other income (expense), net	(79,000)	(709,000)
Net before taxes	(2,299,000)	(4,578,000)
Income taxes	(561,000)	519,000
Income contin. oper.	(1,738,000)	(5,097,000)
Net income	3,756,000	(4,848,000)
Earnings common share		
Primary	\$0.19	\$(0.24)
Fully Diluted	\$0.19	\$(0.24)
Common Shares:		
Full Diluted	20,106,000	19,957,000
Year-end	17,530,834	

DIODES, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):		
	2018	2017
Net Sales	578,597,000	500,527,000
Cost & expenses	504,368,000	457,938,000
Operating income	64,784,000	33,185,000
Interest income	957,000	603,000
Other income (expense), net	5,012,000	531,000
Foreign currency	(2,729,000)	(5,422,000)
Net before taxes	62,723,000	21,965,000
Income taxes	18,536,000	6,599,000
Net income	44,187,000	15,366,000
Balance for common	43,594,000	14,396,000
Earnings common share		
Primary	\$0.88	\$0.30
Fully Diluted	\$0.86	\$0.29
Common Shares:		
Full Diluted	50,727,000	49,807,000
Year-end	49,846,164	48,734,340

DISCOVERY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):		
	2018	2017
Total Revenues	5,152,000	3,358,000
Cost & expenses	3,695,000	2,081,000
Deprec., depl. & amort.	603,000	160,000
Operating income	854,000	1,117,000
Interest income	15,000	
Interest expense	373,000	182,000
Other income (expense), net	(105,000)	(149,000)
Gains or losses	10,000	(2,000)
Net before taxes	350,000	749,000
Income taxes	103,000	148,000
Net income	247,000	601,000
Earnings common share		
Primary	\$0.31	\$1.02
Fully Diluted	\$0.31	\$1.01
Common Shares:		
Full Diluted	661,000	583,000
Year-end	522,424	378,967

DISH NETWORK CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):		
	2018	2017
Total Revenues	6,919,332	7,323,993
Cost & expenses	5,451,492	6,048,269
Operating income	1,102,166	859,423
Interest income	19,936	26,739
Interest expense	5,822	55,439
Other income (expense), net	1,333	3,153
Gains or losses	(20,848)	
Invest. income	6,139	4,759
Net before taxes	1,102,904	838,635
Income taxes	257,297	389,798
Net income	845,607	448,837
Earnings common share		
Primary	\$1.73	\$0.89
Fully Diluted	\$1.53	\$0.86
Common Shares:		
Full Diluted	525,607	519,861
Year-end	467,516	

DIXIE GROUP INC.

Earnings, 6 mos. to (Consol. - \$000):		
	06/30/18	07/01/17
Net Sales	205,297	204,728
Cost & expenses	207,014	200,780
Operating income	(1,870)	3,795
Other income (expense), net	(3)	(18)
Net before taxes	(5,049)	1,058
Income taxes	(192)	408
Income contin. oper.	(4,857)	650
Net income	(4,722)	498
Earnings common share		
Primary	\$(0.30)	\$0.03
Fully Diluted	\$(0.30)	\$0.03
Common Shares:		
Full Diluted	15,739	15,805
Year-end	16,452	16,126

DMC GLOBAL INC

Earnings, 6 mos. to Jun 30(Consol. - \$):		
	2018	2017
Net Sales	148,228,000	86,152,000
Cost & expenses	131,091,000	84,488,000
Operating income	15,541,000	(324,000)
Interest income	2,000	1,000
Other income (expense), net	(704,000)	(529,000)
Net before taxes	14,236,000	(1,688,000)
Income taxes	3,944,000	1,144,000
Net income	10,292,000	(2,832,000)
Earnings common share		
Primary	\$0.69	\$(0.20)
Fully Diluted	\$0.69	\$(0.20)
Common Shares:		
Full Diluted	14,491,569	14,308,954
Year-end	14,899,727	14,770,719

DORCHESTER MINERALS LP

Earnings, 6 mos. to Jun 30(Consol. - \$000):		
	2018	2017
Total Revenues	37,006	25,280
Cost & expenses	5,211	4,661
Net income	27,327	16,971
Earnings common share		
Primary	\$0.82	\$0.53
Fully Diluted	\$0.82	\$0.53
Common Shares:		
Full Diluted	32,280	30,684
Year-end	32,280	32,280

DORMAN PRODUCTS INC

Earnings, 6 mos. to (Consol. - \$000):		
	06/30/18	07/01/17
Net Sales	465,409	450,887
Cost & expenses	382,635	360,846
Operating income	82,774	90,041
Net before taxes	82,998	90,346
Income taxes	18,013	32,722
Net income	64,985	57,624
Earnings common share		
Primary	\$1.95	\$1.68
Fully Diluted	\$1.95	\$1.68
Common Shares:		
Full Diluted	33,355	34,350
Year-end	33,226	34,144

DOVA PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):		
	2018	2017
Total Revenues	4,584	
Cost & expenses	37,269	10,429
Operating income	(32,685)	(10,429)
Other income (expense), net	27	19
Net income	(33,427)	(10,931)
Earnings common share		
Primary	\$(1.22)	\$(0.63)
Fully Diluted	\$(1.22)	\$(0.63)
Common Shares:		
Full Diluted	27,396	17,332
Year-end	28,202	17,332

DRONE AVIATION HOLDING CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

FIBROCELL SCIENCE INC

Earnings, 6 mos. to Jun 30(Consol. - \$):		
	2018	2017
Cost & expenses	6,058,000	9,481,000
Operating income	(6,058,000)	(9,481,000)
Interest expense	381,000	368,000
Other income (expense), net	644,000	(9,176,000)
Net income	(5,795,000)	(19,025,000)
Balance for common	(6,207,000)	(22,995,000)
Earnings common share		
Primary	\$(1.03)	\$(7.82)
Fully Diluted	\$(1.03)	\$(7.82)
Common Shares:		
Full Diluted	6,026,454	2,940,763
Year-end	7,840,902	2,941,994

FIDUS INVESTMENT CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):		
	2018	2017
Cost & expenses	19,812,000	16,673,000
Operating income	16,533,000	16,826,000
Net before taxes	16,533,000	16,826,000
Income taxes	198,000	25,000
Net income	16,335,000	16,801,000
Earnings common share		
Primary	\$0.67	\$0.75
Fully Diluted	\$0.67	\$0.75
Common Shares:		
Full Diluted	24,480,484	22,550,846
Year-end	24,463,119	24,480,624

FIESTA RESTAURANT GROUP, INC

Earnings, 6 mos. to (Consol. - \$000):		
	07/01/18	07/02/17
Total Revenues	346,311	348,231
Net Sales	344,985	346,982
Cost & expenses	307,764	355,845
Operating income	20,378	(25,396)
Interest expense	2,055	1,238
Net before taxes	18,323	(26,634)
Income taxes	4,646	(9,414)
Net income	13,677	(17,220)
Earnings common share		
Primary	\$0.50	\$(0.64)
Fully Diluted	\$0.50	\$(0.64)
Common Shares:		
Full Diluted	26,902	26,795
Year-end	26,919	26,835

FIREEYE INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):		
	2018	2017
Total Revenues	401,766	376,481
Cost & expenses	511,026	499,461
Operating income	(109,260)	(122,980)
Other income (expense), net	(12,966)	112
Net before taxes	(142,225)	(143,298)
Income taxes	2,464	2,258
Net income	(144,689)	(145,556)
Balance for common	(144,689)	(145,556)
Earnings common share		
Primary	\$(0.77)	\$(0.83)
Fully Diluted	\$(0.77)	\$(0.83)
Common Shares:		
Full Diluted	188,085	174,453
Year-end	194,987	

FIRST HARTFORD CORP**Annual Report**

Consolidated Income Statement, Years Ended Apr. 30 (\$):			
	2018	2017	2016
		(revised)	(revised)
Rental income	31,419,431	31,984,825	30,416,900
Service income	5,192,144	5,453,919	6,791,095
Sales of real estate	40,424,504	34,373,493	21,100,182
Other revenues	5,982,883	3,858,059	3,555,335
Total revenues	83,018,962	75,670,296	61,863,512
Rental expenses	20,954,278	20,090,504	20,728,432
Service expenses	5,341,070	5,098,899	5,791,175
Cost of real estate sales	32,454,414	27,723,800	17,673,023
Other expenses	6,777,589	3,981,173	
Selling, general &			

administrative expenses	5,867,999	5,096,886	7,141,236
Total operating costs & expenses	71,395,350	61,991,262	51,333,866
Income from operations	11,623,612	13,679,034	10,529,646
Equity in earnings of unconsolidated subsidiaries	681,267	685,452	666,851
Other income	148,919	137,186	606,723
Gain (loss) on derivatives	1,531,013	2,669,416	(2,177,879)
Gain on forgiveness of debt	0
Gain (loss) on defeasance	0	(437,776)	...
Gain on voluntary foreclosure	2,649,850
Loss on impairment	40,000	0	330,700
Interest expense	10,816,099	10,393,998	9,368,956
Total non-operating income (expense)	(8,494,900)	(7,339,720)	(7,954,111)
Income (loss) before income taxes	3,128,712	6,339,314	2,575,535
Current provision for income taxes - federal	43,757	49,999	80,000
Current provision (benefit) for income taxes - state	288,362	350,313	180,915
Deferred provision for income taxes - federal	756,854	1,265,977	551,708
Deferred provision (benefit) for income taxes - state	124,506	193,652	119,524
Income tax expense (benefit)	1,213,479	1,859,941	932,147
Consolidated net income (loss)	1,915,233	4,479,373	1,643,388
Net loss (income) attributable to noncontrolling interests	(340,628)	(1,491,141)	124,538
Net income (loss) attributable to First Hartford Corporation	1,574,605	2,988,232	1,767,926
Weighted average shares outstanding - basic	2,320,799	2,375,617	2,407,526
Weighted average shares outstanding - diluted	2,320,799	2,375,617	2,407,526
Year end shares outstanding	2,315,799	2,340,799	2,404,590
Net income (loss) per share - basic	\$0.68	\$1.26	\$0.73
Net income (loss) per share - diluted	\$0.68	\$1.26	\$0.73
Number of full time employees	111	111	101
Number of part time employees	89	29	32
Number of common stockholders	276	318	345

Reclassified to conform with 2018 presentation; Including depreciation & amortization - Rental expenses: \$5,719,173; Including depreciation & amortization - Rental expenses: \$5,668,173; Including depreciation & amortization - Rental expenses: \$5,519,043; Approximately

Consolidated Balance Sheet, Years Ended Apr. 30 (\$):

	2018	2017	2016
		(revised)	(revised)
Developed properties & property under construction	251,892,715	236,865,867	
Equipment & tenant improvements	4,274,824	3,689,442	
Less: accumulated			

depreciation & amortization	52,650,839	47,449,316	
Real estate & equipment, net	203,516,700	193,105,993	
Property held for sale	7,465,163	11,389,591	
Cash & cash equivalents	7,206,445	6,250,757	
Cash & cash equivalents - restricted	992,923	526,012	
Marketable securities	619,432	1,538,839	
Accounts & notes receivable, gross	3,098,554	3,640,543	
Less: allowance for doubtful accounts	56,930	135,002	
Accounts & notes receivable, net	3,041,624	3,505,541	
Other receivables	4,494,150	4,064,876	
Deposits & escrow accounts	15,284,884	15,930,999	
Prepaid expenses	1,726,281	1,644,320	
Deferred expenses, net	3,064,329	5,712,547	
Investment in affiliates	429,847	100	
Due from related parties & affiliates	199,101	152,776	
Deferred tax asset	0	671,147	
Total assets	248,040,879	244,493,498	
Construction loans payable	32,168,786	26,929,537	
Mortgages payable	191,597,385	195,763,409	
Notes payable	1,704,697	1,704,697	
Lines of credit	4,760,000	6,400,000	
Less: deferred debt issuance costs	(2,975,038)	(3,067,098)	
Total mortgages & other notes payable	227,255,828	227,730,545	
Accounts payable	3,295,223	2,915,400	
Other payables	6,556,675	4,966,246	
Accrued liabilities	7,456,930	5,699,875	
Derivative liability	659,780	2,023,793	
Deferred income	885,635	622,461	
Other liabilities	1,007,642	1,328,909	
Due to related parties & affiliates	616,516	598,843	
Deferred tax liability	210,215	0	
Total liabilities	247,944,444	245,886,072	
Preferred stock	0	0	
Common stock	3,211,843	3,236,843	
Capital in excess of par	5,043,779	5,093,779	
Retained earnings (accumulated deficit)	(4,037,658)	(5,612,263)	
Accumulated other comprehensive income (loss)	0	0	
Treasury stock, at cost	4,989,384	4,989,384	
Total First Hartford Corporation shareholders' equity (deficiency)	(771,420)	(2,271,025)	
Noncontrolling interests	867,855	878,451	
Total shareholders' equity (deficiency)	96,435	(1,392,574)	

Including amount for variable interest entities - Developed properties & property under construction: \$79,969,791; Including amount for variable interest entities - Developed properties & property under construction: \$77,898,958; Including for variable interest entities - Equipment & tenant improvements: \$2,551,778; Including for variable interest entities - Equipment & tenant improvements: \$2,424,964; Including for variable interest entities - Accumulated depreciation & amortization: \$18,042,184; Including for variable interest entities - Accumulated depreciation & amortization: \$15,918,495; Including for variable interest entities - Cash & cash equivalents: \$2,689,207; Including for variable interest entities - Cash & cash equivalents: \$2,063,103; Including for variable interest entities - Cash & cash equivalents - restricted: \$386,505; Including for variable interest entities - Cash & cash equivalents - restricted: \$396,361; Including for variable interest entities - Marketable securities: \$619,432; Including for variable interest entities - Marketable securities: \$1,538,839; Including for variable interest entities - Accounts & notes receivable: \$49,668; Including for vari-

Common Shares:		
Full Diluted	74,427	73,185
Year-end	73,358	

FORRESTER RESEARCH INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	174,102	166,927
Cost & expenses	160,904	150,025
Operating income	8,739	13,349
Other income (expense), net	153	102
Gains or losses	(45)	(225)
Net before taxes	8,847	13,226
Income taxes	2,792	4,132
Net income	6,055	9,094
Earnings common share		
Primary	\$0.34	\$0.51
Fully Diluted	\$0.33	\$0.50
Common Shares:		
Full Diluted	18,313	18,293
Year-end	17,940	17,612

FORTERRA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Net Sales	706,047	774,987
Cost & expenses	690,368	795,077
Operating income	15,679	(20,090)
Interest expense	31,053	30,620
Other income (expense), net	6,016	
Net before taxes	(9,358)	(50,710)
Income taxes	3,558	(16,994)
Net income	(12,916)	(33,716)
Earnings common share		
Primary	\$(0.20)	\$(0.53)
Fully Diluted	\$(0.20)	\$(0.53)
Common Shares:		
Full Diluted	63,865	63,791
Year-end	64,228	64,166

FORTINET INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	840,300	704,045
Cost & expenses	757,200	670,135
Operating income	83,100	33,910
Interest income	10,300	5,555
Other income (expense), net	(5,200)	1,545
Net before taxes	88,200	41,010
Income taxes	(2,700)	7,260
Net income	90,900	33,750
Earnings common share		
Primary	\$0.54	\$0.19
Fully Diluted	\$0.53	\$0.19
Common Shares:		
Full Diluted	172,600	178,993
Year-end	169,000	175,735

FORTRESS BIOTECH INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	119,259	95,379
Net Sales	12,198	6,139
Cost & expenses	177,626	135,143
Deprec., depl. & amort.	1,716	1,006
Operating income	(60,083)	(40,770)
Interest income	572	326
Interest expense	4,227	2,078
Other income (expense), net	(8,758)	5,011
Net before taxes	(72,496)	
Income taxes	1,438	
Net income	(73,934)	(37,511)
Balance for common	(42,629)	(29,347)
Earnings common share		
Primary	\$(0.99)	\$(0.73)
Fully Diluted	\$(0.99)	\$(0.73)
Common Shares:		
Full Diluted	42,949	40,458
Year-end	54,247	50,509

FORTY SEVEN INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Cost & expenses	31,954	21,828
Operating income	(31,954)	(21,828)
Other income (expense), net	457	93
Net income	(31,497)	(21,735)
Earnings common share		
Primary	\$(4.76)	\$(3.39)
Fully Diluted	\$(4.76)	\$(3.39)
Common Shares:		
Full Diluted	6,619	6,404
Year-end	31,048	

FOSSIL GROUP INC**Earnings, 6 mos. to** (Consol. – \$):

	06/30/18	07/01/17
Net Sales	1,145,739,000	178,636,000
Cost & expenses	1,173,007,000	653,655,000
Operating income	(27,268,000)	475,019,000
Other income (expense), net	(2,442,000)	7,640,000
Net before taxes	(51,469,000)	487,404,000
Income taxes	3,273,000	(97,516,000)
Net income	(54,742,000)	389,888,000
Earnings common share		
Primary	\$(1.15)	\$(8.12)
Fully Diluted	\$(1.15)	\$(8.12)
Common Shares:		
Full Diluted	48,970,000	48,399,000
Year-end	49,339,000	

FOSTER (L.B.) CO**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Net Sales	295,344	263,562
Cost & expenses	287,668	258,600
Operating income	4,116	1,508
Net before taxes	4,116	1,508
Income taxes	1,198	906
Net income	2,918	602
Earnings common share		
Primary	\$0.28	\$0.06
Fully Diluted	\$0.28	\$0.06
Common Shares:		
Full Diluted	10,477	10,527
Year-end	10,365	10,342

FOUNDATION MEDICINE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	109,846	61,332
Cost & expenses	178,351	152,333
Operating income	(68,505)	(91,001)
Other income (expense), net	182	144
Net income	(70,794)	(90,711)
Earnings common share		
Primary	\$(1.92)	\$(2.55)
Fully Diluted	\$(1.92)	\$(2.55)
Common Shares:		
Full Diluted	36,932	35,544
Year-end	37,147	

FOUNDATION MEDICINE INC

Merger Completed On July 31, 2018, Roche Holdings, Inc. ("Parent"), a wholly-owned subsidiary of Roche Holding Ltd. ("Roche Holding"), through its wholly-owned subsidiary, 062018 Merger Subsidiary, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each issued and outstanding common stock share, par value \$0.0001 per share (the "Shares"), of Co. (other than (1) Shares owned at the commencement of the Offer and immediately prior to the Effective Time by Parent, Roche Holding or any other direct or indirect subsidiary of Parent or Roche Holding, (2) Shares owned immediately prior to the Effective Time by Co. or any direct or indirect subsidiary of Co., and (3) Shares held by stockholders who were entitled to, and who had properly exercised their demands for appraisal of such Shares in accordance with Section 262 of the DGCL and have neither withdrawn nor lost such rights prior to the Effective Time), was converted into the right to receive \$137.00 per Share (the "Offer Price"), net to the seller in cash (the "Merger Consideration"), without interest and subject to any required tax withholding. In addition, (i) each vested outstanding Co. stock option, whether or not exercisable, was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the excess, if any, of the Merger

Consideration over the per Share exercise price applicable to such Co. stock option, multiplied by (y) the total number of Shares subject to such Co. stock option, (ii) each outstanding unvested Co. stock option was cancelled and converted into the right to receive, upon the satisfaction of the original vesting conditions applicable to the underlying Co. stock option, an amount in cash equal to the product of (x) the excess, if any, of the Merger Consideration over the per Share exercise price applicable to such Co. stock option, multiplied by (y) the total number of Shares subject to such Co. stock option and (iii) each Co. restricted stock unit was cancelled and converted into the right to receive, upon the satisfaction of the original vesting conditions applicable to the underlying Co. restricted stock unit, an amount in cash equal to the product of (x) the Merger Consideration, multiplied by (y) the number of Shares underlying such award. The aggregate consideration paid by Merger Sub in the Offer and Merger to purchase all outstanding Shares (other than the Shares owned by Parent and its affiliates) and other equity-based interests of Co. pursuant to the Offer and the Merger, was approximately \$2,200,000,000.

FOX FACTORY HOLDING CORP**Earnings, 6 mos. to** (Consol. – \$000):

	06/29/18	06/30/17
Total Revenues	286,617	227,141
Cost & expenses	243,323	195,143
Operating income	40,226	30,607
Interest expense	1,631	1,094
Other income (expense), net	(200)	(467)
Net before taxes	38,395	29,046
Income taxes	(1,868)	4,792
Net income	40,263	24,254
Earnings common share		
Primary	\$1.05	\$0.65
Fully Diluted	\$1.02	\$0.63
Common Shares:		
Full Diluted	38,846	38,643
Year-end	37,759	37,429

FRANKLIN ELECTRIC CO., INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Net Sales	639,600	525,601
Cost & expenses	576,426	472,825
Operating income	63,174	52,776
Interest expense	5,034	5,758
Other income (expense), net	(159)	6,178
Foreign currency	(1,550)	103
Net before taxes	56,431	53,299
Income taxes	5,177	7,121
Net income	51,254	46,178
Earnings common share		
Primary	\$1.10	\$0.97
Fully Diluted	\$1.09	\$0.97
Common Shares:		
Full Diluted	47,000	47,000
Year-end	46,543	46,482

FREIGHTCAR AMERICA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues	149,716	258,208
Cost & expenses	161,854	257,836
Operating income	(12,138)	372
Other income (expense), net	969	(115)
Net before taxes	(11,228)	185
Income taxes	(2,488)	(5)
Net income	(8,740)	190
Earnings common share		
Primary	\$(0.70)	\$0.02
Fully Diluted	\$(0.70)	\$0.02
Common Shares:		
Full Diluted	12,312	12,277
Year-end	12,464	

FREQUENCY ELECTRONICS INC**Annual Report****Consolidated Income Statement, Years Ended Apr. 30**

	2018	2017	2016
			(revised)
Revenues	39,407	50,351	55,416
Cost of revenues	34,244	39,102	36,141
Gross margin	5,163	11,249	19,275
Selling & administrative			

expenses	10,608	11,898	11,379	Net income (loss) per share - diluted	\$ (2.69)	\$ (0.55)	\$ 0.11	& held in treasury - at cost	1,361	1,592
Research & development expenses	6,950	6,876	5,428	Number of full time employees	2 300	2 325	...	Change in market value of marketable securities	(125)	1,167
Income (loss) from operations	(12,395)	(7,525)	2,468	Number of common stockholders	2 655	2 655	...	Foreign currency translation adjustment	(790)	1,114
Investment income	1,268	549	490	Foreign currency translation adjustments	(38)	(753)	Accumulated other comprehensive income (loss)	(915)	2,281
Interest expense	79	150	131					Total stockholders' equity	63,262	89,332
Other income (expense), net	(69)	87	447							
Income (loss) before income taxes - United States	(10,785)	(6,625)	4,011	□ Restated to reflect the discontinued operations of Gillam-FEI s.a.; □ As is; □ Approximately; □ As of July 26, 2018; □ As of July 25, 2017						
Income (loss) before income taxes - foreign	(490)	(414)	(737)	Consolidated Balance Sheet, Years Ended Apr. 30 (\$000):						
Income (loss) before provision (benefit) for income taxes	(11,275)	(7,039)	3,274		2018	2017				
Current income taxes provision (benefit) - federal	(869)	(677)	1,060	Cash & cash equivalents	7,869	2,163		Recent Dividends:		
Current income taxes provision (benefit) - state	(124)	(84)	250	Marketable securities	6,149	7,815		1. Frequency Electronics Inc common.		
Total current income taxes provision (benefit)	(993)	(761)	1,310	Accounts receivable, gross	4,449	11,173		No dividends paid.		
Deferred income taxes provision (benefit) - federal	10,702	(1,861)	(150)	Less allowance for doubtful accounts	181	187		Annual Dividends:		
Deferred income taxes provision (benefit) - foreign	267	Accounts receivable, net	4,268	10,986		1. Frequency Electronics Inc common.		
Deferred income taxes provision (benefit) - state	1,200	507	(90)	Costs & estimated earnings in excess of billings, net	5,094	7,964		No dividends paid.		
Total deferred income taxes provision (benefit)	12,169	(1,354)	(240)	Raw materials & component parts	16,206	17,702		FRESHPET INC		
Provision (benefit) for income taxes	11,176	(2,115)	1,070	Work in progress	8,216	7,340		Earnings, 6 mos. to Jun 30 (Consol. - \$):		
Net (loss) income from continuing operations	(22,451)	(4,924)	2,204	Finished goods	1,764	4,009		2018	2017	
Income (loss) from discontinued operations, net of tax	(967)	103	(1,199)	Inventories, net	26,186	29,051		Net Sales	90,794,557	74,482,918
Income (loss) on sale of discontinued operations	(359)	Prepaid income taxes	1,459	2,606		Cost & expenses	97,614,114	79,050,510
Total income (loss) from discontinued operations	(1,326)	103	...	Prepaid expenses & other current assets	1,050	1,105		Operating income	(6,819,557)	(4,567,592)
Net income (loss)	(23,777)	(4,821)	1,005	Current assets of discontinued operations	8,165		Other income (expense), net	3,090	(556,909)
Weighted average shares outstanding - basic	8,841	8,787	8,728	Total current assets	52,075	69,855		Net before taxes	(6,983,392)	(5,490,180)
Weighted average shares outstanding - diluted	8,841	8,787	8,937	Buildings & building improvements	2,790	2,646		Income taxes	38,064	41,507
Year end shares outstanding	8,867	8,817	8,753	Machinery, equipment & furniture	57,503	56,435		Net income	(7,021,456)	(5,531,687)
Income (loss) per share - continuing operations - basic	\$(2.54)	\$(0.56)	\$0.25	Property, plant & equipment, gross	60,293	59,081		Balance for common	(7,021,456)	(5,531,687)
Income (loss) per share - discontinued operations - basic	\$(0.15)	\$0.01	\$(0.13)	Less accumulated depreciation	46,166	44,268		Earnings common share		
Net income (loss) per share - basic	\$(2.69)	\$(0.55)	\$0.12	Property, plant & equipment, net	14,127	14,813		Primary	\$(0.20)	\$(0.16)
Income (loss) per share - continuing operations - diluted	\$(2.54)	\$(0.56)	\$0.24	Deferred income taxes	11,902		Fully Diluted	\$(0.20)	\$(0.16)
Income (loss) per share - discontinued operations - diluted	\$(0.15)	\$0.01	\$(0.13)	Goodwill & other intangible assets	617	617		Common Shares:		
				Cash surrender value of life insurance	13,915	13,376		Full Diluted	35,189,636	34,138,251
				Other assets	2,850	2,187		Year-end	35,303,351	34,513,231
				Non-current assets of discontinued operations	569				
				Total assets	83,584	113,319		FTD COMPANIES INC		
				Accounts payable - trade	1,841	2,437		Earnings, 6 mos. to Jun 30 (Consol. - \$000):		
				Accrued vacation & other compensation	1,433	1,467		2018	2017	
				Accrued incentive compensation	411	265		Total Revenues	618,091	644,639
				Accrued payroll taxes	113	128		Cost & expenses	746,628	601,411
				Deferred revenue	68	232		Operating income	(131,534)	35,589
				Accrued warranty reserve	520	557		Interest income	241	237
				Accrued commissions	307	234		Interest expense	7,116	4,950
				Other accrued liabilities	564	542		Other income (expense), net	136	198
				Accrued liabilities	3,416	3,425		Net before taxes	(138,273)	31,074
				Current liabilities of discontinued operations	2,249		Income taxes	(13,592)	12,335
				Total current liabilities	5,257	8,111		Net income	(124,681)	18,739
				Deferred compensation	13,541	13,252		Balance for common	(124,681)	18,305
				Deferred rent & other liabilities	1,524	1,409		Earnings common share		
				Non-current liabilities of discontinued operations	1,215		Primary	\$(4.49)	\$0.67
				Total liabilities	20,322	23,987		Fully Diluted	\$(4.49)	\$0.67
				Common stock	9,164	9,164		Common Shares:		
				Additional paid-in capital	56,439	55,767		Full Diluted	17,891	18,156
				Retained earnings (accumulated deficit)	(65)	23,712		Year-end	17,963	17,740
				Common stock reacquired				FUNKO INC		
								Earnings, 6 mos. to Jun 30 (Consol. - \$000):		
								2018	2017	
								Net Sales	275,934	203,798
								Cost & expenses	240,705	184,053
								Operating income	16,278	5,423
								Interest expense	11,480	14,677
								Other income (expense), net	(1,160)	113
								Net before taxes	3,638	(9,141)
								Income taxes	530	1,024

Net income	3,108	(10,165)
Earnings common share		
Primary	\$0.06	\$
Fully Diluted	\$0.05	\$
Common Shares:		
Full Diluted	50,725	
Year-end	48,321	

FUTURE FINTECH GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	1,350,220	5,735,706
Cost & expenses	7,606,804	10,346,648
Operating income	(6,256,584)	(4,610,942)
Interest income	(1,028)	2,179
Interest expense	861,379	626,109
Other income (expense), net	(7,377)	201,915
Minority interest	(935,977)	(203,821)
Net before taxes	(5,032,957)	
Income taxes		260,085
Income contin. oper.	(6,190,391)	(5,089,221)
Net income	(6,239,901)	(5,185,929)
Earnings common share		
Primary	\$(0.41)	\$(1.14)
Fully Diluted	\$(0.41)	\$(1.12)
Common Shares:		
Full Diluted	15,324,570	4,599,740
Year-end	26,071,083	5,173,187

G1 THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	42,378,000	27,758,000
Operating income	(42,378,000)	(27,758,000)
Other income (expense), net	1,099,000	219,000
Net income	(41,279,000)	(27,539,000)
Balance for common	(41,279,000)	(32,296,000)
Earnings common share		
Primary	\$(1.33)	\$(4.09)
Fully Diluted	\$(1.33)	\$(4.09)
Common Shares:		
Full Diluted	31,080,650	7,887,341
Year-end	33,077,765	28,285,478

GAIA INC (NEW)

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	20,075,000	12,342,000
Cost & expenses	34,462,000	25,550,000
Operating income	(14,387,000)	(13,208,000)
Net before taxes	(14,210,000)	(13,120,000)
Income taxes	(1,826,000)	(629,000)
Net income	(12,384,000)	(12,491,000)
Earnings common share		
Primary	\$(0.74)	\$(0.82)
Fully Diluted	\$(0.74)	\$(0.82)
Common Shares:		
Full Diluted	16,627,000	15,155,000
Year-end	17,900,139	15,159,548

GAMING & LEISURE PROPERTIES, INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	498,271	486,104
Cost & expenses	137,702	126,722
Operating income	305,092	302,702
Other income (expense), net	(3,473)	
Net before taxes	191,868	195,047
Income taxes	3,098	4,722
Net income	188,770	190,325
Balance for common	188,505	190,010
Earnings common share		
Primary	\$0.88	\$0.91
Fully Diluted	\$0.88	\$0.90
Common Shares:		
Full Diluted	214,506	210,824
Year-end	213,738	212,218

GAMING PARTNERS INTERNATIONAL CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	43,361,000	35,187,000
Cost & expenses	39,946,000	33,654,000
Operating income	3,415,000	1,533,000

Other income (expense), net	40,000	16,000
Foreign currency	(99,000)	23,000
Net before taxes	3,253,000	1,450,000
Income taxes	746,000	470,000
Net income	2,507,000	980,000
Earnings common share		
Primary	\$0.32	\$0.12
Fully Diluted	\$0.31	\$0.12
Common Shares:		
Full Diluted	8,026,000	8,058,000
Year-end	7,954,523	8,219,577

GCI LIBERTY INC

Earnings, 6 mos. to Jun 30(Consol. - \$Millions):

	2018	2017
Total Revenues	295	10
Cost & expenses	222	32
Deprec., depl. & amort.	80	2
Operating income	(8)	(23)
Other income (expense), net	8	4
Gains or losses	(500)	798
Net before taxes	(544)	779
Income taxes	(70)	297
Net income	(474)	482
Earnings common share		
Primary	\$(4.40)	\$4.42
Fully Diluted	\$(4.40)	\$4.42
Common Shares:		
Full Diluted	108	
Year-end	109	

GELTECH SOLUTIONS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	660,436	570,505
Cost & expenses	2,380,457	2,225,394
Operating income	(1,720,021)	(1,654,889)
Interest income	3	8
Interest expense	357,323	423,748
Net income	(2,077,341)	(2,078,629)
Earnings common share		
Primary	\$(0.03)	\$(0.04)
Fully Diluted	\$(0.03)	\$(0.04)
Common Shares:		
Full Diluted	81,803,910	56,487,308
Year-end	87,294,690	60,778,617

GEMPHIRE THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	13,598	18,018
Operating income	(13,598)	(18,018)
Other income (expense), net	(5)	
Net income	(13,902)	(17,998)
Earnings common share		
Primary	\$(1.04)	\$(1.79)
Fully Diluted	\$(1.04)	\$(1.79)
Common Shares:		
Full Diluted	13,341	10,065
Year-end	14,232	10,607

GENCOR INDUSTRIES INC

Earnings, 9 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	78,069,000	62,052,000
Cost & expenses	67,831,000	52,654,000
Operating income	10,238,000	9,398,000
Other income (expense), net	7,000	
Gains or losses	(1,061,000)	810,000
Net before taxes	10,259,000	10,592,000
Income taxes	1,468,000	3,195,000
Net income	8,791,000	7,397,000
Earnings common share		
Primary	\$0.61	\$0.51
Fully Diluted	\$0.60	\$0.50
Common Shares:		
Full Diluted	14,724,000	14,680,000
Year-end	14,493,694	14,401,686

GENMARK DIAGNOSTICS, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	35,586,000	24,894,000
Cost & expenses	62,178,000	55,717,000

Operating income	(26,592,000)	(30,823,000)
Other income (expense), net	(102,000)	151,000
Net before taxes	(27,890,000)	(31,827,000)
Income taxes	54,000	78,000
Net income	(27,944,000)	(31,905,000)
Earnings common share		
Primary	\$(0.50)	\$(0.67)
Fully Diluted	\$(0.50)	\$(0.67)
Common Shares:		
Full Diluted	55,377,000	47,460,000
Year-end	55,753,000	54,665,000

GENOCEA BIOSCIENCES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	20,172	28,374
Operating income	(20,172)	(28,374)
Interest expense	442	728
Other income (expense), net	286	(8)
Net income	(20,328)	(29,110)
Earnings common share		
Primary	\$(0.26)	\$(1.02)
Fully Diluted	\$(0.26)	\$(1.02)
Common Shares:		
Full Diluted	78,428	28,519
Year-end	86,626	28,624

GENOMIC HEALTH INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	185,532	175,435
Operating income	2,712	(5,968)
Other income (expense), net	1,471	452
Gains or losses		2,807
Net before taxes	5,000	(2,345)
Income taxes	458	1,200
Net income	4,542	(3,545)
Earnings common share		
Primary	\$0.13	\$(0.10)
Fully Diluted	\$0.12	\$(0.10)
Common Shares:		
Full Diluted	36,360	34,219
Year-end	35,855	

GENTEX CORP.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	920,401,545	896,674,323
Cost & expenses	665,203,208	636,382,689
Operating income	255,198,337	260,291,634
Other income (expense), net	652,634	(691,632)
Gains or losses	4,881,738	3,208,665
Net before taxes	260,732,709	262,808,667
Income taxes	40,459,984	76,715,979
Net income	220,272,725	186,092,688
Earnings common share		
Primary	\$0.81	\$0.65
Fully Diluted	\$0.80	\$0.64
Common Shares:		
Full Diluted	275,660,418	290,538,242
Year-end	268,915,947	285,549,444

GENTHERM INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	489,426	432,669
Operating income	36,242	59,976
Interest expense	2,420	2,383
Other income (expense), net	1,326	505
Gains or losses	596	(14,580)
Net before taxes	35,744	43,518
Income taxes	6,119	9,603
Net income	29,625	33,915
Earnings common share		
Primary	\$0.81	\$0.92
Fully Diluted	\$0.81	\$0.92
Common Shares:		
Full Diluted	36,663	36,796
Year-end	36,401	36,822

GEOSPACE TECHNOLOGIES CORP

Earnings, 9 mos. to Jun 30(Consol. - \$000):

Full Diluted	19,208	19,252	Other income (expense), net	252	94		2018	2017
Year-end	18,826		Net before taxes	16,045	12,140	Total Revenues	29,102,000	67,519,000
ICONIX BRAND GROUP INC			Income taxes	34,622	1,792	Cost & expenses	104,596,000	85,548,000
Earnings, 6 mos. to Jun 30(Consol. - \$):			Net income	(18,577)	10,348	Operating income	(75,494,000)	(18,029,000)
	2018	2017	Earnings common share			Other income (expense), net	(515,000)	885,000
Cost & expenses	176,525,000	69,658,000	Primary	\$(0.89)	\$0.48	Gains or losses	1,476,000	258,000
Operating income	(79,050,000)	49,489,000	Fully Diluted	\$(0.89)	\$0.48	Net income	(80,237,000)	(26,212,000)
Interest expense	29,376,000	28,876,000	Common Shares:			Earnings common share		
Other income (expense), net	62,688,000	(19,399,000)	Full Diluted	21,193	21,551	Primary	\$(0.61)	\$(0.30)
Foreign currency	(152,000)	(3,845,000)	Year-end	21,206	21,434	Fully Diluted	\$(0.61)	\$(0.30)
Net before taxes	(45,676,000)	(2,364,000)	ILG INC			Common Shares:		
Income taxes	(1,154,000)	386,000	Earnings, 6 mos. to Jun 30(Consol. - \$Millions):			Full Diluted	132,512,000	87,167,000
Income contin. oper.		(9,136,000)	Total Revenues	944	885	Year-end	149,021,000	89,597,000
Income discount. oper.		48,498,000	Cost & expenses	786	737	IMPERVA INC		
Net income	(51,670,000)	39,362,000	Operating income	117	108	Earnings, 6 mos. to Jun 30(Consol. - \$000):		
Earnings common share			Interest income	1			2018	2017
Primary	\$(0.91)	\$0.65	Interest expense	15	12	Total Revenues	169,044	146,743
Fully Diluted	\$(0.91)	\$0.65	Other income (expense), net	1	11	Cost & expenses	184,391	162,594
Common Shares:			Gains or losses		2	Operating income	(15,611)	(16,300)
Full Diluted	62,566,000	57,568,000	Net before taxes	104	109	Other income (expense), net	1,949	66
Year-end	68,561,000	57,200,000	Income taxes	33	38	Gains or losses		35,871
ICU MEDICAL INC			Net income	71	71	Net before taxes	(13,662)	19,637
Earnings, 6 mos. to Jun 30(Consol. - \$000):			Earnings common share			Income taxes	19,178	44
	2018	2017	Primary	\$0.56	\$0.56	Net income	(32,840)	19,593
Total Revenues	732,493	579,253	Fully Diluted	\$0.55	\$0.55	Earnings common share		
Net Sales	732,493	578,461	Common Shares:			Primary	\$(0.95)	\$0.59
Cost & expenses	699,564	632,168	Full Diluted	126	126	Fully Diluted	\$(0.95)	\$0.58
Operating income	32,929	(52,915)	Year-end	124		Common Shares:		
Other income (expense), net	756	60,624	ILLUMINA INC			Full Diluted	34,638	33,984
Net before taxes	33,420	6,671	Earnings, 6 mos. to (Consol. - \$000):			Year-end	34,956	33,814
Income taxes	(2,509)	(12,132)	Total Revenues	07/01/18	07/02/17	IMPERVA INC		
Net income	35,929	18,803	Cost & expenses	1,612,000	1,261,000	Merger Completed On Aug. 9, 2018, Co.'s wholly-owned subsidiary, Pahlmeyer Acquisition Sub, Inc. ("Merger Sub"), merged with and into Prevoty, Inc. ("Prevoty"), a cloud-based security company, with Prevoty continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, Co. paid in exchange for all outstanding vested shares of Prevoty capital stock and vested options to purchase Prevoty capital stock approximately \$140,000,000 in cash, plus approximately \$10,600,000 based on Prevoty's closing working capital. Outstanding unvested shares of Prevoty stock were exchanged for an aggregate of approximately \$600,000, subject to continued vesting. In addition, Co. assumed unvested options to purchase Prevoty capital stock held by persons joining Co. as service providers following the closing of the Merger and Co. has agreed to file a Registration Statement on Form S-8 covering these unvested Prevoty options. Co. also granted new restricted stock unit awards worth approximately \$4,600,000 to certain continuing employees under Co.'s Amended and Restated 2015 Equity Inducement Plan.		
Earnings common share			Operating income	445,000	195,000	INCYTE CORPORATION		
Primary	\$1.77	\$0.98	Interest income	16,000	9,000	Earnings, 6 mos. to Jun 30(Consol. - \$000):		
Fully Diluted	\$1.67	\$0.93	Interest expense	22,000	16,000		2018	2017
Common Shares:			Other income (expense), net	14,000	457,000	Total Revenues	903,798	710,526
Full Diluted	21,536	20,312	Net before taxes	453,000	645,000	Cost & expenses	887,669	836,514
Year-end	20,460	19,844	Income taxes	56,000	177,000	Operating income	16,129	(125,988)
IDENTIV INC			Net income	397,000	468,000	Other income (expense), net	(11,962)	(80,269)
Earnings, 6 mos. to Jun 30(Consol. - \$000):			Earnings common share			Net before taxes	13,654	(207,367)
	2018	2017	Primary	\$2.84	\$3.38	Income taxes	2,400	(7,800)
Total Revenues	36,822	28,232	Fully Diluted	\$2.82	\$3.35	Net income	11,254	(199,567)
Cost & expenses	39,625	30,406	Common Shares:			Earnings common share		
Operating income	(2,803)	(2,174)	Full Diluted	148,000	147,000	Primary	\$0.05	\$(1.00)
Other income (expense), net	(1,369)	977	Year-end	147,000	146,000	Fully Diluted	\$0.05	\$(1.00)
Foreign currency	154	(151)	IMMERSION CORP			Common Shares:		
Net before taxes	(4,966)	(2,700)	Earnings, 6 mos. to Jun 30(Consol. - \$000):			Full Diluted	215,294	200,200
Income taxes	80	(119)	Total Revenues	2018	2017	Year-end	212,409	
Net income	(5,046)	(2,581)	Total Revenues	91,560	16,254	INDUSTRIAL LOGISTICS PROPERTIES TRUST		
Earnings common share			Cost & expenses	29,750	44,017	Earnings, 6 mos. to Jun 30(Consol. - \$000):		
Primary	\$(0.33)	\$(0.22)	Operating income	61,810	(27,763)		2018	2017
Fully Diluted	\$(0.33)	\$(0.22)	Net before taxes	62,416	(27,459)	Total Revenues	80,025	78,045
Common Shares:			Income taxes	291	251	Cost & expenses	20,998	21,311
Full Diluted	15,349	12,008	Net income	62,125	(27,710)	Deprec., depl. & amort.	13,763	13,666
Year-end	15,339	14,073	Earnings common share			Operating income	45,264	43,068
IDEXX LABORATORIES, INC.			Primary	\$2.06	\$(0.95)	Interest income	63	
Earnings, 6 mos. to Jun 30(Consol. - \$):			Fully Diluted	\$2.00	\$(0.95)	Interest expense	7,354	1,115
	2018	2017	Common Shares:			Net before taxes	37,973	41,953
Total Revenues	1,118,408,000	970,961,000	Full Diluted	31,074	29,109	Income taxes	15	22
Cost & expenses	859,770,000	756,154,000	Year-end	30,762	29,254	Net income	37,958	41,931
Operating income	258,638,000	214,807,000	IMMUNE DESIGN CORP			Earnings common share		
Interest income	751,000	2,259,000	Earnings, 6 mos. to Jun 30(Consol. - \$000):			Primary	\$0.60	\$0.93
Interest expense	17,731,000	17,744,000	Total Revenues	2018	2017	Fully Diluted	\$0.60	\$0.93
Net before taxes	241,658,000	199,322,000	Total Revenues	1,258	6,194	IMMUNOGEN, INC.		
Income taxes	43,502,000	44,857,000	Cost & expenses	29,459	32,979	Earnings, 6 mos. to Jun 30(Consol. - \$):		
Net income	198,156,000	154,465,000	Operating income	(28,201)	(26,785)	Earnings, 6 mos. to Jun 30(Consol. - \$):		
Earnings common share			Net income	(27,108)	(26,466)	Total Revenues	80,025	78,045
Primary	\$2.27	\$1.75	Earnings common share			Cost & expenses	20,998	21,311
Fully Diluted	\$2.23	\$1.72	Primary	\$(0.56)	\$(1.04)	Deprec., depl. & amort.	13,763	13,666
Common Shares:			Fully Diluted	\$(0.56)	\$(1.04)	Operating income	45,264	43,068
Full Diluted	88,786,000	89,962,000	Common Shares:			Interest income	63	
Year-end	86,642,000	87,447,000	Full Diluted	48,124	25,516	Interest expense	7,354	1,115
IES HOLDINGS INC			Year-end	48,165	25,590	Net before taxes	37,973	41,953
Earnings, 9 mos. to Jun 30(Consol. - \$000):			IMMUNOGEN, INC.			Income taxes	15	22
	2018	2017	Earnings, 6 mos. to Jun 30(Consol. - \$):			Net income	37,958	41,931
Total Revenues	636,553	604,163	Earnings, 6 mos. to Jun 30(Consol. - \$):			Earnings common share		
Cost & expenses	619,333	590,836	Total Revenues	2018	2017	Primary	\$0.60	\$0.93
Operating income	17,220	13,327	Total Revenues	1,258	6,194	Fully Diluted	\$0.60	\$0.93
Interest expense	1,427	1,281	Cost & expenses	29,459	32,979			

	2018	2017	Operating income	(6,899)	(4,599)		06/30/18	06/24/17
Total Revenues	20,006	18,791	Other income (expense), net	24	(3)	Net Sales	837,550	767,498
Cost & expenses	38,633	39,010	Net before taxes	(6,875)	(4,602)	Cost & expenses	757,912	686,260
Operating income	(18,627)	(20,219)	Income taxes	8	14	Operating income	79,638	81,238
Interest income	164	110	Net income	(6,883)	(4,616)	Gains or losses	4,687	3,824
Interest expense	1,568	1,014	Earnings common share			Net before taxes	84,592	84,411
Other income (expense), net	(116)	(2,481)	Primary	\$(0.59)	\$(0.40)	Income taxes	4,381	29,580
Net income	(20,147)	(23,604)	Fully Diluted	\$(0.59)	\$(0.40)	Net income	80,211	54,831
Earnings common share			Common Shares:			Earnings common share		
Primary	\$(0.95)	\$(1.39)	Full Diluted	11,636	11,532	Primary	\$4.29	\$2.93
Fully Diluted	\$(0.95)	\$(1.39)	Year-end	11,664	11,559	Fully Diluted	\$4.27	\$2.91
Common Shares:						Common Shares:		
Full Diluted	21,102	16,972	IRIDIUM COMMUNICATIONS INC			Full Diluted	18,801	18,818
Year-end	24,074	17,041	Earnings, 6 mos. to Jun 30(Consol. - \$):			Year-end	18,697	18,729
				2018	2017			
IONIS PHARMACEUTICALS INC			Total Revenues	254,079,000	216,030,000	J2 GLOBAL INC (NEW)		
Earnings, 6 mos. to Jun 30(Consol. - \$000):			Cost & expenses	129,339,000	90,978,000	Earnings, 6 mos. to Jun 30(Consol. - \$):		
	2018	2017	Operating income	35,784,000	91,344,000		2018	2017
Total Revenues	262,165	228,073	Other income (expense), net	102,000	(143,000)	Total Revenues	568,512,000	527,843,000
Cost & expenses	315,748	202,138	Net before taxes	18,736,000	92,866,000	Cost & expenses	467,971,000	421,308,000
Operating income	(53,583)	25,935	Income taxes	11,682,000	30,140,000	Operating income	100,541,000	106,535,000
Other income (expense), net	(123)	(1,438)	Net income	7,054,000	62,726,000	Interest expense	31,254,000	26,079,000
Gains or losses	8,748	4,744	Balance for common	1,086,000	55,008,000	Other income (expense), net	(4,912,000)	(4,551,000)
Net before taxes	(67,009)	6,100	Earnings common share			Equity earnings	2,971,000	
Income taxes	372	222	Primary	\$0.01	\$0.56	Net before taxes	64,375,000	75,905,000
Net income	(67,381)	5,878	Fully Diluted	\$0.01	\$0.49	Income taxes	14,055,000	18,709,000
Earnings common share			Common Shares:			Net income	47,349,000	57,196,000
Primary	\$(0.30)	\$0.05	Full Diluted	109,405,000	126,659,000	Balance for common	46,714,000	56,488,000
Fully Diluted	\$(0.30)	\$0.05	Year-end	110,750,000		Earnings common share		
Common Shares:						Primary	\$0.98	\$1.19
Full Diluted	127,030	123,428	IROBOT CORP			Fully Diluted	\$0.95	\$1.16
Year-end	137,156		Earnings, 6 mos. to (Consol. - \$000):			Common Shares:		
				06/30/18	07/01/17	Full Diluted	48,962,835	48,857,405
IOVANCE BIOTHERAPEUTICS INC			Total Revenues	443,385	351,615	Year-end	47,994,805	47,591,011
Earnings, 6 mos. to Jun 30(Consol. - \$):			Cost & expenses	404,083	325,889			
	2018	2017	Operating income	38,760	25,726	JACK IN THE BOX, INC.		
Cost & expenses	58,255,000	44,464,000	Other income (expense), net	2,026	1,689	Earnings, 9 mos. to (Consol. - \$000):		
Operating income	(58,255,000)	(44,464,000)	Net before taxes	40,786	27,415		07/08/18	07/09/17
Net income	(57,175,000)	(44,061,000)	Income taxes	9,914	3,153	Total Revenues	692,218	865,166
Earnings common share			Net income	30,872	24,262	Cost & expenses	449,945	630,458
Primary	\$(0.65)	\$(0.71)	Earnings common share			Deprec., depl. & amort.	46,306	52,721
Fully Diluted	\$(0.65)	\$(0.71)	Primary	\$1.11	\$0.89	Operating income	195,967	181,987
Common Shares:			Fully Diluted	\$1.08	\$0.85	Interest income	425	63
Full Diluted	87,310,000	62,371,000	Common Shares:			Interest expense	34,491	28,891
Year-end	92,741,672	62,680,390	Full Diluted	28,658	28,581	Net before taxes	161,901	153,159
			Year-end	27,402	27,644	Income taxes	75,898	55,928
IPG PHOTONICS CORP						Income contin. oper.	86,003	97,231
Earnings, 6 mos. to Jun 30(Consol. - \$000):			IRONWOOD PHARMACEUTICALS INC			Net income	105,102	105,374
	2018	2017	Earnings, 6 mos. to Jun 30(Consol. - \$000):			Earnings common share		
Net Sales	773,477	655,219		2018	2017	Primary	\$3.63	\$3.40
Cost & expenses	469,987	412,596	Total Revenues	150,261	117,243	Fully Diluted	\$3.59	\$3.37
Operating income	303,490	242,623	Cost & expenses	219,097	197,118	Common Shares:		
Other income (expense), net	829	(506)	Operating income	(75,788)	(80,716)	Full Diluted	29,284	31,234
Net before taxes	305,360	242,893	Interest expense	18,656	18,029	Year-end	27,256	
Income taxes	77,409	63,858	Other income (expense), net	507	1,129			
Net income	227,951	179,035	Net income	(92,524)	(96,725)	JAKKS PACIFIC INC.		
Earnings common share			Earnings common share			Earnings, 6 mos. to Jun 30(Consol. - \$):		
Primary	\$4.24	\$3.35	Primary	\$(0.61)	\$(0.65)		2018	2017
Fully Diluted	\$4.14	\$3.29	Fully Diluted	\$(0.61)	\$(0.65)	Net Sales	198,785,000	214,070,000
Common Shares:			Common Shares:			Cost & expenses	246,583,000	243,902,000
Full Diluted	55,111	54,450	Full Diluted	151,591	148,285	Operating income	(47,798,000)	(29,832,000)
Year-end	53,724	53,794	Year-end	152,853	149,555	Other income (expense), net	308,000	287,000
						Gains or losses	(3,431,000)	
IRHYTHM TECHNOLOGIES INC			ITRON INC			Net before taxes	(55,026,000)	(35,000,000)
Earnings, 6 mos. to Jun 30(Consol. - \$000):			Earnings, 6 mos. to Jun 30(Consol. - \$000):			Income taxes	(245,000)	(28,000)
	2018	2017		2018	2017	Net income	(54,781,000)	(34,972,000)
Total Revenues	66,034	45,291	Total Revenues	1,193,111	980,674	Earnings common share		
Cost & expenses	88,355	55,957	Cost & expenses	1,277,257	902,700	Primary	\$(2.37)	\$(1.77)
Operating income	(22,321)	(10,666)	Operating income	(119,885)	68,455	Fully Diluted	\$(2.37)	\$(1.77)
Interest expense	1,719	1,661	Interest expense	30,149	6,610	Common Shares:		
Other income (expense), net	717	580	Other income (expense), net	(164)	(5,956)	Full Diluted	23,103,000	19,865,000
Net income	(23,323)	(11,747)	Net before taxes	(148,904)	56,628	Year-end	26,057,073	
Earnings common share			Income taxes	(7,407)	25,607			
Primary	\$(0.99)	\$(0.53)	Net income	(141,497)	31,021	JAMBA INC		
Fully Diluted	\$(0.99)	\$(0.53)	Balance for common	(143,009)	29,942	Earnings, 6 mos. to (Consol. - \$000):		
Common Shares:			Earnings common share				07/03/18	07/04/17
Full Diluted	23,614	22,258	Primary	\$(3.66)	\$0.78	Total Revenues	45,466	38,127
Year-end	23,925	22,588	Fully Diluted	\$(3.66)	\$0.76	Cost & expenses	43,816	37,664
			Common Shares:			Deprec., depl. & amort.	1,741	1,780
IRIDEX CORP.			Full Diluted	39,095	39,274	Operating income	(91)	(1,317)
Earnings, 6 mos. to (Consol. - \$000):			Year-end	39,279		Net before taxes	(242)	(1,388)
	06/30/18	07/01/17				Income taxes	6	39
Total Revenues	19,813	20,485	J&J SNACK FOODS CORP.			Net income	(248)	(1,427)
Cost & expenses	26,712	25,084	Earnings, 9 mos. to (Consol. - \$000):			Earnings common share		

Primary	\$(0.02)	\$(0.09)
Fully Diluted	\$(0.02)	\$(0.09)
Common Shares:		
Full Diluted	15,595	15,442
Year-end	15,641	15,568

JETBLUE AIRWAYS CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	3,461,000	2,733,000
Operating income	(16,000)	490,000
Net before taxes	(50,000)	447,000
Income taxes	(18,000)	158,000
Net income	(32,000)	289,000
Earnings common share		
Primary	\$(0.10)	\$0.87
Fully Diluted	\$(0.10)	\$0.86
Common Shares:		
Full Diluted	318,000	334,800
Year-end	312,847	

JOHNSON OUTDOORS INC

Earnings, 9 mos. to (Consol. - \$000):

	06/29/18	06/30/17
Net Sales	453,136	398,810
Cost & expenses	388,142	353,143
Operating income	64,994	45,667
Interest income	493	84
Interest expense	170	687
Other income (expense), net	4,231	2,288
Net before taxes	69,548	47,352
Income taxes	23,923	12,784
Net income	45,625	34,568
Earnings common share		
Primary	\$4.62	\$3.50
Fully Diluted	\$4.54	\$3.45
Common Shares:		
Full Diluted	9,988	9,908
Year-end	9,997	9,995

JOINT CORP (NEW)

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	14,654,747	11,507,197
Cost & expenses	14,401,821	13,126,820
Deprec., depl. & amort.	792,392	1,081,212
Operating income	(539,466)	(2,700,835)
Other income (expense), net	(22,884)	(43,496)
Gains or losses	75,264	
Net before taxes	(487,086)	(2,744,331)
Income taxes	(57,404)	43,192
Net income	(429,682)	(2,787,523)
Earnings common share		
Primary	\$(0.03)	\$(0.21)
Fully Diluted	\$(0.03)	\$(0.21)
Common Shares:		
Full Diluted	13,605,370	13,085,159
Year-end	13,723,994	

JOUNCE THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	49,982	43,853
Operating income	(19,409)	(3,275)
Other income (expense), net	1,707	1,384
Net before taxes	(1,891)	(1,891)
Income taxes	1,104	
Net income	(17,702)	(2,995)
Earnings common share		
Primary	\$(0.55)	\$(0.14)
Fully Diluted	\$(0.55)	\$(0.14)
Common Shares:		
Full Diluted	32,435	27,867
Year-end	32,596	32,155

JUNIPER PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	30,834,000	25,203,000
Cost & expenses	31,761,000	27,014,000
Operating income	(927,000)	(1,811,000)
Other income (expense), net	559,000	52,000
Net before taxes	(442,000)	
Income taxes	300,000	

Net income	(742,000)	(1,817,000)
Pfd. dividends		(445,000)
Balance for common	(742,000)	(1,372,000)
Earnings common share		
Primary	\$(0.07)	\$(0.13)
Fully Diluted	\$(0.07)	\$(0.13)
Common Shares:		
Full Diluted	11,023,000	10,803,000
Year-end	11,105,000	10,844,000

JUNIPER PHARMACEUTICALS INC

Merger Completed On Aug. 14, 2018, Catalent Boston, Inc., ("Merger Sub") a wholly owned subsidiary of Catalent Pharma Solutions, Inc. ("Catalent"), merged with and into Co. (the "Merger"), with Co. continuing as the surviving corporation and became a new subsidiary of Catalent. As a result of the Merger, Merger Sub purchased all of the issued and outstanding shares of Co.'s common stock, par value \$0.01 per share, for a purchase price of \$11.50 per Share, net to the seller in cash, without interest, and upon the terms and subject to the conditions set forth in the offer to Purchase dated July 17, 2018 and in the related Letter of Transmittal.

K2M GROUP HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	141,456	127,577
Cost & expenses	161,869	144,805
Operating income	(20,413)	(17,228)
Interest expense	3,865	3,463
Foreign currency	(478)	847
Net before taxes	(24,756)	(19,844)
Income taxes	(2,564)	88
Net income	(22,192)	(19,932)
Earnings common share		
Primary	\$(0.51)	\$(0.47)
Fully Diluted	\$(0.51)	\$(0.47)
Common Shares:		
Full Diluted	43,140	42,434
Year-end	43,602	43,269

KAISER ALUMINUM CORP.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	803,400	711,600
Cost & expenses	710,200	620,700
Operating income	71,800	71,800
Interest income	100	
Interest expense	11,300	11,100
Other income (expense), net	(3,600)	(700)
Invest. income	3,100	1,400
Net before taxes	60,100	61,400
Income taxes	13,700	20,700
Net income	46,400	40,700
Earnings common share		
Primary	\$2.78	\$2.37
Fully Diluted	\$2.74	\$2.34
Common Shares:		
Full Diluted	16,962	17,418
Year-end	16,666	16,924

KALA PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	25,657	19,201
Operating income	(25,657)	(19,201)
Interest income	522	83
Interest expense	781	406
Other income (expense), net	(1,221)	
Net income	(25,916)	(20,745)
Earnings common share		
Primary	\$(1.06)	\$(17.56)
Fully Diluted	\$(1.06)	\$(17.56)
Common Shares:		
Full Diluted	24,555	1,181
Year-end	24,592	1,181

KALVISTA PHARMACEUTICALS INC**Annual Report**

Consolidated Income Statement, Years Ended (\$000):

	04/30/18	04/30/17	12/31/15
Grant income	8,394	1,504	
License revenue			29
Research &			

development expenses	18,237	12,666	16,199
General & administrative expenses	8,862	11,177	4,866
Total operating expenses	27,099	23,843	21,065
Income (loss) from operations	(18,705)	(22,339)	(21,036)
Interest income	82	36	5
Interest expense			1,188
Foreign currency exchange rate gain (loss)	(1,574)	1,371	
Loss on extinguishment of convertible promissory notes			(3,177)
Other income (expense), net	4,392	2,329	550
Total other income (expense), net	2,900	3,736	(3,810)
Net income (loss)	(15,805)	(18,603)	(24,846)
Dividend on series A		935	
Dividend on series B		1,237	
Net income (loss) attributable to common shareholders	(15,805)	(20,775)	(24,846)
Weighted average shares outstanding			
- basic	10,322	4,647	1,363
Weighted average shares outstanding			
- diluted	10,322	4,647	1,363
Year end shares outstanding	10,800	9,713	1,880
Net earnings (loss) per share - basic	\$(1.53)	\$(4.47)	18.20
Net earnings (loss) per share - diluted	\$(1.53)	\$(4.47)	18.20
Number of full time employees	33	28	
Total number of employees			5
Number of common stockholders	46	59	29
Foreign currency translation adjustments		(2,568)	

2015 and prior financial of Carbylan Therapeutics Inc. before reverse acquisition of KalVista Pharmaceuticals Limited; 2 Adjusted for 1-for-14 stock split, November 22, 2016; 3 As is; 4 As of June 30, 2018; 5 As of March 15, 2016

Consolidated Balance Sheet, Years Ended Apr. 30 (\$000):

	2018	2017
Cash & cash equivalents	51,055	30,950
Research & development tax credit receivable	6,834	2,250
Grants & other receivables		297
Prepaid expenses & other current assets	1,491	701
Total current assets	59,380	34,198
Other assets	173	50
Laboratory equipment	1,277	373
Office equipment	33	31
Furniture & fixtures	76	6
Leasehold improvements	1,005	
Property & equipment, gross	2,391	410
Less: accumulated depreciation & amortization	555	313
Property & equipment, net	1,836	97
Total assets	61,389	34,345
Accounts payable	1,433	1,153
Accrued research expenses	1,192	348

Table with 3 columns: Description, 2018, 2017. Rows include Accrued compensation, Accrued professional fees, Other accrued expenses, etc.

Reclassified to conform with 2018 presentation

Recent Dividends:

- 1. KalVista Pharmaceuticals Inc common. No dividends paid.
2. KalVista Pharmaceuticals Inc convertible preferred. No dividends paid.
Annual Dividends:
1. KalVista Pharmaceuticals Inc common. No dividends paid.
2. KalVista Pharmaceuticals Inc convertible preferred. No dividends paid.

KANDI TECHNOLOGIES GROUP INC

Table with 3 columns: Description, 2018, 2017. Rows include Total Revenues, Cost & expenses, Operating income, etc.

KARYOPHARM THERAPEUTICS INC

Table with 3 columns: Description, 2018, 2017. Rows include Total Revenues, Cost & expenses, Operating income, etc.

KCAP FINANCIAL INC

Table with 3 columns: Description, 2018, 2017. Rows include Cost & expenses, Net income, Earnings common share, etc.

KELLY SERVICES, INC.

Earnings, 6 mos. to (Consol. - \$000):

Table with 3 columns: Description, 07/01/18, 07/02/17. Rows include Cost & expenses, Operating income, Other income (expense), net, etc.

KEMP Pharm INC

Table with 3 columns: Description, 2018, 2017. Rows include Earnings, 6 mos. to Jun 30 (Consol. - \$000): Cost & expenses, Operating income, etc.

KEYW HOLDING CORP

Table with 3 columns: Description, 2018, 2017. Rows include Earnings, 6 mos. to Jun 30 (Consol. - \$000): Total Revenues, Cost & expenses, etc.

KEZAR LIFE SCIENCES INC

Table with 3 columns: Description, 2018, 2017. Rows include Earnings, 6 mos. to Jun 30 (Consol. - \$000): Cost & expenses, Operating income, etc.

KFORCE INC.

Table with 3 columns: Description, 2018, 2017. Rows include Earnings, 6 mos. to Jun 30 (Consol. - \$000): Total Revenues, Cost & expenses, etc.

KINSALE CAPITAL GROUP INC

Table with 3 columns: Description, 2018, 2017. Rows include Earnings, 6 mos. to Jun 30 (Consol. - \$000): Total Revenues, Cost & expenses

Table with 3 columns: Description, 2018, 2017. Rows include Operating income, Net before taxes, Income taxes, Net income, Earnings common share, etc.

KLA-TENCOR CORP Annual Report

Consolidated Income Statement, Years Ended Jun. 30 (\$000):

Table with 4 columns: Description, 2018, 2017 (revised), 2016 (revised). Rows include Product revenues, Service revenues, Total revenues, Costs of revenues, etc.

Full Diluted 16,942,000 16,354,000
 Year-end 17,654,217 17,063,996

per share - basic \$14.73 \$10.47 \$5.75 currency translation
 Net income (loss) adjustment (32,722) (42,371)
 per share - diluted \$13.17 \$9.24 \$5.22 Accumulated unrealized
 Total number of holding gain (loss) on
 full time employees .. $\square\square$ 10,900 $\square\square\square$ 9,400 $\square\square$ 7,500 cash flow hedges (4,042) (811)
 Number of common Accumulated unrealized
 stockholders $\square\square$ 418 $\square\square$ 440 $\square\square$ 454 holding gain (loss) on
 Dividends per available-for-sale
 common share \$2.55 \$1.65 \$1.20 investments (1,190) 1,106
 Foreign currency Accumulated unrealized
 translation components of defined
 adjustments (2,843) (4,403) benefit plans (19,495) (19,624)
 Accumulated other
 comprehensive income

LAM RESEARCH CORP
Annual Report

Consolidated Income Statement, Years Ended (\$000):

06/24/18 \square 06/25/17 \square 06/26/16
 (revised) (revised)
 Revenue 11,076,998 8,013,620 5,885,893
 Cost of goods sold ... 5,911,966 4,410,261 3,266,971
 Gross margin 5,165,032 3,603,359 2,618,922
 Research &
 development expenses 1,189,514 1,033,742 913,712
 Selling, general &
 administrative expenses 762,219 667,485 630,954
 Total operating expenses 1,951,733 1,701,227 1,544,666
 Operating income (loss) 3,213,299 1,902,132 1,074,256
 Interest income 85,813 57,858 29,512
 Interest expense 97,387 117,734 134,773
 Gains (losses) on deferred
 compensation plan related assets 14,692 17,880 (3,995)
 Loss on impairment of investments 42,456
 Gains (losses) on extinguishment of debt, net 542 (36,252) ...
 Foreign exchange gains (losses), net (3,382) (569) 308
 Other income (expense), net (19,332) (11,642) (5,191)
 Income (loss) before income taxes - United States 128,190 7,553 (113,607)
 Income (loss) before income taxes - foreign 3,023,599 1,804,120 1,073,724
 Income (loss) before income taxes .. 3,151,789 1,811,673 960,117
 Federal income taxes expense (benefit) - current 630,148 (70,858) 1,426
 Federal income taxes expense (benefit) - deferred 12,871 99,700 (38,616)
 Total federal income taxes expense (benefit) 643,019 28,842 (37,190)
 State income taxes expense (benefit) - current 5,348 (963) 2,892
 State income taxes expense (benefit) - deferred (3,273) (2,246) (7,600)
 Total state income taxes expense (benefit) 2,075 (3,209) (4,708)
 Foreign income taxes expense (benefit) - current 132,566 85,479 90,752
 Foreign income taxes expense (benefit) - deferred (6,552) 2,798 (2,786)
 Total foreign income taxes expense (benefit) 126,014 88,277 87,966
 Income tax expense (benefit) 771,108 113,910 46,068
Net income (loss) 2,380,681 1,697,763 914,049
 Weighted average shares outstanding - basic 161,643 162,222 158,919
 Weighted average shares outstanding - diluted 180,782 183,770 175,159
 Year end shares outstanding 156,892 161,723 160,201
 Net income (loss)

\square Reclassified to conform with 2018 presentation; \square As is; \square Approximately; \square As of August 9, 2018; \square As of August 10, 2017; \square As of August 10, 2016

Consolidated Balance Sheet, Years Ended (\$000):

06/24/18 \square 06/25/17 (revised)
 Cash & cash equivalents 4,512,257 2,377,534
 Investments 437,338 3,663,628
 Accounts receivable, gross 2,182,279 1,678,501
 Less allowance for doubtful accounts 5,343 5,103
 Accounts receivable, net 2,176,936 1,673,398
 Raw materials 916,438 625,600
 Work-in-process 222,921 213,066
 Finished goods 736,803 394,250
 Inventories 1,876,162 1,232,916
 Prepaid expenses & other current assets 147,218 195,022
 Total current assets 9,149,911 9,142,498
 Manufacturing, engineering & office equipment 911,140 819,239
 Computer equipment & software 182,451 166,441
 Land 46,155 46,155
 Buildings & improvements 530,032 358,081
 Office equipment, furniture & fixtures 66,378 52,959
 Property & equipment, gross 1,736,156 1,442,875
 Less: accumulated depreciation & amortization 833,609 757,280
 Property & equipment, net 902,547 685,595
 Restricted cash & investments 256,301 256,205
 Goodwill 1,484,904 1,385,673
 Intangible assets, net 317,836 410,995
 Other assets 367,979 241,799
 Total assets 12,479,478 12,122,765
 Trade accounts payable 510,983 464,643
 Accrued compensation 506,471 447,363
 Warranty reserves 192,480 161,981
 Income & other taxes payable 185,384 95,127
 Dividends payable 174,372 72,738
 Other accrued expenses & other current liabilities 250,502 192,152
 Deferred profit 720,086 607,672
 Commercial paper & current portion of convertible notes & capital leases 610,030 908,439
 Total current liabilities 3,150,308 2,950,115
 Senior notes, convertible notes, & capital leases, less current portion 1,806,562 1,784,974
 Income taxes payable 851,936 120,178
 Other long-term liabilities 90,629 280,186
 Total liabilities 5,899,435 5,135,453
 Temporary equity, convertible notes 78,192 169,861
 Common stock 157 162
 Additional paid-in capital 6,144,425 5,845,485
 Treasury stock, at cost 7,846,476 5,216,187
 Accumulated foreign

Retained earnings (accumulated deficit) 8,261,194 6,249,691
 Total stockholders' equity 6,501,851 6,817,451

\square Reclassified to conform with 2018 presentation

Recent Dividends:
1. Lam Research Corp common.

ExDate	Amt	Declared	Record	Payable
12/08/2014	0.18	11/10/2014	12/10/2014	01/07/2015
03/09/2015	0.18	02/11/2015	03/11/2015	04/01/2015
06/08/2015	0.30	05/18/2015	06/10/2015	07/01/2015
09/04/2015	0.30	08/27/2015	09/09/2015	09/30/2015
12/07/2015	0.30	11/06/2015	12/09/2015	01/06/2016
03/07/2016	0.30	02/19/2016	03/09/2016	04/06/2016
06/06/2016	0.30	05/13/2016	06/08/2016	06/29/2016
09/12/2016	0.30	09/01/2016	09/14/2016	09/28/2016
12/12/2016	0.45	11/18/2016	12/14/2016	01/04/2017
03/06/2017	0.45	02/09/2017	03/08/2017	03/29/2017
06/05/2017	0.45	05/12/2017	06/07/2017	06/28/2017
09/12/2017	0.45	08/07/2017	09/13/2017	10/04/2017
12/05/2017	0.50	11/14/2017	12/06/2017	01/10/2018
03/06/2018	0.50	02/08/2018	03/07/2018	03/28/2018
06/05/2018	1.10	05/17/2018	06/06/2018	06/27/2018

Annual Dividends:
1. Lam Research Corp common.
 2015 0.96 2016 1.20 2017 1.80
 2018 2.10

LAMAR ADVERTISING CO (NEW)
Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Total Revenues	780,826	743,440
Cost & expenses	467,080	436,591
Operating income	201,584	203,642
Other income (expense), net	(15,429)	(71)
Net before taxes	120,840	140,113
Income taxes	5,357	5,932
Net income	115,483	134,181
Balance for common	115,301	133,999
Earnings common share		
Primary	\$1.17	\$1.37
Fully Diluted	\$1.17	\$1.36
Common Shares:		
Full Diluted	98,725	98,276
Year-end	98,825	98,034

LANDEC CORP.

Annual Report
Consolidated Income Statement, Years Ended (\$000):

	05/27/18	\square 05/28/17 (revised)	\square 05/29/16 (revised)
Product sales revenue	524,227	469,776	476,918
Cost of product sales	445,889	390,564	410,137
Gross profit	78,338	79,212	66,781
Research & development expenses	12,800	9,473	7,228
Selling, general & administrative expenses	51,951	52,491	46,181
Legal settlement charge		2,580	
Impairment of			

GreenLine tradename.	34,000	Cash & cash equivalents	2,899	5,998	No dividends paid.
Operating income (loss)	13,587	14,668	(20,628)	Accounts receivables, gross	54,179	46,260
Dividend income	1,650	1,650	1,650	Allowance for doubtful accounts	302	361
Interest income	211	16	71	Accounts receivable, net	53,877	45,899
Interest expense, net	1,950	1,826	1,987	Finished goods	12,861	10,015
Gain (loss) on debt refinancing	(1,233)	...	Raw materials	15,286	10,158
Other income	2,900	900	1,200	Work in progress	3,672	3,447
Net income (loss) before taxes	16,398	14,175	(19,694)	Inventories	31,819	23,620
Current federal income taxes	(2,854)	1,388	2,085	Prepaid expenses & other current assets	7,958	3,498
Current state income taxes	60	39	(96)	Other current assets, discontinued operations	510	2,265
Current foreign income taxes	83	82	83	Total current assets	97,063	81,280
Total current income taxes	(2,711)	1,509	2,072	Investment in non-public company, fair value	66,500	63,600
Deferred federal income taxes	(7,122)	2,270	(9,165)	Land & buildings	90,712	86,983
Deferred state income taxes	470	261	(611)	Leasehold improvements	2,607	1,190
Total deferred income taxes	(6,652)	2,531	(9,776)	Computer, capitalized software, machinery, equipment & auto	120,418	97,375
Income tax expense (benefit)	(9,363)	4,040	(7,704)	Furniture & fixtures	1,673	1,272
Income (loss) from continuing operations	25,761	10,135	...	Construction in process	13,100	6,811
Income (loss) from discontinued operations	(1,188)	837	842	Gross property & equipment	228,510	193,631
Income tax benefit (expense)	350	(295)	(300)	Less accumulated depreciation & amortization	68,886	60,411
Income (loss) from discontinued operations, net of tax	(838)	542	542	Property & equipment, net	159,624	133,220
Consolidated net income (loss)	24,923	10,677	(11,448)	Goodwill, net	54,510	54,510
Non-controlling interest	(94)	(87)	(193)	Trademarks/trade names, net	16,028	16,028
Net income (loss) applicable to common stockholders	24,829	10,590	(11,641)	Customer relationships, net	5,814	6,783
Weighted average shares outstanding-basic	27,535	27,276	27,044	Other assets, discontinued operations	5,164	2,918
Weighted average shares outstanding-diluted	27,915	27,652	27,044	Total assets	404,703	358,608
Year end shares outstanding	27,702	27,499	27,148	Accounts payable	34,668	24,527
Earnings (loss) per share-continuing operations-basic	\$0.93	\$0.37	\$(0.45)	Accrued compensation	9,978	7,506
Earnings (loss) per share-total discontinued operations-basic	\$(0.03)	\$0.02	\$0.02	Other accrued liabilities	8,706	9,045
Net earnings (loss) per share-basic	\$0.90	\$0.39	\$(0.43)	Deferred revenue	2,625	310
Earnings (loss) per share-continuing operations-diluted	\$0.92	\$0.36	\$(0.45)	Lines of credit	27,000	3,000
Earnings (loss) per share-total discontinued operations-diluted	\$(0.03)	\$0.02	\$0.02	Current portion of long-term debt, net	4,940	4,940
Net earnings (loss) per share-diluted	\$0.89	\$0.38	\$(0.43)	Other current liabilities, discontinued operations	458	2,126
Number of full time employees	710	Total current liabilities	88,375	51,454
Number of common stockholders	47	Term loan	42,500	47,500
				Less: unamortized debt issuance costs	(200)	(261)
				Long term debt, net unamortized debt issuance costs	42,300	47,239
				Less: current portion	4,940	4,940
				Long term debt	37,360	42,299
				Capital lease obligation, less current portion	3,641	3,731
				Deferred taxes	17,485	24,581
				Other non-current liabilities	5,280	8,391
				Total liabilities	152,141	130,456
				Common stock	28	27
				Additional paid-in capital	142,087	141,680
				Retained earnings (accumulated deficit)	109,299	84,470
				Accumulated other comprehensive income	1,148	432
				Total stockholders' equity (deficit)	252,562	226,609
				Non-controlling interest	1,543
				Total equity	252,562	228,152

Restated to reflect the discontinued operations of Food Export business segment

Recent Dividends:
1. Landec Corp. common.
 No dividends paid.
Annual Dividends:
1. Landec Corp. common.

LANDEC CORP.
Auditor's Report Auditor's Comment
 The following is an excerpt from the Report of the Independent Auditors, Ernst & Young LLP, as it appeared in Co.'s 2018 10K: "We have audited the accompanying consolidated balance sheets of Landec Corporation and subsidiaries (the Company) as of May 27, 2018 and May 28, 2017, and the related consolidated statements income (loss), comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended May 27, 2018, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at May 27, 2018 and May 28, 2017, and the results of its operations and its cash flows for each of the three years in the period ended May 27, 2018, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of May 27, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated August 9, 2018 expressed an adverse opinion thereon."

LANDMARK INFRASTRUCTURE PARTNERS LP
Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	3,787,000	4,606,000
Operating income	13,049,000	6,204,000
Interest expense	12,680,000	8,154,000
Other income (expense), net	4,434,000	(50,000)
Net before taxes	13,049,000	...
Income taxes	203,000	...
Net income	12,846,000	6,204,000
Earnings common share		
Primary	\$0.33	\$0.14
Fully Diluted	\$0.31	\$0.14
Common Shares:		
Full Diluted	24,811,000	22,689,000
Year-end	25,130,604	...

LANTHEUS HOLDINGS INC
Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	168,203	170,196
Cost & expenses	137,140	140,372
Operating income	31,063	29,824
Interest expense	8,348	9,705
Other income (expense), net	1,543	(1,172)
Foreign currency	(287)	140
Net before taxes	23,971	19,087
Income taxes	6,015	1,354
Net income	17,956	17,733
Earnings common share		
Primary	\$0.47	\$0.48
Fully Diluted	\$0.45	\$0.46
Common Shares:		
Full Diluted	39,468	38,726
Year-end	38,298	37,348

LATTICE SEMICONDUCTOR CORP
Earnings, 6 mos. to (Consol. - \$000):

	06/30/18	07/01/17
Total Revenues	201,338	198,724
Cost & expenses	205,538	190,904
Operating income	(14,359)	(9,431)
Other income (expense), net	206	(77)
Net before taxes	(24,235)	(19,732)
Net income	(26,175)	(20,297)
Earnings common share		
Primary	\$(0.21)	\$(0.17)
Fully Diluted	\$(0.21)	\$(0.17)
Common Shares:		
Full Diluted	124,460	122,095
Year-end	125,613	122,730

LAUREATE EDUCATION INC
Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	2,133,205	2,133,372
Cost & expenses	1,894,891	1,952,389
Operating income	238,314	180,983

Restated to reflect the discontinued operations of Food Export business segment; As is; Approximate; As of July 27, 2018
Consolidated Balance Sheet, Years Ended (\$000):
 05/27/18 05/28/17
 (revised)

	2018	2017	Earnings from investment			Intangibles assets, net	43,499,000	...
Total Revenues	171,809	208,650	410,553	39,000	...	
Cost & expenses	183,606	229,842	Other expense	22,000	207,000	68,027,000	1,556,000	
Operating income	(15,172)	(25,420)	Total other income			10,996,000	542,000	
Net before taxes	(14,396)	(25,129)	(expense), net	(4,137,000)	(8,765,000)	232,055	1,158,000	
Income taxes	(3,824)	91	Income (loss)			53,000	240,000	
Net income	(10,572)	(25,220)	before income tax			12,207,000	782,000	
Earnings common share			provision	(19,014,000)	(14,250,000)	7,667,000	...	
Primary	\$(0.33)	\$(0.80)	Income tax			294,000	277,000	
Fully Diluted	\$(0.33)	\$(0.80)	provision	6,000	...	3,500,000	...	
Common Shares:			Income (loss) from			1,046,000	...	
Full Diluted	31,984	31,369	continuing			968,000	3,671,000	
Year-end	32,110	31,486	operations	(19,020,000)	(14,250,000)	25,682,000	4,730,000	

LITTELFUSE INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/30/18	07/01/17
Net Sales	876,996	598,797
Cost & expenses	754,432	477,559
Operating income	97,193	109,123
Interest expense	11,205	6,401
Other income (expense), net	3,621	(52)
Foreign currency	7,354	2,115
Net before taxes	96,963	104,785
Income taxes	18,609	17,255
Net income	78,354	87,530
Earnings common share		
Primary	\$3.18	\$3.84
Fully Diluted	\$3.12	\$3.80
Common Shares:		
Full Diluted	25,086	23,005
Year-end	24,596	22,713

LIVEPERSON INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	119,901	104,993
Cost & expenses	130,690	115,737
Operating income	(11,637)	(11,686)
Other income (expense), net	160	221
Net before taxes	(11,477)	(11,465)
Income taxes	47	1,744
Net income	(11,524)	(13,209)
Earnings common share		
Primary	\$(0.20)	\$(0.24)
Fully Diluted	\$(0.20)	\$(0.24)
Common Shares:		
Full Diluted	57,983	55,965
Year-end	62,367	58,764

LIVEXLIVE MEDIA INC**Annual Report****Consolidated Income Statement, Years Ended Mar. 31 (\$):**

	2018	2017
Subscription revenue	6,459,000	...
Advertising & licensing revenue	736,000	225,000
Revenues	7,195,000	225,000
Cost of sales	6,694,000	730,000
Sales & marketing	662,000	93,000
Product development	1,578,000	...
General & administrative expenses	10,715,000	4,887,000
Amortization of intangible assets	2,423,000	...
Selling, general & administrative	...	3,619,000
Related party expenses	...	360,000
Total operating expenses	22,072,000	5,710,000
Net income (loss) from operations	(14,877,000)	(5,485,000)
Interest expense	3,922,000	512,000
Fair value of warrants	193,000	5,389,000
Loss on sale of investment	...	(2,790,000)
Equity earnings from investment in affiliate	...	133,000

Restated to reflect the discontinued operations of LiveXLive Tickets, Inc.; As reported by the Company; Adjusted for 1-for-3 reverse split, October 17, 2017; Adjusted for 2-for-1 stock split, September 28, 2016; Shares increased due to the effect shared issued for services to consultants, employees, exercise of warrants, Wantickets assets acquisition, debt conversion, offering and Slacker acquisition; As of June 25, 2018; As of July 11, 2016

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2018	2017
Cash & cash equivalents	10,285,000	1,477,000
Restricted cash	3,685,000	...
Accounts receivables	2,990,000	...
Prepaid expense & other assets	1,759,000	22,000
Total current assets	18,719,000	1,499,000
Production equipment	51,000	51,000
Computer, machinery & software equipment	449,000	42,000
Furniture & fixtures	23,000	...
Leasehold improvements	19,000	...
Total property & equipment	542,000	93,000
Less: accumulated depreciation & amortization	149,000	36,000
Fixed assets, net	393,000	57,000
Goodwill	5,377,000	...

Total assets	68,027,000	1,556,000
Accounts payable	10,996,000	542,000
Accrued liabilities	1,158,000	...
Due to related parties	53,000	240,000
Accounts payable & accrued expenses	12,207,000	782,000
Accrued royalties	7,667,000	...
Note payable	294,000	277,000
Bank debt	3,500,000	...
Deferred revenue	1,046,000	...
Current portion of unsecured convertible notes, net of discount	968,000	3,671,000
Total current liabilities	25,682,000	4,730,000
Unsecured convertible note	4,481,000	3,654,000
Less: accumulated amortization of valuation discount	(533,000)	(39,000)
Unsecured convertible notes - related party, net of discount	3,948,000	3,615,000
Less: convertible note payable - related party, current	...	(3,603,000)
Convertible notes payable - related party, long-term	3,948,000	12,000
Unsecured convertible notes	1,166,000	1,403,000
Total unsecured convertible notes payable	1,166,000	1,403,000
Less accumulated amortization of valuation discount	(198,000)	(1,115,000)
Net unsecured convertible notes payable	968,000	288,000
Total unsecured convertible notes, current	968,000	68,000
Unsecured convertible notes, long term	...	220,000
Total unsecured convertible notes, current	968,000	3,671,000
Unsecured convertible notes, net of discount	3,948,000	232,000
Total liabilities	29,630,000	4,962,000
Common stock	51,000	35,000
Additional paid-in capital	89,778,000	24,655,000
Retained earnings (accumulated deficit)	(51,432,000)	(28,096,000)
Total stockholders' equity (deficit)	38,397,000	(3,406,000)

Restated to reflect the discontinued operations of LiveXLive Tickets, Inc.

Recent Dividends:**1. LiveXLive Media Inc common.**

No dividends paid.

Annual Dividends:**1. LiveXLive Media Inc common.**

No dividends paid.

LIVEXLIVE MEDIA INC**Earnings, 3 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	7,590,000	...
Cost & expenses	15,269,000	1,874,000
Operating income	(10,102,000)	(1,874,000)
Interest expense	616,000	635,000
Other income (expense), net	(50,000)	...
Income contin. oper.	(2,509,000)	...
Net income	(10,768,000)	(2,815,000)
Earnings common share		
Primary	\$(0.21)	\$(0.08)
Fully Diluted	\$(0.21)	\$(0.08)
Common Shares:		
Full Diluted	51,527,861	35,528,121
Year-end	51,901,418	...

Consolidated Balance Sheet Items, as of (\$):

Primary	\$(0.24)	\$0.20
Fully Diluted	\$(0.24)	\$0.19
Common Shares:		
Full Diluted	2,696,000	2,775,000
Year-end	2,402,612	2,711,372

MANKIND CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	7,358	5,172
Cost & expenses	54,684	56,345
Operating income	(47,326)	(51,173)
Interest income	161	114
Other income (expense), net	8	5,959
Net before taxes	(52,820)	
Income taxes	240	
Net income	(53,060)	(51,663)
Earnings common share		
Primary	\$(0.41)	\$(0.53)
Fully Diluted	\$(0.41)	\$(0.53)
Common Shares:		
Full Diluted	130,535	97,816
Year-end	145,619	

MANTECH INTERNATIONAL CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	964,280	832,068
Cost & expenses	909,530	782,743
Operating income	54,750	49,325
Other income (expense), net	62	44
Equity earnings	(19)	(5)
Net before taxes	53,463	48,810
Income taxes	13,500	18,226
Net income	39,982	30,589
Earnings common share		
Primary	\$1.01	\$0.79
Fully Diluted	\$1.01	\$0.78
Common Shares:		
Full Diluted	26,577	25,803
Year-end	39,571	38,869

MARCHEX INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	42,114,000	46,391,000
Cost & expenses	44,186,000	51,213,000
Operating income	(2,072,000)	(4,822,000)
Net before taxes	(1,563,000)	(4,765,000)
Income taxes	21,000	25,000
Net income	(1,584,000)	(4,790,000)
Balance for common	(1,584,000)	(4,790,000)
Earnings common share		
Primary	\$(0.04)	\$(0.11)
Fully Diluted	\$(0.04)	\$(0.11)
Common Shares:		
Full Diluted	42,867,000	42,491,000
Year-end	41,781,000	43,342,615

MARIN SOFTWARE INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	29,653	39,075
Cost & expenses	47,185	54,620
Operating income	(17,532)	(15,545)
Other income (expense), net	672	(301)
Net before taxes	(16,860)	(15,846)
Income taxes	528	825
Net income	(17,388)	(16,671)
Balance for common	(17,388)	(16,671)
Earnings common share		
Primary	\$(3.02)	\$(3.01)
Fully Diluted	\$(3.02)	\$(3.01)
Common Shares:		
Full Diluted	5,751	5,572
Year-end	5,784	5,649

MARINUS PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	15,685,000	9,893,000
Operating income	(15,685,000)	(9,893,000)
Interest income	181,000	71,000
Interest expense		156,000

Other income (expense), net	(12,000)	
Net income	(15,504,000)	(9,990,000)
Earnings common share		
Primary	\$(0.38)	\$(0.47)
Fully Diluted	\$(0.38)	\$(0.47)
Common Shares:		
Full Diluted	40,384,429	21,288,545
Year-end	40,554,244	22,419,504

MARKETAXESS HOLDINGS INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	221,678	199,278
Cost & expenses	98,412	85,652
Deprec., depl. & amort.	11,059	9,483
Operating income	112,207	104,143
Other income (expense), net	2,016	1,037
Net before taxes	114,223	105,180
Income taxes	25,796	24,694
Net income	88,427	80,486
Earnings common share		
Primary	\$2.39	\$2.18
Fully Diluted	\$2.33	\$2.11
Common Shares:		
Full Diluted	37,874	38,095
Year-end	37,579	37,554

MARLIN BUSINESS SERVICES CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	48,548	47,891
Operating income	16,391	9,314
Net before taxes	16,391	9,314
Income taxes	3,739	3,221
Net income	12,652	6,093
Balance for common	12,417	5,932
Earnings common share		
Primary	\$1.02	\$0.49
Fully Diluted	\$1.01	\$0.48
Common Shares:		
Full Diluted	12,255	12,235
Year-end	12,439	12,526

MARRIOTT INTERNATIONAL, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$Millions):

	2018	2017
Total Revenues	10,352	10,123
Cost & expenses	9,000	8,711
Operating income	1,240	1,290
Interest income	11	15
Interest expense	160	143
Other income (expense), net	207	48
Net before taxes	1,298	1,210
Income taxes	290	350
Net income	1,008	860
Earnings common share		
Primary	\$2.83	\$2.25
Fully Diluted	\$2.80	\$2.23
Common Shares:		
Full Diluted	360	387
Year-end	347	

MARTIN MIDSTREAM PARTNERS LP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	500,775	447,247
Net Sales	393,694	337,437
Cost & expenses	431,096	366,989
Deprec., depl. & amort.	40,101	45,662
Operating income	29,578	34,596
Interest expense	26,451	22,139
Other income (expense), net	2,726	2,308
Net before taxes	5,853	14,765
Income taxes	281	193
Net income	5,572	14,572
Earnings common share		
Primary	\$0.14	\$0.38
Fully Diluted	\$0.14	\$0.38
Common Shares:		
Full Diluted	38,834	37,895
Year-end	39,052	38,452

MARTIN MIDSTREAM PARTNERS LP

Interest Sale Completed On July 31, 2018, Co. sold its 20% non-operating interest in West Texas LPG Pipeline L.P., a company that owns an approximate 2,300 mile common-carrier pipeline system that primarily transports NGLs from New Mexico and Texas to Mont Belvieu, Texas for fractionation, to ONEOK, Inc. for cash proceeds of \$195,000,000 at closing, before transaction fees and expenses.

MASIMO CORP.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	06/30/18	07/01/17
Total Revenues	424,574	388,949
Cost & expenses	319,077	292,949
Operating income	105,497	96,000
Other income (expense), net	3,052	1,032
Net before taxes	108,549	97,032
Income taxes	19,066	361
Net income	89,483	96,671
Earnings common share		
Primary	\$1.72	\$1.89
Fully Diluted	\$1.60	\$1.73
Common Shares:		
Full Diluted	55,842	55,868
Year-end	52,170	

MATCH GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	828,563	608,336
Cost & expenses	549,140	450,211
Operating income	262,398	141,846
Other income (expense), net	3,783	(15,528)
Net before taxes	230,099	88,296
Income taxes	(937)	12,197
Net income	231,036	71,537
Balance for common	232,236	71,483
Earnings common share		
Primary	\$0.84	\$0.28
Fully Diluted	\$0.78	\$0.24
Common Shares:		
Full Diluted	297,574	299,376
Year-end	277,004	260,602

MATTEL INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	1,549,120	1,710,095
Cost & expenses	2,014,892	1,884,738
Operating income	(465,772)	(174,643)
Other income (expense), net	(2,455)	(5,622)
Net before taxes	(547,927)	(219,414)
Income taxes	4,257	(50,108)
Net income	(552,184)	(169,306)
Earnings common share		
Primary	\$(1.60)	\$(0.49)
Fully Diluted	\$(1.60)	\$(0.49)
Common Shares:		
Full Diluted	344,507	343,020
Year-end	344,200	342,700

MATTERSIGHT CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	25,439	21,517
Cost & expenses	28,711	26,537
Operating income	(6,055)	(8,291)
Other income (expense), net	(14)	(1,433)
Net before taxes	(6,678)	(11,743)
Income taxes	(9)	12
Net income	(6,669)	(11,755)
Balance for common	(6,961)	(12,047)
Earnings common share		
Primary	\$(0.22)	\$(0.41)
Fully Diluted	\$(0.22)	\$(0.41)
Common Shares:		
Full Diluted	31,837	29,379
Year-end	33,216	32,749

MATTERSIGHT CORP

Merger Completed On Aug. 20, 2018, NICE Ltd. ("NICE") wholly-owned subsidiary, NICE Systems, Inc. ("Parent"), through its wholly-owned subsidiary, NICE Acquisition Sub, Inc. ("Purchaser"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each Co.'s common stock

("Common Stock") and Co.'s 7% Series B Convertible Preferred Stock ("Preferred Stock", and together with the Common Stock, the "Co. Shares") prior to the Effective Time and not tendered pursuant to the Offer (other than shares owned by Parent, Co. or Purchaser or any of their direct or indirect wholly-owned subsidiaries and shares with respect to which appraisal rights were properly exercised in accordance with the DGCL) was cancelled and automatically converted into the right to receive (i) \$2.70 per share of Common Stock (the "Common Offer Price") and (ii) \$7.80 per share of Preferred Stock, plus accrued and unpaid dividends payable thereon, if any, as of immediately prior to the Effective Time (the "Preferred Offer Price" and, together with the Common Offer Price, the "Offer Price"), in each case, net to the holder thereof in cash, without interest. As the per share exercise price of each warrant to purchase Common Stock (the "Co. Warrants") was equal to or greater than the Common Offer Price, immediately prior to the Merger, each Co. Warrant was cancelled without cash payment. Each option to purchase Common Stock under Co.'s 1999 Stock Incentive Plan, as amended (such plan, the "Co. Stock Plan" and each such option, a "Co. Option") that was outstanding, whether or not vested, immediately prior to the Effective Time, was cancelled and converted into the right to receive, in exchange for the cancellation of such Co. Option, an amount in cash, without interest and less applicable tax withholdings, equal to (i) the Common Offer Price, less the per share exercise price of such Co. Option, multiplied by (ii) the total number of shares of Co.'s Common Stock issuable upon exercise in full of such Co. Option (the "Co. Option Consideration"). If the per share exercise price of any Co. Option was equal to or greater than the Common Offer Price, such Co. Option was cancelled without cash payment. As of the Effective Time, (i) each vested Co. restricted stock award outstanding, and each unvested Co. restricted stock award outstanding under Co. Stock Plan (each, a "Restricted Stock Award" and collectively, the "Restricted Stock Awards") held by a holder holding less, in the aggregate, than 2,000 shares of Common Stock subject to such Restricted Stock Award, was cancelled and converted into a right to receive an amount in cash, without interest, equal to (x) the amount of the Common Offer Price multiplied by (y) the total number of shares of Common Stock subject to such award and (ii) with respect to each unvested Restricted Stock Award held by a holder holding, in the aggregate, 2,000 or more shares of Common Stock subject to such unvested Restricted Stock Award (x) 2,000 shares of Common Stock subject to such unvested Restricted Stock Award were cancelled and converted into the right to receive cash in an amount per such share equal to the Common Offer Price and (y) the remaining shares subject to such unvested Restricted Stock Award were assumed by Parent and converted into restricted American depositary shares of NICE, each representing one ordinary share, par value one New Israeli Shekel per share, of NICE (collectively, the "Restricted Stock Award Consideration"). All Restricted Stock Award Consideration will be paid without interest and less any applicable tax withholdings. The total amount of funds required by NICE, Parent, and Purchaser to consummate the Offer and purchase all outstanding Co. Shares (including outstanding shares of restricted stock) in the Offer, to fund the Merger and to fund payments in respect of outstanding stock options of Co., was approximately \$104,200,000, excluding related fees and expenses.

MATTHEWS INTERNATIONAL CORP

Earnings, 9 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	1,195,136,000	1,119,544,000
Cost & expenses	1,086,262,000	1,019,928,000
Operating income	85,610,000	82,677,000
Interest expense	26,782,000	19,750,000
Other income (expense), net	(887,000)	7,227,000
Gains or losses	931,000	1,548,000
Net before taxes	58,872,000	71,702,000
Income taxes	(18,703,000)	17,318,000
Net income	77,575,000	54,384,000
Earnings common share		
Primary	\$2.45	\$1.70
Fully Diluted	\$2.44	\$1.68
Common Shares:		
Full Diluted	31,825,000	32,596,000
Year-end	32,097,422	32,186,971

MAXIM INTEGRATED PRODUCTS, INC.

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	06/30/18	06/24/17	06/25/16
Net revenues	2,480,066	2,295,615	2,194,719
Cost of goods sold	853,945	849,135	950,331

Gross margin	1,626,121	1,446,480	1,244,388
Research & development	450,943	453,977	467,161
Selling, general & administrative expenses	322,918	291,511	288,899
Intangible asset amortization	4,467	9,189	12,205
Impairment of long-lived assets	892	7,517	160,582
Impairment of goodwill & intangible assets	27,602
Severance & restructuring expenses	15,060	12,453	24,479
Other operating expenses (income), net	(1,607)	(22,944)	(50,389)
Total operating expenses	792,673	751,703	930,539
Operating income	833,448	694,777	313,849
Interest income (expense), net	(50,215)	(34,274)	(32,676)
Interest income	38,292	11,568	2,919
Other income (expense), net	3,360	7,518	962
Interest & other income (expense), net	(8,563)	(15,188)	(28,795)
Domestic pre-tax income (loss)	149,056	154,628	(48,985)
Foreign pre-tax income	675,829	524,961	334,039
Income before provision for income taxes	824,885	679,589	285,054
Federal income taxes - current	318,288	107,303	98,810
Federal income taxes (benefit) - deferred	25,769	(8,171)	(52,240)
State income taxes - current	117	(361)	1,808
State income taxes (benefit) - deferred	1,325	(436)	(2,406)
Foreign income taxes - current	11,450	8,930	10,278
Foreign income taxes (benefit) - deferred	618	711	1,329
Income tax provision	357,567	107,976	57,579
Net income (loss)	467,318	571,613	227,475
Weighted average shares outstanding-basic	280,979	283,147	285,081
Weighted average shares outstanding-diluted	285,674	287,974	289,479
Year end shares outstanding	278,664	282,912	283,909
Net earnings per share-basic	\$1.66	\$2.02	\$0.80
Net earnings per share-diluted	\$1.64	\$1.98	\$0.79
Dividends declared per share	\$1.56	\$1.32	\$1.20
Total number of employees	7,149	7,040	7,213
Number of common stockholders	643	677	717

□ Reclassified to conform with 2017 presentation; □ As is; □ Approximately; □ As of August 3, 2018; □ As of August 4, 2017; □ As of August 5, 2016

Consolidated Balance Sheet, Years Ended (\$000):

	06/30/18	06/24/17	06/25/16
Cash & cash equivalents	1,543,484	2,246,121	498,718
Short-term investments	1,082,915	498,718	...
Accounts receivable,

gross	420,368	303,029
Allowance for doubtful accounts	140,296	46,575
Accounts receivable, net	280,072	256,454
Raw materials	16,251	11,779
Work-in-process	173,859	151,614
Finished goods	92,280	83,849
Inventories	282,390	247,242
Other current assets	21,548	57,059
Total current assets	3,210,409	3,305,594
Land	17,731	18,952
Buildings & building improvements	254,733	254,513
Machinery & equipment	1,309,487	1,286,031
Property, plant & equipment, gross	1,581,951	1,559,496
Less: accumulated depreciation & amortization	1,002,587	952,915
Property, plant & equipment, net	579,364	606,581
Intangible assets, net	78,246	90,867
Goodwill	532,251	491,015
Other assets	51,291	76,176
Total assets	4,451,561	4,570,233
Accounts payable	92,572	77,373
Income taxes payable	17,961	3,688
Accrued bonuses	92,288	85,600
Accrued vacation	30,695	29,621
Accrued salaries	8,210	14,528
Accrued fringe benefits	4,752	4,317
Other accrued salary & related expenses	15,737	11,233
Accrued salary & related expenses	151,682	145,299
Accrued expenses	35,774	37,663
Deferred revenue on shipments to distributors	...	14,974
Current portion of debt	499,406	...
Total current liabilities	797,395	278,997
Fixed rate notes	1,500,000	1,500,000
Total outstanding debt	1,500,000	1,500,000
Less: current portion	499,406	...
Less: reduction for unamortized discount & debt issuance costs	(9,447)	(12,322)
Long-term debt	991,147	1,487,678
Income taxes payable	661,336	557,498
Other liabilities	70,743	43,366
Total liabilities	2,520,621	2,367,539
Common stock	279	283
Retained earnings (accumulated deficit)	1,945,646	2,212,301
Unrealized gain (loss) on intercompany receivables	(6,280)	(6,280)
Unrealized gain (loss) on post-retirement benefits	(2,516)	(1,258)
Cumulative translation adjustment	(1,136)	(1,136)
Unrealized gain (loss) on cash flow hedges	(1,383)	18
Unrealized gain (loss) on available-for-sale securities	(3,670)	(1,234)
Accumulated other comprehensive income (loss)	(14,985)	(9,890)
Total stockholders' equity (deficit)	1,930,940	2,202,694

Recent Dividends:

1. Maxim Integrated Products, Inc. common.

ExDate	Amt	Declared	Record	Payable
02/17/2015	0.28	01/21/2015	02/19/2015	03/05/2015
05/19/2015	0.28	04/23/2015	05/21/2015	06/04/2015
08/18/2015	0.30	07/23/2015	08/20/2015	09/03/2015
11/17/2015	0.30	10/22/2015	11/19/2015	12/03/2015
02/16/2016	0.30	01/21/2016	02/18/2016	03/03/2016
05/17/2016	0.30	04/21/2016	05/19/2016	06/02/2016
08/16/2016	0.33	07/21/2016	08/18/2016	09/01/2016
11/29/2016	0.33	10/20/2016	12/01/2016	12/15/2016
02/28/2017	0.33	01/26/2017	03/02/2017	03/16/2017

(benefit).....	1,833	1,966	1,415
Foreign income tax expense (benefit) - current.....	186	240	59
Foreign income tax expense (benefit) - deferred.....	(272)	156	(10)
Total foreign income expense (benefit).....	(86)	396	49
Tax provision (benefit).....	1,690	6,193	5,544
Net income (loss)	40,883	24,875	19,742
Weighted average shares outstanding - basic.....	46,719	41,986	34,241
Weighted average shares outstanding - diluted.....	47,471	43,018	35,097
Year end shares outstanding.....	46,924	46,303	38,675
Net income (loss) per share - basic.....	\$0.88	\$0.59	\$0.58
Net income (loss) per share - diluted.....	\$0.86	\$0.58	\$0.56
Total number of employees.....	² 1,320	² 1,159	² 965
Number of common stockholders.....	² ³ 312	² ³ 291	² ³ 309
Number of nominee stockholders.....	² ³ 20,920	² ³ 21,830	² ³ 11,302
Foreign currency translation adjustments.....	...	(93)	171

¹ Reclassified to conform with 2018 presentation; ² As is; ³ As of July 31, 2018; ⁴ As of July 31, 2017; ⁵ As of July 31, 2016; ⁶ As of July 17, 2017; ⁷ As of July 14, 2016

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2018	2017
Cash & cash equivalents.....	66,521	41,637
Accounts receivable, gross.....	104,399	76,424
Less: allowance for doubtful accounts.....	359	83
Accounts receivable, net.....	104,040	76,341
Unbilled receivables & cost in excess of billings.....	39,774	37,332
Raw materials.....	61,748	48,645
Work in process.....	30,841	22,567
Finished goods.....	15,996	9,859
Inventory.....	108,585	81,071
Prepaid income taxes.....	3,761	1,434
Prepaid expenses & other current assets.....	9,062	8,381
Total current assets.....	331,743	246,196
Computer equipment & software.....	71,799	64,374
Furniture & fixtures.....	4,927	4,810
Leasehold improvements.....	21,552	19,092
Machinery & equipment.....	47,419	42,193
Property, plant & equipment, gross.....	145,697	130,469
Less: accumulated depreciation.....	94,717	78,826
Property & equipment, net.....	50,980	51,643
Goodwill.....	497,442	380,846
Intangible assets, net.....	177,904	129,037
Other non-current assets.....	6,411	8,023
Total assets.....	1,064,480	815,745
Accounts payable.....	21,323	27,485
Accrued expenses.....	16,386	20,594
Accrued compensation.....	21,375	18,406
Deferred revenues & customer advances.....	12,596	6,360
Total current liabilities.....	71,680	72,845
Deferred income taxes.....	13,635	4,856
Income taxes payable.....	998	855
Long-term debt.....	195,000	...
Other non-current		

liabilities.....	11,276	11,772
Total liabilities.....	292,589	90,328
Common stock.....	469	463
Additional paid-in capital.....	590,163	584,795
Retained earnings.....	179,968	139,085
Accumulated other comprehensive income (loss).....	1,291	1,074
Total shareholders' equity.....	771,891	725,417

Recent Dividends:

1. Mercury Systems Inc common.

No dividends paid.

Annual Dividends:

1. Mercury Systems Inc common.

No dividends paid.

MERIDIAN BIOSCIENCE INC.

Earnings, 9 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales.....	160,471,000	151,074,000
Cost & expenses.....	135,997,000	122,499,000
Operating income.....	24,474,000	28,575,000
Interest income.....	271,000	102,000
Other income (expense), net.....	(94,000)	356,000
Net before taxes.....	23,502,000	27,795,000
Income taxes.....	5,087,000	11,964,000
Net income	18,415,000	15,831,000
Earnings common share		
Primary.....	\$0.44	\$0.38
Fully Diluted.....	\$0.43	\$0.37
Common Shares:		
Full Diluted.....	42,712,000	42,556,000
Year-end.....	42,358,182	42,202,807

MERRIMACK PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses.....	34,567	61,788
Operating income.....	(34,567)	(61,788)
Interest income.....	557	396
Interest expense.....	28,741	28,741
Other income (expense), net.....	(1,541)	(661)
Gains or losses.....	1,703	1,703
Net before taxes.....	(89,091)	(89,091)
Income taxes.....	(30,239)	(30,239)
Income contin. oper.....	(58,852)	(58,852)
Net income	(35,551)	480,686
Earnings common share		
Primary.....	\$(2.66)	\$36.64
Fully Diluted.....	\$(2.66)	\$36.64
Common Shares:		
Full Diluted.....	13,343	13,153
Year-end.....	13,343	13,274

MERSANA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues.....	7,255	8,017
Cost & expenses.....	32,720	25,234
Interest income.....	709	209
Net income	(24,756)	(17,008)
Balance for common.....	(24,756)	(17,008)
Earnings common share		
Primary.....	\$(1.08)	\$(12.36)
Fully Diluted.....	\$(1.08)	\$(12.36)
Common Shares:		
Full Diluted.....	22,892	1,376
Year-end.....	23,118	1,491

MESA LABORATORIES, INC.

Earnings, 3 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues.....	25,142,000	22,673,000
Cost & expenses.....	20,378,000	20,691,000
Operating income.....	4,764,000	1,982,000
Other income (expense), net.....	(364,000)	(679,000)
Net before taxes.....	4,400,000	1,303,000
Income taxes.....	170,000	(214,000)
Net income	4,230,000	1,517,000
Earnings common share		
Primary.....	\$1.11	\$0.41

Fully Diluted.....	\$1.06	\$0.39
Common Shares:		
Full Diluted.....	4,006,000	3,923,000
Year-end.....	3,848,025	3,758,175

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents.....		7,400,000
Inventories.....		8,632,000
Current assets.....		32,832,000
Net property & equip.....		23,298,000
Total assets.....		161,458,000
Liabilities:		
Current liabilities.....		15,639,000
Long-term debt.....		37,662,000
Stockholders' equity.....		105,451,000
Net current assets.....		17,193,000

MGE ENERGY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues.....	281,894	283,286
Cost & expenses.....	203,980	199,621
Operating income.....	50,419	57,431
Interest expense.....	9,522	9,780
Other income (expense), net.....	9,650	7,095
Net before taxes.....	50,547	54,746
Income taxes.....	12,195	19,903
Net income	38,352	34,843
Earnings common share		
Primary.....	\$1.11	\$1.01
Fully Diluted.....	\$1.11	\$1.01
Common Shares:		
Full Diluted.....	34,668	34,668
Year-end.....	34,668	34,668

MGP INGREDIENTS INC (NEW)

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales.....	176,208	172,922
Cost & expenses.....	154,687	151,016
Operating income.....	21,521	21,906
Other income (expense), net.....	(348)	(348)
Net before taxes.....	21,025	20,848
Income taxes.....	4,571	5,801
Net income	16,454	15,047
Balance for common.....	16,131	14,614
Earnings common share		
Primary.....	\$0.96	\$0.87
Fully Diluted.....	\$0.96	\$0.87
Common Shares:		
Full Diluted.....	16,856	16,727
Year-end.....	16,848	16,716

MICROCHIP TECHNOLOGY INC

Earnings, 3 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales.....	1,212,500	972,100
Cost & expenses.....	946,500	629,700
Operating income.....	132,300	221,600
Interest income.....	5,700	3,500
Interest expense.....	90,400	49,500
Other income (expense), net.....	(9,900)	(9,400)
Net before taxes.....	37,700	166,200
Income taxes.....	2,000	(4,400)
Net income	35,700	170,600
Earnings common share		
Primary.....	\$0.15	\$0.74
Fully Diluted.....	\$0.14	\$0.70
Common Shares:		
Full Diluted.....	252,200	242,900
Year-end.....	235,494	...

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents.....		635,200
Inventories.....		1,104,800
Current assets.....		2,818,400
Net property & equip.....		1,078,400
Total assets.....		19,248,800
Liabilities:		
Current liabilities.....		2,139,300
Long-term debt.....		10,019,800
Stockholders' equity.....		5,123,800
Net current assets.....		679,100

MICROSOFT CORPORATION**Annual Report****Consolidated Income Statement, Years Ended Jun. 30****(\$000):**

	2018	2017 (revised)	2016 (revised)
Product revenue	64,497,000	63,811,000	67,336,000
Service & other revenue	45,863,000	32,760,000	23,818,000
Revenue	110,360,000	96,571,000	91,154,000
Cost of revenue - product	15,420,000	15,175,000	17,880,000
Cost of revenue - service & other	22,933,000	19,086,000	14,900,000
Cost of revenue	38,353,000	34,261,000	32,780,000
Gross margin	72,007,000	62,310,000	58,374,000
Research & development	14,726,000	13,037,000	11,988,000
Sales & marketing	17,469,000	15,461,000	14,635,000
General & administrative	4,754,000	4,481,000	4,563,000
Impairment, restructuring & other	0	306,000	1,110,000
Operating income (loss)	35,058,000	29,025,000	26,078,000
Dividends & interest income	2,214,000	1,387,000	903,000
Interest expense	2,733,000	2,222,000	1,243,000
Net recognized gains (losses) on investments	2,399,000	2,583,000	668,000
Net gains (losses) on derivatives	(187,000)	(510,000)	(443,000)
Net gains (losses) on foreign currency remeasurements	(218,000)	(111,000)	(129,000)
Other income (expense)	(59,000)	(251,000)	(195,000)
Income (loss) before income taxes - United States	11,527,000	6,843,000	5,125,000
Income (loss) before income taxes - foreign	24,947,000	23,058,000	20,514,000
Income (loss) before income taxes	36,474,000	29,901,000	25,639,000
Current taxes provision (benefit) - United States	19,764,000	2,739,000	545,000
Current taxes provision (benefit) - United States state & local	934,000	30,000	136,000
Current taxes provision (benefit) - foreign	4,348,000	2,472,000	1,940,000
Current taxes provision (benefit)	25,046,000	5,241,000	2,621,000
Deferred taxes provision (benefit) - United States	(4,292,000)	(554,000)	1,919,000
Deferred taxes provision (benefit) - United States state & local	(458,000)	269,000	111,000
Deferred taxes provision (benefit) - foreign	(393,000)	(544,000)	449,000
Deferred taxes provision (benefit)	(5,143,000)	(829,000)	2,479,000
Provision (benefit) for income taxes	19,903,000	4,412,000	5,100,000
Net income (loss)	16,571,000	25,489,000	20,539,000
Weighted average shares outstanding - basic	7,700,000	7,746,000	7,925,000
Weighted average shares outstanding - diluted	7,794,000	7,832,000	8,013,000
Year end shares			

outstanding	7,677,000	7,708,000	...
Net earnings (loss) per share - basic	\$2.15	\$3.29	\$2.59
Net earnings (loss) per share - diluted	\$2.13	\$3.25	\$2.56
Cash dividends declared per common share	\$1.68	\$1.56	\$1.44
Number of full time employees	97,535	124,000	114,000
Number of common stockholders	131,000	101,825	106,534
Foreign currency translation adjustments	...	228,000	(519,000)

Restated to reflect change in accounting policy for revenue recognition and leases; As is; As of July 31, 2018; Approximately; As of July 31, 2017; As of July 25, 2016

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	11,946,000	7,663,000
Short-term investments	121,822,000	125,318,000
Accounts receivable, gross	26,858,000	22,776,000
Allowance for doubtful accounts	377,000	345,000
Accounts receivable, net	26,481,000	22,431,000
Raw materials	655,000	797,000
Work in process	54,000	145,000
Finished goods	1,953,000	1,239,000
Inventories	2,662,000	2,181,000
Other current assets	6,751,000	5,103,000
Total current assets	169,662,000	162,696,000
Land	1,254,000	1,107,000
Buildings & improvements	20,604,000	16,284,000
Leasehold improvements	4,735,000	5,064,000
Computer equipment & software	27,633,000	21,414,000
Furniture & equipment	4,457,000	4,044,000
Total property & equipment, at cost	58,683,000	47,913,000
Accumulated depreciation - property & equipment	29,223,000	24,179,000
Property & equipment, net	29,460,000	23,734,000
Operating lease right-of-use assets	6,686,000	6,555,000
Equity & other investments	1,862,000	6,023,000
Goodwill	35,683,000	35,122,000
Intangible assets, net	8,053,000	10,106,000
Other long-term assets	7,442,000	6,076,000
Total assets	258,848,000	250,312,000
Accounts payable	8,617,000	7,390,000
Short-term debt	0	9,072,000
Current portion of long-term debt	3,998,000	1,049,000
Accrued compensation	6,103,000	5,819,000
Short term income taxes	2,121,000	718,000
Short-term unearned revenue	28,905,000	24,013,000
Other current liabilities	8,744,000	7,684,000
Total current liabilities	58,488,000	55,745,000
Long-term income taxes	30,265,000	13,485,000
Long-term unearned revenue	3,815,000	2,643,000
Deferred income taxes	541,000	5,734,000
Operating lease liabilities	5,568,000	5,372,000
Other long-term liabilities	5,211,000	3,549,000
Total liabilities	176,130,000	162,601,000
Common stock & paid-in capital	71,223,000	69,315,000
Retained earnings (accumulated deficit)	13,682,000	17,769,000
Derivatives	173,000	134,000
Investments	(892,000)	1,825,000
Translation adjustments & other accumulated other comprehensive		

income	(1,510,000)	(1,332,000)
Cumulative effect of accounting change	42,000	0
Accumulated other comprehensive income	(2,187,000)	627,000
Total stockholders' equity	82,718,000	87,711,000

Restated to reflect change in accounting policy for revenue recognition and leases

Recent Dividends:**1. Microsoft Corporation common.**

ExDate	Amt	Declared	Record	Payable
02/17/2015	0.31	12/03/2014	02/19/2015	03/12/2015
05/19/2015	0.31	03/10/2015	05/21/2015	06/11/2015
08/18/2015	0.31	06/09/2015	08/20/2015	09/10/2015
11/17/2015	0.36	09/15/2015	11/19/2015	12/10/2015
02/16/2016	0.36	12/02/2015	02/18/2016	03/10/2016
05/17/2016	0.36	03/15/2016	05/19/2016	06/09/2016
08/16/2016	0.36	06/14/2016	08/18/2016	09/08/2016
11/15/2016	0.39	09/20/2016	11/17/2016	12/08/2016
02/14/2017	0.39	11/30/2016	02/16/2017	03/09/2017
05/16/2017	0.39	03/14/2017	05/18/2017	06/08/2017
08/15/2017	0.39	06/13/2017	08/17/2017	09/14/2017
11/15/2017	0.42	09/19/2017	11/16/2017	12/14/2017
02/14/2018	0.42	11/29/2017	02/15/2018	03/08/2018
05/16/2018	0.42	03/12/2018	05/17/2018	06/14/2018

Annual Dividends:**1. Microsoft Corporation common.**

2015	1.29	2016	1.47	2017	1.59
2018	0.84				

MICROSTRATEGY INC.**Earnings, 6 mos. to Jun 30 (Consol. - \$000):**

	2018	2017
Total Revenues	243,569	241,452
Cost & expenses	244,651	206,541
Operating income	(1,082)	34,911
Interest income	5,257	2,000
Other income (expense), net	2,867	(4,474)
Net before taxes	7,042	32,437
Income taxes	541	6,927
Net income	6,501	25,510
Earnings common share		
Primary	\$0.57	\$2.23
Fully Diluted	\$0.57	\$2.20
Common Shares:		
Full Diluted	11,488	11,593
Year-end	11,467	

MICROVISION INC.**Earnings, 6 mos. to Jun 30 (Consol. - \$):**

	2018	2017
Total Revenues	4,202,000	1,907,000
Cost & expenses	19,773,000	13,504,000
Operating income	(15,571,000)	(11,597,000)
Other income (expense), net	(20,000)	(8,000)
Net income	(15,591,000)	(11,605,000)
Earnings common share		
Primary	\$(0.19)	\$(0.16)
Fully Diluted	\$(0.19)	\$(0.16)
Common Shares:		
Full Diluted	79,973,000	68,747,000
Year-end	93,073,000	

MID-CON ENERGY PARTNERS LP**Earnings, 6 mos. to Jun 30 (Consol. - \$000):**

	2018	2017
Total Revenues	18,025	34,961
Cost & expenses	25,766	33,295
Deprec., depl. & amort.	6,834	9,500
Operating income	(14,575)	(7,834)
Interest expense	2,749	2,989
Other income (expense), net	49	61
Net income	(17,273)	(10,757)
Earnings common share		
Primary	\$(0.64)	\$(0.40)
Fully Diluted	\$(0.64)	\$(0.40)
Common Shares:		
Full Diluted	30,241	29,936
Year-end	30,306	29,945

MIDDLEBY CORP

Earnings, 6 mos. to (Consol. – \$000):

	06/30/18	07/01/17
Net Sales	1,252,928	1,109,640
Cost & expenses	1,054,626	903,375
Operating income	198,302	206,265
Other income (expense), net	18,190	14,781
Net before taxes	197,265	209,539
Income taxes	47,857	61,268
Net income	149,408	148,271
Earnings common share		
Primary	\$2.69	\$2.59
Fully Diluted	\$2.69	\$2.59
Common Shares:		
Full Diluted	55,575	57,201
Year-end	55,724	57,611

MIDWEST HOLDING INC

Earnings, 6 mos. to Jun 30 (Consol. – \$):

	2018	2017
Total Revenues	1,225,765	2,266,079
Cost & expenses	2,391,349	3,807,604
Operating income	(1,368,497)	(1,834,379)
Net income	(1,368,497)	(1,834,379)
Earnings common share		
Primary	\$(0.06)	\$(0.08)
Fully Diluted	\$(0.06)	\$(0.08)
Common Shares:		
Full Diluted	22,860,701	22,763,160
Year-end	22,860,701	22,764,294

MILLER (HERMAN) INC.

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	06/02/18	06/03/17 (revised)	05/28/16 (revised)
Net sales	2,381,200	2,278,200	2,264,900
Cost of sales	1,508,200	1,414,000	1,390,700
Gross margin	873,000	864,200	874,200
Selling, general, & administrative expenses	616,700	587,800	585,600
Restructuring & impairment expenses	5,700	12,500	...
Design & research expenses	73,100	73,100	77,100
Total operating expenses	695,500	673,400	662,700
Operating earnings (loss)	177,500	190,800	211,500
Interest expense	13,500	15,200	15,400
Interest & other investment income	4,400	2,200	800
Other income (expenses), net	(300)	(200)	(300)
Net other income (expenses)	(9,400)	(13,200)	(14,900)
Earnings (loss) before income taxes - domestic	121,600	131,400	154,900
Earnings (loss) before income taxes - foreign	46,500	46,200	41,700
Earnings (loss) before income taxes	168,100	177,600	196,600
Current provision (benefit) for federal income taxes	30,200	28,700	36,400
Current provision (benefit) for state income taxes	4,300	2,300	6,400
Current provision (benefit) for foreign income taxes	10,700	11,100	6,300
Current provision (benefit) for income taxes	45,200	42,100	49,100
Deferred provision (benefit) for federal income taxes	(4,100)	9,200	7,500
Deferred provision			

(benefit) for state income taxes	100	2,800	200
Deferred provision (benefit) for foreign income taxes	1,200	1,000	2,700
Deferred provision (benefit) for income taxes	(2,800)	13,000	10,400
Income tax expense (benefit)	42,400	55,100	59,500
Equity earnings (loss) from nonconsolidated affiliates, net of tax	3,000	1,600	400
Net earnings (loss)	128,700	124,100	137,500
Net earnings attributable to noncontrolling interests	(600)	(200)	(800)
Net earnings (loss) attributable to Herman Miller, Inc.	128,100	123,900	136,700
Weighted average shares outstanding - basic	59,681	59,872	59,845
Weighted average shares outstanding - diluted	60,311	60,555	60,529
Year end shares outstanding	59,231	59,716	59,868
Net earnings (loss) per share - basic	\$2.15	\$2.07	\$2.28
Net earnings (loss) per share - diluted	\$2.12	\$2.05	\$2.26
Dividends per share	\$0.72	\$0.68	\$0.59
Total number of employees	7,681	7,478	7,607
Number of common stockholders	19,500	19,500	20,000
Foreign currency translation adjustments	...	(7,200)	(8,800)

As is; [□] Approximately; [▣] As of July 26, 2018; [▤] As of July 27, 2017; [▥] As of July 21, 2016

Consolidated Balance Sheet, Years Ended (\$000):

	06/02/18	06/03/17 (revised)
Cash & cash equivalents	203,900	96,200
Marketable securities	8,600	8,600
Accounts receivable, gross	222,400	189,900
Less allowances	3,100	3,300
Accounts receivable, net	219,300	186,600
Finished goods & work in process	124,200	119,000
Raw materials	38,200	33,400
Inventories, net	162,400	152,400
Prepaid taxes	9,900	17,700
Other current assets	41,300	30,400
Total current assets	645,400	491,900
Land & improvements	24,400	24,000
Buildings & improvements	238,600	229,000
Machinery & equipment	700,000	662,400
Construction in progress	57,800	53,300
Gross property & equipment	1,020,800	968,700
Less: accumulated depreciation	689,400	654,100
Net property & equipment	331,400	314,600
Goodwill	304,100	304,500
Indefinite-lived intangibles	78,100	78,100
Other amortizable intangibles, net	41,300	45,400
Other assets	79,200	71,800
Total assets	1,479,500	1,306,300
Accounts payable	171,400	148,400
Accrued compensation & benefits	86,300	79,700
Accrued warranty	51,500	47,700

Unearned revenue	30,400	33,200
Other accrued liabilities	74,200	76,700
Total current liabilities	413,800	385,700
Senior notes	...	149,900
Debt securities	50,000	50,000
Syndicated revolving line of credit	225,000	...
Construction-type lease	7,000	7,000
Supplier financing program	3,800	3,200
Less: current portion long-term debt	10,800	10,200
Long-term debt	275,000	199,900
Pension & post-retirement benefits	15,600	38,500
Other liabilities	79,800	69,900
Total liabilities	784,200	694,000
Redeemable noncontrolling interest	30,500	24,600
Common stock	11,700	11,900
Additional paid-in capital	116,600	139,300
Retained earnings (accumulated deficit)	598,300	519,500
Cumulative translation adjustments	(34,100)	(36,800)
Pension & other post-retirement benefit plans adjustments	(37,200)	(47,600)
Interest rate swap agreement at beginning of period	9,900	2,100
Available-for-sale securities at beginning of period	100	100
Accumulated other comprehensive income (loss)	(61,300)	(82,200)
Key executive deferred compensation	700	1,000
Herman Miller, Inc. stockholders' equity	664,600	587,500
Noncontrolling interests	200	200
Total stockholders' equity (deficit)	664,800	587,700

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Miller (Herman) Inc. common.

ExDate	Amt	Declared	Record	Payable
11/25/2014	0.14	10/06/2014	11/28/2014	01/15/2015
02/25/2015	0.14	01/23/2015	02/28/2015	04/15/2015
05/27/2015	0.14	04/14/2015	05/30/2015	07/15/2015
08/26/2015	0.15	06/24/2015	08/29/2015	10/15/2015
11/24/2015	0.15	10/12/2015	11/28/2015	01/15/2016
02/24/2016	0.15	01/15/2016	02/27/2016	04/15/2016
05/25/2016	0.15	04/11/2016	05/28/2016	07/15/2016
08/31/2016	0.17	06/20/2016	09/03/2016	10/15/2016
11/30/2016	0.17	10/10/2016	12/03/2016	01/15/2017
03/01/2017	0.17	01/19/2017	03/04/2017	04/15/2017
05/31/2017	0.17	04/10/2017	06/03/2017	07/15/2017
08/30/2017	0.18	07/05/2017	09/02/2017	10/15/2017
11/30/2017	0.18	10/09/2017	12/02/2017	01/15/2018
03/01/2018	0.18	01/17/2018	03/03/2018	04/15/2018
05/31/2018	0.18	04/09/2018	06/02/2018	07/15/2018

Annual Dividends:

1. Miller (Herman) Inc. common.

2015	0.57	2016	0.61	2017	0.69
2018	0.54				

MINDBODY INC

Earnings, 6 mos. to Jun 30 (Consol. – \$000):

	2018	2017
Total Revenues	115,434	86,321
Cost & expenses	135,797	93,947
Operating income	(20,363)	(7,626)
Interest income	1,099	324
Interest expense	1,334	621
Other income (expense), net	36	(101)
Net before taxes	(20,562)	(8,024)
Income taxes	(1,980)	260

Full Diluted.....	178,281	154,514
Year-end.....	172,415	155,861

NEOGEN CORP
Annual Report

Consolidated Income Statement, Years Ended May 31 (\$):

	2018	2017 (revised)	2016 (revised)
Product revenues.....	335,554,000	306,512,000	273,570,000
Service revenues.....	66,698,000	55,082,000	47,705,000
Total revenues.....	402,252,000	361,594,000	321,275,000
Cost of product revenues.....	174,067,000	156,568,000	137,766,000
Cost of service revenues.....	37,933,000	33,058,000	30,445,000
Total cost of revenues.....	212,000,000	189,626,000	168,211,000
Gross margin.....	190,252,000	171,968,000	153,064,000
Sales & marketing expenses.....	70,909,000	62,424,000	57,599,000
General & administrative expenses.....	38,294,000	34,214,000	29,189,000
Research & development expenses.....	10,855,000	10,385,000	9,890,000
Operating income (loss).....	70,194,000	64,945,000	56,386,000
Interest income.....	2,043,000	838,000	322,000
Royalty income.....	147,000	171,000	217,000
Change in purchase consideration.....	0
Other income (expense), net.....	1,081,000	719,000	(1,412,000)
Total other income (expense).....	3,271,000	1,728,000	(873,000)
Income before income taxes - U.S. ...	62,310,000	55,171,000	50,662,000
Income before income taxes - foreign.....	11,155,000	11,502,000	4,851,000
Income (loss) before income taxes ..	73,465,000	66,673,000	55,513,000
Current provision for income taxes - U.S.	10,129,000	20,259,000	14,630,000
Current provision (benefit) for income taxes - foreign.....	3,066,000	2,514,000	1,756,000
Deferred provision (benefit) for income taxes.....	(2,945,000)	(73,000)	2,589,000
Provision for income taxes.....	10,250,000	22,700,000	18,975,000
Net income (loss).....	63,215,000	43,973,000	36,538,000
Net loss (income) attributable to non-controlling interest.....	(70,000)	(180,000)	26,000
Net income attributable to Neogen Corporation & subsidiaries.....	63,145,000	43,793,000	36,564,000
Weighted average shares outstanding - basic.....	51,358,000	50,544,000	49,869,333
Weighted average shares outstanding - diluted.....	52,149,000	51,165,333	50,500,000
Year end shares outstanding.....	51,735,732	50,932,489	50,090,252
Net income (loss) per share - basic	\$1.23	\$0.87	\$0.73
Net income (loss) per share - diluted....	\$1.21	\$0.85	\$0.73
Number of full time employees.....	1,546	1,413	1,235
Number of common stockholders.....	266	281	304
Number of beneficiary stockholders.....	12,000	12,000	11,736

Foreign currency translation adjustments.....	(2,543,000)	(3,257,000)	(1,504,000)
---	-------------	-------------	-------------

Reclassified to conform with 2018 presentation; Adjusted for 4-for-3 stock split, January 2, 2018; Approximately: As of June 30, 2018; As of June 30, 2017; As of June 30, 2016

Consolidated Balance Sheet, Years Ended May 31 (\$):

	2018	2017 (revised)
Cash & cash equivalents.....	83,074,000	77,567,000
Marketable securities.....	127,736,000	66,068,000
Accounts receivable, gross.....	80,636,000	70,576,000
Less: allowance.....	1,550,000	2,000,000
Accounts receivable, net.....	79,086,000	68,576,000
Raw materials.....	36,702,000	33,190,000
Work-in-process.....	5,993,000	4,831,000
Finished goods.....	33,310,000	35,123,000
Inventories.....	76,005,000	73,144,000
Prepaid expenses & other current assets.....	9,888,000	7,606,000
Total current assets.....	375,789,000	292,961,000
Land & improvements.....	4,730,000	3,094,000
Buildings & improvements.....	44,008,000	37,917,000
Machinery & equipment.....	74,911,000	64,867,000
Furniture & fixtures.....	3,568,000	3,333,000
Construction in progress.....	2,654,000	2,290,000
Property & equipment, gross.....	129,871,000	111,501,000
Less accumulated depreciation.....	56,802,000	49,753,000
Net property & equipment.....	73,069,000	61,748,000
Goodwill.....	99,558,000	104,759,000
Other non-amortizable intangible assets.....	14,938,000	14,323,000
Amortizable customer-based intangible assets, gross.....	56,420,000	56,829,000
Less: accumulated amortization - amortizable customer-based intangible assets.....	24,579,000	20,846,000
Amortizable customer-based intangible assets, net.....	31,841,000	35,983,000
Other non-current intangible assets, net.....	22,814,000	18,635,000
Total assets.....	618,009,000	528,409,000
Accounts payable.....	20,750,000	16,244,000
Accruals - compensation & benefits.....	6,065,000	5,002,000
Accruals - federal income taxes.....	165,000	936,000
Accruals - other.....	11,708,000	13,820,000
Total current liabilities.....	38,688,000	36,002,000
Deferred income taxes.....	14,103,000	17,048,000
Other long-term liabilities.....	5,043,000	3,602,000
Total liabilities.....	57,834,000	56,652,000
Common stock.....	8,278,000	8,149,000
Additional paid-in capital.....	202,572,000	174,742,000
Accumulated other comprehensive income (loss).....	(9,746,000)	(7,203,000)
Retained earnings (accumulated deficit).....	359,071,000	295,926,000
Total Neogen Corporation & subsidiaries stockholders' equity.....	560,175,000	471,614,000
Non-controlling interest.....	...	143,000
Total equity.....	560,175,000	471,757,000

Reclassified to conform with 2018 presentation

Recent Dividends:
1. Neogen Corp common.

No dividends paid.
After 4-for-3 split: No dividends paid.

Annual Dividends:

1. Neogen Corp common.
No dividends paid.
After 4-for-3 split: No dividends paid.

NEON THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses.....	35,874	19,312
Operating income.....	(35,874)	(19,312)
Interest income.....	464	241
Other income (expense), net.....	(10)
Net income.....	(35,420)	(19,071)
Balance for common.....	(41,791)	(24,050)
Earnings common share		
Primary.....	\$(17.05)	\$(15.62)
Fully Diluted.....	\$(17.05)	\$(15.62)
Common Shares:		
Full Diluted.....	2,450	1,540
Year-end.....	28,279

NEOS THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses.....	47,878	42,249
Operating income.....	(25,786)	(31,439)
Interest expense.....	4,452	4,602
Other income (expense), net.....	595	175
Net income.....	(29,643)	(35,866)
Earnings common share		
Primary.....	\$(1.02)	\$(1.70)
Fully Diluted.....	\$(1.02)	\$(1.70)
Common Shares:		
Full Diluted.....	29,003	21,127
Year-end.....	29,015

NETAPP, INC.

Earnings, 3 mos. to (Consol. - \$000):

	07/27/18	07/28/17
Total Revenues.....	1,474,000	1,321,000
Cost & expenses.....	1,220,000	1,181,000
Operating income.....	254,000	140,000
Other income (expense), net.....	7,000	2,000
Net before taxes.....	272,000	145,000
Income taxes.....	(11,000)	14,000
Net income.....	283,000	131,000
Earnings common share		
Primary.....	\$1.08	\$0.49
Fully Diluted.....	\$1.05	\$0.47
Common Shares:		
Full Diluted.....	269,000	278,000
Year-end.....	260,000

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents.....	2,627,000
Inventories.....	97,000
Current assets.....	5,853,000
Net property & equip.....	768,000
Total assets.....	8,905,000
Liabilities:	
Current liabilities.....	2,840,000
Long-term debt.....	1,542,000
Stockholders' equity.....	1,922,000
Net current assets.....	3,013,000

NETGEAR INC

Earnings, 6 mos. to (Consol. - \$000):

	07/01/18	07/02/17
Total Revenues.....	711,793	654,380
Cost & expenses.....	706,301	612,498
Operating income.....	5,492	41,882
Interest income.....	1,820	887
Other income (expense), net.....	(191)	718
Net before taxes.....	7,121	43,487
Income taxes.....	6,761	12,911
Net income.....	360	30,576
Earnings common share		
Primary.....	\$0.01	\$0.94
Fully Diluted.....	\$0.01	\$0.91
Common Shares:		
Full Diluted.....	32,722	33,656
Year-end.....	31,808	31,605

NETSCOUT SYSTEMS INC

Earnings, 3 mos. to Jun 30(Consol. - \$000):

	2018	2017	Primary	\$(0.01)	\$(0.01)	(losses) of			
Total Revenues	205,111	225,756	Primary Diluted	\$(0.01)	\$(0.01)	affiliates	(1,006,000)	(295,000)	30,000
Cost & expenses	258,699	240,928	Common Shares:			Interest, net	(7,000)	39,000	43,000
Operating income	(77,053)	(33,555)	Full Diluted	44,550,000	44,050,000	Loss on the			
Interest expense	5,888	2,550	Year-end	44,550,000	44,050,000	Transaction	(337,000)
Other income (expense), net	254	(1,065)				Gain on sale of			
Net before taxes	(81,746)	(36,690)				cost method			
Income taxes	(19,242)	(12,468)				investments	32,000
Net income	(62,504)	(24,222)				Gain on sale of REA			
Earnings common share						Group's European		107,000	...
Primary	\$(0.78)	\$(0.27)				business	...		
Fully Diluted	\$(0.78)	\$(0.27)				Impairment of			
Common Shares:						marketable			
Full Diluted	80,358	91,180				securities & cost			
Year-end	80,535	...				method investments	33,000	21,000	21,000
Consolidated Balance Sheet Items, as of (\$000):						Other income			
Assets:						(expenses)	13,000	46,000	39,000
Cash & equivalents	353,416	...				Income (loss)			
Inventories	32,739	...				before income tax			
Current assets	718,074	...				expense (benefit) -			
Net property & equip.	60,006	...				U.S.	(55,000)	84,000	(125,000)
Total assets	3,277,608	...				Income (loss)			
Liabilities:						before income tax			
Current liabilities	359,825	...				expense (benefit) -			
Long-term debt	600,000	...				foreign	(1,034,000)	(699,000)	306,000
Stockholders' equity	2,045,201	...				(Loss) income from			
Net current assets	358,249	...				continuing			
						operations before			
						income tax expense			
						(benefit)	(1,089,000)	(615,000)	181,000
						Current U.S.			
						federal income tax			
						expense (benefit)	4,000	1,000	15,000
						Current U.S. state			
						& local income tax			
						expense (benefit)	8,000	4,000	5,000
						Current foreign			
						income tax expense			
						(benefit)	107,000	118,000	102,000
						Total current			
						income tax expense			
						(benefit)	119,000	123,000	122,000
						Deferred U.S.			
						federal income tax			
						expense (benefit)	269,000	57,000	(71,000)
						Deferred U.S. state			
						& local income tax			
						expense (benefit)	(9,000)	(1,000)	(106,000)
						Deferred foreign			
						income tax expense			
						(benefit)	(24,000)	(151,000)	1,000
						Total deferred			
						income tax expense			
						(benefit)	236,000	(95,000)	(176,000)
						Income tax expense			
						(benefit)	355,000	28,000	(54,000)
						Income (loss) from			
						continuing			
						operations	(1,444,000)	(643,000)	235,000
						Income (loss) from			
						discontinued			
						operations, net of			
						tax	15,000
						Net income (loss)	(1,444,000)	(643,000)	250,000
						Less: net income			
						attributable to			
						noncontrolling			
						interests	(70,000)	(95,000)	(71,000)
						Net income (loss)			
						attributable to New			
						Corporation			
						stockholders	(1,514,000)	(738,000)	179,000
						Weighted average			
						shares outstanding			
						- basic	582,700	581,400	580,600
						Weighted average			
						shares outstanding			
						- diluted	582,700	581,400	582,500
						Year end shares			
						outstanding	583,016	581,925	580,121
						Income (loss) from			
						continuing			
						operations per			
						share - basic	\$(2.60)	\$(1.27)	\$0.28

Income (loss) from discontinued operations per share - basic	\$0.02
Net income (loss) per share - basic	\$(2.60)	\$(1.27)	\$0.30
Income (loss) from continuing operations per share - diluted	\$(2.60)	\$(1.27)	\$0.28
Income (loss) from discontinued operations per share - diluted	\$0.02
Net income (loss) per share - diluted	\$(2.60)	\$(1.27)	\$0.30
Cash dividends declared per share of common stock	\$0.20	\$0.20	\$0.20
Total number of employees	28,000	26,000	24,000
Number of Class A common stockholders	21,000	23,000	25,000
Number of Class B common stockholders	600	600	760
Foreign currency translation adjustments	...	84,000	(398,000)

Reclassified to conform with 2018 presentation; As is; As of August 7, 2017

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	2,034,000	2,016,000
Receivables, gross	1,829,000	1,484,000
Allowances for sales returns	171,000	166,000
Allowances for doubtful accounts	46,000	42,000
Inventories	376,000	208,000
Total current assets	4,394,000	3,815,000
Investments	393,000	2,027,000
Land	150,000	153,000
Buildings & leaseholds	1,742,000	1,733,000
Digital set top units & installations	744,000	...
Machinery & equipment	3,131,000	2,985,000
Less: accumulated depreciation & amortization	3,352,000	3,339,000
Construction in progress	145,000	92,000
Property, plant & equipment, net	2,560,000	1,624,000
Intangible assets, net	2,671,000	2,281,000
Goodwill	5,218,000	3,838,000
Deferred income tax assets	279,000	525,000
Royalty advances to authors	312,000	298,000
Inventory	143,000	31,000
Other non-current assets	376,000	113,000
Total assets	16,346,000	14,552,000
Accounts payable	605,000	222,000
Accrued expenses	1,340,000	1,204,000
Deferred revenue	516,000	426,000
Current borrowings	462,000	103,000
Current tax payable	17,000	39,000
Royalties & commissions payable	187,000	152,000
Other current liabilities	168,000	306,000
Total current liabilities	3,295,000	2,452,000
Credit facilities	1,302,000	368,000
U.S. private placement	650,000	...
Other obligations	...	11,000
Total debt	1,952,000	379,000
Less: current portion	462,000	103,000
Borrowings	1,490,000	276,000
Retirement benefit obligations	245,000	319,000
Deferred income tax liabilities	389,000	61,000
Other non-current

liabilities	430,000	351,000
Redeemable preferred stock	20,000	20,000
Class A common stock	4,000	4,000
Class B common stock	2,000	2,000
Additional paid-in capital	12,322,000	12,395,000
Retained earnings (accumulated deficit)	(2,163,000)	(648,000)
Unrealized holding gains (losses) on securities	22,000	(5,000)
Cash flow hedge	4,000	...
Benefit plan adjustments	(309,000)	(437,000)
Foreign currency translation	(591,000)	(510,000)
Share of other comprehensive income from equity affiliates, net	...	(12,000)
Accumulated other comprehensive income (loss)	(874,000)	(964,000)
Total News Corporation stockholders' equity	9,291,000	10,789,000
Noncontrolling interests	1,186,000	284,000
Total equity	10,477,000	11,073,000

Reclassified to conform with 2018 presentation

Recent Dividends:

- 1. News Corp (New) class A common. No dividends paid.
- 2. News Corp (New) class B common. No dividends paid.

Annual Dividends:

- 1. News Corp (New) class A common. No dividends paid.
- 2. News Corp (New) class B common. No dividends paid.

NEWTEK BUSINESS SERVICES CORP

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Cost & expenses	27,143	22,485
Deprec., depl. & amort.	236	185
Net income	(4,907)	(3,773)
Earnings common share		
Primary	\$(0.26)	\$(0.22)
Common Shares:		
Year-end	18,745	...

NEXSTAR MEDIA GROUP INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Total Revenues	1,275,659	1,166,432
Cost & expenses	827,149	737,997
Operating income	292,110	243,049
Interest expense	110,870	134,922
Other income (expense), net	3,475	(28,347)
Net before taxes	184,715	79,780
Income taxes	50,768	26,381
Net income	133,947	53,399
Earnings common share		
Primary	\$2.96	\$1.10
Fully Diluted	\$2.87	\$1.07
Common Shares:		
Full Diluted	47,414	46,815
Year-end	45,522	...

NIC INC.

Earnings, 6 mos. to Jun 30 (Consol. - \$):

	2018	2017
Total Revenues	179,223,000	168,503,000
Cost & expenses	131,969,000	124,374,000
Operating income	43,044,000	40,828,000
Interest income	58,000	...
Net before taxes	43,102,000	40,828,000
Income taxes	10,582,000	14,074,000
Net income	32,520,000	26,754,000
Balance for common	32,165,000	26,509,000
Earnings common share		
Primary	\$0.48	\$0.40
Fully Diluted	\$0.48	\$0.40
Common Shares:		
Full Diluted	66,447,000	66,147,000
Year-end	66,556,000	66,265,000

NII HOLDINGS INC.

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Total Revenues	337,023	476,089
Cost & expenses	354,995	602,509
Operating income	(34,306)	(148,780)
Interest income	6,979	16,944
Interest expense	54,616	57,967
Other income (expense), net	(9,581)	5,860
Foreign currency	(47,854)	(1,977)
Income taxes	...	(5,778)
Income contin. oper.	(139,378)	(180,142)
Net income	(142,161)	(177,483)
Earnings common share		
Primary	\$(1.42)	\$(1.77)
Fully Diluted	\$(1.42)	\$(1.77)
Common Shares:		
Full Diluted	100,388	100,279
Year-end	100,456	100,383

NLIGHT INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Total Revenues	94,172	64,551
Cost & expenses	84,415	62,043
Operating income	9,757	2,508
Interest expense	225	971
Other income (expense), net	34	(797)
Net before taxes	9,566	740
Income taxes	1,997	2,240
Net income	7,569	(1,500)
Balance for common	3,154	(1,500)
Earnings common share		
Primary	\$0.23	\$(0.57)
Fully Diluted	\$0.17	\$(0.57)
Common Shares:		
Full Diluted	18,797	2,613
Year-end	34,792	...

NN, INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Net Sales	365,497	315,502
Cost & expenses	331,557	263,386
Deprec., depl. & amort.	30,539	25,622
Operating income	3,401	26,494
Interest expense	27,984	27,177
Other income (expense), net	(14,512)	(39,215)
Equity earnings	(1,478)	(2,937)
Net before taxes	(39,095)	(39,898)
Income taxes	(7,123)	(12,480)
Income contin. oper.	...	(24,811)
Net income	(30,494)	(13,727)
Earnings common share		
Primary	\$(1.10)	\$(0.50)
Fully Diluted	\$(1.10)	\$(0.50)
Common Shares:		
Full Diluted	27,632	27,358
Year-end	27,729	27,537

NOBILITY HOMES, INC.

New Accountant On Aug. 20, 2018, Co. dismissed Withum-Smith+Brown, PC and engaged Dazskal Bolton LLP as its new independent public accounting firm.

NOODLES & CO

Earnings, 6 mos. to (Consol. - \$000):

	07/03/18	07/04/17
Total Revenues	227,921	229,507
Cost & expenses	223,144	243,415
Operating income	(6,840)	(26,454)
Interest expense	2,292	1,935
Other income (expense), net	(626)	...
Net before taxes	(9,758)	(28,389)
Income taxes	(248)	271
Net income	(9,510)	(28,660)
Balance for common	(9,510)	(36,627)
Earnings common share		
Primary	\$(0.23)	\$(1.06)
Fully Diluted	\$(0.23)	\$(1.06)
Common Shares:		
Full Diluted	41,151	34,404
Year-end	41,267	41,099

NORTHERN TECHNOLOGIES INTERNATIONAL CORP.

Earnings, 9 mos. to May 31 (Consol. - \$):

	2018	2017	Earnings common share		07/29/18	07/30/17
Net Sales	36,680,850	28,667,945	Primary	\$(0.25) \$(0.32)	6,330,000	4,167,000
Cost & expenses	30,698,598	25,803,704	Fully Diluted	\$(0.25) \$(0.32)	3,878,000	2,925,000
Operating income	5,982,252	2,864,241	Common Shares:		2,452,000	1,242,000
Interest income	84,569	19,075	Full Diluted	356,555,000	278,836,000	
Interest expense	14,007	15,502	Year-end	381,683,985		
Net before taxes	6,052,814	2,867,814				
Income taxes	1,128,583	480,423	NUANCE COMMUNICATIONS INC			
Net income	4,924,231	2,387,391	Earnings, 9 mos. to Jun 30(Consol. – \$000):			
Earnings common share			2018	2017		
Primary	\$1.00	\$0.45	Total Revenues	1,518,756	1,473,452	
Fully Diluted	\$0.98	\$0.45	Cost & expenses	1,540,819	1,318,698	
Common Shares:			Operating income	(91,914)	69,823	
Full Diluted	4,663,847	4,571,395	Interest income	6,910	4,255	
Year-end	4,541,304	4,527,018	Interest expense	103,785	116,296	
			Other income (expense), net	(1,477)	(21,251)	
			Net before taxes	(190,266)	(63,469)	
			Income taxes	(65,404)	22,103	
NORTHFIELD BANCORP INC (DE)			Net income	(124,862)	(85,572)	
Earnings, 6 mos. to Jun 30(Consol. – \$000):			Earnings common share			
2018	2017		Primary	\$(0.43)	\$(0.30)	
Cost & expenses	50,173	46,188	Fully Diluted	\$(0.43)	\$(0.30)	
Operating income	25,293	25,125	Common Shares:			
Net before taxes	25,293	25,125	Full Diluted	292,703	289,269	
Income taxes	4,237	6,767	Year-end	287,392	288,467	
Net income	21,056	18,358	NUTRISYSTEM INC			
Earnings common share			Earnings, 6 mos. to Jun 30(Consol. – \$000):			
Primary	\$0.46	\$0.41	2018	2017		
Fully Diluted	\$0.45	\$0.39	Total Revenues	402,241	407,571	
Common Shares:			Cost & expenses	358,754	354,839	
Full Diluted	47,056	46,879	Deprec., depl. & amort.	7,600	7,566	
Year-end	49,482	48,857	Operating income	35,887	45,166	
			Net before taxes	36,085	45,192	
NORTHWEST PIPE CO.			Income taxes	7,146	13,273	
Acquisition Completed On July 27, 2018, Co. acquired			Net income	28,939	31,919	
all the issued and outstanding membership interests of Ameron			Balance for common	28,703	31,632	
Water Transmission Group, LLC, from National Oilwell Varco			Earnings common share			
Inc. wholly-owned subsidiary, Ameron International Corp., for			Primary	\$0.97	\$1.07	
approximately \$38,300,000, subject to a post-closing adjustment			Fully Diluted	\$0.96	\$1.05	
based on changes in net working capital.			Common Shares:			
NORTHWEST PIPE CO.			Full Diluted	29,911	30,096	
Earnings, 6 mos. to Jun 30(Consol. – \$000):			Year-end	29,437	30,004	
2018	2017					
Net Sales	62,150	58,349	NUVASIVE INC			
Cost & expenses	70,319	64,653	Earnings, 6 mos. to Jun 30(Consol. – \$000):			
Operating income	(8,169)	(6,304)	2018	2017		
Interest income	218		Total Revenues	542,086	508,412	
Other income (expense), net	190	27	Cost & expenses	506,692	433,374	
Net before taxes	(8,017)	(6,529)	Operating income	(20,914)	31,779	
Income taxes	(380)	(1,566)	Interest income	250	276	
Income contin. oper.		(4,963)	Interest expense	19,423	19,882	
Income discont. oper.		(973)	Other income (expense), net	(12,082)	(243)	
Net income	(7,637)	(5,936)	Net before taxes	(20,914)	31,779	
Earnings common share			Income taxes	(5,313)	8,061	
Primary	\$(0.79)	\$(0.62)	Net income	(15,601)	23,718	
Fully Diluted	\$(0.79)	\$(0.62)	Earnings common share			
Common Shares:			Primary	\$(0.30)	\$0.48	
Full Diluted	9,717	9,607	Fully Diluted	\$(0.30)	\$0.42	
Year-end	9,735		Common Shares:			
			Full Diluted	51,292	58,059	
			Year-end	56,512		
NOVAN INC						
Earnings, 6 mos. to Jun 30(Consol. – \$000):			NUVECTRA CORP			
2018	2017		Earnings, 6 mos. to Jun 30(Consol. – \$000):			
Total Revenues	1,307	1,041	2018	2017		
Cost & expenses	18,011	21,800	Total Revenues	23,723	12,263	
Operating income	(16,704)	(20,759)	Cost & expenses	44,143	35,535	
Interest income	159	56	Operating income	(20,420)	(23,272)	
Interest expense	523	524	Interest expense	1,786	768	
Other income (expense), net	4,273		Other income (expense), net	(77)	(320)	
Net income	(12,795)	(21,222)	Net before taxes	(22,283)		
Earnings common share			Income taxes	28		
Primary	\$(0.50)	\$(1.33)	Net income	(22,311)	(24,360)	
Fully Diluted	\$(0.50)	\$(1.33)	Earnings common share			
Common Shares:			Primary	\$(2.04)	\$(2.34)	
Full Diluted	25,536	15,972	Fully Diluted	\$(2.04)	\$(2.34)	
Year-end	26,040	15,982	Common Shares:			
			Full Diluted	10,922	10,396	
			Year-end	14,254	10,489	
NOVAVAX, INC.						
Earnings, 6 mos. to Jun 30(Consol. – \$):			NVIDIA CORP			
2018	2017		Earnings, 6 mos. to Jun 30(Consol. – \$000):			
Total Revenues	20,426,000	12,412,000	2018	2017		
Cost & expenses	105,932,000	94,709,000	Total Revenues	35,723	12,263	
Operating income	(85,506,000)	(82,297,000)	Cost & expenses	44,143	35,535	
Other income (expense), net	130,000	10,000	Operating income	(20,420)	(23,272)	
Gains or losses	1,338,000	997,000	Interest expense	1,786	768	
Net income	(90,844,000)	(88,319,000)	Other income (expense), net	(77)	(320)	
			Net before taxes	(22,283)		
			Income taxes	28		
			Net income	(22,311)	(24,360)	
			Earnings common share			
			Primary	\$(2.04)	\$(2.34)	
			Fully Diluted	\$(2.04)	\$(2.34)	
			Common Shares:			
			Full Diluted	10,922	10,396	
			Year-end	14,254	10,489	
			ODONATE THERAPEUTICS INC			
			Earnings, 6 mos. to Jun 30(Consol. – \$000):			
			2018	2017		
			Total Revenues	988	913	
			Cost & expenses	28,007	34,924	
			Operating income	(27,019)	(34,011)	
			Interest income	391	205	
			Interest expense	941	911	
			Net income	(27,569)	(34,717)	
			Earnings common share			
			Primary	\$(0.76)	\$(1.22)	
			Fully Diluted	\$(0.76)	\$(1.22)	
			Common Shares:			
			Full Diluted	36,160	28,352	
			Year-end	38,477		

	2018	2017	Operating income	(58,304)	(24,665)		2018	2017
Cost & expenses	36,660	6,626	Interest expense	6,502	5,386	Total Revenues	8,848,268	8,169,580
Operating income	(36,660)	(6,626)	Other income (expense), net	1,056	603	Cost & expenses	7,942,935	7,730,484
Interest income	389		Net income	(63,750)	(29,448)	Deprec., depl. & amort.	385,295	366,958
Net income	(36,271)	(6,626)	Earnings common share			Operating income	520,038	72,138
Earnings common share			Primary	\$(1.32)	\$(0.67)	Other income (expense), net	(18,384)	(3,370)
Primary	\$(1.49)	\$(0.57)	Fully Diluted	\$(1.32)	\$(0.67)	Net before taxes	501,654	68,768
Fully Diluted	\$(1.49)	\$(0.57)	Common Shares:			Income taxes	130,392	39,816
Common Shares:			Full Diluted	48,334	43,933	Net income	371,262	28,952
Full Diluted	24,377	11,609	Year-end	48,498	44,448	Earnings common share		
Year-end	26,891					Primary	\$0.03	\$0.00
						Fully Diluted	\$0.03	\$0.00

OFFICE DEPOT, INC.**Earnings, 6 mos. to (Consol. - \$000):**

	06/30/18	07/01/17
Net Sales	5,458,000	5,039,000
Cost & expenses	5,333,000	4,874,000
Operating income	125,000	165,000
Interest income	12,000	12,000
Interest expense	60,000	27,000
Other income (expense), net	6,000	6,000
Net before taxes	83,000	156,000
Income taxes	31,000	61,000
Income contin. oper.	52,000	95,000
Income discont. oper.	5,000	45,000
Net income	57,000	140,000
Earnings common share		
Primary	\$0.10	\$0.27
Fully Diluted	\$0.10	\$0.26
Common Shares:		
Full Diluted	564,000	532,000
Year-end	554,453	

OFS CAPITAL CORP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	19,281	16,012
Cost & expenses	10,908	8,356
Net income	8,374	7,656
Earnings common share		
Primary	\$0.63	\$0.67
Fully Diluted	\$0.63	\$0.67
Common Shares:		
Full Diluted	13,345	11,459
Year-end	13,350	13,332

OLYMPIC STEEL INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	828,515	691,088
Cost & expenses	783,195	661,327
Operating income	36,664	20,684
Other income (expense), net	(139)	(54)
Net before taxes	31,869	17,216
Net income	23,477	12,496
Earnings common share		
Primary	\$2.06	\$1.10
Fully Diluted	\$2.06	\$1.10
Common Shares:		
Full Diluted	11,419	11,387
Year-end	11,008	10,968

OMEGA FLEX INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	52,244	49,412
Cost & expenses	40,386	38,773
Operating income	11,858	10,639
Other income (expense), net	(40)	(22)
Net before taxes	11,963	10,666
Income taxes	2,948	3,399
Net income	9,015	7,267
Earnings common share		
Primary	\$0.89	\$0.71
Fully Diluted	\$0.89	\$0.71
Common Shares:		
Full Diluted	10,092	10,092
Year-end	10,154	10,092

OMEROS CORP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	29,408	29,408
Cost & expenses	61,548	54,073

OMNICELL INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	371,292	329,595
Cost & expenses	363,325	346,848
Operating income	7,967	(17,253)
Net before taxes	4,342	(19,513)
Income taxes	(4,966)	(11,058)
Net income	9,308	(8,455)
Earnings common share		
Primary	\$0.24	\$(0.23)
Fully Diluted	\$0.23	\$(0.23)
Common Shares:		
Full Diluted	39,854	37,046
Year-end	39,204	

OMNITEK ENGINEERING CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	729,085	537,968
Cost & expenses	891,855	921,235
Deprec., depl. & amort.	5,726	12,448
Operating income	(168,496)	(395,715)
Interest expense	6,287	4,115
Other income (expense), net	950	
Net before taxes	(173,833)	(399,830)
Income taxes	800	800
Net income	(174,633)	(400,630)
Earnings common share		
Primary	\$(0.01)	\$(0.02)
Fully Diluted	\$(0.01)	\$(0.02)
Common Shares:		
Full Diluted	20,281,082	20,281,082
Year-end	20,281,082	20,281,082

ON SEMICONDUCTOR CORP**Earnings, 6 mos. to (Consol. - \$000):**

	06/29/18	06/30/17
Total Revenues	2,833,500	2,774,700
Cost & expenses	2,395,300	2,379,900
Operating income	382,900	337,100
Interest income	2,000	1,100
Interest expense	64,100	73,100
Other income (expense), net	24,900	(6,900)
Gains or losses	4,600	
Net before taxes	350,300	258,200
Income taxes	53,500	85,100
Net income	296,800	173,100
Earnings common share		
Primary	\$0.69	\$0.41
Fully Diluted	\$0.66	\$0.40
Common Shares:		
Full Diluted	444,400	426,000
Year-end	426,360	

ONCOMED PHARMACEUTICALS INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	14,719	12,408
Cost & expenses	25,539	50,601
Operating income	(10,820)	(38,193)
Net before taxes	(9,933)	(37,825)
Income taxes	(383)	8
Net income	(9,550)	(37,833)
Earnings common share		
Primary	\$(0.25)	\$(1.01)
Fully Diluted	\$(0.25)	\$(1.01)
Common Shares:		
Full Diluted	38,317	37,448
Year-end	38,431	37,627

ONLINE VACATION CENTER HOLDINGS CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

--	--	--

Total Revenues	8,848,268	8,169,580
Cost & expenses	7,942,935	7,730,484
Deprec., depl. & amort.	385,295	366,958
Operating income	520,038	72,138
Other income (expense), net	(18,384)	(3,370)
Net before taxes	501,654	68,768
Income taxes	130,392	39,816
Net income	371,262	28,952
Earnings common share		
Primary	\$0.03	\$0.00
Fully Diluted	\$0.03	\$0.00
Common Shares:		
Full Diluted	11,261,878	11,261,878
Year-end	11,261,878	11,261,878

OPHTHOTECH CORP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues		3,323
Cost & expenses	28,179	69,347
Operating income	(28,179)	(66,024)
Other income (expense), net	(16)	(22)
Net before taxes	(27,120)	(65,324)
Income taxes	(838)	2
Net income	(26,282)	(65,326)
Earnings common share		
Primary	\$(0.73)	\$(1.82)
Fully Diluted	\$(0.73)	\$(1.82)
Common Shares:		
Full Diluted	36,171	35,831
Year-end	36,188	35,932

OPKO HEALTH INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	518,598	558,981
Cost & expenses	531,819	594,147
Operating income	(47,719)	(71,047)
Interest income	67	385
Interest expense	4,989	2,931
Other income (expense), net	14,121	12,028
Equity earnings	9,669	7,758
Net before taxes	(38,520)	(61,565)
Income taxes	1,126	(17,904)
Net income	(49,315)	(51,419)
Earnings common share		
Primary	\$(0.09)	\$(0.09)
Fully Diluted	\$(0.09)	\$(0.11)
Common Shares:		
Full Diluted	559,508	563,617
Year-end	559,620	559,405

OPTINOSE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	2,139	
Cost & expenses	54,169	15,640
Operating income	(52,030)	(15,640)
Interest income	1,058	95
Interest expense	4,494	862
Other income (expense), net	333	93
Foreign currency	(21)	31
Net income	(55,154)	(16,283)
Balance for common	(55,154)	(24,507)
Earnings common share		
Primary	\$(1.44)	\$(6.02)
Fully Diluted	\$(1.44)	\$(6.02)
Common Shares:		
Full Diluted	38,271	4,068
Year-end	41,122	

ORASURE TECHNOLOGIES INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	85,612,000	72,722,000
Cost & expenses	80,552,000	49,964,000
Operating income	5,060,000	22,758,000
Other income (expense), net	1,148,000	563,000
Net before taxes	6,208,000	23,321,000
Income taxes	4,206,000	5,452,000
Net income	2,002,000	17,869,000
Earnings common share		
Primary	\$0.03	\$0.31

Fully Diluted	\$0.03	\$0.30
Common Shares:		
Full Diluted	62,379,000	59,755,000
Year-end	61,174,000	59,330,000

ORBCOMM INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	138,761	108,878
Cost & expenses	120,108	88,731
Deprec., depl. & amort.	24,065	22,422
Operating income	(5,412)	(2,275)
Other income (expense), net	(12)	(4,046)
Net before taxes	(14,997)	(13,334)
Income taxes	2,168	713
Net income	(17,165)	(14,047)
Balance for common	(17,319)	(14,083)
Earnings common share		
Primary	\$(0.23)	\$(0.20)
Fully Diluted	\$(0.23)	\$(0.20)
Common Shares:		
Full Diluted	76,404	71,703
Year-end	78,563	73,489

ORGANOVO HOLDINGS INC

Earnings, 3 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	689,000	990,000
Cost & expenses	8,266,000	11,190,000
Operating income	(7,577,000)	(10,200,000)
Interest income	162,000	98,000
Gains or losses	2,000	
Income taxes	3,000	
Net income	(7,416,000)	(10,102,000)
Earnings common share		
Primary	\$(0.07)	\$(0.10)
Fully Diluted	\$(0.07)	\$(0.10)
Common Shares:		
Full Diluted	111,458,445	104,689,391
Year-end	113,318,380	

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	39,613,000	
Inventories	1,044,000	
Current assets	42,312,000	
Net property & equip.	2,504,000	
Total assets	45,092,000	
Liabilities:		
Current liabilities	3,210,000	
Stockholders' equity	41,356,000	
Net current assets	39,102,000	

ORIGIN BANCORP INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	74,958	73,579
Operating income	31,653	14,423
Net before taxes	31,653	14,423
Income taxes	5,544	3,353
Net income	26,109	11,070
Balance for common	23,265	8,471
Earnings common share		
Primary	\$1.14	\$0.44
Fully Diluted	\$1.13	\$0.43
Common Shares:		
Full Diluted	20,726	19,620
Year-end	23,504	

ORTHOPIX MEDICAL INC

Name Change Development On July 18, 2018, Co.'s shareholders adopted a resolution to allow Co. to change the jurisdiction of organization of Co. from Curaao to the State of Delaware (the "Domestication"). In connection with the planned upcoming Domestication, Co.'s name will be changed to Orthofix Medical Inc., and Co.'s common stock will continue to be traded on the Nasdaq Global Select Market under the symbol "OFIX." The number of shares of common stock that each Co. shareholder will own in Orthofix Medical Inc. on the effective date of the Domestication will be the same as the number of common shares such shareholder held in Co. immediately prior to the effectuation of the Domestication. Co. currently expects that the Domestication will be effective as of the opening of trading on or about Aug. 1, 2018.

ORTHOPIX MEDICAL INC

New Name On Aug. 1, 2018, Co. changed its name from Orthofix International N.V. to Orthofix Medical Inc.

ORTHOPIX MEDICAL INC

Restructuring On Aug. 1, 2018, Co. reorganized into 1 share of Orthofix Medical Inc. for each ordinary share held.

ORTHOPEDIATRICS CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	27,171	21,564
Cost & expenses	33,686	23,078
Operating income	(6,515)	(1,514)
Interest expense	1,114	1,095
Other income (expense), net	(63)	58
Net income	(7,692)	(2,551)
Balance for common	(7,692)	(5,431)
Earnings common share		
Primary	\$(0.62)	\$(3.11)
Fully Diluted	\$(0.62)	\$(3.11)
Common Shares:		
Full Diluted	12,313	1,745
Year-end	12,789	

OSIRIS THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	65,510	56,132
Cost & expenses	65,845	57,339
Operating income	(335)	(1,207)
Other income (expense), net	569	392
Net before taxes	234	(815)
Income taxes	70	64
Net income	164	(879)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	34,551	34,523
Year-end	34,526	

OTONOMY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	424	684
Cost & expenses	26,164	51,598
Operating income	(25,740)	(50,914)
Interest income	763	615
Net income	(24,977)	(50,299)
Earnings common share		
Primary	\$(0.82)	\$(1.66)
Fully Diluted	\$(0.82)	\$(1.66)
Common Shares:		
Full Diluted	30,581	30,263
Year-end	30,630	30,297

OURPET'S COMPANY

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	12,643,929	12,720,610
Cost & expenses	12,339,700	11,943,538
Operating income	304,229	777,072
Other income (expense), net	(16,453)	(14,244)
Net before taxes	230,422	718,069
Income taxes	(62,549)	88,073
Net income	292,971	629,996
Earnings common share		
Primary	\$0.01	\$0.03
Fully Diluted	\$0.01	\$0.03
Common Shares:		
Full Diluted	19,973,078	18,691,913
Year-end	19,820,566	19,522,001

OVASCIENCE INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	148	147
Cost & expenses	15,634	32,664
Operating income	(15,486)	(32,517)
Other income (expense), net	(2)	(910)
Net before taxes	(33,059)	(33,059)
Income taxes	22	22
Net income	(15,073)	(33,081)
Earnings common share		
Primary	\$(0.42)	\$(0.93)
Fully Diluted	\$(0.42)	\$(0.93)

Common Shares:

Full Diluted	35,743	35,653
Year-end	35,789	

OVASCIENCE INC.

Merger Development On Aug. 8, 2018, Co., Orion Merger Sub, Inc., a wholly-owned subsidiary of Co. ("Merger Sub"), and Millendo Therapeutics, Inc. ("Millendo"), a clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Millendo, with Millendo continuing as a wholly-owned subsidiary of Co. and the surviving corporation of the merger (the "Merger"). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended. Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (a) each outstanding share of Millendo common stock and Millendo preferred stock will be converted into the right to receive shares of Co. common stock ("Co. Common Stock") (subject to the payment of cash in lieu of fractional shares and after giving effect to a reverse stock split of Co. Common Stock, as described below) equal to the Exchange Ratio described below; and (b) each outstanding Millendo stock option that has not previously been exercised prior to the closing of the Merger will be assumed by Co. Under the exchange ratio formula in the Merger Agreement (the "Exchange Ratio"), upon the closing of the Merger, on a pro forma basis and based upon the number of shares of Co. common stock to be issued in the Merger, current Co. shareholders will own approximately 20% of the combined company and current Millendo investors will own approximately 80% of the combined company (before accounting for the additional financing transaction referenced below). The actual allocation will be subject to adjustment based on Co.'s net cash balance at the time of closing and the amount of any additional financing consummated by Millendo at or before the closing of the Merger. For purposes of calculating the Exchange Ratio, the number of outstanding shares of Co. common stock immediately before the Merger takes into account the dilutive effect, calculated using the treasury method under U.S. GAAP, of the shares of Co. common stock underlying options outstanding as of the date of the Merger Agreement based on certain assumptions and probability analysis. The Exchange Ratio will be adjusted to the extent that Co.'s net cash at closing is less than \$40,000,000 or greater than \$42,000,000, as further described in the Merger Agreement. The merger is expected to close in the fourth quarter of 2018, subject to the approval of Co. shareholders at a special shareholder meeting, as well as other customary conditions.

OVASCIENCE INC.

Name Change Development On Aug. 8, 2018, Co. announced that it will seek the approval of its stockholders to amend its certificate of incorporation to change the name of Co. to Millendo Therapeutics, Inc.

OVASCIENCE INC.

Stock Split Development On Aug. 8, 2018, Co. announced that it will seek the approval of its stockholders to amend its certificate of incorporation to effect a reverse split of Co. Common Stock at a ratio to be determined by Co., which is intended to ensure that the listing requirements of the Nasdaq Global Market, or such other stock market on which the Co. Common Stock is trading, are satisfied.

OVERSTOCK.COM INC (DE)

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	928,464	864,459
Cost & expenses	1,049,394	876,503
Operating income	(120,930)	(12,044)
Interest income	1,164	261
Interest expense	1,269	1,426
Other income (expense), net	359	(3,131)
Net before taxes	(120,676)	(16,340)
Income taxes	(304)	(2,315)
Net income	(120,372)	(14,025)
Balance for common	(113,190)	(13,093)
Earnings common share		
Primary	\$(3.94)	\$(0.52)
Fully Diluted	\$(3.94)	\$(0.52)
Common Shares:		
Full Diluted	28,736	25,035
Year-end	29,007	25,000

OVID THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):	2018	2017
Cost & expenses	26,639,557	44,550,394
Operating income	(26,639,557)	(44,550,394)
Net income	(26,117,895)	(44,487,189)
Balance for common	(26,117,895)	(44,487,189)
Earnings common share		
Primary	\$(1.06)	\$(3.18)
Fully Diluted	\$(1.06)	\$(3.18)
Common Shares:		
Full Diluted	24,617,555	13,998,428
Year-end	24,631,972	24,601,936

OXFORD SQUARE CAPITAL CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):	2018	2017
Cost & expenses	9,454,415	17,147,484
Net income	16,411,107	16,330,149
Earnings common share		
Primary	\$0.36	\$0.41
Fully Diluted	\$0.36	\$0.41
Common Shares:		
Full Diluted	50,640,236	59,727,707
Year-end	49,407,609	

P & F INDUSTRIES, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):	2018	2017
Total Revenues	31,930,000	28,575,000
Cost & expenses	31,260,000	28,593,000
Operating income	670,000	(18,000)
Interest expense	92,000	74,000
Other income (expense), net	(57,000)	24,000
Net before taxes	521,000	(68,000)
Income taxes	151,000	(24,000)
Net income	370,000	(44,000)
Earnings common share		
Primary	\$0.10	\$(0.01)
Fully Diluted	\$0.10	\$(0.01)
Common Shares:		
Full Diluted	3,714,000	3,605,000
Year-end	3,711,000	3,619,000

PACCAR INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):	2018	2017
Cost & expenses	9,722,900	7,619,200
Operating income	1,389,000	987,200
Gains or losses	24,600	16,800
Net before taxes	1,389,000	987,200
Income taxes	317,300	303,900
Net income	1,071,700	683,300
Earnings common share		
Primary	\$3.04	\$1.94
Fully Diluted	\$3.04	\$1.94
Common Shares:		
Full Diluted	353,000	352,700
Year-end	350,700	351,300

PACIFIC BIOSCIENCES OF CALIFORNIA INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):	2018	2017
Total Revenues	40,940	44,988
Cost & expenses	86,634	92,674
Operating income	(45,694)	(47,686)
Other income (expense), net	154	(56)
Net income	(46,719)	(49,406)
Earnings common share		
Primary	\$(0.37)	\$(0.52)
Fully Diluted	\$(0.37)	\$(0.52)
Common Shares:		
Full Diluted	127,847	95,177
Year-end	131,888	

PACIFIC GOLD CORP

Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$):	2017	2016	2015
Total revenue	524
Depreciation	49,911
Gross margin	524	...	(49,911)
General &			

administrative expenses	90,359	125,235	393,716
Mining claims	6,200
Total operating expenses	96,559	125,235	393,716
Income (loss) from operations	(96,035)	(125,235)	(443,627)
Gain (loss) on extinguishment of debt	...	91,762	...
Gain (loss) on sale of subsidiary	390,917
Gain (loss) on sale of royalty	125,000
Sublease rents	20,000
Foreign exchange gain (loss)	1,822
Gain (loss) on sale of equipment	(1,433)
Interest expense	287,207	270,390	244,144
Amortization of debt discount	...	312,500	625,000
Total other income (expenses)	(162,207)	(491,128)	(457,838)
Net income (loss)	(258,242)	(616,363)	(901,465)
Weighted average shares outstanding - basic	6,247,649,135	4,370,455,857	4,255,603,853
Weighted average shares outstanding - diluted	6,247,649,135	4,370,455,857	4,255,603,853
Year end shares outstanding	8,944,909,409	4,469,909,409	4,269,909,409
Net income (loss) per share - basic	\$(0.00)	\$(0.00)	\$(0.00)
Net income (loss) per share - diluted	\$(0.00)	\$(0.00)	\$(0.00)
Total number of employees	1	...	1
Number of beneficiary stockholders	7,000
Number of stockholders	7,000

As reported from December 31, 2017 10K; Approximately; As of August 31, 2017; As of July 10, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016
Cash & cash equivalents	58,538	229
Total current assets	58,538	229
Total assets	58,538	229
Accounts payable	396,641	395,757
Accrued expenses	264,420	199,457
Total current liabilities	661,061	595,214
Accrued interest - promissory notes	47,970	15,990
Promissory notes, long-term portion	319,840	319,840
Accrued interest - related party notes payable	339,267	129,040
Related party notes payable - long-term portion	2,451,844	2,593,348
Total liabilities	3,819,982	3,653,432
Preferred stock	...	300
Additional paid-in capital	44,789,026	44,638,725
Retained earnings (accumulated deficit)	(48,550,470)	(48,292,228)
Total stockholders' equity (deficit)	(3,761,444)	(3,653,203)

As reported from December 31, 2017 10K

Recent Dividends:

- 1. Pacific Gold Corp preferred. No dividends paid.
- 2. Pacific Gold Corp common. No dividends paid.

Annual Dividends:

- 1. Pacific Gold Corp preferred. No dividends paid.
- 2. Pacific Gold Corp common. No dividends paid.

PACIFIC GOLD CORP

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, BF Borgers CPA PC, as it appeared in Co.'s 2017 10-K: "In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 9 to the financial statements, the Company's significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

PACIFIC GOLD CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	14,605	16,742
Operating income	(14,605)	(16,742)
Gains or losses	45,842	...
Net income	(38,053)	(89,596)
Earnings common share		
Primary	\$(0.00)	\$(0.00)
Fully Diluted	\$(0.00)	\$(0.00)
Common Shares:		
Full Diluted	8,944,909,409	4,370,455,857
Year-end	8,944,909,409	...

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Liabilities:	
Current liabilities	619,086
Long-term debt	2,763,884
Stockholders' equity	(3,799,496)
Net current assets	(619,086)

PACIRA PHARMACEUTICALS INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	158,714	140,217
Cost & expenses	159,109	170,046
Operating income	(395)	(29,829)
Interest income	2,906	1,738
Interest expense	10,553	7,815
Other income (expense), net	(4)	(3,643)
Net before taxes	(8,046)	(39,549)
Income taxes	70	60
Net income	(8,116)	(39,609)
Earnings common share		
Primary	\$(0.20)	\$(1.01)
Fully Diluted	\$(0.20)	\$(1.01)
Common Shares:		
Full Diluted	40,751	39,079
Year-end	40,955	40,318

PAPA JOHN'S INTERNATIONAL, INC.

Earnings, 6 mos. to (Consol. - \$000):

	07/01/18	06/25/17
Total Revenues	835,328	884,044
Cost & expenses	759,374	782,035
Operating income	52,684	80,898
Net before taxes	42,067	77,329
Income taxes	12,022	22,448
Net income	30,045	54,881
Earnings common share		
Primary	\$0.87	\$1.44
Fully Diluted	\$0.86	\$1.42
Common Shares:		
Full Diluted	32,860	37,283
Year-end	31,547	36,440

PAPA MURPHY'S HOLDINGS INC

Earnings, 6 mos. to (Consol. - \$000):

	07/02/18	07/03/17
Total Revenues	65,565	76,280
Cost & expenses	54,764	84,571
Deprec., depl. & amort.	4,015	6,023
Operating income	6,786	(14,314)
Other income (expense), net	(103)	(92)

Net before taxes	4,095	(16,919)
Income taxes	1,129	(5,627)
Net income	2,966	(11,292)
Earnings common share		
Primary	\$0.18	\$(0.67)
Fully Diluted	\$0.17	\$(0.67)
Common Shares:		
Full Diluted	16,953	16,854
Year-end	17,011	

PARATEK PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	54,490,000	50,948,000
Operating income	(54,440,000)	(43,416,000)
Interest expense	4,410,000	2,258,000
Other income (expense), net	(1,000)	(15,000)
Net before taxes	(45,099,000)	
Income taxes	753,000	
Net income	(57,482,000)	(45,852,000)
Earnings common share		
Primary	\$(1.85)	\$(1.78)
Fully Diluted	\$(1.85)	\$(1.78)
Common Shares:		
Full Diluted	31,076,788	25,780,756
Year-end	31,714,649	

PARK PLACE ENERGY INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015 (revised)
Oil & gas revenue	3,883,059
Production	2,814,672
Depletion	774,547
Depreciation	21,390
Accretion of asset retirement obligation	224,759
General & administrative expenses	2,509,940	3,985,026	835,387
Total expenses	6,345,308	3,985,026	835,387
Income (loss) before other income (expense)	(2,462,249)	(3,985,026)	(835,387)
Reversed tax penalties	120,000
Interest income	...	2,420	1,810
Interest expense	76,026	12,396	86
Foreign exchange gain (loss)	(15,512)	(4,089)	(50,434)
Other gain	63,023
Taxes	11,767
Gain on bargain purchase option	15,695
Total other income (expense)	(24,587)	(14,065)	71,290
Net income (loss) for the year	(2,486,836)	(3,999,091)	(764,097)
Weighted average shares outstanding			
- basic	56,001,794	50,462,715	45,730,015
Weighted average shares outstanding			
- diluted	56,001,794	50,462,715	45,730,015
Year end shares outstanding	58,243,904	50,281,482	45,731,482
Net income (loss) per share - basic	\$(0.04)	\$(0.08)	\$(0.02)
Net income (loss) per share - diluted	\$(0.04)	\$(0.08)	\$(0.02)
Number of independent contractors	25
Total number of employees	13
Number of common stockholders	183	169	144

¹ Reclassified to conform with 2016 presentation; ² As of October 18, 2016; ³ Approximately; ⁴ As of August 6, 2018; ⁵ As of March 7, 2017; ⁶ As of March 21, 2016

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016
Cash	130,476	1,550,937
Accounts receivables	600,312	21
Prepaid expenses & deposits	316,694	10,924
Deposit for Tiway acquisition	...	500,000
Total current assets	1,047,482	2,061,882
Unproven properties Bulgaria	...	2,939,829
Oil & gas properties	5,723,394	2,939,829
Property & equipment, net	97,777	...
Restricted cash	127,688	...
Note receivable	46,109	40,453
Total assets	7,042,450	5,042,164
Accounts payable & accrued liabilities	1,584,050	357,749
Loan payable	965,287	899,000
Total current liabilities	2,549,337	1,256,749
Asset retirement obligation	2,527,259	...
Total liabilities	5,076,596	1,256,749
Common stock	582	503
Additional paid-in capital	22,905,377	21,273,494
Stock subscriptions & stock to be issued	80,400	905,000
Accumulated other comprehensive gain	(135,469)	4,618
Retained earnings (accumulated deficit)	(20,885,036)	(18,398,200)
Total stockholders' equity (deficit)	1,965,854	3,785,415

Recent Dividends:**1. Park Place Energy Inc common.**

No dividends paid.

Annual Dividends:**1. Park Place Energy Inc common.**

No dividends paid.

PARK PLACE ENERGY INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Whitley Penn LLP, as it appeared in Co.'s 2017 Annual Report: "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 2 to the financial statements, the entity has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

PARK-OHIO HOLDINGS CORP.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	837,900	694,700
Cost & expenses	790,500	651,500
Operating income	47,400	43,200
Interest expense	17,200	15,300
Other income (expense), net	4,400	(7,900)
Gains or losses	1,900	...
Net before taxes	36,500	20,000
Income taxes	11,300	6,700
Net income	25,200	13,300
Earnings common share		
Primary	\$2.00	\$1.05
Fully Diluted	\$1.96	\$1.03
Common Shares:		
Full Diluted	12,600	12,500
Year-end	12,827	12,508

PATRIOT TRANSPORTATION HOLDING INC (NEW)**Earnings, 9 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	85,284	84,255
Cost & expenses	76,789	74,940
Operating income	1,805	2,107
Interest income	97	4
Interest expense	29	79
Net before taxes	1,873	2,032
Income taxes	(2,617)	404
Net income	4,490	1,628
Earnings common share		
Primary	\$1.35	\$0.49
Fully Diluted	\$1.35	\$0.49
Common Shares:		
Full Diluted	3,316	3,301
Year-end	3,328	3,304

PATTERN ENERGY GROUP INC

Acquisition Completed On Aug. 10, 2018, Co.'s wholly-owned subsidiary, Pattern Canada Finance Company ULC ("Pattern Canada"), (i) subscribed for a 50.99% limited partnership interest in MSM LP (which in turn purchased all the issued and outstanding units in the capital of the MSM Project LP held by the existing limited partner of the MSM Project LP) and (ii) purchased from an affiliate of Pattern Energy Group LP ("Pattern Development 1.0") 70% of the issued and outstanding shares in the capital of Pattern MSM GP Holdings Inc. ("Pattern GP"), the general partner of MSM LP and holds a 50% interest in Parc Eolien Sainte-Marguerite Inc. ("MSM GP"), the general partner of Parc Eolien Mont Sainte-Marguerite S.E.C. (the "MSM Project LP"), and 70% of the issued and outstanding shares in the capital of Pattern Development MSM Management ULC ("MSM Development"), in exchange for aggregate consideration of C\$53,040,000. Concurrently, Vertuous Energy Canada Inc. ("Vertuous Canada"), a wholly-owned subsidiary of Public Sector Pension Investment Board ("PSP Investments") (i) subscribed for a 48.99% limited partnership interest in MSM LP and (ii) purchased from an affiliate of Pattern Development 1.0 30% of the issued and outstanding shares in the capital of Pattern GP and 30% of the issued and outstanding shares in the capital of MSM Development, in exchange for aggregate consideration of C\$50,960,000. As noted above, (1) Pattern GP is the general partner of MSM LP and holds a 50% interest in MSM GP, the general partner of the MSM Project LP, (2) MSM LP is the sole limited partner of the MSM Project LP and (3) MSM Development acts as the manager in respect of the MSM Project LP. The MSM Project LP operates the approximately 143-megawatt wind farm located in the municipalities of Saint-Sylvestre (MRC de Lotbiniere), Saint-Severin (MRC Robert-Cliche), Sacre-Coeur-de-Jesus (MRC des Appalaches) and Saint-Frederic (MRC Robert-Cliche), which achieved commercial operations in the first quarter of 2018. Immediately after the closing, Co.'s owned capacity with respect to the wind farm was approximately 73 megawatts.

PATTERN ENERGY GROUP INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	251,599,000	208,593,000
Cost & expenses	225,255,000	189,458,000
Operating income	26,344,000	19,135,000
Interest expense	53,153,000	47,394,000
Other income (expense), net	26,709,000	26,549,000
Gains or losses	(3,100,000)	(1,119,000)
Net before taxes	(3,200,000)	(2,829,000)
Income taxes	11,194,000	9,316,000
Net income	(14,394,000)	(12,145,000)
Balance for common	168,483,000	19,825,000
Earnings common share		
Primary	\$1.73	\$0.23
Fully Diluted	\$1.67	\$0.23
Common Shares:		
Full Diluted	105,662,687	87,257,130
Year-end	98,096,323	87,637,816

PATTERSON-UTI ENERGY INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	1,663,582,000	884,361,000
Cost & expenses	1,272,412,000	741,691,000
Operating income	(31,106,000)	232,875,000
Interest income	3,783,000	1,048,000
Interest expense	26,292,000	17,345,000
Other income (expense), net	385,000	148,000
Net before taxes	(53,230,000)	249,024,000
Income taxes	(8,100,000)	(93,301,000)
Net income	(45,130,000)	155,723,000

Balance for common	(45,130,000)	155,723,000	accounts	375	266	Operating income	40,419	33,892
Earnings common share			Accounts receivable, net	3,453	2,040	Net before taxes	40,717	33,920
Primary	\$(0.21)	\$(0.86)	Prepaid expenses & other			Income taxes	11,191	12,903
Fully Diluted	\$(0.21)	\$(0.86)	current assets	11,980	14,879	Net income	29,526	21,017
Common Shares:			Funds held for clients	1,225,614	942,459	Earnings common share		
Full Diluted	220,436,000	180,747,000	Total current assets	1,378,240	1,062,846	Primary	\$1.10	\$0.79
Year-end	219,822,025	213,328,565	Long-term prepaid expenses	1,504	1,535	Fully Diluted	\$1.10	\$0.78
PAYLOCITY HOLDING CORP			Capitalized internal-use software, net	21,094	17,394	Common Shares:		
Annual Report			Office equipment	3,743	3,591	Full Diluted	26,868	26,879
Consolidated Income Statement, Years Ended Jun. 30 (\$000):			Computer equipment	29,768	24,411	Year-end	26,703	26,785
	2018	2017 (revised)	Furniture & fixtures	10,382	7,547	PC-TEL INC		
			Software	5,965	4,954	Earnings, 6 mos. to Jun 30 (Consol. - \$):		
			Leasehold improvements	36,366	21,426		2018	2017
Recurring fees	354,432	284,817	Time clocks rented by clients	4,534	4,240	Total Revenues	43,313,000	44,471,000
Interest income on funds held for clients	9,093	3,631	Property & equipment, gross	90,758	66,169	Cost & expenses	45,888,000	44,540,000
Implementation services & other revenues	14,002	11,562	Less: accumulated depreciation & amortization	28,729	25,413	Operating income	(2,823,000)	(317,000)
Total revenues	377,527	300,010	Property & equipment, net	62,029	40,756	Other income (expense), net	6,000	(10,000)
Recurring revenues	104,009	85,399	Intangibles assets, net	13,002	8,907	Foreign currency	(9,000)	(53,000)
Implementation services & other cost of revenue	45,188	38,588	Goodwill	9,590	6,003	Net before taxes	(2,563,000)	(275,000)
Total cost of revenues	149,197	123,987	Deferred income tax assets, net	22,140	...	Income taxes	(479,000)	(274,000)
Gross profit	228,330	176,023	Total assets	1,507,599	1,137,441	Income contin. oper.	...	(1,000)
Sales & marketing	95,484	77,506	Accounts payable	2,990	2,046	Net income	(2,084,000)	(383,000)
Research & development	37,645	29,098	Accrued payroll & personnel costs	31,206	25,131	Earnings common share		
General & administrative expenses	79,252	62,123	Lease exit obligations	2,143	...	Primary	\$(0.12)	\$(0.02)
Total operating expenses	212,381	168,727	Other accrued expenses	8,892	5,170	Fully Diluted	\$(0.12)	\$(0.02)
Operating income (loss)	15,949	7,296	Accrued expenses	42,241	30,301	Common Shares:		
Other income (expense)	802	73	Client fund obligations	1,225,614	942,459	Full Diluted	17,099,000	16,437,000
Income (loss) before income taxes	16,751	7,369	Total current liabilities	1,270,845	974,806	Year-end	18,318,141	17,791,498
United States current federal income taxes	294	...	Deferred rent	22,812	14,621	PCM, INC		
Current state & local income taxes	364	500	Other long-term liabilities	1,118	...	Earnings, 6 mos. to Jun 30 (Consol. - \$000):		
United States deferred federal income taxes	(15,167)	137	Deferred income tax liabilities, net	...	401		2018	2017
Deferred state & local income taxes	(7,338)	14	Total liabilities	1,294,775	989,828	Net Sales	1,089,262	1,078,842
Income tax expense (benefit)	(21,847)	651	Common stock	53	52	Cost & expenses	1,069,825	1,068,727
Net income (loss)	38,598	6,718	Additional paid-in capital	219,588	192,837	Operating income	19,437	10,115
Weighted average shares outstanding - basic	52,425	51,415	Retained earnings (accumulated deficit)	(6,678)	(45,276)	Interest expense	4,777	3,639
Weighted average shares outstanding - diluted	54,887	54,057	Accumulated other comprehensive income (loss)	(139)	...	Other income (expense), net	304	273
Year end shares outstanding	52,758	51,738	Total stockholders' equity (deficit)	212,824	147,613	Net before taxes	14,964	6,749
Net earnings (loss) per share - basic	\$0.74	\$0.13	Recent Dividends:			Income taxes	4,270	211
Net earnings (loss) per share - diluted	\$0.70	\$0.12	1. Paylocity Holding Corp common.			Net income	10,694	6,538
Number of full time employees	2,600	2,115	No dividends paid.			Earnings common share		
Number of common stockholders	17	17	Annual Dividends:			Primary	\$0.90	\$0.52
			1. Paylocity Holding Corp common.			Fully Diluted	\$0.88	\$0.48
			No dividends paid.			Common Shares:		
			PAYPAL HOLDINGS INC			Full Diluted	12,145	13,483
			Earnings, 6 mos. to Jun 30 (Consol. - \$Millions):			Year-end	11,894	12,594
				2018	2017	PDC ENERGY INC		
			Total Revenues	7,542	6,111	Earnings, 6 mos. to Jun 30 (Consol. - \$):		
			Cost & expenses	6,071	4,866		2018	2017
			Deprec., depl. & amort.	365	384	Total Revenues	473,131,000	548,865,000
			Operating income	1,106	861	Cost & expenses	399,282,000	137,197,000
			Other income (expense), net	51	24	Operating income	(188,563,000)	176,339,000
			Net before taxes	1,157	885	Interest income	217,000	1,008,000
			Income taxes	120	90	Interest expense	34,939,000	39,084,000
			Net income	1,037	795	Net before taxes	(223,285,000)	138,263,000
			Earnings common share			Income taxes	(49,889,000)	50,867,000
			Primary	\$0.87	\$0.66	Net income	(173,396,000)	87,396,000
			Fully Diluted	\$0.86	\$0.65	Earnings common share		
			Common Shares:			Primary	\$(2.63)	\$1.33
			Full Diluted	1,209	1,216	Fully Diluted	\$(2.63)	\$1.32
			Year-end	1,184	1,202	Common Shares:		
			PC CONNECTION, INC.			Full Diluted	66,012,000	66,066,000
			Earnings, 6 mos. to Jun 30 (Consol. - \$000):			Year-end	66,065,856	65,863,080
				2018	2017	PDF SOLUTIONS INC.		
			Net Sales	1,331,465	1,420,386	Earnings, 6 mos. to Jun 30 (Consol. - \$000):		
			Cost & expenses	1,291,046	1,386,494		2018	2017
			PDL BIOPHARMA INC			Total Revenues	45,856	48,578
			Earnings, 6 mos. to Jun 30 (Consol. - \$):			Cost & expenses	49,038	49,462
				2018	2017	Operating income	(3,399)	(1,068)
						Net before taxes	(3,340)	(1,270)
						Income taxes	(820)	(1,976)
						Net income	(2,520)	706
						Earnings common share		
						Primary	\$(0.08)	\$0.02
						Fully Diluted	\$(0.08)	\$0.02
						Common Shares:		
						Full Diluted	32,065	33,491
						Year-end	32,075	32,162

□ Reclassified to conform with 2017 presentation; □ As is; □ Approximately; □ As of August 3, 2018; □ As of August 4, 2017; □ As of August 5, 2016

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	137,193	103,468
Accounts receivable, gross	3,828	2,306
Allowance for doubtful		

PC CONNECTION, INC.

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Net Sales	1,331,465	1,420,386
Cost & expenses	1,291,046	1,386,494

PDL BIOPHARMA INC

Earnings, 6 mos. to Jun 30 (Consol. - \$):

	2018	2017
Total Revenues	85,093,000	189,275,000
Cost & expenses	193,250,000	45,827,000
Operating income	(120,834,000)	131,285,000
Other income (expense), net		6,271,000
Net before taxes	(123,940,000)	128,058,000
Income taxes	(13,246,000)	60,425,000
Net income	(110,694,000)	67,633,000
Earnings common share		
Primary	\$(0.74)	\$0.42
Fully Diluted	\$(0.74)	\$0.42
Common Shares:		
Full Diluted	149,186,000	160,168,000
Year-end	145,971,000	154,081,000

PEGASYSTEMS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	431,961	442,905
Cost & expenses	447,188	385,945
Operating income	(15,227)	56,960
Other income (expense), net	363	287
Foreign currency	159	(1,497)
Net before taxes	(13,312)	56,157
Income taxes	(15,103)	(508)
Net income	1,791	56,665
Earnings common share		
Primary	\$0.02	\$0.74
Fully Diluted	\$0.02	\$0.69
Common Shares:		
Full Diluted	83,247	82,412
Year-end	78,748	

PENN NATIONAL GAMING INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	1,642,998	1,572,687
Cost & expenses	1,170,160	1,158,206
Deprec., depl. & amort.	118,949	139,205
Operating income	353,889	275,276
Interest income	490	2,881
Interest expense	231,613	231,764
Other income (expense), net	7,590	(15,787)
Net before taxes	130,356	30,606
Income taxes	30,931	8,423
Net income	99,425	22,183
Balance for common	99,425	22,183
Earnings common share		
Primary	\$1.09	\$0.24
Fully Diluted	\$1.05	\$0.24
Common Shares:		
Full Diluted	94,834	92,543
Year-end	92,196	91,340

PENNANTPARK INVESTMENT CORPORATION

Earnings, 9 mos. to Jun 30(Consol. – \$):		
	2018	2017
Cost & expenses	41,294,134	52,998,268
Net income	39,359,402	43,669,954
Earnings common share		
Primary	\$0.55	\$0.61
Fully Diluted	\$0.55	\$0.61
Common Shares:		
Full Diluted	70,990,105	71,060,836
Year-end	69,988,077	71,060,836

PEPSICO INC

Acquisition Development On Aug. 20, 2018, Co. and SodaStream International Ltd. ("SodaStream") announced that they have entered into an agreement under which Co. has agreed to acquire all outstanding shares of SodaStream for \$144.00 per share in cash, which represents a 32% premium to the 30-day volume weighted average price, in a transaction valued at \$3,200,000,000. The acquisition has been unanimously approved by the Boards of Directors of both companies. The transaction is subject to a SodaStream shareholder vote, certain regulatory approvals and other customary conditions, and closing is expected by Jan. 2019.

PERFICIENT INC.

Earnings, 6 mos. to Jun 30(Consol. – \$):		
	2018	2017
Total Revenues	242,739,000	228,046,000
Cost & expenses	217,376,000	205,336,000
Operating income	15,281,000	13,084,000
Other income (expense), net	(49,000)	69,000

Net before taxes	14,345,000	12,149,000
Income taxes	3,567,000	7,030,000
Net income	10,778,000	5,119,000
Earnings common share		
Primary	\$0.33	\$0.15
Fully Diluted	\$0.32	\$0.15
Common Shares:		
Full Diluted	33,894,000	34,080,000
Year-end	33,228,199	33,607,808

PERFORMANT FINANCIAL CORP

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	88,357	69,016
Cost & expenses	79,505	70,669
Operating income	8,852	(1,653)
Interest income	13	
Interest expense	2,411	3,224
Net before taxes	6,454	(4,877)
Income taxes	1,590	522
Net income	4,864	(5,399)
Earnings common share		
Primary	\$0.09	\$(0.11)
Fully Diluted	\$0.09	\$(0.11)
Common Shares:		
Full Diluted	53,501	50,443
Year-end	51,920	50,785

PERNIX THERAPEUTICS HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):		
	2018	2017
Total Revenues	49,227,000	64,058,000
Cost & expenses	51,437,000	60,027,000
Operating income	(13,505,000)	(32,731,000)
Interest expense	18,990,000	18,168,000
Other income (expense), net	21,000	(84,000)
Gains or losses	446,000	
Foreign currency	(21,000)	
Net before taxes	(32,049,000)	(50,983,000)
Income taxes	48,000	95,000
Net income	(32,097,000)	(51,078,000)
Earnings common share		
Primary	\$(2.70)	\$(5.10)
Fully Diluted	\$(2.70)	\$(5.10)
Common Shares:		
Full Diluted	11,907,000	10,016,000
Year-end	12,065,487	10,015,641

PERSHING GOLD CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):		
	2018	2017
Cost & expenses	8,269,897	6,605,522
Operating income	(8,269,897)	(6,605,522)
Other income (expense), net		9,673
Foreign currency	(1,531)	(10,655)
Net income	(8,264,948)	(6,607,373)
Balance for common	(8,264,948)	(6,607,373)
Earnings common share		
Primary	\$(0.25)	\$(0.23)
Fully Diluted	\$(0.25)	\$(0.23)
Common Shares:		
Full Diluted	33,603,861	28,394,151
Year-end	33,629,260	28,402,389

PETIQ INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	286,208	154,207
Cost & expenses	279,918	142,738
Operating income	6,290	11,469
Interest expense	3,981	999
Other income (expense), net	(973)	
Gains or losses	58	(121)
Net before taxes	1,394	
Income taxes	(47)	
Net income	1,441	10,349
Earnings common share		
Primary	\$0.03	
Fully Diluted	\$0.03	
Common Shares:		
Full Diluted	15,329	
Year-end	25,691	

PETMED EXPRESS INC

Earnings, 3 mos. to Jun 30(Consol. – \$):

Net Sales	87,390,000	79,657,000
Cost & expenses	71,077,000	64,710,000
Operating income	15,757,000	14,416,000
Interest income	379,000	83,000
Other income (expense), net	317,000	241,000
Net before taxes	16,453,000	14,740,000
Income taxes	3,871,000	5,464,000
Net income	12,582,000	9,276,000
Earnings common share		
Primary	\$0.62	\$0.46
Fully Diluted	\$0.62	\$0.45
Common Shares:		
Full Diluted	20,449,000	20,448,000
Year-end	20,601,000	20,525,000

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	94,561,000	
Inventories	25,046,000	
Current assets	123,316,000	
Net property & equip.	28,491,000	
Total assets	152,667,000	
Liabilities:		
Current liabilities	27,955,000	
Stockholders' equity	123,881,000	
Net current assets	95,361,000	

PETROSHARE CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):		
	2018	2017
Total Revenues	6,694,468	5,918,887
Cost & expenses	2,783,893	3,916,697
Operating income	1,978,803	(579)
Interest income		246
Interest expense	3,543,861	2,872,275
Other income (expense), net	(11,661)	
Gains or losses	(21,100)	
Net income	(1,597,819)	(2,872,608)
Earnings common share		
Primary	\$(0.06)	\$(0.13)
Fully Diluted	\$(0.06)	\$(0.13)
Common Shares:		
Full Diluted	27,891,210	22,265,712
Year-end	28,064,765	22,654,537

PILGRIMS PRIDE CORP.

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	07/01/18	06/25/17
Net Sales	5,583,391	5,231,626
Cost & expenses	5,196,686	4,686,567
Operating income	386,705	545,059
Interest income	6,424	1,472
Other income (expense), net	2,434	4,115
Foreign currency	(3,909)	1,612
Net before taxes	301,087	510,579
Income taxes	75,519	164,650
Net income	225,568	345,929
Pfd. dividends	116	228
Earnings common share		
Primary	\$0.91	\$1.32
Fully Diluted	\$0.91	\$1.32
Common Shares:		
Full Diluted	249,025	248,950
Year-end	248,980	261,752

PINNACLE ENTERTAINMENT INC (NEW)

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	1,276,029	1,293,616
Cost & expenses	941,079	963,977
Deprec., depl. & amort.	99,664	112,175
Operating income	235,286	217,464
Interest income	200	200
Other income (expense), net	(89)	(90)
Net before taxes	41,715	26,636
Income taxes	(1,845)	1,002
Net income	43,560	25,634
Earnings common share		
Primary	\$0.77	\$0.47
Fully Diluted	\$0.70	\$0.43
Common Shares:		
Full Diluted	62,255	61,463
Year-end	58,879	57,778

PIONEER POWER SOLUTIONS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	48,068,000	52,340,000
Cost & expenses	47,056,000	49,361,000
Operating income	1,012,000	2,979,000
Other income (expense), net	(138,000)	(53,000)
Net before taxes	(525,000)	1,766,000
Income taxes	135,000	(133,000)
Income contin. oper.	(660,000)	1,899,000
Net income	(1,370,000)	1,392,000
Earnings common share		
Primary	\$(0.16)	\$0.17
Fully Diluted	\$(0.16)	\$0.17
Common Shares:		
Full Diluted	8,726,000	8,737,000
Year-end	8,726,045	

PIXELWORKS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	34,543	43,431
Cost & expenses	38,287	38,044
Operating income	(3,744)	5,387
Other income (expense), net	1,272	
Net before taxes	(2,903)	5,187
Income taxes	308	1,102
Net income	(3,211)	4,085
Earnings common share		
Primary	\$(0.09)	\$0.14
Fully Diluted	\$(0.09)	\$0.13
Common Shares:		
Full Diluted	35,445	31,601
Year-end	35,914	33,804

PLEXUS CORP.

Earnings, 9 mos. to (Consol. - \$000):

	06/30/18	07/01/17
Net Sales	2,102,330	1,858,200
Cost & expenses	2,021,012	1,762,257
Operating income	81,318	95,943
Interest income	4,049	3,555
Interest expense	10,182	9,830
Other income (expense), net	(1,875)	1,147
Net before taxes	73,310	90,815
Income taxes	133,012	7,762
Net income	(59,702)	83,053
Earnings common share		
Primary	\$(1.79)	\$2.47
Fully Diluted	\$(1.79)	\$2.40
Common Shares:		
Full Diluted	33,300	34,585
Year-end	32,361	33,583

PLURALSIGHT INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	103,216	76,130
Cost & expenses	159,734	101,150
Operating income	(56,518)	(25,020)
Interest expense	6,134	5,124
Other income (expense), net	(4,050)	(1,813)
Net before taxes	(66,702)	(31,957)
Income taxes	252	126
Net income	(66,954)	(32,083)
Earnings common share		
Primary	\$(0.19)	\$
Fully Diluted	\$(0.19)	\$
Common Shares:		
Full Diluted	62,252	
Year-end	135,075	

POOL CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	1,643,704	1,534,603
Cost & expenses	1,448,121	1,349,419
Operating income	195,583	185,184
Equity earnings	(106)	(78)
Net before taxes	186,065	177,585
Income taxes	37,783	60,772
Net income	148,388	116,891
Earnings common share		
Primary	\$3.67	\$2.84

Fully Diluted	\$3.55	\$2.73
Common Shares:		
Full Diluted	41,840	42,937
Year-end	40,371	41,340

PORTOLA PHARMACEUTICALS, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	10,655	8,915
Cost & expenses	199,650	115,287
Operating income	(188,995)	(106,372)
Interest expense	6,685	5,095
Net income	(190,481)	(111,178)
Balance for common	(190,372)	(111,373)
Earnings common share		
Primary	\$(2.90)	\$(1.96)
Fully Diluted	\$(2.90)	\$(1.96)
Common Shares:		
Full Diluted	65,698	56,873
Year-end	65,954	57,577

POTBELLY CORP

Earnings, 6 mos. to (Consol. - \$000):

	07/01/18	06/25/17
Total Revenues	213,264	209,835
Net Sales	211,628	208,241
Cost & expenses	204,115	195,763
Operating income	(2,535)	1,427
Interest expense	55	69
Net before taxes	(2,590)	1,358
Income taxes	(202)	739
Net income	(2,388)	619
Earnings common share		
Primary	\$(0.10)	\$0.02
Fully Diluted	\$(0.10)	\$0.02
Common Shares:		
Full Diluted	25,348	25,981
Year-end	25,652	25,125

POTLATCHDELTIC CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	468,130	312,910
Cost & expenses	370,882	245,036
Operating income	97,248	67,874
Interest expense	15,016	12,318
Other income (expense), net	(3,765)	(3,192)
Net before taxes	78,467	52,364
Income taxes	17,722	11,199
Net income	60,745	41,165
Earnings common share		
Primary	\$1.07	\$1.01
Fully Diluted	\$1.06	\$1.00
Common Shares:		
Full Diluted	57,128	41,144
Year-end	62,755	40,611

POWELL INDUSTRIES, INC.

Earnings, 9 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	313,819	300,948
Cost & expenses	325,857	313,184
Operating income	(12,199)	(12,499)
Interest income	711	287
Interest expense	153	122
Other income (expense), net	507	1,522
Net before taxes	(11,134)	(10,812)
Income taxes	(2,443)	(6,469)
Net income	(8,691)	(4,343)
Earnings common share		
Primary	\$(0.76)	\$(0.38)
Fully Diluted	\$(0.76)	\$(0.38)
Common Shares:		
Full Diluted	11,503	11,449
Year-end	11,470	11,429

POWER INTEGRATIONS INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	212,563	212,251
Cost & expenses	182,983	185,138
Operating income	29,580	27,113
Other income (expense), net	1,721	971
Net before taxes	31,301	28,084

Income taxes	1,720	83
Net income	29,581	28,001
Earnings common share		
Primary	\$1.00	\$0.95
Fully Diluted	\$0.97	\$0.92
Common Shares:		
Full Diluted	30,387	30,370
Year-end	29,407	29,759

PRA GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	445,626,000	412,890,000
Cost & expenses	327,243,000	301,061,000
Operating income	108,929,000	101,573,000
Interest income	1,866,000	2,783,000
Other income (expense), net	(157,000)	
Gains or losses		48,167,000
Foreign currency	2,983,000	(337,000)
Net before taxes	54,850,000	105,640,000
Income taxes	9,994,000	42,175,000
Net income	44,856,000	63,465,000
Earnings common share		
Primary	\$0.90	\$1.30
Fully Diluted	\$0.90	\$1.29
Common Shares:		
Full Diluted	45,410,000	46,344,000
Year-end	45,300,000	45,166,000

PRA HEALTH SCIENCES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	1,424,678	1,021,484
Cost & expenses	1,223,041	875,355
Deprec., depl. & amort.	55,893	31,293
Operating income	145,744	114,836
Interest expense	29,437	19,531
Other income (expense), net	(133)	(205)
Equity earnings	(74)	(68)
Foreign currency	393	(22,210)
Net before taxes	116,567	72,890
Income taxes	35,144	18,076
Net income	81,497	54,882
Earnings common share		
Primary	\$1.27	\$0.88
Fully Diluted	\$1.22	\$0.84
Common Shares:		
Full Diluted	66,120	65,586
Year-end	64,257	

PREFORMED LINE PRODUCTS CO.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	207,054,000	182,081,000
Cost & expenses	189,975,000	173,529,000
Operating income	17,079,000	8,552,000
Interest income	229,000	264,000
Interest expense	628,000	577,000
Other income (expense), net	173,000	137,000
Net before taxes	16,853,000	8,376,000
Income taxes	4,590,000	2,702,000
Net income	12,263,000	5,674,000
Earnings common share		
Primary	\$2.43	\$1.11
Fully Diluted	\$2.42	\$1.11
Common Shares:		
Full Diluted	5,064,000	5,132,000
Year-end	4,023,860	

PRGX GLOBAL, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	78,823	72,079
Cost & expenses	76,259	70,591
Operating income	(2,671)	(2,285)
Other income (expense), net	(17)	194
Foreign currency	(660)	1,509
Net before taxes	(4,232)	(667)
Income taxes	976	1,506
Income contin. oper.	(5,208)	(2,173)
Income discount oper.	(359)	(685)
Net income	(5,567)	(2,858)
Earnings common share		
Primary	\$(0.24)	\$(0.13)

Fully Diluted	\$(0.24)	\$(0.13)
Common Shares:		
Full Diluted	22,930	22,087
Year-end	23,471	22,395

PRIMO WATER CORP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	149,461	135,554
Cost & expenses	125,681	123,063
Operating income	11,609	(720)
Interest expense	16,444	10,024
Other income (expense), net		(3,220)
Net before taxes	(4,835)	(13,964)
Income taxes	(6,496)	373
Net income	1,661	(14,337)
Earnings common share		
Primary	\$0.05	\$(0.44)
Fully Diluted	\$0.05	\$(0.44)
Common Shares:		
Full Diluted	35,836	32,865
Year-end	37,636	29,845

PRIMORIS SERVICES CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	1,152,906,000	1,192,667,000
Cost & expenses	1,126,735,000	1,138,962,000
Operating income	26,171,000	53,705,000
Interest expense	5,189,000	4,407,000
Other income (expense), net	(783,000)	(13,000)
Foreign currency	1,513,000	132,000
Net before taxes	22,324,000	49,600,000
Income taxes	3,917,000	18,692,000
Net income	18,407,000	30,908,000
Earnings common share		
Primary	\$0.24	\$0.57
Fully Diluted	\$0.24	\$0.56
Common Shares:		
Full Diluted	51,770,000	51,771,000
Year-end	51,530,572	

PROGENICS PHARMACEUTICALS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	7,067,000	5,112,000
Cost & expenses	33,823,000	35,925,000
Operating income	(26,756,000)	(30,813,000)
Income taxes	(96,000)	
Net income	(28,596,000)	(32,996,000)
Earnings common share		
Primary	\$(0.39)	\$(0.47)
Fully Diluted	\$(0.39)	\$(0.47)
Common Shares:		
Full Diluted	73,271,000	70,214,000
Year-end	74,759,000	70,261,000

PROOFPOINT INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	334,336	238,076
Cost & expenses	388,450	267,662
Operating income	(54,114)	(29,586)
Other income (expense), net	(290)	55
Net before taxes	(60,412)	(41,345)
Income taxes	(13,958)	2,433
Net income	(46,454)	(43,778)
Earnings common share		
Primary	\$(0.92)	\$(1.00)
Fully Diluted	\$(0.92)	\$(1.00)
Common Shares:		
Full Diluted	50,721	43,562
Year-end	51,189	

PROTAGENIC THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	1,291,809	1,129,509
Operating income	(1,291,809)	(1,129,509)
Gains or losses	18,222	12,544
Invest. income	1,568	(92)
Net income	(1,270,369)	(1,108,945)
Earnings common share		
Primary	\$(0.12)	\$(0.11)

Fully Diluted	\$(0.12)	\$(0.11)
Common Shares:		
Full Diluted	10,261,419	10,261,419
Year-end	10,261,419	10,261,419

PROTAGONIST THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	39,923	29,404
Operating income	(17,468)	(29,404)
Interest income	1,144	324
Net income	(16,324)	(29,080)
Earnings common share		
Primary	\$(0.77)	\$(1.73)
Fully Diluted	\$(0.77)	\$(1.73)
Common Shares:		
Full Diluted	21,160	16,821
Year-end	21,217	16,899

PROTEON THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	11,365	12,466
Operating income	(11,365)	(12,466)
Other income (expense), net	207	282
Gains or losses	198	78
Net income	(10,960)	(12,106)
Balance for common	(10,960)	(12,106)
Earnings common share		
Primary	\$(0.62)	\$(0.72)
Fully Diluted	\$(0.62)	\$(0.72)
Common Shares:		
Full Diluted	17,675	16,924
Year-end	17,727	

PROTEOSTASIS THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,785	2,168
Cost & expenses	28,784	34,550
Operating income	(26,999)	(32,382)
Interest income	359	360
Other income (expense), net	136	(32)
Net income	(26,504)	(32,054)
Balance for common	(26,504)	(32,054)
Earnings common share		
Primary	\$(0.75)	\$(1.28)
Fully Diluted	\$(0.75)	\$(1.28)
Common Shares:		
Full Diluted	35,246	25,030
Year-end	36,636	

PROVIDENCE SERVICE CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	803,878,000	781,522,000
Deprec., depl. & amort.	13,677,000	13,169,000
Operating income	285,000	12,786,000
Interest expense	570,000	681,000
Gains or losses	(2,468,000)	(530,000)
Foreign currency	629,000	(400,000)
Net before taxes	(2,124,000)	11,175,000
Income taxes	3,496,000	5,402,000
Income contin. oper.	(5,620,000)	5,773,000
Income discount oper.	(57,000)	(5,984,000)
Net income	(5,677,000)	(211,000)
Balance for common	(7,980,000)	(3,037,000)
Earnings common share		
Primary	\$(0.61)	\$(0.22)
Fully Diluted	\$(0.61)	\$(0.22)
Common Shares:		
Full Diluted	13,056,765	13,687,183
Year-end	12,806,373	

PTC INC**Earnings, 9 mos. to (Consol. - \$000):**

	06/30/18	07/01/17
Total Revenues	929,303	857,660
Cost & expenses	844,197	810,344
Operating income	61,540	23,330
Interest expense	31,072	32,239
Net before taxes	27,987	(6,860)
Income taxes	(10,809)	4,336
Net income	38,796	(11,196)

Earnings common share		
Primary	\$0.33	\$(0.10)
Fully Diluted	\$0.33	\$(0.10)
Common Shares:		
Full Diluted	117,687	115,511
Year-end	115,491	115,454

PTC INC

Stock Interest Change Development On July 19, 2018, Rockwell Automation, Inc. acquired 10,582,010 shares of Co., par value \$0.01 (the "Shares"), at a purchase price of \$94.50 per share for an aggregate purchase price of approximately \$1,000,000,000 in cash, representing an approximate 8.4% ownership interest in Co.

PTC THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	124,805,000	74,510,000
Cost & expenses	136,100,000	113,360,000
Operating income	(22,317,000)	(38,850,000)
Other income (expense), net	332,000	(2,139,000)
Net before taxes	(28,172,000)	(46,216,000)
Income taxes	610,000	316,000
Net income	(28,782,000)	(46,532,000)
Balance for common	(28,782,000)	(46,532,000)
Earnings common share		
Primary	\$(0.62)	\$(1.26)
Fully Diluted	\$(0.62)	\$(1.26)
Common Shares:		
Full Diluted	46,257,397	36,978,528
Year-end	46,680,482	41,304,008

PTC THERAPEUTICS INC

Merger Completed On Aug. 23, 2018, Co.'s indirect wholly-owned subsidiary, Agility Merger Sub, Inc., merged with and into Agilis Biotherapeutics, Inc. ("Agilis"), a private biotechnology company focused on the advancement of innovative gene therapy programs for rare genetic disorders that affect the central nervous system (CNS), with Agilis continuing as the surviving corporation and became an indirect wholly-owned subsidiary of Co. As the result of the merger, Co. paid to Agilis equity-holders total upfront consideration of approximately \$200,000,000. The total upfront consideration was composed of (i) approximately \$50,000,000, funded with cash on hand less Agilis transaction expenses and all amounts outstanding under the Bridge Loan Agreement (defined below) as of the closing and subject to certain other pre and post-closing adjustments, and (ii) 3,500,907 shares of Co.'s common stock (the "Closing Stock Consideration"). The Closing Stock Consideration was determined by dividing \$150,000,000 by the volume-weighted average price per share of Co.'s common stock on the Nasdaq Global Select Market for the ten consecutive trading day period ending on the second trading day immediately preceding the closing of the Merger. As previously disclosed, and subject to the terms and conditions of the Merger Agreement, Agilis equity-holders may become entitled to receive contingent payments from Co. based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products. Under the Merger Agreement, Co. was required to pay \$40,000,000 of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. As previously disclosed, in connection with its entry into the Merger Agreement, Co. entered into a Bridge Loan and Security Agreement (the "Bridge Loan Agreement") on July 19, 2018 with Agilis and certain of Agilis's domestic subsidiaries, as guarantors. Under the Bridge Loan Agreement, Co. made a term loan advance to Agilis on July 23, 2018 in an original principal amount of \$10,000,000. In connection with the closing of the Merger, the original principal amount of \$10,000,000 plus all accrued and unpaid interest thereon was credited against the cash portion of the upfront consideration paid by Co. pursuant to the terms of the Merger Agreement in satisfaction of Agilis's outstanding payment obligations under the Bridge Loan Agreement, and Co. will have no further obligation to extend any further loan amounts under the Bridge Loan Agreement.

PUMA BIOTECHNOLOGY INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	117,283,000	
Cost & expenses	182,120,000	151,384,000
Operating income	(64,837,000)	151,384,000
Interest income	503,000	730,000
Interest expense	3,666,000	
Other income (expense), net	(679,000)	(43,000)

Net income	(68,679,000)	150,697,000
Balance for common	(68,679,000)	150,697,000
Earnings common share		
Primary	\$(1.82)	\$(4.08)
Fully Diluted	\$(1.82)	\$(4.08)
Common Shares:		
Full Diluted	37,759,729	36,961,760
Year-end	37,890,220	

Q2EARTH INC**Earnings, 6 mos. to Jun 30**(Consol. - \$):

	2018	2017
Total Revenues		37,980
Cost & expenses	571,422	785,392
Operating income	(571,422)	(747,412)
Interest expense	144,856	136,560
Other income (expense), net	345,324	(267,132)
Net income	(370,954)	(1,151,104)
Balance for common	(393,575)	(1,168,956)
Earnings common share		
Primary	\$(0.01)	\$(0.03)
Fully Diluted	\$(0.01)	\$(0.03)
Common Shares:		
Full Diluted	48,458,986	41,427,404
Year-end	48,997,460	48,422,386

QORVO INC**Earnings, 3 mos. to** (Consol. - \$000):

	06/30/18	07/01/17
Total Revenues	692,670	640,831
Cost & expenses	711,885	668,660
Operating income	(19,215)	(27,829)
Interest income	3,394	766
Interest expense	14,353	12,271
Other income (expense), net	(31,955)	(934)
Net before taxes	(62,129)	(40,268)
Income taxes	(32,136)	(9,644)
Net income	(29,993)	(30,624)
Balance for common	(29,993)	(30,624)
Earnings common share		
Primary	\$(0.24)	\$(0.24)
Fully Diluted	\$(0.24)	\$(0.24)
Common Shares:		
Full Diluted	126,198	126,961
Year-end	125,598	127,225

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	334,039	
Inventories	501,578	
Current assets	1,367,706	
Net property & equip.	1,368,588	
Total assets	5,782,332	
Liabilities:		
Current liabilities	403,364	
Long-term debt	558,280	
Stockholders' equity	4,678,105	
Net current assets	964,342	

QUALCOMM INC**Earnings, 9 mos. to** (Consol. - \$000):

	06/24/18	06/25/17
Total Revenues	16,928,000	16,387,000
Cost & expenses	15,533,000	14,106,000
Operating income	1,395,000	2,281,000
Other income (expense), net	(128,000)	(180,000)
Gains or losses	77,000	45,000
Invest. income	24,000	330,000
Foreign currency	20,000	(26,000)
Net before taxes	1,288,000	2,586,000
Income taxes	5,659,000	290,000
Net income	(4,371,000)	2,296,000
Earnings common share		
Primary	\$(2.96)	\$1.55
Fully Diluted	\$(2.96)	\$1.54
Common Shares:		
Full Diluted	1,479,000	1,491,000
Year-end	1,469,000	1,476,000

QUALITY SYSTEMS, INC.**Earnings, 3 mos. to Jun 30**(Consol. - \$):

	2018	2017
Total Revenues	133,200,000	130,922,000
Cost & expenses	128,615,000	122,135,000
Operating income	3,417,000	6,740,000

Interest income	29,000	9,000
Interest expense	730,000	677,000
Other income (expense), net	374,000	(22,000)
Net before taxes	3,090,000	6,050,000
Income taxes	442,000	2,154,000
Net income	2,648,000	3,896,000
Earnings common share		
Primary	\$0.04	\$0.06
Fully Diluted	\$0.04	\$0.06
Common Shares:		
Full Diluted	64,054,000	62,643,000
Year-end	64,220,000	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	34,064,000	
Inventories	161,000	
Current assets	155,811,000	
Net property & equip.	26,567,000	
Total assets	535,135,000	
Liabilities:		
Current liabilities	135,074,000	
Long-term debt	44,000,000	
Stockholders' equity	336,892,000	
Net current assets	20,737,000	

QUALYS, INC.**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Total Revenues	133,031	108,423
Cost & expenses	113,730	91,758
Operating income	19,301	16,665
Interest income	2,542	1,022
Interest expense	77	3
Other income (expense), net	(336)	(206)
Net before taxes	21,430	17,478
Income taxes	1,995	(11,654)
Net income	19,435	29,132
Earnings common share		
Primary	\$0.50	\$0.79
Fully Diluted	\$0.46	\$0.74
Common Shares:		
Full Diluted	42,074	39,207
Year-end	38,986	37,502

QUANTENNA COMMUNICATIONS INC**Earnings, 6 mos. to** (Consol. - \$000):

	07/01/18	07/02/17
Total Revenues	98,544	84,976
Cost & expenses	101,790	84,996
Operating income	(3,246)	(20)
Interest expense	339	339
Other income (expense), net	564	387
Net before taxes	(2,682)	28
Income taxes	(467)	744
Net income	(2,215)	(716)
Earnings common share		
Primary	\$(0.06)	\$(0.02)
Fully Diluted	\$(0.06)	\$(0.02)
Common Shares:		
Full Diluted	36,179	33,494
Year-end	36,848	34,450

QUANTERIX CORP**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Total Revenues	16,164	10,551
Cost & expenses	30,639	23,076
Operating income	(14,475)	(12,525)
Other income (expense), net	(61)	(2)
Net income	(14,545)	(13,023)
Balance for common	(14,545)	(15,244)
Earnings common share		
Primary	\$(0.67)	\$(6.31)
Fully Diluted	\$(0.67)	\$(6.31)
Common Shares:		
Full Diluted	21,840	2,417
Year-end	21,981	

QUICKLOGIC CORP**Earnings, 6 mos. to** (Consol. - \$):

	07/01/18	07/02/17
Total Revenues	5,886,000	6,196,000
Cost & expenses	13,203,000	13,217,000
Operating income	(7,317,000)	(7,021,000)

Interest expense	56,000	82,000
Net before taxes	(7,364,000)	(7,102,000)
Income taxes	90,000	70,000
Net income	(7,454,000)	(7,172,000)
Earnings common share		
Primary	\$(0.09)	\$(0.10)
Fully Diluted	\$(0.09)	\$(0.10)
Common Shares:		
Full Diluted	83,176,000	74,327,000
Year-end	94,575,000	80,103,000

QUIDEL CORP.**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Total Revenues	272,298	111,959
Cost & expenses	220,801	103,757
Operating income	51,497	8,202
Interest expense	14,689	5,603
Other income (expense), net	(6,965)	
Net before taxes	29,843	2,599
Income taxes	(1,039)	151
Net income	30,882	2,448
Balance for common	30,882	2,448
Earnings common share		
Primary	\$0.84	\$0.07
Fully Diluted	\$0.81	\$0.07
Common Shares:		
Full Diluted	42,255	34,295
Year-end	39,001	33,413

QURATE RETAIL INC**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Total Revenues	6,463,000	4,679,000
Cost & expenses	5,489,000	3,798,000
Deprec., depl. & amort.	322,000	414,000
Operating income	652,000	467,000
Interest expense	194,000	179,000
Other income (expense), net	50,000	234,000
Net before taxes	508,000	522,000
Income taxes	54,000	160,000
Income contin. oper.	454,000	362,000
Net income	595,000	703,000
Earnings common share		
Common Shares:		
Year-end	461,140	

R1 RCM INC**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Total Revenues	355,200	186,300
Cost & expenses	383,700	205,000
Operating income	(28,500)	(18,700)
Net before taxes	(34,100)	(18,600)
Income taxes	(7,900)	(3,600)
Net income	(26,200)	(15,000)
Balance for common	(35,600)	(23,700)
Earnings common share		
Primary	\$(0.33)	\$(0.23)
Fully Diluted	\$(0.33)	\$(0.23)
Common Shares:		
Full Diluted	107,001	101,919
Year-end	109,970	104,890

RA PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Cost & expenses	32,850	24,293
Operating income	(32,850)	(24,293)
Other income (expense), net	606	270
Net income	(32,244)	(24,023)
Earnings common share		
Primary	\$(1.08)	\$(1.06)
Fully Diluted	\$(1.08)	\$(1.06)
Common Shares:		
Full Diluted	29,789	22,562
Year-end	32,336	

RADISYS CORP.**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Total Revenues	50,603	72,703
Cost & expenses	58,052	86,013
Operating income	(7,845)	(15,830)
Interest expense	2,795	496
Other income (expense), net	750	(427)
Net before taxes	(9,890)	(16,753)
Income taxes	1,189	809
Net income	(11,079)	(17,562)
Earnings common share		
Primary	\$(0.28)	\$(0.45)
Fully Diluted	\$(0.28)	\$(0.45)
Common Shares:		
Full Diluted	39,424	38,840
Year-end	39,610	39,037

RADIUS HEALTH INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	159,671	127,504
Operating income	(122,495)	(126,524)
Interest income	3,240	1,164
Interest expense	11,248	
Other income (expense), net	66	(17)
Net income	(130,437)	(125,377)
Balance for common	(130,437)	(125,377)
Earnings common share		
Primary	\$(2.89)	\$(2.90)
Fully Diluted	\$(2.89)	\$(2.90)
Common Shares:		
Full Diluted	45,186	43,300
Year-end	45,476	

RADNET INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	475,787,000	459,027,000
Cost & expenses	424,863,000	404,853,000
Operating income	14,982,000	20,908,000
Interest expense	20,680,000	20,543,000
Other income (expense), net	6,719,000	5,162,000
Gains or losses		2,301,000
Net before taxes	1,021,000	7,828,000
Income taxes	8,000	3,065,000
Net income	1,013,000	4,763,000
Earnings common share		
Primary	\$(0.04)	\$0.09
Fully Diluted	\$(0.04)	\$0.09
Common Shares:		
Full Diluted	47,896,216	47,068,563
Year-end	48,284,925	47,266,352

RAMACO RESOURCES INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	121,221,205	22,611,774
Cost & expenses	99,561,327	29,038,059
Operating income	16,266,996	(6,893,301)
Interest expense	416,919	22,820
Other income (expense), net	1,002,008	118,235
Income taxes	1,385,606	
Net income	15,469,713	(6,581,114)
Earnings common share		
Primary	\$0.39	\$(0.18)
Fully Diluted	\$0.38	\$(0.18)
Common Shares:		
Full Diluted	40,241,917	35,592,366
Year-end	40,082,467	39,509,311

RAMBUS INC. (DE)**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	102,884	192,071
Cost & expenses	166,484	170,393
Operating income	(63,600)	21,678
Net before taxes	(55,290)	15,494
Income taxes	(4,244)	9,883
Net income	(51,046)	5,611
Earnings common share		
Primary	\$(0.47)	\$0.05
Fully Diluted	\$(0.47)	\$0.05
Common Shares:		
Full Diluted	108,542	114,091
Year-end	107,345	109,277

RAPID7 INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	112,956	92,688
Cost & expenses	143,881	115,055
Operating income	(30,925)	(22,367)
Other income (expense), net	(248)	114
Net before taxes	(30,468)	(21,866)
Income taxes	226	316
Net income	(30,694)	(22,182)
Earnings common share		
Primary	\$(0.67)	\$(0.52)
Fully Diluted	\$(0.67)	\$(0.52)
Common Shares:		
Full Diluted	45,747	42,395
Year-end	46,739	43,532

RBC BEARINGS INC**Earnings, 3 mos. to (Consol. - \$000):**

	06/30/18	07/01/17
Net Sales	175,985	163,897
Cost & expenses	139,987	131,938
Operating income	35,998	31,959
Interest expense	1,711	2,029
Other income (expense), net	(1,034)	(531)
Net before taxes	33,253	29,399
Income taxes	5,786	7,590
Net income	27,467	21,809
Earnings common share		
Primary	\$1.14	\$0.92
Fully Diluted	\$1.12	\$0.90
Common Shares:		
Full Diluted	24,544	24,189
Year-end	24,228	24,254

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	55,656	
Inventories	311,305	
Current assets	490,798	
Net property & equip.	191,636	
Total assets	1,147,963	
Liabilities:		
Current liabilities	84,779	
Long-term debt	143,823	
Stockholders' equity	866,568	
Net current assets	406,019	

RCI HOSPITALITY HOLDINGS INC**Earnings, 9 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	125,072	105,686
Cost & expenses	92,403	79,047
Operating income	26,863	21,703
Net before taxes	19,557	15,758
Income taxes	(4,899)	5,247
Net income	24,456	10,511
Earnings common share		
Primary	\$2.51	\$1.08
Fully Diluted	\$2.51	\$1.08
Common Shares:		
Full Diluted	9,719	9,751
Year-end	9,719	9,719

RCM TECHNOLOGIES, INC.**Earnings, 6 mos. to (Consol. - \$):**

	06/30/18	07/01/17
Total Revenues	102,522,000	91,853,000
Cost & expenses	99,100,000	89,161,000
Operating income	2,610,000	1,885,000
Foreign currency	(29,000)	55,000
Net before taxes	1,915,000	1,668,000
Income taxes	483,000	929,000
Net income	1,432,000	739,000
Earnings common share		
Primary	\$0.12	\$0.06
Fully Diluted	\$0.12	\$0.06
Common Shares:		
Full Diluted	12,259,459	12,058,362
Year-end	12,239,758	11,962,516

REALNETWORKS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	35,374,000	41,296,000
Cost & expenses	47,161,000	52,711,000
Operating income	(11,787,000)	(11,415,000)
Interest income	198,000	237,000
Other income (expense), net	(83,000)	(1,336,000)
Net before taxes	(11,672,000)	(12,514,000)
Income taxes	436,000	815,000
Income contin. oper.		(13,329,000)
Net income	(12,108,000)	(12,810,000)
Earnings common share		
Primary	\$(0.32)	\$(0.35)
Fully Diluted	\$(0.32)	\$(0.35)
Common Shares:		
Full Diluted	37,514,000	37,067,000
Year-end	37,612,000	

	2018	2017
Total Revenues	417,553	314,225
Cost & expenses	382,475	298,266
Operating income	35,078	15,959
Interest income	467	259
Interest expense	16,772	4,183
Other income (expense), net	117	52
Net before taxes	18,890	12,087
Income taxes	(490)	(2,321)
Net income	19,380	14,408
Earnings common share		
Primary	\$0.23	\$0.18
Fully Diluted	\$0.22	\$0.18
Common Shares:		
Full Diluted	87,332	81,644
Year-end	93,960	

REALPAGE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	39,962	25,538
Cost & expenses	62,152	43,667
Deprec., depl. & amort.	206	239
Operating income	(24,123)	(18,687)
Interest expense	1,413	473
Other income (expense), net	(1,007)	
Gains or losses	693	154
Net before taxes	(24,123)	(18,687)
Income taxes	6	2
Net income	(24,129)	(18,689)
Earnings common share		
Primary	\$(0.92)	\$(0.84)
Fully Diluted	\$(0.92)	\$(0.84)
Common Shares:		
Full Diluted	26,167	22,358
Year-end	26,206	22,366

REATA PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	736,907,000	737,940,000
Cost & expenses	682,586,000	661,899,000
Operating income	2,805,000	26,824,000
Net before taxes	(2,987,000)	21,387,000
Income taxes	(5,493,000)	2,889,000
Net income	2,506,000	18,498,000
Earnings common share		
Primary	\$0.19	\$1.44
Fully Diluted	\$0.19	\$1.43
Common Shares:		
Full Diluted	13,080,000	12,971,000
Year-end	13,003,000	12,934,000

RED ROBIN GOURMET BURGERS INC**Earnings, 6 mos. to (Consol. - \$):**

	07/15/18	07/09/17
Total Revenues	837,227	835,881
Cost & expenses	502,439	681,948
Operating income	245,632	61,873
Interest expense	62,709	68,797
Other income (expense), net	24,010	1,038
Net before taxes	206,933	(5,886)
Income taxes	25,701	(1,134)
Net income	181,232	(4,752)
Earnings common share		

RED ROCK RESORTS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	102,884	192,071
Cost & expenses	166,484	170,393
Operating income	(63,600)	21,678
Net before taxes	(55,290)	15,494
Income taxes	(4,244)	9,883
Net income	(51,046)	5,611
Earnings common share		
Primary	\$(0.47)	\$0.05
Fully Diluted	\$(0.47)	\$0.05
Common Shares:		
Full Diluted	108,542	114,091
Year-end	107,345	109,277

Primary	\$1.94	\$(0.09)
Fully Diluted	\$1.46	\$(0.09)
Common Shares:		
Full Diluted	116,973	66,506
Year-end	116,511	

REDFIN CORP

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	222,536	164,802
Cost & expenses	257,254	188,653
Operating income	(34,718)	(23,851)
Interest income	1,307	76
Other income (expense), net	179	13
Net income	(33,232)	(23,762)
Balance for common	(33,232)	(159,452)
Earnings common share		
Primary	\$(0.40)	\$(10.74)
Fully Diluted	\$(0.40)	\$(10.74)
Common Shares:		
Full Diluted	82,591	14,841
Year-end	83,785	

REGENERON PHARMACEUTICALS, INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	3,119,507	2,789,107
Cost & expenses	1,930,088	1,808,253
Operating income	1,189,419	980,854
Interest expense	13,357	12,902
Other income (expense), net	65,410	(9,813)
Net before taxes	1,241,472	958,139
Income taxes	212,080	321,464
Net income	1,029,392	636,675
Earnings common share		
Primary	\$9.56	\$6.02
Fully Diluted	\$8.97	\$5.51
Common Shares:		
Full Diluted	114,697	115,607
Year-end	107,956	

REGENXBIO INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	172,422	7,017
Cost & expenses	64,047	44,995
Operating income	108,375	(37,978)
Gains or losses	2,055	1,512
Net before taxes	118,683	
Income taxes	3,850	
Net income	114,833	(36,466)
Earnings common share		
Primary	\$3.60	\$(1.27)
Fully Diluted	\$3.29	\$(1.27)
Common Shares:		
Full Diluted	34,884	28,678
Year-end	32,275	

REGULUS THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	36	36
Cost & expenses	28,963	41,046
Operating income	(28,927)	(41,010)
Net before taxes	(29,872)	(41,761)
Income taxes	1	(132)
Net income	(29,873)	(41,629)
Earnings common share		
Primary	\$(0.29)	\$(0.78)
Fully Diluted	\$(0.29)	\$(0.78)
Common Shares:		
Full Diluted	104,170	53,087
Year-end	104,424	53,182

RENEWABLE ENERGY GROUP, INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	1,269,402	953,996
Cost & expenses	1,027,462	959,098
Operating income	241,940	(5,102)
Interest expense	9,576	9,015
Other income (expense), net	14,053	(33,571)
Gains or losses	4,454	
Net before taxes	250,871	(47,688)

Income taxes	2,632	3,035
Net income	248,239	(50,723)
Balance for common	241,983	(50,723)
Earnings common share		
Primary	\$6.35	\$(1.31)
Fully Diluted	\$5.94	\$(1.31)
Common Shares:		
Full Diluted	40,713	38,640
Year-end	37,259	38,685

RENT-A-CENTER INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	1,353,773	1,419,621
Cost & expenses	1,301,564	1,382,093
Operating income	16,881	279
Interest income	411	315
Other income (expense), net		(1,936)
Net before taxes	(4,874)	(24,235)
Income taxes	1,216	(8,663)
Net income	(6,090)	(15,572)
Earnings common share		
Primary	\$(0.11)	\$(0.29)
Fully Diluted	\$(0.11)	\$(0.29)
Common Shares:		
Full Diluted	53,428	53,255
Year-end	53,500	53,302

REPLIGEN CORP.

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2018	2017
Total Revenues	92,561,000	63,045,000
Cost & expenses	82,312,000	51,895,000
Operating income	10,249,000	11,150,000
Interest expense	3,321,000	3,187,000
Other income (expense), net	321,000	(448,000)
Gains or losses	693,000	206,000
Net before taxes	7,942,000	7,721,000
Income taxes	1,757,000	(3,785,000)
Net income	6,185,000	11,506,000
Earnings common share		
Primary	\$0.14	\$0.34
Fully Diluted	\$0.14	\$0.33
Common Shares:		
Full Diluted	44,694,745	34,715,797
Year-end	43,798,572	

RESOURCES CONNECTION INC

Annual Report
Consolidated Income Statement, Years Ended (\$000):

	05/26/18	05/27/17 (revised)	05/28/16 (revised)
Revenue	654,129	583,411	598,521
Direct cost of services, primarily payroll & related taxes for professional services employees	408,074	362,086	366,355
Gross margin	246,055	221,325	232,166
Selling, general & administrative expenses	209,042	183,471	174,806
Amortization of intangible assets	2,298	...	90
Depreciation expense	4,091	3,452	3,467
Income (loss) from operations	30,624	34,402	53,803
Interest expense	1,867	773	...
Interest income	132	144	186
Income before provision for income taxes - domestic	26,774	32,390	53,417
Income (loss) before provision for income taxes - foreign	2,115	1,383	572
Income (loss) before provision for income taxes	28,889	33,773	53,989
Current federal income tax			

provision (benefit)	10,785	10,901	18,320
Current state income tax provision (benefit)	2,829	2,551	4,168
Current foreign income tax provision (benefit)	(392)	1,472	1,398
Total current income tax provision (benefit)	13,222	14,924	23,886
Deferred federal income tax provision (benefit)	(3,011)	259	(178)
Deferred state income tax provision (benefit)	367	62	(27)
Deferred foreign income tax provision (benefit)	(515)	(123)	(135)
Total deferred income tax provision (benefit)	(3,159)	198	(340)
Provision (benefit) for income taxes	10,063	15,122	23,546
Net income (loss)	18,826	18,651	30,443
Weighted average shares outstanding - basic	30,741	32,851	37,037
Weighted average shares outstanding - diluted	31,210	33,471	37,608
Year end shares outstanding	31,614	29,662	36,229
Net income (loss) per share - basic	\$0.61	\$0.57	\$0.82
Net income (loss) per share - diluted	\$0.60	\$0.56	\$0.81
Cash dividends per common share	\$0.48	\$0.44	\$0.40
Total number of employees	4,153	3,301	3,283
Number of common stockholders	48	43	40
Foreign currency translation adjustments	1,011	(602)	123

□ As is; □ Approximately; □ As of July 13, 2018; □ As of July 13, 2017; □ As of July 11, 2016

Consolidated Balance Sheet, Years Ended (\$000):

	05/26/18	05/27/17 (revised)
Cash & cash equivalents	56,470	62,329
Trade accounts receivable, gross	132,092	100,739
Less: allowance for doubtful accounts	1,640	2,517
Trade accounts receivable, net	130,452	98,222
Prepaid expenses & other current assets	7,230	4,395
Income taxes receivable	729	1,899
Total current assets	194,881	166,845
Goodwill	191,950	171,088
Intangible assets, net	18,531	...
Building & land	14,198	14,198
Computers, equipment & software	18,965	17,811
Leasehold improvements	19,802	19,403
Furniture	10,427	9,653
Property & equipment, gross	63,392	61,065
Less: accumulated depreciation & amortization	40,979	37,711
Property & equipment, net	22,413	23,354
Deferred income taxes	2,850	973
Other assets	2,049	1,868
Total assets	432,674	364,128
Accounts payable & accrued expenses	23,280	14,102
Accrued salaries &		

related obligations	22,613	18,741
Accrued bonuses	18,506	15,600
Accrued vacation	17,299	14,900
Accrued salaries & related obligations	58,418	49,241
Other liabilities	12,826	8,428
Total current liabilities	94,524	71,771
Long-term debt	63,000	48,000
Deferred income taxes	...	1,280
Other long-term liabilities	6,325	4,935
Total liabilities	163,849	125,986
Common stock	613	590
Additional paid-in capital	429,578	398,828
Accumulated other comprehensive income (loss)	(10,385)	(11,396)
Retained earnings (accumulated deficit)	335,741	332,024
Treasury stock at cost	486,722	481,904
Total stockholders' equity (deficit)	268,825	238,142

Recent Dividends:**1. Resources Connection Inc common.**

ExDate	Amt	Declared	Record	Payable
02/17/2015	0.08	01/27/2015	02/19/2015	03/19/2015
05/19/2015	0.08	04/28/2015	05/21/2015	06/18/2015
08/21/2015	0.10	08/03/2015	08/25/2015	09/22/2015
11/23/2015	0.10	11/03/2015	11/26/2015	12/24/2015
02/16/2016	0.10	01/26/2016	02/18/2016	03/17/2016
05/17/2016	0.10	04/27/2016	05/19/2016	06/16/2016
08/22/2016	0.11	08/02/2016	08/24/2016	09/21/2016
11/15/2016	0.11	10/26/2016	11/17/2016	12/15/2016
02/14/2017	0.11	01/24/2017	02/16/2017	03/16/2017
05/16/2017	0.11	04/25/2017	05/18/2017	06/15/2017
08/22/2017	0.12	08/01/2017	08/24/2017	09/21/2017
11/15/2017	0.12	10/24/2017	11/16/2017	12/14/2017
02/14/2018	0.12	01/23/2018	02/15/2018	03/15/2018
05/16/2018	0.12	04/25/2018	05/17/2018	06/14/2018

Annual Dividends:**1. Resources Connection Inc common.**

2015	0.36	2016	0.42	2017	0.46
2018	0.24				

RESTORATION ROBOTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	10,480	11,264
Cost & expenses	22,694	20,133
Operating income	(12,214)	(8,869)
Interest expense	858	1,115
Other income (expense), net	(579)	(174)
Net before taxes	(13,651)	(10,158)
Income taxes	24	24
Net income	(13,675)	(10,182)
Balance for common	(13,675)	(10,182)
Earnings common share		
Primary	\$(0.47)	\$(6.29)
Fully Diluted	\$(0.47)	\$(6.29)
Common Shares:		
Full Diluted	29,039	1,619
Year-end	29,138	

RESTORBIO INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	24,313	7,414
Operating income	(24,313)	(7,414)
Other income (expense), net	863	
Net income	(23,450)	(7,414)
Earnings common share		
Primary	\$(0.95)	\$(2.09)
Fully Diluted	\$(0.95)	\$(2.09)
Common Shares:		
Full Diluted	24,803	3,550
Year-end	28,048	

RETAIL OPPORTUNITY INVESTMENTS CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	146,736,000	132,540,000
Cost & expenses	45,092,000	41,237,000
Deprec., depl. & amort.	50,548,000	46,703,000
Operating income	51,096,000	44,600,000
Net income	19,926,000	20,448,000
Earnings common share		
Primary	\$0.16	\$0.17
Fully Diluted	\$0.16	\$0.17
Common Shares:		
Full Diluted	124,177,938	121,156,169
Year-end	112,719,459	109,730,196

RETROPHIN, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	119,241,000	100,426,000
Operating income	(39,472,000)	(28,006,000)
Interest expense	557,000	790,000
Other income (expense), net	(282,000)	488,000
Net before taxes	(40,311,000)	(28,308,000)
Income taxes	396,000	(3,989,000)
Net income	(40,707,000)	(24,319,000)
Earnings common share		
Primary	\$(1.03)	\$(0.63)
Fully Diluted	\$(1.03)	\$(0.63)
Common Shares:		
Full Diluted	39,641,334	38,545,982
Year-end	40,370,521	38,290,876

REVANCE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	880	150
Cost & expenses	71,461	54,077
Operating income	(70,581)	(53,927)
Interest income	2,103	658
Interest expense	44	335
Other income (expense), net	(596)	(425)
Net income	(69,118)	(54,029)
Balance for common	(69,118)	(54,029)
Earnings common share		
Primary	\$(1.92)	\$(1.84)
Fully Diluted	\$(1.92)	\$(1.84)
Common Shares:		
Full Diluted	36,038	29,295
Year-end	36,918	30,416

RGC RESOURCES, INC.**Earnings, 9 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	55,563,594	52,124,422
Cost & expenses	39,510,895	36,522,548
Deprec., depl. & amort.	5,204,634	4,702,185
Operating income	10,848,065	10,899,689
Interest expense	1,829,423	1,400,301
Other income (expense), net	586,806	266,771
Net before taxes	9,605,448	9,766,159
Income taxes	2,992,702	3,693,180
Net income	6,612,746	6,072,979
Earnings common share		
Primary	\$0.88	\$0.84
Fully Diluted	\$0.87	\$0.84
Common Shares:		
Full Diluted	7,579,925	7,244,564
Year-end	7,985,752	7,231,535

RHYTHM PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	32,022	13,143
Operating income	(32,022)	(13,143)
Interest income	1,151	63
Other income (expense), net		(82)
Net income	(30,871)	(13,162)
Balance for common	(30,871)	(15,534)
Earnings common share		
Primary	\$(1.12)	\$(1.52)
Fully Diluted	\$(1.12)	\$(1.52)
Common Shares:		
Full Diluted	27,624	10,196
Year-end	34,173	10,196

RICHARDSON ELECTRONICS LTD**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	06/02/18	05/27/17	05/28/16
		(revised)	(revised)
Net sales	163,212	136,872	142,016
Cost of sales	108,130	92,989	97,181
Gross profit	55,082	43,883	44,835
Selling, general, & administrative expenses	51,729	49,854	51,632
Gain (loss) on disposal of business	...	209	...
Gain (loss) on disposal of assets	276	...	244
Operating income (loss)	3,629	(5,762)	(6,553)
Investment or interest income	432	234	562
Foreign exchange gain (loss)	(224)	(612)	(212)
Other income (expense), net	23	24	(17)
Total other income (expense)	231	(354)	333
Income (loss) before income taxes - United States	(211)	(8,150)	(7,274)
Income before income taxes - foreign	4,071	2,034	1,054
Income (loss) from continuing operations before income taxes	3,860	(6,116)	(6,220)
Current federal income tax provision (benefit)	...	(117)	...
Current state income tax provision (benefit)	(12)	3	17
Current foreign income tax provision (benefit)	1,220	1,035	441
Total current income tax provision (benefit)	1,208	921	458
Deferred federal income tax provision (benefit)	124
Deferred foreign income tax provision (benefit)	202	(109)	88
Total deferred income tax provision (benefit)	326	(109)	88
Income (loss) from continuing operations	2,326	(6,928)	(6,766)
Income (loss) from discontinued operations	1,496
Net income (loss)	3,822	(6,928)	(6,766)
Weighted average shares outstanding - basic	10,765	10,705	10,908
Weighted average class B shares outstanding - basic	2,137	2,140	2,141
Weighted average shares outstanding - diluted	10,824	10,705	10,908
Year end shares outstanding	12,943	12,849	12,844
Income (loss) per share - continuing operations - basic	\$0.18	\$(0.55)	\$(0.53)
Income (loss) per share - discontinued operations - basic	\$0.12
Net income (loss)			

per share - basic	\$0.30	\$(0.55)	\$(0.53)	Additional					
Income (loss) per				paid-in-capital	60,061	59,436			
share - continuing				Retained earnings					
operations -				(accumulated deficit)	70,107	69,333			
diluted	\$0.18	\$(0.55)	\$(0.53)	Accumulated other					
Income (loss) per				comprehensive income					
share -				(loss)	4,366	2,916			
discontinued				Total stockholders'					
operations -				equity (deficit)	135,181	132,327			
diluted	\$0.12						
Net income (loss)									
per share - diluted	\$0.30	\$(0.55)	\$(0.53)						
Dividends per									
common share	\$0.24	\$0.24	\$0.24						
Dividends per class									
B common share	\$0.22	\$0.22	\$0.22						
Number of full time									
employees	2373						
Total number of									
employees	2421	2366	...						
Number of common									
stockholders	2547	2558	2576						
Number of class B									
common stockholders	215	215	216						
Foreign currency									
translation									
adjustments	90	(759)						

□ Reclassified to conform with 2017 presentation; □ As is; □ As of July 23, 2018; □ As of July 24, 2017; □ As of July 25, 2016

Consolidated Balance Sheet, Years Ended (\$000):			
	06/02/18	05/27/17	
		(revised)	
Cash & cash equivalents	60,465	55,327	
Accounts receivable,			
gross	23,201	21,180	
Less: allowance for			
doubtful accounts	309	398	
Accounts receivable, net	22,892	20,782	
Inventories, net	50,720	42,749	
Prepaid expenses & other			
assets	3,747	3,070	
Investments - current	6,429	
Total current assets	137,824	128,357	
Land & improvements	1,301	1,301	
Buildings & improvements	21,673	19,885	
Computer, communications			
equipment & software	9,652	8,551	
Construction in progress	1,582	2,063	
Machinery & other			
equipment	12,004	10,387	
Property, plant &			
equipment, gross	46,212	42,187	
Accumulated depreciation	27,980	26,374	
Property, plant &			
equipment, net	18,232	15,813	
Goodwill	6,332	6,332	
Intangible assets, net	3,014	3,441	
Non-current deferred			
income taxes	927	1,102	
Investments - non-current	2,419	
Total non-current assets	28,505	29,107	
Total assets	166,329	157,464	
Accounts payable	19,603	15,933	
Accrued compensation &			
payroll taxes	3,449	3,250	
Accrued severance	454	706	
Accrued professional fees	527	535	
Deferred revenue	2,395	1,460	
Other accrued expenses	3,518	2,360	
Accrued liabilities	10,343	8,311	
Total current liabilities	29,946	24,244	
Non-current deferred			
income tax liabilities	281	158	
Other non-current			
liabilities	921	735	
Total non-current			
liabilities	1,202	893	
Total liabilities	31,148	25,137	
Common stock	540	535	
Class B common stock,			
convertible	107	107	

Additional		
paid-in-capital	60,061	59,436
Retained earnings		
(accumulated deficit)	70,107	69,333
Accumulated other		
comprehensive income		
(loss)	4,366	2,916
Total stockholders'		
equity (deficit)	135,181	132,327

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Richardson Electronics Ltd class B common. No dividends paid.
2. Richardson Electronics Ltd common.

ExDate	Amt	Declared	Record	Payable
02/04/2015	0.06	01/07/2015	02/06/2015	02/20/2015
05/05/2015	0.06	04/08/2015	05/07/2015	05/22/2015
08/04/2015	0.06	07/22/2015	08/06/2015	08/21/2015
11/04/2015	0.06	10/07/2015	11/06/2015	11/20/2015
02/04/2016	0.06	01/06/2016	02/08/2016	02/24/2016
05/06/2016	0.06	04/06/2016	05/10/2016	05/24/2016
08/04/2016	0.06	07/20/2016	08/08/2016	08/24/2016
11/03/2016	0.06	10/05/2016	11/07/2016	11/22/2016
02/03/2017	0.06	01/04/2017	02/07/2017	02/24/2017
05/05/2017	0.06	04/05/2017	05/09/2017	05/24/2017
08/03/2017	0.06	07/19/2017	08/07/2017	08/24/2017
11/06/2017	0.06	10/11/2017	11/07/2017	11/22/2017
02/08/2018	0.06	01/10/2018	02/09/2018	02/22/2018
05/08/2018	0.06	04/11/2018	05/09/2018	05/24/2018
08/06/2018	0.06	07/25/2018	08/07/2018	08/23/2018

Annual Dividends:

1. Richardson Electronics Ltd class B common. No dividends paid.
 2. Richardson Electronics Ltd common.
- | | | | | | |
|------------|------|------------|------|------------|------|
| 2015 | 0.24 | 2016 | 0.24 | 2017 | 0.24 |
| 2018 | 0.18 | | | | |

RIGEL PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):			
	2018	2017	
Total Revenues	1,787	3,584	
Cost & expenses	52,632	39,130	
Operating income	(50,845)	(35,546)	
Interest income	903	353	
Gains or losses		732	
Net income	(49,942)	(34,461)	
Earnings common share			
Primary	\$(0.32)	\$(0.29)	
Fully Diluted	\$(0.32)	\$(0.29)	
Common Shares:			
Full Diluted	154,385	118,074	
Year-end	166,443	124,393	

RIGNET INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):			
	2018	2017	
Total Revenues	113,840	97,234	
Cost & expenses	106,297	86,871	
Deprec., depl. & amort.	16,343	14,868	
Operating income	(8,800)	(4,505)	
Interest expense	1,966	1,232	
Other income (expense), net	618	(147)	
Net before taxes	(10,148)	(5,884)	
Income taxes	(323)	313	
Net income	(9,825)	(6,197)	
Balance for common	(9,885)	(6,275)	
Earnings common share			
Primary	\$(0.54)	\$(0.35)	
Fully Diluted	\$(0.54)	\$(0.35)	
Common Shares:			
Full Diluted	18,394	17,929	
Year-end	19,270		

RIMINI STREET INC (DE)

Earnings, 6 mos. to Jun 30(Consol. - \$):			
	2018	2017	
Total Revenues	122,454,000		
Cost & expenses	103,202,000	483,609	
Operating income	19,252,000	(483,609)	
Interest income	451,511		

Interest expense	22,732,000	
Other income (expense), net	(17,396,000)	2,684
Net before taxes	(20,876,000)	
Income taxes	1,063,000	
Net income	(21,939,000)	(29,414)
Earnings common share		
Primary	\$(0.37)	\$(0.01)
Fully Diluted	\$(0.37)	\$(0.01)
Common Shares:		
Full Diluted	59,534,000	5,658,219
Year-end	60,005,000	20,009,776

ROBINSON (C.H.) WORLDWIDE, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):			
	2018	2017	
Total Revenues	8,201,364	7,125,143	
Cost & expenses	7,790,771	6,755,365	
Operating income	410,593	369,778	
Net before taxes	394,765	351,108	
Income taxes	93,305	117,957	
Net income	301,460	233,151	
Earnings common share			
Primary	\$2.16	\$1.65	
Fully Diluted	\$2.14	\$1.65	
Common Shares:			
Full Diluted	140,960	141,713	
Year-end	138,744	140,679	

ROCKET PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):			
	2018	2017	
Cost & expenses	29,277	15,822	
Operating income	(29,277)	(15,822)	
Interest income	805	355	
Interest expense	2,834	1,765	
Other income (expense), net	196		
Net income	(31,110)	(17,232)	
Earnings common share			
Primary	\$(0.82)	\$(2.56)	
Fully Diluted	\$(0.82)	\$(2.56)	
Common Shares:			
Full Diluted	37,955	6,748	
Year-end	39,507	6,753	

ROCKWELL MEDICAL, INC

Earnings, 6 mos. to Jun 30(Consol. - \$):			
	2018	2017	
Net Sales	29,861,943	27,835,361	
Cost & expenses	47,877,650	39,511,840	
Operating income	(18,015,707)	(11,676,479)	
Net income	(17,780,313)	(11,825,007)	
Earnings common share			
Primary	\$(0.35)	\$(0.23)	
Fully Diluted	\$(0.35)	\$(0.23)	
Common Shares:			
Full Diluted	51,288,424	50,859,927	
Year-end	51,768,424	51,740,040	

ROCKWELL MEDICAL, INC

New Accountant On July 26, 2018, Co. engaged Marcum LLP as its new independent public accounting firm.

ROCKY BRANDS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):			
	2018	2017	
Net Sales	119,592,513	121,527,907	
Cost & expenses	111,991,754	116,903,150	
Operating income	7,600,759	4,624,757	
Other income (expense), net	(178,497)	(147,633)	
Net before taxes	7,422,262	4,477,124	
Income taxes	1,522,000	1,522,000	
Net income	5,900,262	2,955,124	
Earnings common share			
Primary	\$0.80	\$0.40	
Fully Diluted	\$0.79	\$0.40	
Common Shares:			
Full Diluted	7,445,060	7,441,514	
Year-end	7,414,509	7,441,851	

ROCKY MOUNTAIN CHOCOLATE FACTORY INC (DE)

Earnings, 3 mos. to May 31(Consol. - \$):			
	2018	2017	
Total Revenues	8,366,085	9,346,447	
Cost & expenses	7,281,849	7,857,639	
Deprec., depl. & amort.	301,000	194,934	

stockholders	(44,503)	(11,764)	2018	2017	2018	2017		
Weighted average shares outstanding - basic	8,024	7,201	Cost & expenses	15,447	4,783	Total Revenues	417,689	413,019
Weighted average shares outstanding - diluted	8,024	7,201	Operating income	(15,447)	(4,783)	Cost & expenses	373,345	366,173
Year end shares outstanding	14,977	7,886	Interest expense	83	50	Operating income	44,344	46,846
Net earnings (loss) per share - basic	\$(5.55)	\$(1.63)	Other income (expense), net	275	(24)	Net before taxes	44,344	46,846
Net earnings (loss) per share - diluted	\$(5.55)	\$(1.63)	Net income	(15,255)	(4,857)	Income taxes	8,403	13,722
Number of full time employees	2283	...	Balance for common	(15,255)	(5,233)	Net income	35,941	33,124
Number of common stockholders	2268	...	Earnings common share	Balance for common	35,724	32,912
			Primary	\$(1.83)	\$(0.68)	Earnings common share
			Fully Diluted	\$(1.83)	\$(0.68)	Primary	\$2.37	\$2.19
			Common Shares:	Fully Diluted	\$2.35	\$2.18
			Full Diluted	8,355	7,662	Common Shares:
			Year-end	14,997	...	Full Diluted	15,202	15,106
				Year-end	15,287	15,219

As Is; As of June 15, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	104,288	6,834
Prepaid expenses & other current assets	700	53
Total current assets	104,988	6,887
Laboratory equipment	2,751	831
Leasehold improvements	117	117
Computer equipment	57	57
Construction in progress	74	...
Total property & equipment, gross	2,999	1,005
Less accumulated depreciation & amortization	584	137
Property & equipment, net	2,415	868
Restricted cash	284	234
Total assets	107,687	7,989
Accounts payable	2,033	1,180
Accrued employee compensation & benefits	1,339	253
Accrued research & development expenses	1,230	237
Accrued professional fees	219	178
Accrued other	198	71
Accrued expenses & other current liabilities	2,986	739
Current portion of long-term debt	2,139	933
Total current liabilities	7,158	2,852
Principal amount of long-term debt	5,500	4,000
Less: Current portion of long-term debt	2,139	933
Long-term debt, net of current portion	3,361	3,067
Debt discount	(59)	(76)
Long-term debt, net of current portion	3,302	2,991
Deferred rent	158	136
Preferred stock warrant liability	866	67
Liability for early exercise of stock options	100	...
Total liabilities	11,584	6,046
Convertible preferred shares (series A, B & C)	139,790	19,067
Common stock	15	8
Additional paid-in capital	17,277	...
Retained earnings (accumulated deficit)	(60,979)	(17,132)
Total stockholders' equity (deficit)	(43,687)	(17,124)

Recent Dividends:

1. Rubius Therapeutics Inc common.
No dividends paid.

Annual Dividends:

1. Rubius Therapeutics Inc common.
No dividends paid.

RUBIUS THERAPEUTICS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	136,471	193,583
Current assets	193,583	14,251
Net property & equip.	14,251	209,730
Total assets	209,730	...
Liabilities:
Current liabilities	11,307	12,001
Long-term debt	12,001	(55,526)
Stockholders' equity	(55,526)	182,276
Net current assets	182,276	...

RUSH ENTERPRISES INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	2,589,612	2,248,320
Cost & expenses	2,469,196	2,161,128
Deprec., depl. & amort.	44,601	24,936
Operating income	75,815	62,256
Interest expense	8,800	5,615
Net before taxes	67,015	56,641
Income taxes	16,587	20,163
Net income	50,428	36,478
Earnings common share
Primary	\$1.27	\$0.92
Fully Diluted	\$1.23	\$0.90
Common Shares:
Full Diluted	40,967	40,737
Year-end	39,077	39,431

RUTH'S HOSPITALITY GROUP INC

Earnings, 6 mos. to (Consol. - \$000):

	07/01/18	06/25/17
Total Revenues	226,160	205,553
Net Sales	213,902	193,600
Cost & expenses	188,933	170,527
Operating income	28,093	27,790
Interest expense	783	324
Other income (expense), net	34	39
Net before taxes	27,344	27,505
Income taxes	4,147	8,616
Income contin. oper.	23,197	18,889
Net income	23,219	18,859
Earnings common share
Primary	\$0.78	\$0.62
Fully Diluted	\$0.76	\$0.60
Common Shares:
Full Diluted	30,377	31,255
Year-end	29,696	30,360

SABRE CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	1,972,745	1,816,016
Cost & expenses	1,668,511	1,633,972
Operating income	304,234	182,044
Other income (expense), net	(7,352)	(14,575)
Net before taxes	219,364	89,811
Income taxes	36,350	16,241
Income contin. oper.	183,014	73,570
Net income	182,567	71,871
Balance for common	180,126	69,452
Earnings common share
Primary	\$0.66	\$0.25
Fully Diluted	\$0.65	\$0.25
Common Shares:
Full Diluted	276,565	279,919
Year-end	275,125	278,629

SAFETY INSURANCE GROUP, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

SAGA COMMUNICATIONS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	60,243	56,416
Cost & expenses	51,891	48,567
Operating income	8,352	7,849
Other income (expense), net	277	...
Net before taxes	8,155	7,412
Income taxes	2,455	2,990
Income contin. oper.	...	4,422
Net income	5,700	6,472
Balance for common	5,603	6,358
Earnings common share
Primary	\$0.96	\$1.10
Fully Diluted	\$0.96	\$1.10
Common Shares:
Full Diluted	5,838	5,804
Year-end	5,028	5,908

SAGE THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	190,266	128,334
Operating income	(100,266)	(128,334)
Interest income	8,666	1,379
Other income (expense), net	24	(24)
Net income	(91,576)	(126,979)
Earnings common share
Primary	\$(2.02)	\$(3.40)
Fully Diluted	\$(2.02)	\$(3.40)
Common Shares:
Full Diluted	45,440	37,315
Year-end	46,604	...

SAIA INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	392,805	323,090
Cost & expenses	342,196	285,476
Operating income	27,579	17,527
Interest expense	1,226	911
Other income (expense), net	103	(98)
Net before taxes	26,456	16,518
Income taxes	5,331	5,123
Net income	21,125	11,395
Earnings common share
Primary	\$0.82	\$0.45
Fully Diluted	\$0.80	\$0.44
Common Shares:
Full Diluted	26,308	25,971
Year-end	25,680	...

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	496	225,999
Current assets	225,999	760,858
Net property & equip.	...	1,015,547
Total assets	1,015,547	...
Liabilities:
Current liabilities	178,677	127,782
Long-term debt	127,782	607,394
Stockholders' equity	607,394	47,322
Net current assets	47,322	...

SAIA INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	821,537	687,494
Cost & expenses	704,122	598,012
Operating income	69,144	47,213

SUNPOWER CORP

Earnings, 6 mos. to (Consol. - \$000):

	07/01/18	07/02/17
Total Revenues	840,985	657,076
Cost & expenses	1,452,944	877,627
Operating income	(611,959)	(220,551)
Interest income	1,193	1,325
Interest expense	51,824	43,407
Other income (expense), net	52,418	(88,772)
Equity earnings	15,559	(9,325)
Net before taxes	(610,172)	(351,405)
Income taxes	5,709	4,384
Net income	(631,440)	(346,464)
Earnings common share		
Primary	\$(4.01)	\$(2.23)
Fully Diluted	\$(4.01)	\$(2.23)
Common Shares:		
Full Diluted	140,569	139,175
Year-end	140,985	

SUNPOWER CORP

Interest Sale Completed On Aug. 9, 2018, Enphase Energy, Inc. ("Enphase") acquired from Co. certain assets primarily relating to Co.'s microinverter business for (i) \$15,000,000 payable in cash (the "Initial Cash Payment") at the closing under the Purchase Agreement (the "Closing"); (ii) 7,500,000 shares of Enphase common stock issuable to Co. at the Closing (the "Closing Shares"); and (iii) an additional cash payment of \$10,000,000 payable by Enphase to Co. on the earlier of the four-month anniversary of the Closing and Dec. 28, 2018 (the "Additional Cash Payment").

SUNRUN INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	314,901	235,731
Cost & expenses	404,479	323,001
Operating income	(91,680)	(89,372)
Interest expense	60,070	42,529
Other income (expense), net	1,184	(683)
Net before taxes	(150,566)	(132,584)
Income taxes	12,581	16,181
Net income	(163,147)	(148,765)
Earnings common share		
Primary	\$0.33	\$0.27
Fully Diluted	\$0.31	\$0.26
Common Shares:		
Full Diluted	113,930	106,911
Year-end	110,487	

SUPERIOR GROUP OF COMPANIES INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	155,479,000	126,591,000
Cost & expenses	147,062,000	116,503,000
Operating income	8,417,000	11,106,000
Gains or losses		1,018,000
Net before taxes	8,417,000	11,106,000
Income taxes	2,150,000	2,930,000
Net income	6,267,000	8,176,000
Earnings common share		
Primary	\$0.42	\$0.57
Fully Diluted	\$0.40	\$0.55
Common Shares:		
Full Diluted	15,508,517	14,985,063
Year-end	15,311,541	14,768,272

SUPERNUS PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	189,967	133,405
Cost & expenses	122,853	90,550
Operating income	67,114	42,855
Interest income	4,870	1,187
Other income (expense), net		(128)
Net before taxes	65,038	42,648
Income taxes	7,949	14,983
Net income	57,089	27,665
Earnings common share		
Primary	\$1.10	\$0.55
Fully Diluted	\$1.06	\$0.52
Common Shares:		
Full Diluted	54,022	53,026
Year-end	52,179	50,774

SURFACE ONCOLOGY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	47,923	7,867
Cost & expenses	33,463	22,950
Operating income	14,460	(15,083)
Other income (expense), net	900	262
Net before taxes	(14,821)	(14,821)
Income taxes	378	
Net income	15,360	(15,199)
Balance for common	8,272	(15,219)
Earnings common share		
Primary	\$0.68	\$(6.30)
Fully Diluted	\$0.60	\$(6.30)
Common Shares:		
Full Diluted	13,805	2,416
Year-end	27,601	

SURGERY PARTNERS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	862,144	574,536
Cost & expenses	744,986	472,551
Deprec., depl. & amort.	32,434	22,525
Operating income	84,724	79,460
Interest expense	70,209	50,782
Net before taxes	14,515	28,678
Income taxes	5,080	2,629
Net income	9,435	26,049
Balance for common	(52,711)	(7,225)
Earnings common share		
Primary	\$(1.10)	\$(0.15)
Fully Diluted	\$(1.10)	\$(0.15)
Common Shares:		
Full Diluted	48,012	48,113
Year-end	48,902	

SURMODICS INC

Earnings, 9 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	58,298	53,054
Cost & expenses	62,779	44,576
Operating income	(6,359)	6,688
Gains or losses	566	274
Invest. income	177	
Net before taxes	(5,503)	6,841
Income taxes	(2,799)	3,315
Net income	(2,704)	3,526
Earnings common share		
Primary	\$(0.21)	\$0.27
Fully Diluted	\$(0.21)	\$0.26
Common Shares:		
Full Diluted	13,117	13,404
Year-end	13,348	13,110

SYKES ENTERPRISES, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	811,156,000	759,452,000
Cost & expenses	753,174,000	684,422,000
Operating income	20,744,000	37,381,000
Interest income	346,000	299,000
Interest expense	2,355,000	3,564,000
Other income (expense), net	(2,471,000)	962,000
Gains or losses	2,089,000	644,000
Net before taxes	18,353,000	35,722,000
Income taxes	227,000	8,165,000
Net income	18,126,000	27,557,000
Earnings common share		
Primary	\$0.43	\$0.66
Fully Diluted	\$0.43	\$0.66
Common Shares:		
Full Diluted	42,197,000	41,919,000
Year-end	42,699,000	

SYNACOR, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	68,838	57,756
Cost & expenses	68,406	62,397
Deprec., depl. & amort.	4,879	4,408
Operating income	(4,447)	(9,049)
Interest expense	185	201
Other income (expense), net	(14)	73

Net before taxes	(4,646)	(9,177)
Income taxes	313	755
Net income	(4,959)	(9,932)
Earnings common share		
Primary	\$(0.13)	\$(0.29)
Fully Diluted	\$(0.13)	\$(0.29)
Common Shares:		
Full Diluted	38,809	34,228
Year-end	38,856	38,331

SYNALLOY CORP.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	130,374,365	93,714,624
Cost & expenses	117,709,713	91,048,779
Operating income	12,664,652	2,665,845
Other income (expense), net	(2,398,385)	27,894
Net before taxes	9,548,432	2,172,419
Income taxes	2,035,998	641,000
Net income	7,512,434	1,531,419
Earnings common share		
Primary	\$0.86	\$0.18
Fully Diluted	\$0.85	\$0.18
Common Shares:		
Full Diluted	8,833,986	8,704,330
Year-end	8,802,207	8,716,893

SYNDAX PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	758	610
Cost & expenses	39,460	27,629
Operating income	(38,702)	(27,019)
Other income (expense), net	(17)	(140)
Net income	(37,785)	(26,610)
Balance for common	(37,785)	(26,610)
Earnings common share		
Primary	\$(1.54)	\$(1.41)
Fully Diluted	\$(1.54)	\$(1.41)
Common Shares:		
Full Diluted	24,592	18,868
Year-end	22,706	

SYNEOS HEALTH INC

Acquisition Completed On Aug. 20, 2018, Co. acquired Kinapse Topco Ltd., a market advisory and operational solutions provider to the global life sciences industry, from Hg, a specialist investor based in the U.K. Terms of the transaction were not disclosed.

SYNEOS HEALTH INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	2,129,726	773,053
Cost & expenses	1,953,306	696,895
Operating income	40,897	45,002
Interest income	2,494	264
Interest expense	64,630	6,386
Other income (expense), net	(2,479)	(177)
Gains or losses	168	(4,152)
Foreign currency	19,633	(5,882)
Net before taxes	(3,917)	28,669
Income taxes	7,075	4,093
Net income	(10,992)	24,576
Earnings common share		
Primary	\$(0.11)	\$0.45
Fully Diluted	\$(0.11)	\$0.45
Common Shares:		
Full Diluted	103,674	55,215
Year-end	102,871	

SYNERGY PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	20,840,000	2,412,000
Cost & expenses	88,585,000	138,722,000
Operating income	(67,745,000)	(136,310,000)
Interest expense	6,328,000	1,135,000
Other income (expense), net	8,278,000	(1,048,000)
Net income	(65,795,000)	(138,493,000)
Earnings common share		
Primary	\$(0.27)	\$(0.63)
Fully Diluted	\$(0.27)	\$(0.63)
Common Shares:		
Full Diluted	246,827,974	220,269,223
Year-end	247,863,222	224,954,941

SYNOLOGIC INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	608	608
Cost & expenses	27,596	14,540
Operating income	(26,988)	
Interest income		182
Interest expense	26	
Other income (expense), net	1,258	
Net income	(25,756)	(14,358)
Balance for common		(14,358)
Earnings common share		
Primary	\$(1.14)	\$(4.83)
Fully Diluted	\$(1.14)	\$(4.83)
Common Shares:		
Full Diluted	22,504	2,979
Year-end	25,433	2,980

SYNTEL INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	495,044	452,680
Cost & expenses	373,781	347,126
Operating income	121,263	105,554
Interest expense	4,626	6,592
Other income (expense), net	2,031	958
Net before taxes	118,078	99,258
Income taxes	31,291	24,226
Net income	86,787	75,032
Earnings common share		
Primary	\$1.04	\$0.90
Fully Diluted	\$1.04	\$0.89
Common Shares:		
Full Diluted	83,426	83,844
Year-end	82,968	83,676

SYNTEL INC.

Merger Development On July 20, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among Co., Atos S.E. ("Parent"), and Green Merger Sub Inc., a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub will be merged with and into Co. (the "Merger"), with Co. continuing as the surviving company in the Merger. Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger, each share of common stock, no par value per share, of Co. ("Co. Common Stock") issued and outstanding immediately prior to the effective time of the Merger (other than shares of Co. Common Stock owned by Co., Merger Sub, Parent, or any of their respective direct or indirect wholly-owned subsidiaries, in each case not held on behalf of third parties) will be converted into the right to receive \$41.00 per share in cash, without interest (the "Merger Consideration"). Upon consummation of the Merger, each restricted stock unit of Co. ("Co. RSU") granted on or prior to July 20, 2018 and outstanding as of the effective time of the Merger will vest in full and, by virtue of the Merger and without any action on the part of the holder thereof, will be cancelled as of the effective time of the Merger and entitle the holder thereof to receive an amount in cash, without interest, equal to the amount of any accumulated and unpaid dividends plus the product obtained by multiplying (i) the number of shares of Co. Common Stock subject to such Co. RSU immediately prior to the effective time of the Merger by (ii) the Merger Consideration, subject to any required withholding of taxes. At the effective time of the Merger, each Company RSU granted after July 20, 2018 and outstanding as of the effective time will, by virtue of the Merger and without any action on the part of the holder thereof, be converted into a restricted stock unit denominated in shares of Parent common stock (a "Parent RSU") equal to the product (rounded to the nearest whole number) of (i) the number of shares of Co. common stock subject to such Co. RSU immediately prior to the effective time of the Merger multiplied by (ii) the quotient obtained by dividing (A) the average closing price per share of Co. Common Stock on NASDAQ during the twenty (20) consecutive trading days ending on July 20, 2018 by (B) the average closing price per share of Parent common stock on the Euronext Paris market during the twenty (20) consecutive trading days ending on July 20, 2018, and such Parent RSU will continue to vest in accordance with the original vesting schedule of such Co. RSU, subject to acceleration in full on a qualifying termination of employment.

SYPRIS SOLUTIONS, INC.

Earnings, 6 mos. to (Consol. – \$000):		
	07/01/18	07/02/17
Total Revenues	42,913	39,434

Cost & expenses	45,081	47,258
Operating income	(2,168)	(7,824)
Interest expense	434	394
Other income (expense), net	1,707	1,778
Net before taxes	(895)	(6,440)
Income taxes	86	15
Net income	(981)	(6,455)
Earnings common share		
Primary	\$(0.05)	\$(0.32)
Fully Diluted	\$(0.05)	\$(0.32)
Common Shares:		
Full Diluted	20,468	20,261
Year-end	21,398	21,436

SYROS PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	745	1,101
Cost & expenses	30,114	26,227
Operating income	(29,369)	(25,126)
Other income (expense), net	859	243
Net income	(28,510)	(24,883)
Earnings common share		
Primary	\$(0.90)	\$(1.02)
Fully Diluted	\$(0.90)	\$(1.02)
Common Shares:		
Full Diluted	31,621	24,511
Year-end	33,621	

T-MOBILE US INC

Earnings, 6 mos. to Jun 30(Consol. – \$Millions):		
	2018	2017
Total Revenues	21,026	19,826
Cost & expenses	15,085	14,290
Deprec., depl. & amort.	3,209	3,083
Operating income	2,732	2,453
Interest income	12	13
Other income (expense), net	(54)	(90)
Net before taxes	1,949	1,541
Income taxes	496	262
Net income	1,453	1,279
Balance for common	1,453	1,251
Earnings common share		
Primary	\$1.71	\$1.51
Fully Diluted	\$1.69	\$1.47
Common Shares:		
Full Diluted	859	871
Year-end	849	831

T2 BIOSYSTEMS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	6,242	1,897
Cost & expenses	28,564	28,947
Operating income	(22,322)	(27,050)
Interest expense	3,074	3,291
Other income (expense), net	159	181
Net income	(25,237)	(30,160)
Earnings common share		
Primary	\$(0.68)	\$(0.99)
Fully Diluted	\$(0.68)	\$(0.99)
Common Shares:		
Full Diluted	37,127	30,596
Year-end	43,472	

TABULA RASA HEALTHCARE INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	92,542	57,414
Cost & expenses	134,734	57,713
Operating income	(50,206)	(3,863)
Interest expense	183	153
Net before taxes	(50,389)	(4,016)
Income taxes	(3,269)	260
Net income	(47,120)	(4,276)
Balance for common	(47,120)	(4,276)
Earnings common share		
Primary	\$(2.50)	\$(0.26)
Fully Diluted	\$(2.50)	\$(0.26)
Common Shares:		
Full Diluted	18,873	16,373
Year-end	20,226	

TACTILE SYSTEMS TECHNOLOGY INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
--	--	--

Total Revenues	60,981	46,114
Cost & expenses	61,497	48,316
Operating income	(516)	(2,202)
Other income (expense), net	223	119
Net before taxes	(293)	(2,083)
Income taxes	(2,815)	(4,366)
Net income	2,522	2,283
Earnings common share		
Primary	\$0.14	\$0.13
Fully Diluted	\$0.13	\$0.12
Common Shares:		
Full Diluted	19,204	18,713
Year-end	18,287	17,541

TAKE-TWO INTERACTIVE SOFTWARE, INC.

Earnings, 3 mos. to Jun 30(Consol. – \$):		
	2018	2017
Total Revenues	387,982,000	418,216,000
Cost & expenses	307,876,000	360,254,000
Deprec., depl. & amort.	9,260,000	7,743,000
Operating income	70,846,000	50,219,000
Net before taxes	77,447,000	47,411,000
Income taxes	5,754,000	(12,865,000)
Net income	71,693,000	60,276,000
Earnings common share		
Primary	\$0.63	\$0.57
Fully Diluted	\$0.62	\$0.56
Common Shares:		
Full Diluted	115,985,000	117,753,000
Year-end	113,509,000	105,835,000

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	464,804,000
Inventories	10,642,000
Current assets	2,074,347,000
Net property & equip.	105,852,000
Total assets	3,456,004,000
Liabilities:	
Current liabilities	1,391,216,000
Long-term debt	5,232,000
Stockholders' equity	1,852,205,000
Net current assets	683,131,000

TANDEM DIABETES CARE INC

Earnings, 6 mos. to Jun 30(Consol. – \$):		
	2018	2017
Net Sales	61,402,000	40,303,000
Cost & expenses	90,884,000	80,497,000
Operating income	(29,482,000)	(40,194,000)
Other income (expense), net	(56,777,000)	
Net income	(92,053,000)	(45,593,000)
Earnings common share		
Primary	\$(2.32)	\$(11.10)
Fully Diluted	\$(2.32)	\$(11.10)
Common Shares:		
Full Diluted	39,594,000	4,101,300
Year-end	53,186,000	

TANDY LEATHER FACTORY INC

Earnings, 6 mos. to Jun 30(Consol. – \$):		
	2018	2017
Net Sales	39,466,685	39,430,615
Cost & expenses	35,716,243	36,037,687
Operating income	3,750,442	3,392,928
Interest expense	142,824	90,024
Other income (expense), net	85,613	19,663
Net before taxes	3,693,231	3,322,567
Income taxes	979,520	1,063,570
Net income	2,713,711	2,258,997
Earnings common share		
Primary	\$0.29	\$0.24
Fully Diluted	\$0.29	\$0.24
Common Shares:		
Full Diluted	9,222,533	9,225,474
Year-end	9,154,215	9,270,862

TCG BDC INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Cost & expenses	46,555	32,119
Operating income	53,380	40,724
Net before taxes	53,380	40,724
Income taxes	40	169

Net income	53,340	40,555
Earnings common share		
Primary	\$0.55	\$0.72
Fully Diluted	\$0.55	\$0.72
Common Shares:		
Full Diluted	62,535	43,854
Year-end	62,569	61,406

TD AMERITRADE HOLDING CORP

Earnings, 9 mos. to Jun 30 (Consol. - \$):	2018	2017
Cost & expenses	2,478,000,000	457,000,000
Operating income	1,363,000,000	105,000,000
Other income (expense), net	(2,000,000)	(1,000,000)
Gains or losses	(11,000,000)	
Net before taxes	1,278,000,000	105,000,000
Income taxes	259,000,000	395,000,000
Net income	1,019,000,000	661,000,000
Earnings common share		
Primary	\$1.80	\$1.25
Fully Diluted	\$1.79	\$1.25
Common Shares:		
Full Diluted	570,000,000	530,000,000
Year-end	568,000,000	528,000,000

TECHTARGET INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):	2018	2017
Total Revenues	58,771	50,241
Cost & expenses	47,536	45,672
Operating income	8,987	2,303
Net before taxes	8,143	2,046
Income taxes	1,629	714
Net income	6,514	1,332
Balance for common	6,514	1,332
Earnings common share		
Primary	\$0.24	\$0.05
Fully Diluted	\$0.23	\$0.05
Common Shares:		
Full Diluted	28,664	28,261
Year-end	27,578	27,421

TELIGENT INC (NEW)

Earnings, 6 mos. to Jun 30 (Consol. - \$000):	2018	2017
Total Revenues	38,299	38,299
Cost & expenses	39,732	37,114
Operating income	(8,436)	1,185
Other income (expense), net	(10,069)	
Foreign currency	(1,895)	4,901
Net before taxes	(25,471)	18
Income taxes	47	106
Net income	(25,518)	(88)
Earnings common share		
Primary	\$(0.48)	\$.....
Fully Diluted	\$(0.48)	\$.....
Common Shares:		
Full Diluted	53,485	53,250
Year-end	53,513	

TELIGENT INC (NEW)

New Auditor On Aug. 13, 2018, Co. dismissed of EisnerAmper LLP as its independent registered public accounting firm and engaged Deloitte & Touche LLP as its new independent registered public accounting firm.

TERRAFORM POWER INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):	2018	2017
Total Revenues	307,435	321,502
Cost & expenses	166,601	159,678
Operating income	5,250	37,615
Interest expense	104,446	136,517
Other income (expense), net	(2,512)	(2,133)
Gains or losses	37,116	
Foreign currency	1,187	4,617
Net before taxes	(100,521)	(59,302)
Income taxes	3,404	(1,157)
Net income	(103,925)	(58,145)
Balance for common	61,459	(21,191)
Earnings common share		
Primary	\$0.40	\$(0.28)
Fully Diluted	\$0.40	\$(0.28)
Common Shares:		
Full Diluted	154,905	92,165
Year-end	209,062	

TESLA INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):	2018	2017
Total Revenues	7,410,982	5,485,827
Cost & expenses	8,629,348	5,984,292
Operating income	(1,218,366)	(498,465)
Other income (expense), net	13,195	(59,306)
Net before taxes	(1,508,021)	(757,683)
Income taxes	19,312	40,925
Net income	(1,527,333)	(798,608)
Earnings common share		
Primary	\$(8.42)	\$(4.07)
Fully Diluted	\$(8.42)	\$(4.07)
Common Shares:		
Full Diluted	169,574	163,679
Year-end	170,516	166,863

TESSCO TECHNOLOGIES, INC.

Earnings, 3 mos. to (Consol. - \$):	07/01/18	06/25/17
Total Revenues	150,919,400	140,010,800
Cost & expenses	149,182,600	138,725,500
Operating income	1,736,800	1,285,300
Net before taxes	1,562,400	1,216,700
Income taxes	404,000	533,800
Net income	1,158,400	682,900
Earnings common share		
Primary	\$0.14	\$0.08
Fully Diluted	\$0.13	\$0.08
Common Shares:		
Full Diluted	8,604,820	8,402,931
Year-end	8,422,082	8,357,501
Consolidated Balance Sheet Items, as of (\$):		
Assets:	2018	
Cash & equivalents	9,000	
Inventories	86,367,200	
Current assets	184,777,400	
Net property & equip.	13,679,200	
Total assets	219,768,400	
Liabilities:		
Current liabilities	110,427,300	
Stockholders' equity	107,865,300	
Net current assets	74,350,100	

TETRA TECH INC

Earnings, 9 mos. to (Consol. - \$000):	07/01/18	07/02/17
Cost & expenses	1,501,191	1,371,288
Operating income	146,801	128,695
Interest expense	11,597	8,802
Net before taxes	135,204	119,893
Income taxes	27,060	36,462
Net income	108,144	83,431
Earnings common share		
Primary	\$1.94	\$1.46
Fully Diluted	\$1.19	\$1.44
Common Shares:		
Full Diluted	56,681	58,116
Year-end	55,332	56,762

TETRAPHASE PHARMACEUTICALS, INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):	2018	2017
Total Revenues	13,469	3,071
Cost & expenses	45,366	64,658
Operating income	(31,897)	(61,587)
Other income (expense), net	778	318
Net income	(31,119)	(61,269)
Earnings common share		
Primary	\$(0.60)	\$(1.63)
Fully Diluted	\$(0.60)	\$(1.63)
Common Shares:		
Full Diluted	51,721	37,686
Year-end	52,851	

TEXAS INSTRUMENTS INC.

Earnings, 6 mos. to Jun 30 (Consol. - \$Millions):	2018	2017
Total Revenues	7,806	7,095
Cost & expenses	4,546	4,363
Operating income	3,260	2,732
Other income (expense), net	52	47
Net before taxes	3,259	2,741
Income taxes	488	688

Net income	2,771	2,053
Balance for common	2,749	2,033
Earnings common share		
Primary	\$2.80	\$2.04
Fully Diluted	\$2.75	\$2.00
Common Shares:		
Full Diluted	1,001	1,017
Year-end	974	992

TEXAS ROADHOUSE INC

Earnings, 6 mos. to (Consol. - \$000):	06/26/18	06/27/17
Total Revenues	1,256,942	1,133,948
Cost & expenses	1,088,155	985,010
Deprec., depl. & amort.	49,649	45,702
Operating income	119,138	103,236
Other income (expense), net	769	790
Net before taxes	119,265	103,315
Income taxes	16,923	28,113
Net income	102,342	75,202
Earnings common share		
Primary	\$1.38	\$1.01
Fully Diluted	\$1.37	\$1.01
Common Shares:		
Full Diluted	71,853	71,398
Year-end	71,474	71,027

THE TRADE DESK INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):	2018	2017
Total Revenues	198,001	126,156
Cost & expenses	161,909	104,526
Operating income	36,092	21,630
Foreign currency	(1,640)	(1,318)
Net before taxes	34,328	19,535
Income taxes	5,915	(4,223)
Net income	28,413	23,758
Earnings common share		
Primary	\$0.68	\$0.60
Fully Diluted	\$0.63	\$0.54
Common Shares:		
Full Diluted	44,895	43,752
Year-end	42,854	40,589

THERAPEUTICSMD INC

Earnings, 6 mos. to Jun 30 (Consol. - \$):	2018	2017
Total Revenues	7,536,402	8,235,897
Cost & expenses	65,149,468	49,249,139
Operating income	(57,738,290)	(41,116,130)
Interest expense	531,382	
Other income (expense), net	648,795	275,022
Net income	(57,620,877)	(40,833,409)
Earnings common share		
Primary	\$(0.27)	\$(0.20)
Fully Diluted	\$(0.27)	\$(0.20)
Common Shares:		
Full Diluted	216,583,067	200,602,778
Year-end	216,834,059	204,027,142

TILE SHOP HOLDINGS INC

Earnings, 6 mos. to Jun 30 (Consol. - \$):	2018	2017
Net Sales	184,048,000	181,599,000
Cost & expenses	170,495,000	156,466,000
Operating income	13,553,000	25,133,000
Other income (expense), net	72,000	98,000
Net before taxes	12,474,000	24,298,000
Income taxes	3,505,000	8,566,000
Net income	8,969,000	15,732,000
Earnings common share		
Primary	\$0.17	\$0.31
Fully Diluted	\$0.17	\$0.30
Common Shares:		
Full Diluted	51,996,263	52,111,134
Year-end	52,508,090	

TILRAY INC

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2017	2016		2018	2017
Total revenues	20,538	12,644	Accounts payable	5,563	757
Cost of sales	9,161	9,974	Accrued expenses & other current liabilities	2,021	1,106
Gross margin	11,377	2,670	Accrued obligations under capital lease	379	...
Research & development	3,171	1,136	Current portion of long-term debt	9,432	...
Sales & marketing expenses	7,164	3,599	Privateer Holdings debt facilities	32,826	20,126
General & administrative expenses	8,540	4,984	Total current liabilities	50,221	21,989
Income (loss) from operations	(7,498)	(7,049)	Accrued obligations under capital lease	8,579	...
Foreign exchange gain (loss), net	1,363	186	Mortgage payable	...	8,909
Interest expense	1,686	1,019	Unamortized deferred financing costs	...	(333)
Other (expense)/income, net	12	(1)	Long-term debt, net	...	8,576
Income before income taxes - Canada	(7,411)	(7,883)	Total liabilities	58,800	30,565
Income before income taxes - other countries	(398)	...	Additional paid-in capital	31,736	31,589
Income (loss) before provision for income taxes	(7,809)	(7,883)	Accumulated other comprehensive income (loss)	3,866	3,584
Net income (loss)	(7,809)	(7,883)	Retained earnings (accumulated deficit)	(40,454)	(32,645)
Weighted average shares outstanding - basic	75,000	75,000	Total shareholders' (deficit) equity	(4,852)	2,528
Weighted average shares outstanding - diluted	75,000	75,000			
Net earnings (loss) per share - basic	\$(0.10)	\$(0.11)			
Net earnings (loss) per share - diluted	\$(0.10)	\$(0.11)			
Number of full time employees	313	...			
Number of part time employees	17	...			
Total number of employees	330	...			

□ As Is; □ As of June 4, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	2,323	7,531
Accounts receivable, gross	983	431
Allowance	...	8
Accounts receivable, net	983	423
Other receivables	1,131	...
Raw materials	163	78
Work-in-process - dry cannabis	1,396	774
Work-in-process - cannabis extracts	30	680
Finished goods - dry cannabis	3,501	2,249
Finished goods - cannabis extracts	2,158	252
Finished goods - accessories	173	70
Inventories	7,421	4,103
Prepaid expenses & other current assets	545	71
Total current assets	12,403	12,128
Land	2,547	1,975
Buildings & leasehold improvements	19,569	18,084
Laboratory & manufacturing equipment	2,815	2,224
Office & computer equipment	571	498
Assets under capital lease	9,191	...
Construction in progress	9,872	90
Property, plant & equipment, gross	44,565	22,871
Less: Accumulated depreciation	4,580	2,926
Property, plant & equipment, net	39,985	19,945
Intangible assets, net	934	822
Deposits & other assets	626	198
Total assets	53,948	33,093

	2018	2017
Accounts payable	5,563	757
Accrued expenses & other current liabilities	2,021	1,106
Accrued obligations under capital lease	379	...
Current portion of long-term debt	9,432	...
Privateer Holdings debt facilities	32,826	20,126
Total current liabilities	50,221	21,989
Accrued obligations under capital lease	8,579	...
Mortgage payable	...	8,909
Unamortized deferred financing costs	...	(333)
Long-term debt, net	...	8,576
Total liabilities	58,800	30,565
Additional paid-in capital	31,736	31,589
Accumulated other comprehensive income (loss)	3,866	3,584
Retained earnings (accumulated deficit)	(40,454)	(32,645)
Total shareholders' (deficit) equity	(4,852)	2,528

Recent Dividends:

1. Tilray Inc class 1 common.

No dividends paid.

2. Tilray Inc class 2 common.

No dividends paid.

Annual Dividends:

1. Tilray Inc class 1 common.

No dividends paid.

2. Tilray Inc class 2 common.

No dividends paid.

TILRAY INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	7,808	5,027
Cost & expenses	11,548	5,415
Operating income	(3,740)	(388)
Interest expense	416	496
Other income (expense), net	121	(14)
Foreign currency	(1,146)	219
Net income	(5,181)	(679)
Earnings common share		
Primary	\$(0.07)	\$(0.01)
Fully Diluted	\$(0.07)	\$(0.01)
Common Shares:		
Full Diluted	75,000	75,000
Year-end	75,000	...

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	12,140	...
Inventories	7,537	...
Current assets	53,808	...
Net property & equip.	50,984	...
Total assets	106,646	...
Liabilities:		
Current liabilities	55,625	...
Long-term debt	8,376	...
Stockholders' equity	42,645	...
Net current assets	(1,817)	...

TIVITY HEALTH INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	301,795,000	279,884,000
Cost & expenses	233,757,000	218,693,000
Operating income	65,781,000	59,615,000
Net before taxes	58,845,000	51,651,000
Income taxes	14,826,000	18,931,000
Income contin. oper.	44,019,000	32,720,000
Net income	44,920,000	28,827,000
Earnings common share		
Primary	\$1.13	\$0.74
Fully Diluted	\$1.03	\$0.70
Common Shares:		
Full Diluted	43,437,000	41,456,000
Year-end	39,963,683	39,350,726

TIVO CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	362,697	414,322
Cost & expenses	287,365	316,692
Operating income	(17,803)	3,398
Interest expense	23,805	20,837
Other income (expense), net	...	(13,943)
Gains or losses	6,152	(1,335)
Net before taxes	(33,346)	(29,957)
Income taxes	8,536	9,475
Income contin. oper.	(41,882)	...
Net income	(38,287)	(39,432)
Earnings common share		
Primary	\$(0.31)	\$(0.33)
Fully Diluted	\$(0.31)	\$(0.33)
Common Shares:		
Full Diluted	122,399	119,515
Year-end	122,971	122,279

TOCAGEN INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	28,191	17,226
Operating income	(28,173)	(17,205)
Interest income	646	140
Interest expense	1,442	1,111
Other income (expense), net	...	37
Net income	(28,969)	(18,139)
Earnings common share		
Primary	\$(1.45)	\$(1.95)
Fully Diluted	\$(1.45)	\$(1.95)
Common Shares:		
Full Diluted	19,914	9,308
Year-end	19,951	19,809

TONIX PHARMACEUTICALS HOLDING CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	13,131,000	9,913,000
Operating income	(13,131,000)	(9,913,000)
Net income	(13,022,000)	(9,844,000)
Earnings common share		
Primary	\$(1.60)	\$(1.74)
Fully Diluted	\$(1.60)	\$(1.74)
Common Shares:		
Full Diluted	8,122,499	5,666,457
Year-end	8,819,887	7,490,151

TOWN SPORTS INTERNATIONAL HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	219,440	199,073
Cost & expenses	192,657	175,348
Deprec., depl. & amort.	18,768	20,325
Operating income	8,015	3,400
Interest income	81	...
Interest expense	6,506	6,263
Other income (expense), net	183	140
Net before taxes	1,773	(2,723)
Income taxes	43	622
Net income	1,730	(3,345)
Earnings common share		
Primary	\$0.07	\$(0.13)
Fully Diluted	\$0.07	\$(0.13)
Common Shares:		
Full Diluted	26,516	25,141
Year-end	27,191	26,687

TPI COMPOSITES INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Net Sales	484,591	448,197
Cost & expenses	463,434	417,412
Operating income	21,157	30,785
Interest income	84	30
Interest expense	6,053	5,961
Other income (expense), net	(1,905)	578
Gains or losses	(4,776)	(2,614)
Net before taxes	8,507	22,818
Income taxes	3,912	8,028
Net income	4,595	14,790
Earnings common share		
Primary	\$0.13	\$0.44

Fully Diluted	\$0.13	\$0.44
Common Shares:		
Full Diluted	35,766	33,827
Year-end	34,229	

TRACON PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Cost & expenses	20,926	14,507
Operating income	(17,926)	(13,250)
Interest expense	192	458
Other income (expense), net	(5)	(5)
Net income	(18,118)	(13,713)
Earnings common share		
Primary	\$(0.76)	\$(0.84)
Fully Diluted	\$(0.76)	\$(0.84)
Common Shares:		
Full Diluted	23,992	16,409
Year-end	29,830	16,656

TRACTOR SUPPLY CO.**Earnings, 6 mos. to (Consol. – \$000):**

	06/30/18	07/01/17
Cost & expenses	3,441,546	3,146,779
Deprec., depl. & amort.	86,397	80,774
Operating income	368,207	354,287
Net before taxes	358,761	348,418
Income taxes	80,039	127,458
Net income	278,722	220,960
Earnings common share		
Primary	\$2.26	\$1.71
Fully Diluted	\$2.25	\$1.70
Common Shares:		
Full Diluted	123,975	129,906
Year-end	121,811	127,231

TRANSACT TECHNOLOGIES INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Net Sales	26,994	27,593
Cost & expenses	24,520	24,871
Operating income	2,474	2,722
Other income (expense), net	(87)	(8)
Net before taxes	2,373	2,698
Income taxes	483	888
Net income	1,890	1,810
Earnings common share		
Primary	\$0.25	\$0.24
Fully Diluted	\$0.24	\$0.24
Common Shares:		
Full Diluted	7,782	7,469
Year-end	7,378	7,364

TRANSCAT INC**Earnings, 3 mos. to (Consol. – \$):**

	06/30/18	06/24/17
Total Revenues	36,658,000	36,279,000
Cost & expenses	34,633,000	34,868,000
Operating income	2,025,000	1,411,000
Net before taxes	1,800,000	1,139,000
Income taxes	372,000	283,000
Net income	1,428,000	856,000
Earnings common share		
Primary	\$0.20	\$0.12
Fully Diluted	\$0.19	\$0.12
Common Shares:		
Full Diluted	7,438,000	7,200,000
Year-end	7,198,513	7,121,748

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	486,000
Inventories	13,310,000
Current assets	38,016,000
Net property & equip.	17,691,000
Total assets	94,510,000
Liabilities:	
Current liabilities	18,614,000
Long-term debt	19,402,000
Stockholders' equity	52,871,000
Net current assets	19,402,000

TRANSLATE BIO INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Cost & expenses	51,450	33,825
Operating income	(51,450)	(33,825)
Interest income	181	158
Other income (expense), net	(45)	60
Net before taxes	(51,314)	(33,607)
Income taxes	(2,602)	(1,721)
Net income	(48,712)	(31,886)
Balance for common	(48,068)	(31,526)
Earnings common share		
Primary	\$(5.26)	\$(4.13)
Fully Diluted	\$(5.26)	\$(4.13)
Common Shares:		
Full Diluted	9,140	7,632
Year-end	9,632	

TRAVELCENTERS OF AMERICA LLC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Total Revenues	3,425,372	2,891,431
Cost & expenses	3,408,933	2,870,736
Deprec., depl. & amort.	57,466	60,449
Operating income	(41,027)	(39,754)
Interest expense	14,448	15,222
Other income (expense), net	(2,193)	1,000
Net before taxes	(57,668)	(53,976)
Income taxes	(13,666)	(21,662)
Net income	(44,002)	(32,314)
Balance for common	(44,090)	(32,384)
Earnings common share		
Primary	\$(1.10)	\$(0.82)
Fully Diluted	\$(1.10)	\$(0.82)
Common Shares:		
Full Diluted	38,002	37,438
Year-end	39,771	

TRAVELZOO**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2018	2017
Total Revenues	58,959,000	54,840,000
Cost & expenses	54,224,000	51,392,000
Operating income	4,735,000	3,448,000
Other income (expense), net	191,000	25,000
Net before taxes	4,926,000	3,473,000
Income taxes	1,947,000	1,980,000
Income contin. oper.		1,493,000
Net income	2,979,000	3,431,000
Earnings common share		
Primary	\$0.24	\$0.26
Fully Diluted	\$0.24	\$0.26
Common Shares:		
Full Diluted	12,622,000	13,229,000
Year-end	12,462,000	

TREVENA INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2018	2017
Cost & expenses	20,788,000	40,859,000
Operating income	(18,288,000)	(40,859,000)
Interest income	425,000	337,000
Interest expense	1,275,000	1,309,000
Other income (expense), net	1,432,000	684,000
Gains or losses	116,000	1,000
Foreign currency	10,000	
Net before taxes	(17,580,000)	
Net income	(18,325,000)	(41,146,000)
Balance for common	(18,325,000)	(41,146,000)
Earnings common share		
Primary	\$(0.27)	\$(0.71)
Fully Diluted	\$(0.27)	\$(0.71)
Common Shares:		
Full Diluted	67,127,711	57,642,379
Year-end	73,507,985	59,456,364

TRICIDA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Cost & expenses	45,377	15,591
Operating income	(45,377)	(15,591)
Interest expense	1,229	4
Other income (expense), net	740	5,660
Net income	(45,866)	(9,935)
Earnings common share		
Primary	\$(19.91)	\$(4.75)

Fully Diluted	\$(19.91)	\$(4.75)
Common Shares:		
Full Diluted	2,304	2,093
Year-end	2,454	

TRIMAS CORP (NEW)**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Net Sales	442,010	413,200
Cost & expenses	375,280	370,870
Operating income	66,730	42,330
Interest expense	7,180	6,970
Other income (expense), net	(2,740)	(920)
Net before taxes	56,810	34,440
Income taxes	12,890	12,600
Net income	43,920	21,840
Earnings common share		
Primary	\$0.96	\$0.48
Fully Diluted	\$0.95	\$0.48
Common Shares:		
Full Diluted	46,215	45,916
Year-end	45,870	45,712

TRIMBLE INC**Earnings, 6 mos. to (Consol. – \$000):**

	06/29/18	06/30/17
Total Revenues	1,527,700	1,270,500
Cost & expenses	1,337,900	1,127,200
Operating income	153,700	113,700
Other income (expense), net	19,600	24,700
Foreign currency	700	1,400
Net before taxes	145,900	127,700
Income taxes	23,100	30,600
Net income	122,800	97,100
Earnings common share		
Primary	\$0.49	\$0.38
Fully Diluted	\$0.49	\$0.38
Common Shares:		
Full Diluted	252,700	256,500
Year-end	249,900	

TRIPADVISOR INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Total Revenues	811,000	796,000
Cost & expenses	683,000	669,000
Operating income	71,000	73,000
Interest expense	6,000	7,000
Net before taxes	63,000	69,000
Income taxes	27,000	29,000
Net income	36,000	40,000
Earnings common share		
Primary	\$0.26	\$0.28
Fully Diluted	\$0.26	\$0.28
Common Shares:		
Full Diluted	140,000	143,000
Year-end	137,521	138,736

TRIUMPH BANCORP INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2018	2017
Cost & expenses	91,401	78,755
Operating income	31,605	31,580
Net before taxes	31,605	31,580
Income taxes	7,152	11,447
Net income	24,453	20,133
Balance for common	24,070	19,748
Earnings common share		
Primary	\$1.04	\$1.10
Fully Diluted	\$1.02	\$1.07
Common Shares:		
Full Diluted	23,950	18,900
Year-end	26,261	18,133

TRONC INC**Earnings, 6 mos. to (Consol. – \$000):**

	07/01/18	06/25/17
Total Revenues	491,576	483,410
Cost & expenses	498,623	454,975
Operating income	(33,006)	4,753
Other income (expense), net	(1,757)	(7,085)
Net before taxes	(46,739)	(15,132)
Income taxes	(2,926)	(2,280)
Income contin. oper.	(43,813)	(12,852)

Net income	250,932	3,852
Earnings common share		
Primary	\$7.14	\$0.11
Fully Diluted	\$7.14	\$0.11
Common Shares:		
Full Diluted	35,045	34,566
Year-end	37,551	

TRUECAR INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	168,911	157,576
Cost & expenses	173,899	159,438
Deprec., depl. & amort.	10,816	11,752
Operating income	(15,804)	(13,614)
Interest income	1,354	382
Interest expense	1,323	1,301
Net before taxes	(15,773)	(14,533)
Income taxes	(96)	322
Net income	(15,677)	(14,855)
Earnings common share		
Primary	\$(0.16)	\$(0.16)
Fully Diluted	\$(0.16)	\$(0.16)
Common Shares:		
Full Diluted	100,862	90,283
Year-end	101,606	97,575

TRUPANION INC

Acquisition Completed On Aug. 9, 2018, Co. purchased the fee simple title to the parcels of real estate, buildings, improvements, fixtures and other rights associated with the property on which Co.'s current home office building is located, for \$55,000,000 in cash and 303,030 shares of Co.'s common stock to Benaroya Capital Company, L.L.C. at the Offering price of \$33.00 per share.

TRUPANION INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	143,152	113,004
Cost & expenses	144,905	114,941
Operating income	(1,753)	(1,937)
Interest expense	551	246
Other income (expense), net	443	1,140
Net before taxes	(1,861)	(1,043)
Income taxes	(4)	28
Net income	(1,857)	(1,071)
Earnings common share		
Primary	\$(0.06)	\$(0.04)
Fully Diluted	\$(0.06)	\$(0.04)
Common Shares:		
Full Diluted	30,485	29,384
Year-end	32,719	29,995

TTEC HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Total Revenues	725,102	691,706
Cost & expenses	651,923	612,869
Operating income	38,444	48,079
Interest income	2,539	1,121
Interest expense	14,224	5,230
Other income (expense), net	(9,775)	2,157
Gains or losses	(2,000)	(3,178)
Net before taxes	14,984	42,949
Income taxes	2,755	6,988
Net income	12,229	35,961
Earnings common share		
Primary	\$0.22	\$0.74
Fully Diluted	\$0.22	\$0.73
Common Shares:		
Full Diluted	46,424	46,224
Year-end	46,034	45,694

TTM TECHNOLOGIES INC

Earnings, 6 mos. to (Consol. – \$):

	07/02/18	07/03/17
Net Sales	1,380,469,000	1,252,429,000
Cost & expenses	1,293,384,000	1,142,981,000
Operating income	61,735,000	97,626,000
Other income (expense), net	5,071,000	(7,535,000)
Net before taxes	32,606,000	63,573,000
Income taxes	(61,495,000)	9,697,000
Net income	94,101,000	53,876,000
Earnings common share		

Primary	\$0.91	\$0.53
Fully Diluted	\$0.75	\$0.46
Common Shares:		
Full Diluted	134,088,000	132,073,000
Year-end	103,674,000	101,814,000

TUESDAY MORNING CORP**Annual Report**

Consolidated Income Statement, Years Ended Jun. 30

(\$000):

	2018	2017	2016
Net sales	1,006,332	966,665	956,396
Cost of sales	665,358	645,920	614,594
Gross profit	340,974	320,745	341,802
Selling, general & administrative expenses	361,924	353,025	339,398
Operating income (loss)	(20,950)	(32,280)	2,404
Interest expense	2,061	1,485	1,068
Other income (expense), net	934	1,420	2,640
Income (loss) before income taxes ..	(22,077)	(32,345)	3,976
Current expense (benefit) for federal income tax ...			(147)
Current expense (benefit) for state & local income tax ...	426	166	399
Total current expense (benefit) for income tax	426	166	252
Deferred expense (benefit) for federal income tax ...	(568)	27	186
Deferred expense (benefit) for state & local income tax ...	3	4	(175)
Total deferred expense (benefit) for income tax	(565)	31	11
Income tax expense (benefit)	(139)	197	263
Net income (loss)	(21,938)	(32,542)	3,713
Less: income to participating securities			40
Net earnings (loss) available to common shareholder	(21,938)	(32,542)	3,673
Weighted average shares outstanding - basic	44,282	43,943	43,705
Weighted average shares outstanding - diluted	44,282	43,943	43,736
Year end shares outstanding	45,865	45,121	44,561
Net income (loss) per share - basic	\$(0.50)	\$(0.74)	\$0.08
Net income (loss) per share - diluted	\$(0.50)	\$(0.74)	\$0.08
Number of full time employees	1,770	1,834	1,934
Number of part time employees	7,292	7,044	7,133
Total number of employees	9,062		
Number of common stockholders	209	220	249

□ As is; □ Approximately; □ As of August 17, 2018; □ As of August 22, 2017; □ As of August 17, 2016

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2018	2017
Cash & cash equivalents	9,510	6,263
Inventories	234,365	221,906
Prepaid expenses	6,301	6,367
Other current assets	1,206	1,982
Total current assets	251,382	236,518

Land	6,628	6,628
Buildings & building improvements	41,479	40,879
Furniture & fixtures	61,963	56,877
Equipment	66,268	65,884
Software	43,664	40,750
Leasehold improvements	57,371	44,838
Assets under capital lease	788	804
Property & equipment, gross	278,161	256,660
Less accumulated depreciation	157,044	138,263
Property & equipment, net	121,117	118,397
Deferred financing costs	671	986
Other assets	3,086	2,252
Total assets	376,256	358,153
Accounts payable	88,912	67,326
Accrued sales tax	3,467	3,543
Accrued self-insurance reserves	12,823	12,192
Accrued wages & benefits	6,006	5,710
Accrued property taxes	1,612	1,524
Accrued freight & distribution expense	4,807	4,490
Accrued capital expenditures	1,585	4,780
Accrued utilities expense	1,234	1,282
Accrued advertising	1,102	525
Deferred rent	2,028	1,408
Accrued cease use liabilities	77	991
Other accrued liabilities	7,024	7,815
Income taxes payable	66	11
Total current liabilities	130,743	111,597
Borrowing under revolving credit facility	38,480	30,500
Deferred rent	22,883	13,883
Asset retirement obligation - non current	3,100	2,307
Other liabilities-non current	796	1,027
Total liabilities	196,002	159,314
Common stock	469	469
Additional paid-in capital	237,957	234,604
Retained earnings (accumulated deficit)	(51,360)	(29,422)
Treasury stock, at cost	6,812	6,812
Total shareholders' equity (deficit)	180,254	198,839

Recent Dividends:**1. Tuesday Morning Corp common.**

No dividends paid.

Annual Dividends:**1. Tuesday Morning Corp common.**

No dividends paid.

TURTLE BEACH CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2018	2017
Total Revenues	101,691,000	33,464,000
Cost & expenses	89,636,000	46,521,000
Operating income	12,055,000	(13,057,000)
Other income (expense), net	(165,000)	265,000
Net before taxes	8,627,000	(16,467,000)
Income taxes	364,000	520,000
Net income	8,263,000	(16,987,000)
Earnings common share		
Primary	\$0.64	\$(1.38)
Fully Diluted	\$0.56	\$(1.38)
Common Shares:		
Full Diluted	14,816,000	12,325,000
Year-end	13,794,251	12,346,502

TWENTY-FIRST CENTURY FOX INC**Annual Report**

Consolidated Income Statement, Years Ended Jun. 30

(\$000):

	2018	2017	2016
Revenues	30,400,000	28,500,000	27,326,000

Other income (expense), net	1,179,000	307,000
Net before taxes	43,080,000	9,885,000
Income taxes	8,406,000	(1,884,000)
Net income	34,674,000	11,769,000
Earnings common share		
Primary	\$1.14	\$0.40
Fully Diluted	\$1.11	\$0.38
Common Shares:		
Full Diluted	31,164,000	30,639,000
Year-end	30,629,308	

ULTRA CLEAN HOLDINGS INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/29/18	06/30/17
Net Sales	605,055	432,855
Cost & expenses	555,483	388,677
Operating income	49,572	44,178
Net before taxes	49,089	42,120
Income taxes	5,388	7,600
Net income	43,701	34,520
Earnings common share		
Primary	\$1.16	\$1.04
Fully Diluted	\$1.14	\$1.01
Common Shares:		
Full Diluted	38,418	34,017
Year-end	38,927	33,554

ULTRAGENYX PHARMACEUTICAL INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	23,471	
Cost & expenses	214,858	148,395
Operating income	(191,387)	(148,395)
Interest income	4,185	2,233
Other income (expense), net	(5,454)	4,995
Gains or losses	170,322	
Net before taxes	(22,334)	(141,167)
Income taxes	141	14
Net income	(22,475)	(141,181)
Earnings common share		
Primary	\$(0.46)	\$(3.35)
Fully Diluted	\$(0.46)	\$(3.35)
Common Shares:		
Full Diluted	49,047	42,096
Year-end	50,116	42,428

ULTRALIFE CORP**Earnings, 6 mos. to (Consol. - \$000):**

	07/01/18	07/02/17
Total Revenues	45,933	41,974
Cost & expenses	41,945	38,811
Operating income	3,988	3,163
Other income (expense), net	6	(33)
Net before taxes	3,940	3,021
Income taxes	133	266
Net income	3,807	2,755
Earnings common share		
Primary	\$0.24	\$0.18
Fully Diluted	\$0.23	\$0.17
Common Shares:		
Full Diluted	16,354	15,752
Year-end	15,942	15,552

UNITED NATURAL FOODS INC.

Merger Development On July 25, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") pursuant to which it has agreed to acquire SUPERVALU INC. ("SUPERVALU"). Under the terms of the Merger Agreement, a wholly owned subsidiary of Co. will merge with and into SUPERVALU, with SUPERVALU surviving the merger as a wholly owned subsidiary of United Natural (the "Merger"). Pursuant to the Merger Agreement, each share of SUPERVALU common stock outstanding at the effective time of the Merger will be converted into the right to receive a cash payment equal to \$32.50 per share, without interest (the "Merger Consideration"). SUPERVALU options, whether vested or unvested, that are unexercised as of immediately prior to the effective time of the Merger will be converted into Co. options in accordance with the adjustment provisions of the SUPERVALU stock plan pursuant to which the SUPERVALU options were granted (based upon the Merger Consideration), with such option having the same terms and conditions as the underlying award. Each other outstanding SUPERVALU equity award (consisting of restricted shares, restricted stock units, deferred share units and performance share units) will be converted into

a cash-settled, time-vesting award equal to the Merger Consideration times the number of shares of SUPERVALU common stock subject to the applicable award, with such payment to be made in accordance with the terms and conditions of the underlying award, including the vesting provisions. Performance share units shall no longer be subject to performance objectives and shall be converted based on the "change of control" provisions set forth in the applicable SUPERVALU performance share unit award agreement. The aggregate purchase price for the transaction is approximately \$1,350,000,000. The transaction has been approved by the boards of directors of both companies and is subject to antitrust approvals, SUPERVALU shareholder approval and other customary closing conditions, and is expected to close during the fourth quarter of calendar year 2018.

UNITED STATES LIME & MINERALS INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	35,287	36,153
Cost & expenses	30,751	30,335
Operating income	4,536	5,818
Interest expense	62	59
Other income (expense), net	353	179
Net before taxes	4,827	5,938
Income taxes	565	1,318
Net income	4,262	4,620
Earnings common share		
Primary	\$0.76	\$0.83
Fully Diluted	\$0.76	\$0.83
Common Shares:		
Full Diluted	5,598	5,585
Year-end	5,593	5,579

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	83,265	12,599
Inventories	12,599	117,517
Current assets	117,517	112,830
Net property & equip.	112,830	231,033
Total assets	231,033	
Liabilities:		
Current liabilities	7,696	209,053
Stockholders' equity	209,053	109,821
Net current assets	109,821	

UNITED STATES LIME & MINERALS INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	74,529	72,671
Cost & expenses	62,921	60,533
Operating income	11,608	12,138
Interest expense	125	118
Other income (expense), net	812	404
Net before taxes	12,295	12,424
Income taxes	1,395	2,526
Net income	10,900	9,898
Earnings common share		
Primary	\$1.95	\$1.77
Fully Diluted	\$1.95	\$1.77
Common Shares:		
Full Diluted	5,601	5,586
Year-end	5,598	5,577

UNITED THERAPEUTICS CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	833,700,000	815,100,000
Cost & expenses	309,400,000	463,000,000
Operating income	524,300,000	352,100,000
Interest expense	5,500,000	2,200,000
Other income (expense), net	8,100,000	(42,100,000)
Net before taxes	526,900,000	307,800,000
Income taxes	109,500,000	185,200,000
Net income	417,400,000	122,600,000
Earnings common share		
Primary	\$9.62	\$2.74
Fully Diluted	\$9.51	\$2.68
Common Shares:		
Full Diluted	43,900,000	45,700,000
Year-end	43,562,343	43,436,076

UNITED-GUARDIAN, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Net Sales	7,478,730	6,561,139
Cost & expenses	4,312,587	4,161,298

Operating income	3,166,143	2,399,841
Gains or losses	51,592	121,562
Invest. income	(113,276)	4,106
Net before taxes	3,104,459	2,525,509
Income taxes	651,935	786,925
Net income	2,452,524	1,738,584
Earnings common share		
Primary	\$0.53	\$0.38
Fully Diluted	\$0.53	\$0.38
Common Shares:		
Full Diluted	4,594,319	4,594,319
Year-end	4,594,319	4,594,319

UNITI GROUP INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	494,244	424,486
Cost & expenses	270,785	257,290
Operating income	(6,104)	(36,764)
Net before taxes	(6,104)	(36,764)
Income taxes	(3,742)	(304)
Net income	(2,362)	(36,460)
Balance for common		
	(6,432)	(40,030)
Earnings common share		
Primary	\$(0.04)	\$(0.25)
Fully Diluted	\$(0.04)	\$(0.25)
Common Shares:		
Full Diluted	174,951	162,460
Year-end	175,029	174,813

UNITY BIOTECHNOLOGY INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	37,280	20,738
Operating income	(37,280)	(20,738)
Interest income	1,178	386
Other income (expense), net	(33)	(10)
Net income	(36,135)	(20,362)
Earnings common share		
Primary	\$(2.41)	\$(6.53)
Fully Diluted	\$(2.41)	\$(6.53)
Common Shares:		
Full Diluted	15,003	3,117
Year-end	42,315	

UNIVERSAL DISPLAY CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	99,721,000	158,079,000
Cost & expenses	73,305,000	74,515,000
Operating income	15,430,000	72,577,000
Other income (expense), net	(59,000)	(13,000)
Net before taxes	18,408,000	74,031,000
Income taxes	1,635,000	16,479,000
Net income	16,773,000	57,552,000
Balance for common		
	16,556,000	56,580,000
Earnings common share		
Primary	\$0.35	\$1.21
Fully Diluted	\$0.35	\$1.21
Common Shares:		
Full Diluted	46,873,109	46,781,120
Year-end	47,289,059	47,086,629

UNIVERSAL ELECTRONICS INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Net Sales	327,221,000	338,986,000
Cost & expenses	336,187,000	332,048,000
Operating income	(8,966,000)	6,938,000
Other income (expense), net	37,000	(31,000)
Gains or losses	35,272,000	(28,000)
Net before taxes	23,994,000	5,924,000
Income taxes	1,922,000	1,121,000
Net income	22,072,000	4,803,000
Earnings common share		
Primary	\$1.57	\$0.33
Fully Diluted	\$1.55	\$0.33
Common Shares:		
Full Diluted	14,195,000	14,700,000
Year-end	13,933,694	14,399,509

UNIVERSAL FOREST PRODUCTS INC.**Earnings, 6 mos. to (Consol. - \$):**

	06/30/18	07/01/17
Net Sales	2,288,297,000	918,505,000
Cost & expenses	2,183,462,000	830,785,000
Operating income	104,835,000	87,720,000
Interest expense	4,025,000	3,343,000
Other income (expense), net		26,000
Net before taxes	101,708,000	84,814,000
Income taxes	22,994,000	28,605,000
Net income	78,714,000	56,209,000
Earnings common share		
Primary	\$1.24	\$0.89
Fully Diluted	\$1.24	\$0.89
Common Shares:		
Full Diluted	60,461,000	60,474,000
Year-end	61,632,401	61,265,325

UNIVERSAL HOSPITAL SERVICES, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	283,062,000	258,863,000
Cost & expenses	225,704,000	235,655,000
Operating income	57,358,000	23,208,000
Net before taxes	30,370,000	(3,686,000)
Income taxes	631,000	497,000
Net income	29,739,000	(4,183,000)
Earnings common share		
Common Shares:		
Year-end	1,000	1,000

UNIVERSAL LOGISTICS HOLDINGS INC

Acquisition Completed On Aug. 10, 2018, Co.'s wholly-owned subsidiary, Mason Dixon Intermodal, Inc., d/b/a Universal Intermodal Services, Inc. ("Universal Intermodal"), acquired all the issued and outstanding shares of capital stock of Southern Counties Express, Inc. and Aquarius Financial, Inc. (collectively, "Southern Counties"), both based in Rancho Dominguez, CA. Southern Counties provides harbor drayage, transloading, warehousing and project cargo services to the Ports of Los Angeles and Long Beach, from The Brian and Rocio Griley Family Trust and Donald Griley Irrevocable Trust for \$65,000,000 on a cash-free, debt-free basis and is subject to customary post-closing adjustments. In addition, upon the closing of the acquisition, Universal Intermodal made an additional cash payment of approximately \$682,000 as reimbursement for certain prepaid expenses of Southern Counties, for a total purchase price of approximately \$65,682,000.

UNIVERSAL LOGISTICS HOLDINGS INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/30/18	07/01/17
Total Revenues	701,038	589,641
Cost & expenses	632,218	552,187
Deprec., depl. & amort.	25,464	21,868
Operating income	43,356	15,586
Other income (expense), net	(59)	532
Net before taxes	37,790	11,401
Income taxes	9,687	4,344
Net income	28,103	7,057
Earnings common share		
Primary	\$0.99	\$0.25
Fully Diluted	\$0.99	\$0.25
Common Shares:		
Full Diluted	28,398	28,439
Year-end	28,395	28,443

UNIVERSAL STAINLESS & ALLOY PRODUCTS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	129,808	101,482
Cost & expenses	119,897	99,299
Operating income	9,911	2,183
Other income (expense), net	642	20
Net before taxes	8,079	116
Income taxes	1,916	107
Net income	6,163	9
Earnings common share		
Primary	\$0.82	\$0.79
Fully Diluted	\$0.79	\$0.79
Common Shares:		
Full Diluted	7,784	7,333
Year-end	8,687	7,521

UNUM THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	3,886	3,906
Cost & expenses	20,311	16,008
Operating income	(16,425)	(12,102)
Interest expense	340	187
Other income (expense), net	327	113
Net income	(15,758)	(11,802)
Balance for common	(15,774)	(11,835)
Earnings common share		
Primary	\$(0.80)	\$(1.16)
Fully Diluted	\$(0.80)	\$(1.16)
Common Shares:		
Full Diluted	19,733	10,190
Year-end	29,867	

UPLAND SOFTWARE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	67,561	44,033
Cost & expenses	62,728	47,989
Deprec., depl. & amort.	5,983	2,463
Operating income	(1,150)	(6,419)
Interest expense	5,637	2,095
Other income (expense), net	(221)	(1,764)
Net before taxes	(7,008)	(10,278)
Income taxes	1,383	1,147
Net income	(8,391)	(11,425)
Earnings common share		
Primary	\$(0.42)	\$(0.66)
Fully Diluted	\$(0.42)	\$(0.66)
Common Shares:		
Full Diluted	19,830	17,375
Year-end	20,768	20,599

US ECOLOGY, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	256,971	236,291
Cost & expenses	223,240	208,236
Operating income	33,731	28,055
Interest expense	63	31
Interest expense	5,716	12,604
Other income (expense), net	2,316	303
Foreign currency	(153)	246
Net before taxes	30,241	16,031
Income taxes	7,778	5,797
Net income	22,463	10,234
Earnings common share		
Primary	\$1.03	\$0.47
Fully Diluted	\$1.02	\$0.47
Common Shares:		
Full Diluted	21,991	21,874
Year-end	21,968	21,825

UTAH MEDICAL PRODUCTS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Net Sales	21,852,000	21,088,000
Cost & expenses	11,825,000	11,330,000
Operating income	10,027,000	9,758,000
Other income (expense), net	538,000	49,000
Net before taxes	10,565,000	9,807,000
Income taxes	2,165,000	2,402,000
Net income	8,400,000	7,405,000
Earnings common share		
Primary	\$2.25	\$1.99
Fully Diluted	\$2.24	\$1.98
Common Shares:		
Full Diluted	3,751,000	3,732,000
Year-end	3,732,000	3,718,000

VACCINEX INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	332	
Cost & expenses	12,598	9,575
Operating income	(12,266)	(9,575)
Interest expense	348	627
Other income (expense), net	(1,856)	(394)
Net income	(14,470)	(10,596)
Balance for common	(16,062)	(12,188)
Earnings common share		
Primary	\$(14.56)	\$(11.07)
Fully Diluted	\$(14.56)	\$(11.07)

	2018	2017
Common Shares:		
Full Diluted	1,103	1,101
Year-end	1,103	

VALERITAS HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	12,578,000	9,399,000
Cost & expenses	33,206,000	30,779,000
Operating income	(20,628,000)	(21,380,000)
Interest expense	1,878,000	2,472,000
Other income (expense), net	(28,000)	64,000
Net income	(22,534,000)	(23,788,000)
Balance for common	(23,634,000)	(24,385,000)
Earnings common share		
Primary	\$(1.85)	\$(5.44)
Fully Diluted	\$(1.85)	\$(5.44)
Common Shares:		
Full Diluted	12,792,578	4,479,565
Year-end	24,699,145	6,842,978

VAREX IMAGING CORP**Earnings, 9 mos. to (Consol. - \$000):**

	06/29/18	06/30/17
Total Revenues	568,600	482,400
Cost & expenses	530,500	425,300
Operating income	38,100	57,100
Other income (expense), net	3,800	5,100
Net before taxes	25,500	56,600
Income taxes	(2,400)	19,600
Net income	27,900	37,000
Earnings common share		
Primary	\$0.73	\$0.98
Fully Diluted	\$0.72	\$0.97
Common Shares:		
Full Diluted	38,300	37,900
Year-end	38,007	37,630

VARONIS SYSTEM INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	115,718	89,024
Cost & expenses	142,520	107,063
Operating income	(26,802)	(18,039)
Other income (expense), net	167	1,419
Net before taxes	(26,635)	(16,620)
Income taxes	1,094	780
Net income	(27,729)	(17,400)
Earnings common share		
Primary	\$(0.97)	\$(0.64)
Fully Diluted	\$(0.97)	\$(0.64)
Common Shares:		
Full Diluted	28,644	27,138
Year-end	29,218	

VERACYTE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	42,792	34,838
Cost & expenses	57,131	48,431
Operating income	(14,872)	(14,126)
Interest expense	929	1,608
Other income (expense), net	376	219
Net income	(15,425)	(15,515)
Earnings common share		
Primary	\$(0.45)	\$(0.46)
Fully Diluted	\$(0.45)	\$(0.46)
Common Shares:		
Full Diluted	34,321	33,849
Year-end	34,442	33,892

VERASTEM INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	10,000	
Cost & expenses	48,955	26,615
Operating income	(38,955)	(26,615)
Interest expense	534	295
Interest expense	996	121
Net income	(39,417)	(26,441)
Earnings common share		
Primary	\$(0.70)	\$(0.71)
Fully Diluted	\$(0.70)	\$(0.71)
Common Shares:		

Full Diluted	56,074	36,992	Net before taxes	(27,367)	(27,439)	Net before taxes	1,487,000	1,641,000
Year-end	73,580		Income taxes	12	3	Income taxes	158,000	417,000
VERISIGN INC			Net income	(27,379)	(27,442)	Income contin. oper.	1,329,000	1,224,000
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Balance for common	(27,379)	(31,912)	Income discont. oper.	23,000	3,000
	2018	2017	Earnings common share			Net income	1,352,000	1,227,000
Total Revenues	601,740	577,166	Primary	\$(1.69)	\$(5.82)	Earnings common share		
Cost & expenses	223,311	226,935	Fully Diluted	\$(1.69)	\$(5.82)	Primary	\$3.29	\$3.01
Operating income	378,429	350,231	Common Shares:			Fully Diluted	\$3.29	\$3.00
Interest expense	69,580	58,113	Full Diluted	16,193	5,484	Common Shares:		
Other income (expense), net	(5,607)	(858)	Year-end	18,317	14,956	Full Diluted	402,900	400,000
Gains or losses		10,607	VERMILLION INC			Year-end	403,100	402,400
Net before taxes	317,313	307,421	Earnings, 6 mos. to Jun 30 (Consol. – \$000):					
Income taxes	54,699	67,909		2018	2017			
Net income	262,614	239,512	Total Revenues	1,357	1,624	VIASAT INC		
Earnings common share			Cost & expenses	7,223	6,626	Earnings, 3 mos. to Jun 30 (Consol. – \$):		
Primary	\$2.49	\$2.35	Operating income	(5,866)	(5,002)		2018	2017
Fully Diluted	\$2.13	\$1.93	Other income (expense), net	(14)	(9)	Total Revenues	438,869,000	380,044,000
Common Shares:			Net income	(5,899)	(5,033)	Cost & expenses	490,895,000	394,734,000
Full Diluted	123,399	124,218	Earnings common share			Operating income	(54,479,000)	(17,950,000)
Year-end	122,189		Primary	\$(0.09)	\$(0.09)	Interest income	36,000	93,000
VERISK ANALYTICS INC			Fully Diluted	\$(0.09)	\$(0.09)	Interest expense	11,324,000	56,000
Earnings, 6 mos. to Jun 30 (Consol. – \$):			Common Shares:			Equity earnings	(1,065,000)	513,000
	2018	2017	Full Diluted	64,721	55,124	Net before taxes	(65,767,000)	(17,913,000)
Total Revenues	1,182,500,000	1,025,800,000	Year-end	75,274	56,164	Income taxes	(29,205,000)	(9,180,000)
Cost & expenses	628,500,000	531,300,000	VERRICA PHARMACEUTICALS INC			Net income	(35,497,000)	(9,246,000)
Operating income	406,800,000	382,700,000	Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Earnings common share		
Interest expense	64,800,000	56,900,000		2018	2017	Primary	\$(0.57)	\$(0.16)
Other income (expense), net	5,300,000	5,300,000	Cost & expenses	8,027	1,665	Fully Diluted	\$(0.57)	\$(0.16)
Net before taxes	347,300,000	331,100,000	Operating income	(8,027)	(1,665)	Common Shares:		
Income taxes	60,800,000	101,300,000	Interest income	194		Full Diluted	59,208,000	57,842,000
Net income	286,500,000	229,800,000	Net income	(7,833)	(1,665)	Year-end	59,527,520	58,011,009
Earnings common share			Earnings common share			Consolidated Balance Sheet Items, as of (\$):		
Primary	\$1.74	\$1.39	Primary	\$(1.82)	\$(0.58)	Assets:		2018
Fully Diluted	\$1.70	\$1.36	Fully Diluted	\$(1.82)	\$(0.58)	Cash & equivalents		54,789,000
Common Shares:			Common Shares:			Inventories		220,018,000
Full Diluted	168,821,869	169,232,579	Full Diluted	4,309	2,850	Current assets		613,869,000
Year-end	164,724,043	164,521,185	Year-end	25,696		Net property & equip.		2,037,228,000
VERITEX HOLDINGS INC			VERSARTIS INC			Total assets		3,544,268,000
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Liabilities:		
	2018	2017		2018	2017	Current liabilities		447,160,000
Cost & expenses	45,739	20,622	Cost & expenses	17,958	65,850	Long-term debt		1,072,901,000
Operating income	26,442	9,865	Operating income	(17,958)	(65,850)	Stockholders' equity		1,882,446,000
Net before taxes	26,442	9,865	Interest income	442	441	Net current assets		166,709,000
Income taxes	5,861	3,152	Other income (expense), net	(1,313)	(782)	VICOR CORP		
Net income	20,581	6,713	Net before taxes		(66,191)	Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
Earnings common share			Income taxes		128		2018	2017
Primary	\$0.85	\$0.44	Net income	(18,829)	(66,319)	Total Revenues	139,465	112,171
Fully Diluted	\$0.84	\$0.43	Earnings common share			Cost & expenses	127,463	114,087
Common Shares:			Primary	\$(0.52)	\$(1.89)	Operating income	12,002	(1,916)
Full Diluted	24,527	15,633	Fully Diluted	\$(0.52)	\$(1.89)	Other income (expense), net	330	628
Year-end	24,181	15,223	Common Shares:			Gains or losses	56	57
VERITEX HOLDINGS INC			Full Diluted	36,010	35,001	Net before taxes	12,388	(1,231)
Merger Development On July 23, 2018, Green Bancorp, Inc. ("Green"), the parent holding company of Green Bank, N.A. ("Green Bank"), Co., the parent holding company of Veritex Community Bank ("Veritex Bank"), and MustMS, Inc. ("Merger Sub"), a wholly-owned subsidiary of Co., entered into an Agreement and Plan of Reorganization (the "Agreement"), pursuant to which, subject to the terms and conditions of the Agreement, among other things, (i) Merger Sub will merge with and into Green (the "Merger"), with Green continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Co., (ii) immediately thereafter, Green (as the surviving corporation in the Merger) will merge with and into Co. (together with the Merger, the "Holdco Mergers"), with Co. being the surviving corporation and (iii) immediately thereafter, Green Bank will merge with and into Veritex Bank, with Veritex Bank continuing as the surviving entity (together with the Holdco Mergers, the "Merger Transactions"). Upon the consummation of the Merger, each share of common stock, par value \$0.01 per share, of Green ("Green Common Stock"), will be converted into the right to receive 0.79 shares of common stock (the "Exchange Ratio"), par value \$0.01 per share, of Co. ("Co. Common Stock").			Year-end	36,241	35,515	Income taxes	497	168
VERITONE INC			VERTEX PHARMACEUTICALS, INC.			Net income	11,891	(1,399)
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Earnings common share		
	2018	2017		2018	2017	Primary	\$0.30	\$(0.04)
Total Revenues	8,556	7,195	Total Revenues	1,392,956	1,258,853	Fully Diluted	\$0.29	\$(0.04)
Cost & expenses	36,239	21,674	Cost & expenses	1,091,177	935,304	Common Shares:		
Operating income	(27,683)	(14,479)	Operating income	301,779	323,549	Full Diluted	40,406	39,121
Other income (expense), net	(33)	(8,726)	Interest expense	21,203	31,429	Year-end	49,200	39,253
VERITONE INC			Other income (expense), net	150,657	(3,081)	VICTORY CAPITAL HOLDINGS INC (DE)		
Earnings, 6 mos. to Jun 30 (Consol. – \$000):			Net before taxes	431,233	289,039	Earnings, 6 mos. to Jun 30 (Consol. – \$000):		
	2018	2017	Income taxes	(2,318)	8,322		2018	2017
Total Revenues	8,556	7,195	Net income	433,551	280,717	Total Revenues	209,363	201,595
Cost & expenses	36,239	21,674	Balance for common	417,460	265,365	Cost & expenses	140,068	146,309
Operating income	(27,683)	(14,479)	Earnings common share			Operating income	56,952	39,001
Other income (expense), net	(33)	(8,726)	Primary	\$1.65	\$1.08	Other income (expense), net	(6,554)	(829)
VIACOM INC			Fully Diluted	\$1.61	\$1.06	Net before taxes	39,067	10,961
Earnings, 9 mos. to Jun 30 (Consol. – \$000):			Common Shares:			Income taxes	9,868	4,194
	2018	2017	Full Diluted	258,557	250,199	Net income	29,199	6,767
Total Revenues	9,458,000	9,944,000	Year-end	254,883	250,770	Earnings common share		
Cost & expenses	7,374,000	7,993,000	VIACOM INC			Primary	\$0.45	\$0.12
Operating income	1,925,000	1,784,000	Earnings, 9 mos. to Jun 30 (Consol. – \$000):			Fully Diluted	\$0.42	\$0.11
Other income (expense), net	(10,000)	41,000		2018	2017	Common Shares:		
Gains or losses		285,000	Total Revenues	9,458,000	9,944,000	Full Diluted	69,353	58,872
VIDEO DISPLAY CORP			Cost & expenses	7,374,000	7,993,000	Year-end	67,901	
Earnings, 3 mos. to May 31 (Consol. – \$000):			Operating income	1,925,000	1,784,000			
	2018	2017	Other income (expense), net	(10,000)	41,000			
Total Revenues	9,458,000	9,944,000	Gains or losses		285,000			
Cost & expenses	7,374,000	7,993,000						
Operating income	1,925,000	1,784,000						
Other income (expense), net	(10,000)	41,000						
Gains or losses		285,000						

	2018	2017
Net Sales	4,021	3,897
Cost & expenses	4,115	4,423
Operating income	(94)	(526)
Other income (expense), net	192	270
Gains or losses	(38)	1
Net before taxes	(259)	(259)
Income taxes	7	7
Net income	54	(266)

Earnings common share		
Primary	\$0.01	\$(0.05)
Fully Diluted	\$0.01	\$(0.05)
Common Shares:		
Full Diluted	6,073	5,891
Year-end	5,878	5,891

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	168	168
Inventories	4,457	4,457
Current assets	6,807	6,807
Net property & equip.	1,406	1,406
Total assets	8,587	8,587
Liabilities:		
Current liabilities	3,190	3,190
Long-term debt	9	9
Stockholders' equity	4,634	4,634
Net current assets	3,617	3,617

VIEWRAY INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	42,633,000	1,925,000
Cost & expenses	72,142,000	25,590,000
Operating income	(29,509,000)	(23,665,000)
Interest income	4,000	2,000
Interest expense	3,784,000	3,529,000
Other income (expense), net	6,485,000	(9,122,000)
Net income	(26,804,000)	(36,314,000)
Balance for common	(29,532,000)	(36,314,000)
Earnings common share		
Primary	\$(0.41)	\$(0.67)
Fully Diluted	\$(0.41)	\$(0.67)
Common Shares:		
Full Diluted	71,776,802	54,540,854
Year-end	75,188,832	

VIKING THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	11,730,000	9,951,405
Operating income	(11,730,000)	(9,951,405)
Other income (expense), net	1,398,000	848,374
Net income	(10,223,000)	(10,393,534)
Earnings common share		
Primary	\$(0.21)	\$(0.45)
Fully Diluted	\$(0.21)	\$(0.45)
Common Shares:		
Full Diluted	48,730,381	23,240,782
Year-end	60,652,794	27,697,284

VIPER ENERGY PARTNERS LP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	137,849	70,274
Cost & expenses	14,435	8,826
Operating income	98,629	43,929
Other income (expense), net	6,203	127
Net before taxes	99,482	
Income taxes	(71,878)	
Net income	171,360	42,801
Earnings common share		
Primary	\$1.52	\$0.44
Fully Diluted	\$1.52	\$0.44
Common Shares:		
Full Diluted	93,612	96,382
Year-end	113,889	97,764

VIRTU FINANCIAL INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	1,143,179,000	292,175,000
Cost & expenses	579,798,000	249,440,000
Operating income	518,160,000	29,074,000
Net before taxes	518,160,000	29,074,000

Income taxes	61,515,000	3,587,000
Net income	456,645,000	25,487,000
Earnings common share		
Primary	\$2.06	\$0.11
Fully Diluted	\$2.02	\$0.11
Common Shares:		
Full Diluted	97,155,104	40,607,791
Year-end	190,330,328	139,359,201

VIRTUS INVESTMENT PARTNERS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	261,960	173,908
Cost & expenses	199,860	157,191
Operating income	49,925	13,231
Other income (expense), net	1,774	693
Gains or losses	1,878	4,604
Net before taxes	63,044	20,086
Income taxes	15,988	6,313
Net income	47,056	13,773
Balance for common	42,202	8,554
Earnings common share		
Primary	\$5.86	\$1.26
Fully Diluted	\$5.52	\$1.22
Common Shares:		
Full Diluted	8,396	7,020
Year-end	7,166	7,218

VIRTUSA CORP**Earnings, 3 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	300,031	227,345
Cost & expenses	286,107	221,275
Operating income	13,924	6,070
Interest income	1,292	1,005
Interest expense	4,254	1,658
Other income (expense), net	95	105
Foreign currency	(10,758)	(77)
Net before taxes	299	5,445
Income taxes	5,864	798
Net income	(5,565)	4,647
Balance for common	(7,383)	2,957
Earnings common share		
Primary	\$(0.25)	\$0.10
Fully Diluted	\$(0.25)	\$0.10
Common Shares:		
Full Diluted	29,633	30,251
Year-end	29,718	29,170

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	154,792	154,792
Current assets	529,324	529,324
Net property & equip.	124,463	124,463
Total assets	1,090,126	1,090,126
Liabilities:		
Current liabilities	211,804	211,804
Long-term debt	285,376	285,376
Stockholders' equity	404,622	404,622
Net current assets	317,520	317,520

VISTEON CORP**Earnings, 6 mos. to Jun 30(Consol. - \$Millions):**

	2017	2016
Net Sales	1,584	1,575
Cost & expenses	1,449	1,472
Operating income	133	97
Interest income	2	3
Interest expense	11	8
Other income (expense), net	7	(1)
Net before taxes	133	97
Income taxes	26	22
Income contin. oper.	107	75
Net income	115	53
Earnings common share		
Primary	\$3.37	\$1.24
Fully Diluted	\$3.31	\$1.23
Common Shares:		
Full Diluted	33	37
Year-end	31	34

VITAL THERAPIES INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	84,466	77,112
Cost & expenses	83,865	73,591

Cost & expenses	27,409	25,236
Operating income	(27,409)	(25,236)
Interest income	331	266
Other income (expense), net	8	(39)
Net income	(27,070)	(25,009)
Earnings common share		
Primary	\$(0.64)	\$(0.67)
Fully Diluted	\$(0.64)	\$(0.67)
Common Shares:		
Full Diluted	42,369	37,453
Year-end	42,369	42,207

VIVUS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	26,860	38,239
Cost & expenses	31,140	35,630
Operating income	(5,644)	2,247
Net before taxes	(23,211)	(14,453)
Income taxes	16	(11)
Net income	(23,227)	(14,442)
Earnings common share		
Primary	\$(0.22)	\$(0.14)
Fully Diluted	\$(0.22)	\$(0.14)
Common Shares:		
Full Diluted	106,065	105,596
Year-end	106,187	105,759

VSE CORP.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	347,291	391,154
Cost & expenses	313,835	353,945
Operating income	25,448	29,201
Interest expense	4,357	4,811
Net before taxes	21,091	24,390
Income taxes	5,288	9,290
Net income	15,803	15,100
Earnings common share		
Primary	\$1.45	\$1.39
Fully Diluted	\$1.45	\$1.39
Common Shares:		
Full Diluted	10,908	10,856
Year-end	10,881	10,838

VTV THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	4,537	43
Cost & expenses	22,529	26,412
Operating income	(17,992)	(26,369)
Interest income	34	60
Other income (expense), net	327	
Net before taxes	(19,356)	
Income taxes	200	
Net income	(19,556)	(27,700)
Earnings common share		
Primary	\$(0.61)	\$(0.84)
Fully Diluted	\$(0.61)	\$(0.84)
Common Shares:		
Full Diluted	9,876	9,693
Year-end	33,966	32,813

VYCOR MEDICAL INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	1,261,632	1,251,056
Operating income	(720,198)	(653,609)
Foreign currency	(151)	1,632
Net income	(745,220)	(673,509)
Balance for common	(907,405)	(835,694)
Earnings common share		
Primary	\$(0.04)	\$(0.05)
Fully Diluted	\$(0.04)	\$(0.05)
Common Shares:		
Full Diluted	20,768,663	16,970,241
Year-end	22,217,049	19,708,401

WAYSIDE TECHNOLOGY GROUP INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Net Sales	84,466	77,112
Cost & expenses	83,865	73,591

capital stock, vested stock options and warrants and the assumption by Co. of unvested stock options and unvested restricted stock units held by Adaptive Insights employees. Co. would also issue new restricted stock unit awards worth up to \$50,000,000 to certain continuing employees.

WYNN RESORTS LTD

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	3,321,002	2,896,649
Cost & expenses	2,848,497	2,122,324
Operating income	198,278	496,819
Interest expense	188,125	196,001
Other income (expense), net	(77,179)	(69,552)
Net before taxes	(52,945)	244,817
Income taxes	(120,747)	5,497
Net income	67,802	239,320
Earnings common share		
Primary	\$(0.46)	\$1.73
Fully Diluted	\$(0.46)	\$1.72
Common Shares:		
Full Diluted	105,195	102,274
Year-end	108,642	

XCEL BRANDS, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	17,253,000	16,800,000
Cost & expenses	13,888,000	14,463,000
Operating income	2,498,000	1,553,000
Interest expense	552,000	726,000
Net before taxes	1,946,000	827,000
Income taxes	1,559,000	1,013,000
Net income	387,000	(186,000)
Earnings common share		
Primary	\$0.02	\$(0.01)
Fully Diluted	\$0.02	\$(0.01)
Common Shares:		
Full Diluted	18,700,911	18,561,453
Year-end	18,266,202	18,471,001

XCEL ENERGY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	5,609,000	5,591,000
Cost & expenses	3,919,000	3,901,000
Operating income	930,000	959,000
Other income (expense), net	57,000	36,000
Net before taxes	670,000	686,000
Income taxes	114,000	219,000
Net income	556,000	467,000
Balance for common	556,000	467,000
Earnings common share		
Primary	\$1.09	\$0.92
Fully Diluted	\$1.09	\$0.92
Common Shares:		
Full Diluted	510,000	509,000
Year-end	508,898	507,763

XENCOR, INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	58,938	40,870
Operating income	(58,938)	(24,870)
Interest income	3,643	2,095
Interest expense	6	5
Other income (expense), net	(60)	30
Net before taxes	(22,750)	
Income taxes	450	
Net income	(55,361)	(23,200)
Balance for common	(55,361)	(23,200)
Earnings common share		
Primary	\$(1.07)	\$(0.50)
Fully Diluted	\$(1.07)	\$(0.50)
Common Shares:		
Full Diluted	51,738	46,684
Year-end	55,821	

XERIS PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	25,169	10,767
Operating income	(24,087)	(9,848)
Interest income	334	
Interest expense	753	1

Other income (expense), net	(388)	(32)
Net income	(24,894)	(9,881)
Earnings common share		
Primary	\$(7.76)	\$(4.92)
Fully Diluted	\$(7.76)	\$(4.92)
Common Shares:		
Full Diluted	3,206	2,010
Year-end	20,688	

XILINX, INC.

Earnings, 3 mos. to (Consol. - \$000):

	06/30/18	07/01/17
Total Revenues	684,370	602,810
Cost & expenses	468,246	433,050
Operating income	215,764	169,055
Other income (expense), net	(6,872)	506
Net before taxes	212,917	170,894
Income taxes	22,879	13,650
Net income	190,038	157,244
Earnings common share		
Primary	\$0.75	\$0.63
Fully Diluted	\$0.74	\$0.59
Common Shares:		
Full Diluted	255,935	265,797
Year-end	252,914	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	1,677,389	
Inventories	247,001	
Current assets	4,125,545	
Net property & equip.	312,084	
Total assets	5,055,192	
Liabilities:		
Current liabilities	942,599	
Long-term debt	1,207,387	
Stockholders' equity	2,318,638	
Net current assets	3,182,946	

XOMA CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	2,718	11,150
Cost & expenses	10,846	20,758
Operating income	(8,128)	(9,608)
Interest expense	348	906
Other income (expense), net	2,723	(1,141)
Gains or losses		1,226
Net income	(5,753)	(10,429)
Balance for common	(5,753)	(16,032)
Earnings common share		
Primary	\$(0.69)	\$(2.21)
Fully Diluted	\$(0.69)	\$(2.21)
Common Shares:		
Full Diluted	8,338	7,240
Year-end	8,379	7,593

XPERI CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Total Revenues	129,486	158,577
Cost & expenses	135,218	147,440
Operating income	(60,097)	(45,569)
Interest expense	12,518	13,505
Other income (expense), net	620	(197)
Net before taxes	(67,232)	(58,808)
Income taxes	(5,959)	(8,722)
Net income	(61,273)	(50,086)
Earnings common share		
Primary	\$(1.25)	\$(1.02)
Fully Diluted	\$(1.25)	\$(1.02)
Common Shares:		
Full Diluted	49,110	49,261
Year-end	48,962	49,511

XTANT MEDICAL HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	36,674,000	43,491,000
Cost & expenses	38,547,000	49,658,000
Operating income	(3,918,000)	(8,918,000)
Interest expense	6,366,000	6,729,000
Other income (expense), net	29,000	167,000
Net income	(10,255,000)	(15,480,000)
Earnings common share		

Primary	\$(1.00)	\$(10.31)
Fully Diluted	\$(1.00)	\$(10.31)
Common Shares:		
Full Diluted	10,299,090	1,501,079
Year-end	13,145,305	1,507,717

YANGTZE RIVER PORT & LOGISTICS LTD

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	3,295,013	1,658,425
Operating income	(3,295,013)	(1,658,425)
Interest income	93	130
Interest expense	4,400,466	4,256,484
Other income (expense), net	(7,537)	(851)
Net before taxes	(7,702,923)	(5,915,630)
Income taxes	(573,401)	(541,757)
Net income	(7,129,522)	(5,373,873)
Earnings common share		
Primary	\$(0.04)	\$(0.03)
Fully Diluted	\$(0.04)	\$(0.03)
Common Shares:		
Full Diluted	172,357,126	204,866,131
Year-end	172,389,446	172,269,446

YOGAWORKS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Total Revenues	30,400,175	26,483,555
Cost & expenses	36,447,076	28,309,084
Operating income	(10,643,929)	(6,194,991)
Net before taxes	(10,593,657)	(7,005,497)
Income taxes	17,912	59,006
Net income	(10,611,569)	(7,064,503)
Pfd. dividends		995,743
Balance for common	(10,611,569)	(8,060,246)
Earnings common share		
Primary	\$(0.65)	\$(1.66)
Fully Diluted	\$(0.65)	\$(1.66)
Common Shares:		
Full Diluted	16,367,796	4,857,160
Year-end	16,460,501	8,909,078

ZAFGEN INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	31,262	26,801
Operating income	(31,262)	(26,801)
Interest income	591	474
Interest expense	924	126
Foreign currency	(136)	95
Net income	(31,731)	(26,358)
Earnings common share		
Primary	\$(1.15)	\$(0.96)
Fully Diluted	\$(1.15)	\$(0.96)
Common Shares:		
Full Diluted	27,553	27,379
Year-end	27,579	27,449

ZAGG INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Net Sales	230,631,000	208,173,000
Cost & expenses	211,974,000	203,299,000
Operating income	13,112,000	(1,152,000)
Interest expense	846,000	1,110,000
Other income (expense), net	(186,000)	48,000
Net before taxes	12,080,000	(2,214,000)
Income taxes	1,835,000	521,000
Net income	10,245,000	(2,735,000)
Earnings common share		
Primary	\$0.36	\$(0.10)
Fully Diluted	\$0.36	\$(0.10)
Common Shares:		
Full Diluted	28,679,000	28,010,000
Year-end	28,176,000	27,982,000

ZEBRA TECHNOLOGIES CORP.

Earnings, 6 mos. to (Consol. - \$000):

	06/30/18	07/01/17
Net Sales	1,989,000	1,761,000
Cost & expenses	1,674,000	1,561,000
Operating income	269,000	98,000
Interest expense	34,000	81,000
Other income (expense), net	2,000	(1,000)

Foreign currency	(4,000)	1,000	Net before taxes	5,242,000	5,447,000
Net before taxes	233,000	17,000	Income taxes	1,510,000	2,533,000
Income taxes	54,000	(8,000)	Net income	3,732,000	2,914,000
Net income	179,000	25,000	Earnings common share		
Earnings common share			Primary	\$0.07	\$0.05
Primary	\$3.35	\$0.49	Fully Diluted	\$0.07	\$0.05
Fully Diluted	\$3.30	\$0.48	Common Shares:		
Common Shares:			Full Diluted	53,347,976	54,075,003
Full Diluted	54,134	53,038	Year-end	54,167,688	55,267,157
Year-end	53,692	53,109			

ZEBRA TECHNOLOGIES CORP.

Merger Completed On Aug. 14, 2018, Co.'s subsidiary, WolfDancer Acquisition Corp. ("Purchaser") merged with and into Xplore Technologies Corp ("Xplore Technologies") (the "Merger"), with Xplore Technologies continuing as the surviving corporation and became a new subsidiary of Co. As a result of the Merger, (a) each of Xplore Technologies's outstanding shares of common stock, par value \$0.001 per share (the "Shares"), that was outstanding immediately prior to the effective time (other than (i) Canceled Shares (as defined below), and (ii) Shares as to which the holder thereof has properly demanded and not otherwise lost appraisal rights in accordance with Section 262 of Delaware General Corporation Law ("Dissenting Shares") was converted into the right to receive cash in an amount equal to \$6.00 per share (the "Offer Price"), upon surrender of the certificate representing such Share (or, in the case of a lost, stolen or destroyed certificate, upon delivery of an appropriate affidavit and/or indemnity, if required by Co.) or non-certificated Share represented by book-entry, in each case in the manner provided in the Merger Agreement; (b) each share that was owned by Xplore Technologies as treasury stock immediately prior to the effective time, each Share owned by Co., Purchaser or any subsidiary of Co. at the commencement of the Offer and that was owned immediately prior to the effective time, and each Share irrevocably accepted for purchase by Purchaser in the Offer (collectively, the "Canceled Shares") was canceled and ceased to exist, and no consideration was paid in exchange therefor; and (c) each share of common stock of Purchaser outstanding immediately prior to the effective time was converted into one share of common stock of the surviving corporation. The aggregate cash consideration paid by Co. in the Offer and Merger was approximately \$74,600,000. Co. and Purchaser funded the consideration paid to stockholders in the Offer and pursuant to the Merger through Co.'s cash on hand and borrowings under its existing credit facilities.

ZILLOW GROUP INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	625,125	512,625
Cost & expenses	646,084	528,019
Operating income	(20,959)	(15,394)
Other income (expense), net	5,535	2,563
Net before taxes	(29,684)	
Income taxes	(8,000)	
Net income	(21,684)	(26,451)
Earnings common share		
Primary	\$(0.11)	\$(0.14)
Fully Diluted	\$(0.11)	\$(0.14)
Common Shares:		
Full Diluted	192,807	184,305
Year-end	195,449	187,016

ZION OIL & GAS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	4,528,000	5,530,000
Operating income	(4,528,000)	(5,530,000)
Other income (expense), net	(2,863,000)	(2,926,000)
Foreign currency	(101,000)	110,000
Net income	(7,492,000)	(8,346,000)
Earnings common share		
Primary	\$(0.13)	\$(0.17)
Fully Diluted	\$(0.13)	\$(0.17)
Common Shares:		
Full Diluted	58,499,000	48,714,000
Year-end	59,280,017	

ZIX CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	34,153,000	32,271,000
Cost & expenses	29,390,000	26,969,000
Operating income	4,763,000	5,302,000
Other income (expense), net	479,000	145,000

ZOGENIX INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	63,868	52,996
Operating income	(63,868)	(43,175)
Other income (expense), net	2,993	749
Net before taxes		(43,578)
Income taxes		1
Income contin. oper.	(59,019)	(43,579)
Income discont. oper.	(198)	(736)
Net income	(59,217)	(44,315)
Earnings common share		
Primary	\$(1.69)	\$(1.79)
Fully Diluted	\$(1.69)	\$(1.79)
Common Shares:		
Full Diluted	35,099	24,817
Year-end	35,827	24,839

ZYNERBA PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	24,365,942	16,068,902
Operating income	(24,365,942)	(16,068,902)
Foreign currency	(309,113)	284,982
Net income	(24,313,567)	(15,582,500)
Earnings common share		
Primary	\$(1.80)	\$(1.24)
Fully Diluted	\$(1.80)	\$(1.24)
Common Shares:		
Full Diluted	13,486,191	12,562,594
Year-end	13,561,373	13,257,279

ZYNGA INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	425,277	403,515
Cost & expenses	424,006	406,803
Operating income	1,271	(3,288)
Interest income	3,610	2,046
Other income (expense), net	6,006	3,050
Net before taxes	10,887	1,808
Income taxes	6,189	6,189
Net income	4,698	(4,381)
Earnings common share		
Primary	\$0.01	\$(0.01)
Fully Diluted	\$0.01	\$(0.01)
Common Shares:		
Full Diluted	890,285	869,025
Year-end	860,181	865,461